Sentence,class,file
"Technical support and advice were provided by M. C., J.C., M.B.and J.-B.F. Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.",Non-OADS,/arxiv_data1/oa_pdf/e4/ac/srep04026.PMC4168524.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 4026 | DOI: 10.1038/srep04026 7",Non-OADS,/arxiv_data1/oa_pdf/e4/ac/srep04026.PMC4168524.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comCase Report A craniopharyngioma with spontaneous involution of a  gadolinium‑enhanced region on magnetic resonance imaging Yasuyuki Kinoshita, Atsushi Tominaga, Satoshi Usui, Kaoru Kurisu Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan E‑mail: *Yasuyuki Kinoshita ‑ y‑kinoshita@hiroshima‑u.ac.jp; Atsushi T ominaga ‑ atom@hiroshima‑u.ac.jp; Satoshi Usui ‑ usui@hiroshima‑u.ac.jp;   Koaru Kurisu ‑ kuka422@hiroshima‑u.ac.jp   *Correspondence author Received: 08 April 14  Accepted: 26 June 14  Published: 20 August 14  Access this article  online Website: www.surgicalneurologyint.com DOI:   10.4103/2152-7806.139377  Quick Response Code: Abstract Background:  It has not been reported previously that the solid enhancing portion  of a craniopharyngioma has involuted without a change in cyst size.",Non-OADS,/arxiv_data1/oa_pdf/17/be/SNI-5-128.PMC4168541.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/128/139377 Copyright: © 2014 Kinoshita Y.,Non-OADS,/arxiv_data1/oa_pdf/17/be/SNI-5-128.PMC4168541.pdf
"Surgical Neurology International 2014, 5:128  http://www.surgicalneurologyint.com/content/5/1/128CASE REPORT A 44‑year‑old female was referred to our department with  a suprasellar mass on MRI associated with headaches and  polyuria.",Non-OADS,/arxiv_data1/oa_pdf/17/be/SNI-5-128.PMC4168541.pdf
"Surgical Neurology International 2014, 5:128  http://www.surgicalneurologyint.com/content/5/1/128DISCUSSION In the present case, the titer of HCG‑ β was positive  in the CSF and the tumor seemed to infiltrate into  the intraaxial hypothalamus within a short period on  preoperative MRI.",Non-OADS,/arxiv_data1/oa_pdf/17/be/SNI-5-128.PMC4168541.pdf
"Surgical Neurology International 2014, 5:128  http://www.surgicalneurologyint.com/content/5/1/128ACKNOWLEDGMENTS This work was supported in part by Research Grants from the  Ministry of Education, Culture, Sports, Science and Technology  of Japan.",Non-OADS,/arxiv_data1/oa_pdf/17/be/SNI-5-128.PMC4168541.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comErratum Surg Neurol Int 2013;4:67 Title: Clinical and radiological aspects of cerebellopontine neurinoma presenting with  recurrent spontaneous bleedings Author Names Maimone Giuseppe, Ganau Mario, Nicassio Nicola, Cambria Mauro   Should read as Giuseppe Maimone, Mario Ganau, Nicola Nicassio, Mauro Cambria Published: 22 August 14 This article may be cited as: Maimone G, Ganau M, Nicassio N, Cambria M. Clinical and radiological aspects of cerebellopontine neurinoma presenting with recurrent spontaneous bleedings.",Non-OADS,/arxiv_data1/oa_pdf/b7/c1/SNI-5-129.PMC4168542.pdf
"Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/129/139409 The error is regretted - Editor, SNI",Non-OADS,/arxiv_data1/oa_pdf/b7/c1/SNI-5-129.PMC4168542.pdf
Available FREE in open access from: http://www.clinicalimagingscience.org/text.asp?2014/4/1/47/139737,Non-OADS,/arxiv_data1/oa_pdf/78/90/JCIS-4-47.PMC4168543.pdf
Available FREE in open access from: http://www.clinicalimagingscience.org/text.asp?2014/4/1/46/139736,Non-OADS,/arxiv_data1/oa_pdf/d6/50/JCIS-4-46.PMC4168544.pdf
Available from: http://www.acr.org/Quality-Saft  ey/Standards-Guidelines-by-Modality/ MRI.,Non-OADS,/arxiv_data1/oa_pdf/d6/50/JCIS-4-46.PMC4168544.pdf
Available from: http://www.cancer.gov/cancertopics/factsheet/detection/probability-breast-cancer.,Non-OADS,/arxiv_data1/oa_pdf/d6/50/JCIS-4-46.PMC4168544.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.asp?2014/5/1/32/139712 Abstract Recent advances in digital imaging is impacting the practice of pathology.,Non-OADS,/arxiv_data1/oa_pdf/f7/7d/JPI-5-32.PMC4168545.pdf
"J Pathol Inform 2014, 1:32  http://www.jpathinformatics.org/content/5/1/32together researchers working in quantitative biomedical  imaging in the Pittsburgh Community.",Non-OADS,/arxiv_data1/oa_pdf/f7/7d/JPI-5-32.PMC4168545.pdf
"J Pathol Inform 2014, 1:32  http://www.jpathinformatics.org/content/5/1/32numerous attempts at quantifying nuclei in a wide variety  of cancers with different degrees of success.",Non-OADS,/arxiv_data1/oa_pdf/f7/7d/JPI-5-32.PMC4168545.pdf
"J Pathol Inform 2014, 1:32  http://www.jpathinformatics.org/content/5/1/32Computer Engineering Carnegie Mellon University,  2Massachusetts Institute of Technology Lincoln  Laboratory, 3Department of Mathematics and Statistics,  Air Force Institute of Technology Wright‑Patterson  AFB, 4Department of Pathology, Children’s Hospital of  Pittsburgh University of Pittsburgh School of Medicine,  Pittsburgh, PA, USA In most surgical pathology practices, certain specimens  recur at relatively high frequency.",Non-OADS,/arxiv_data1/oa_pdf/f7/7d/JPI-5-32.PMC4168545.pdf
"J Pathol Inform 2014, 1:32  http://www.jpathinformatics.org/content/5/1/32key barriers, it is best to approach them systematically  according to the steps involved in the digital imaging  process [Table 1].",Non-OADS,/arxiv_data1/oa_pdf/f7/7d/JPI-5-32.PMC4168545.pdf
"J Pathol Inform 2014, 1:32  http://www.jpathinformatics.org/content/5/1/32given the expense of some medical grade monitors many  pathologists currently do not use these displays to view  digital images.",Non-OADS,/arxiv_data1/oa_pdf/f7/7d/JPI-5-32.PMC4168545.pdf
"J Pathol Inform 2014, 1:32  http://www.jpathinformatics.org/content/5/1/32Proc Natl Acad Sci U S A 2014;111:3448‑53.",Non-OADS,/arxiv_data1/oa_pdf/f7/7d/JPI-5-32.PMC4168545.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.asp?2014/5/1/30/139710 Access this article online Quick Response Code: Website:    www.jpathinformatics.org DOI:  10.4103/2153-3539.139710,Non-OADS,/arxiv_data1/oa_pdf/6f/f4/JPI-5-30.PMC4168546.pdf
"J Pathol Inform 2014, 1:30  http://www.jpathinformatics.org/content/5/1/30were representatives from various publishers, service  providers,	 and	the	National	 Telehealth	 Resource	 Centers.",Non-OADS,/arxiv_data1/oa_pdf/6f/f4/JPI-5-30.PMC4168546.pdf
Available from: http://www.aezonhealth.com/.,Non-OADS,/arxiv_data1/oa_pdf/6f/f4/JPI-5-30.PMC4168546.pdf
Available FREE in open access from: http://www.clinicalimagingscience.org/text.asp?2014/4/1/43/139733CASE REPORT Access this article online Quick Response Code: Website: www.clinicalimagingscience.org DOI: 10.4103/2156-7514.139733  Dr. Alexandre Batista,Non-OADS,/arxiv_data1/oa_pdf/48/c2/JCIS-4-43.PMC4168547.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comOriginal Article Predicting the presigmoid retrolabyrinthine space using a  sigmoid sinus tomography classification: A  cadaveric study José Orlando de Melo Junior, João Klescoski Junior, Cristian Ferrareze Nunes,   Gustavo Augusto Porto Sereno Cabral, Mário Alberto Lapenta1, José Alberto Landeiro2 Departments of Neurosurgery, 1Chairman of the Department of Neurosurgery, Galeão Air Force Hospital, 2Professor and Chairman of the Department of  Neurosurgery, Fluminense Federal University, Niterói, and Professor of the Department of Neurosurgery, Galeão Air Force Hospital, Rio de Janeiro, Brazil E‑mail: *José Orlando de Melo Junior ‑ jomjunior@gmail.com; João Klescoski Junior ‑ klesco@gmail.com; Cristian Ferrareze Nunes ‑ cristian.nunes@gmail.com;  Gustavo Augusto Porto Sereno Cabral ‑ gustavo.cabral@gmail.com; Mário Alberto Lapenta ‑ mariolapenta@hotmail.com;   José Alberto Landeiro ‑ jalandeiro@gmail.com   *Corresponding Author Received: 12 April 14  Accepted: 22 June 14  Published: 30 August 14 Access this article  online Website: www.surgicalneurologyint.com DOI:   10.4103/2152-7806.139819  Quick Response Code: Abstract Background: The presigmoid retrolabyrinthine space is characterized by a widely  variable size.",Non-OADS,/arxiv_data1/oa_pdf/30/71/SNI-5-131.PMC4168548.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/131/139819 Copyright: © 2014 de Melo JO Jr.,Non-OADS,/arxiv_data1/oa_pdf/30/71/SNI-5-131.PMC4168548.pdf
"Surgical Neurology International 2014, 5:131  http://www.surgicalneurologyint.com/content/5/1/131as presigmoid retrolabyrinthine, transcrusal (partial  labyrinthectomy), translabyrinthine, and transchoclear  approaches.",Non-OADS,/arxiv_data1/oa_pdf/30/71/SNI-5-131.PMC4168548.pdf
"Surgical Neurology International 2014, 5:131  http://www.surgicalneurologyint.com/content/5/1/131microscope light was projected over the posterior surface  of the petrous bone and Trautmann’s triangle, and the  limits of the light were outlined and compared between  the two groups.",Non-OADS,/arxiv_data1/oa_pdf/30/71/SNI-5-131.PMC4168548.pdf
"Surgical Neurology International 2014, 5:131  http://www.surgicalneurologyint.com/content/5/1/131group, the posteriorly displaced sigmoid sinus provided  a larger corridor with a higher angle of approach to  dissection and showed a less demanding dissection.",Non-OADS,/arxiv_data1/oa_pdf/30/71/SNI-5-131.PMC4168548.pdf
"Surgical Neurology International 2014, 5:131  http://www.surgicalneurologyint.com/content/5/1/131millimeters.",Non-OADS,/arxiv_data1/oa_pdf/30/71/SNI-5-131.PMC4168548.pdf
"Surgical Neurology International 2014, 5:131  http://www.surgicalneurologyint.com/content/5/1/131REFERENCES 1.",Non-OADS,/arxiv_data1/oa_pdf/30/71/SNI-5-131.PMC4168548.pdf
"Available FREE in open access from: http://www.jpathinformatics.org/text.asp?2014/5/1/29/139709 Abstract Background:  At some institutions, including ours, bone marrow aspirate specimen  triage is complex, with hematopathology triage decisions that need to be communicated  to downstream ancillary testing laboratories and many specimen aliquot transfers  that are handled outside of the laboratory information system (LIS).",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29time intensive, requiring multiple communications to  downstream laboratories and specimen hand‑offs, especially  when aspirate tests require a manual requisition form.",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29requisitions for clinician‑driven downstream testing  may be blank or incorrectly filled out; as such, the  technologists aliquot specimen for each downstream  laboratory with a requisition form and transfer the  specimen to that laboratory.",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29Specimens Awaiting Triage Selecting the SPECIMENS AWAITING TRIAGE  button activates a custom script that finds all records  in the database without a triage complete date and  presents them in a tabular form on the T riage  List  layout [Figure 4].",OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29sample for additional testing, or if they need to reroute  a previously distributed sample from one laboratory to  another.",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29date, thereby removing the core‑only specimen from the  triage list.",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29cytometry residents), 2 fellow users (hematopathology  and MP), 4 hematopathology attending users, 5  laboratory personnel users (hematology, MP , cytogenetics  and CPD), 1 genetic counselor (CPD), 13 technologist  users (hematology laboratory), 1 laboratory supervisor  user (hematopathology) and 2 administrative accounts  encompassing six privilege sets.",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29 Figure 6: Updated workflow utilizing the hemepath database and dashboard.",OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29Example 2 The hematology laboratory received a bone marrow  aspirate (two EDTA tubes and one heparin tube) and  core specimen from a 64‑year‑old man with a history  of chronic lymphocytic leukemia (CLL).",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29CONCLUSIONS Occasionally, pathologists have to handle specimens  and test requests outside of their LIS, including manual  requisitions or testing requiring pathologist review prior to test completion that cannot be easily incorporated  into a standard LIS.",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29Figure 11: Case example 2 hemepath triage.",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"J Pathol Inform 2014, 1:29  http://www.jpathinformatics.org/content/5/1/29technologists in the hematology laboratory for their willingness  to be guinea pigs in the development of this tool and for their  valuable time and insightful recommendations.",Non-OADS,/arxiv_data1/oa_pdf/32/e5/JPI-5-29.PMC4168549.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comI Half a hundred years ago we stood with pride and took an Oath.",Non-OADS,/arxiv_data1/oa_pdf/51/36/SNI-5-127.PMC4168640.pdf
"Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/127/139375 Copyright: © 2014 Watts C. This is an open‑access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/51/36/SNI-5-127.PMC4168640.pdf
"Surgical Neurology International 2014, 5:127  http://www.surgicalneurologyint.com/content/5/1/127But did we do that which we knew to do, or did we yield to those who said: we know because we pay?",Non-OADS,/arxiv_data1/oa_pdf/51/36/SNI-5-127.PMC4168640.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.asp?2014/5/1/31/139711,Non-OADS,/arxiv_data1/oa_pdf/2f/7f/JPI-5-31.PMC4168641.pdf
"J Pathol Inform 2014, 1:31  http://www.jpathinformatics.org/content/5/1/31•	David Wilbur •	Donald Karcher •	Drazen Jukic •	Elizabeth Krupinski •	Elena Brachtel •	Enrique Terrazas •	Eric Glassy •	Gabriel Caponetti •	Gaurav Sharma •	George Birdsong •	Giovanna Crisi •	Gokhan Bilgin •	Gustavo Rohde •	Hal Weiner •	Heike Varnholt •	Heiko Spallek •	Imam Yetik •	Ioan Cucoranu •	J.",Non-OADS,/arxiv_data1/oa_pdf/2f/7f/JPI-5-31.PMC4168641.pdf
Available FREE in open access from: http://www.clinicalimagingscience.org/text.asp?2014/4/1/48/139738CASE REPORT Access this article online Quick Response Code: Website: www.clinicalimagingscience.org DOI: 10.4103/2156-7514.139738,Non-OADS,/arxiv_data1/oa_pdf/79/01/JCIS-4-48.PMC4168642.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.asp?2014/5/1/28/139707 Abstract Background:  Mortality in cancer patients is directly attributable to the ability of cancer  cells to metastasize to distant sites from the primary tumor.,Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28better treatment than ever before.",Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28screening where manual searching is not practical.",Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28analysis.",Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28walks out of the in‑focus imaging plane as the stage is  translated over large distances in x or y.",Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28branches were then pruned from the network and closely  spaced, similarly oriented fibers were merged.",OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28by CT‑FIRE) and an epithelial mask file  (generated by  our epithelial segmentation script).",OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28features were then averaged among all fibers in a given  image and training was performed with a subset of 16  images It∈Ii that had been manually annotated as being  TACS‑3 positive or negative.",OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28comparison to other techniques.",Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28combines features of not only collagen fibers, but both  collagen fibers and cellular structures is most likely to  succeed in predicting survival.",OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28were originally captured in the backwards direction with  elliptically polarized light, causing two artifacts.",Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/28stitching each image together.",Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
"J Pathol Inform 2014, 1:28  http://www.jpathinformatics.org/content/5/1/2826.",Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
Available: http://www.loci.wisc.edu/ software/wiscscan.,Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
Available:  http://www.fiji.sc/Trainable_Weka_Segmentation.,Non-OADS,/arxiv_data1/oa_pdf/af/e3/JPI-5-28.PMC4168643.pdf
Available FREE in open access from: http://www.clinicalimagingscience.org/text.asp?2014/4/1/45/139735,Non-OADS,/arxiv_data1/oa_pdf/7b/72/JCIS-4-45.PMC4168644.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comT echnical Note Shunt implantations and peritoneal catheters: Do not cut beyond  20 cm Angelo Luiz Maset1, Ítalo Capraro Suriano2, Ruy Monteiro3, José Ricardo Camilo Pinto4,  José Ricardo de Andrade4, Bruna Monieli Mancini4, Sérgio Luiz Ramin5, Dionei Freitas Moraes6,  Sérgio Cavalheiro7 1Department of  Neurosurgery, FUNFARME, São José do Rio Preto, SP; Founder and Owner for Ventura Biomedica Ltda, 2São Paulo Federal University, São  Paulo, SP , 3Head of Department Neurosurgery, Hospital Municipal Miguel Couto, Rio de Janeiro, RJ, 4Department of Engineering, Ventura Biomédica Ltda,  5Department of Neurosurgery, 6Chairman, Department of Neurosurgery, FUNFARME, São José do Rio Preto, 7Professor and Chairman, São Paulo Federal  University, São Paulo, SP , Brazil E‑mail: *Angelo Luiz Maset ‑ maset@terra.com.br; Ítalo Capraro Suriano ‑ suriano.ops@terra.com.br; Ruy Monteiro ‑ ruy.monteiro@globo.com;   José Ricardo Camilo Pinto ‑ camilo@ventura.ind.br; José Ricardo de Andrade ‑ andrade@ventura.com.br; Bruna Monieli Mancini ‑ brunamancini@ventura.ind.br;  Sérgio Luiz Ramin ‑ sergio.ramin@yahoo.com; Dionei Freitas Moraes ‑ dionei.fm@terra.com.br; Sérgio Cavalheiro ‑ iscava@uol.com.br   *Corresponding author Received: 27 January 14  Accepted: 07 June 14  Published: 22 August 14 Abstract Background:  Ventriculoperitoneal shunts are supplied with long peritoneal  catheters, most commonly between 80 and 120 cm long.",Non-OADS,/arxiv_data1/oa_pdf/27/52/SNI-5-130.PMC4168645.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/130/139410 Copyright: © 2014 Maset AL.,Non-OADS,/arxiv_data1/oa_pdf/27/52/SNI-5-130.PMC4168645.pdf
"Surgical Neurology International 2014, 5:130  http://www.surgicalneurologyint.com/content/5/1/130INTRODUCTION Neurosurgeons routinely cut off pieces of the peritoneal  catheter upon shunt implantation/revision, and this  occurs more frequently in the pediatric and newborn  population due obviously to the height of the patients.",Non-OADS,/arxiv_data1/oa_pdf/27/52/SNI-5-130.PMC4168645.pdf
"Surgical Neurology International 2014, 5:130  http://www.surgicalneurologyint.com/content/5/1/130Shunt 2, neonatal low‑pressure calibrated at upper border  range [Figure  2a, b; Table  2]: Performed at a pressure of  105, 82, 70, 52, 42, and 35 mmH2O for original catheter  length of 1.000 mm for 50, 40, 30, 20, 10, and 5 ml/h flow,  respectively; performed at a pressure of 87, 70, 58, 47, 35,  and 30 mmH2O for 900 mm catheter length for 50, 40, 30,  20, 10, and 5 ml/h flow, respectively; performed at a pressure  of 76, 65, 53, 41, 30, and 26 mmH2O for 800 mm catheter  length for 50, 40, 30, 20, 10, and 5 ml/h flow, respectively;  performed at a pressure of 69, 59, 43, 34, 27, and 22 mmH2O for 700 mm catheter length for 50, 40, 30, 20, 10,  and 5 ml/h flow, respectively; performed at a pressure of 59,  50, 37, 29, 23, and 18 mmH2O for 600 mm catheter length  for 50, 40, 30, 20, 10, and 5 ml/h flow, respectively.",Non-OADS,/arxiv_data1/oa_pdf/27/52/SNI-5-130.PMC4168645.pdf
"Surgical Neurology International 2014, 5:130  http://www.surgicalneurologyint.com/content/5/1/13010, and 5 ml/h flow, respectively; performed at a pressure  of 60, 50, 38, 30, 25, and 19 mmH2O for 800 mm catheter  length for 50, 40, 30, 20, 10, and 5 ml/h flow, respectively;  performed at a pressure of 52, 44, 35, 26, 21 and 17  mmH2O for 700 mm catheter length for 50, 40, 30, 20,  10, and 5 ml/h flow, respectively; performed at a pressure  of 46, 39, 31, 25, 20, and 17 mmH2O for 600 mm catheter  length for 50, 40, 30, 20, 10, and 5 ml/h flow, respectively.",Non-OADS,/arxiv_data1/oa_pdf/27/52/SNI-5-130.PMC4168645.pdf
"Surgical Neurology International 2014, 5:130  http://www.surgicalneurologyint.com/content/5/1/13036, 29, and 24 mmH2O for 600 mm catheter length for  50, 40, 30, 20, 10, and 5 ml/h flow, respectively; performed  at a pressure of 65, 55, 41, 31, 26, and 21 mmH2O for  500 mm catheter length for 50, 40, 30, 20, 10, and 5 ml/h  flow, respectively.",Non-OADS,/arxiv_data1/oa_pdf/27/52/SNI-5-130.PMC4168645.pdf
"Surgical Neurology International 2014, 5:130  http://www.surgicalneurologyint.com/content/5/1/130DISCUSSION Hydraulic disturbances are common after shunt  implantation,[13,16] and overdrainage is invariably associated  with gravity.",Non-OADS,/arxiv_data1/oa_pdf/27/52/SNI-5-130.PMC4168645.pdf
"Surgical Neurology International 2014, 5:130  http://www.surgicalneurologyint.com/content/5/1/130setting shunt assemblies when the distal catheter is cut  down?",Non-OADS,/arxiv_data1/oa_pdf/27/52/SNI-5-130.PMC4168645.pdf
"Surgical Neurology International 2014, 5:130  http://www.surgicalneurologyint.com/content/5/1/130CONCLUSION We advise not to cut more than 20 cm of the peritoneal  catheter as this changes the shunt resistance in a major  way to maintain a shunt in its original pressure settings.",Non-OADS,/arxiv_data1/oa_pdf/27/52/SNI-5-130.PMC4168645.pdf
J Clin Imaging Sci 2014;4:44.Available FREE in open access from: http://www.clinicalimagingscience.org/text.asp?2014/4/1/44/139734,Non-OADS,/arxiv_data1/oa_pdf/ec/59/JCIS-4-44.PMC4168646.pdf
"http://ce.nurse.com/pain-management Contact hours awarded, some educational activities are free, fee for CEU’s variable for specific courses.",Non-OADS,/arxiv_data1/oa_pdf/a9/7b/TONURSJ-8-25.PMC4168647.pdf
"Geriatric Pain website; http://www.geriatricpain.org/Content/Education/Provider/Pages/default.aspx; this site also includes Geriatric ELNEC (End of Life Nursing Education Consortium) - a national end-of-life educational program administered by the City of Hope National Medical Center (COH) and the American Association of Colleges of Nursing (AACN) The web site is made possible by generous funding from The Mayday Fund American Academy of Pain Management online education center; Two free programs with CEU: Improving the Quality of Care for Patients with Rheumatoid Arthritis and Mind, Body, Spirit Solutions: An Integrative Approach to Fibromyalgia; however many additional programs available for fee This site offers a host of Continuing Education opportunities.",Non-OADS,/arxiv_data1/oa_pdf/a9/7b/TONURSJ-8-25.PMC4168647.pdf
"There are a variety of position papers downloaded for free This site offers educational programs, Cost for active members is $125 American Chronic Pain Association; This organization facilitates peer support and education for individuals with chronic pain and their families so that these individuals may live more fully in spite of their pain; http://theacpa.org/Pain-Management-Programs Free site for patients and families of those with chronic pain American Pain Society; offers a variety of clinical practice guidelines for free Variable cost for membership depending on annual income The International Association for the Study of Pain (IASP) is the leading professional forum for science, practice, and education in the field of pain.",Non-OADS,/arxiv_data1/oa_pdf/a9/7b/TONURSJ-8-25.PMC4168647.pdf
"Membership in IASP is open to all professionals involved in research, diagnosis or treatment of pain; http://www.iasp-pain.org/AM/Template.cfm?Section=Nursing Variable cost depending on annual income National Hospice and Palliative Care Organization; a variety of eweb based educational programs are available; http://www.nhpco.org/education/online-learning Fee for membership, variable cost for educational programs depending on membership National Center for Complementary and Alternative Medicine, National Institutes of Health; NCCAM is offering free, comprehensive video-lectures about research in complementary health approaches.",Non-OADS,/arxiv_data1/oa_pdf/a9/7b/TONURSJ-8-25.PMC4168647.pdf
"Topics range from mind-body pain therapies to acupuncture; http://nccam.nih.gov/ Free video-lectures; clinical practice guidelines, for health professionals, also offers information for patients available free National Comprehensive Cancer Network Guidelines; offers adult cancer pain guidelines; http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#pain Requires registration on line, no fee  Unites States Department of Veterans Affairs; VHA pain management site: This website facilitates effective pain management by providing convenient, centralized access to resources for the provision of pain services within the VA healthcare system.",Non-OADS,/arxiv_data1/oa_pdf/a9/7b/TONURSJ-8-25.PMC4168647.pdf
"The intended users of this site are veterans, veterans' family members, caregivers, VA administrators, clinicians, and researchers who have an interest in any aspect of pain management; http://www.va.gov/PAINMANAGEMENT/Clinical_Resources.asp Free educational resources including clinical tools, clinical practice guidelines",Non-OADS,/arxiv_data1/oa_pdf/a9/7b/TONURSJ-8-25.PMC4168647.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a9/7b/TONURSJ-8-25.PMC4168647.pdf
Available from: http://www.who.int/ageing/about/facts/en/ [Cited: 5th Nov 2013].,Non-OADS,/arxiv_data1/oa_pdf/97/9c/TONURSJ-8-34.PMC4168648.pdf
Available from: http://www.re geringen.se/sb/d/108/ a/138285 [Cited: 5th Nov 2013] (in Swedish).,OADS,/arxiv_data1/oa_pdf/97/9c/TONURSJ-8-34.PMC4168648.pdf
Available from: http://benthamscience.com/open/fulltext/pdf/tonursj/TONUR SJ-7-107.pdf [Cited: 15th Dec 2013].,Non-OADS,/arxiv_data1/oa_pdf/97/9c/TONURSJ-8-34.PMC4168648.pdf
Available from: http://www.or ebro.se/download/18.47c6f44f12dd9e9713780002115/1392724621772/S%C3%A4rskilda+boenden+f%C3%B6r+%C3%A4ldre%2C+deras+anh%C3%B6riga+och+hemv%C3%A5rden+hela+unders%C3%B6kningen+-+brukarunders%C3%B6kning +2010.pdf [Cited: 5th Nov 2013] (in Swedish).,Non-OADS,/arxiv_data1/oa_pdf/97/9c/TONURSJ-8-34.PMC4168648.pdf
"Available from: http://www.biomedcentral.com/1472-6955/13/19 [29] Chinn PL, Kramer MK.",Non-OADS,/arxiv_data1/oa_pdf/97/9c/TONURSJ-8-34.PMC4168648.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/97/9c/TONURSJ-8-34.PMC4168648.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non -Commercial License (http://creativecommons.org/ - licenses/by -nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b5/ef/TOCMJ-8-76.PMC4168649.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/44/9b/TOORTHJ-8-272.PMC4168650.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non -Commercial License (http://creativecommons.org/licenses/   by-nc/3.0/) which permits unrestricted, non -commercial use,  distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d8/8e/TONEUJ-8-15.PMC4168651.pdf
Operative Technique and Rehabilitation  The operative technique was standardized and followed the guidelines of the manufacturer of the implant (http://www.shoulderdoc.co.uk/documents/Philos.pdf).,Non-OADS,/arxiv_data1/oa_pdf/6e/ba/TOORTHJ-8-281.PMC4168652.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6e/ba/TOORTHJ-8-281.PMC4168652.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/23/b1/TOORTHJ-8-288.PMC4168653.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.asp?2014/5/1/33/139714,Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33INTRODUCTION Digital pathology includes the integration of whole slide  images (WSIs) into pathologists’ clinical workflow by  offering them a digital manner to manage, interpret,  analyze, and archive pathology information.",OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33data supporting a return on investment prior to purchasing  expensive WSI scanners and supporting software is a  major factor delaying wide‑scale adoption of digital  pathology.",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33Assumptions The analysis was based on the following assumptions.",OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33Pathologist productivity gains were based on three main  components: Productivity improvements for individual  pathologists within the organization, productivity  improvements for the pathology department as a whole,  and a reduction in the number of second opinion consults  provided by subspecialists to general pathologists within  the organization (i.e.",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33submitted to rule out a cancer diagnosis), was collected.",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33Breast Cancer Errors A similar analysis for over treatment costs due to  false positive interpretive errors of breast cancer was  conducted.",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33at academic hospitals.",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33calendar year was conducted.",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33analyzed [Table 5].",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33cost‑benefit analysis should be conducted.",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33patient outcomes due to reduced interpretative errors  by nonsubspecialists within the pathology department.",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33bandwidth in key locations to support a DPS.",OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"J Pathol Inform 2014, 1:33  http://www.jpathinformatics.org/content/5/1/33slide imaging in surgical pathology quality assurance: Design and pilot  validation studies.",Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
Available from: http://www.cdc.gov/uscs [Last accessed on 2014 Mar 10].,OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
Available from:  http://www.cms.gov/apps/ama/license.asp?file=/hospitaloutpatientpps/ downloads/January‑2013‑Web‑Addendum‑A.zip [Last accessed on 2014  Mar 10].,Non-OADS,/arxiv_data1/oa_pdf/d6/14/JPI-5-33.PMC4168664.pdf
"Copyright © 2014 The Korean Society of Environmental Health and Toxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8 http://e-eht.org/ Introduction DNA hybridization refers to a hydrogen bonding reaction be - tween complementary single stranded DNA (ssDNA).",Non-OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
"The result presented in Characterization of denaturation and renaturation  of DNA for DNA hybridization Xiaofang Wang1, Hyun Jeong Lim2, Ahjeong Son2 1Department of Civil Engineering, Auburn University, Auburn, AL, USA; 2Department of Environmental Science and  Engineering, Ewha Womans University, Seoul, Korea• Original ArticleOpen Access Environmental Health and Toxicology Volume: 29, Article ID: e2014007, 8 pages http://dx.doi.org/10.5620/eht.2014.29.e2014007 eISSN: 2233-6567  Objectives  The present study was designed to systematically characterize the denatur - ation and the renaturation of double stranded DNA (dsDNA), which is suitable for DNA  hybridization.",Non-OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
"Keywords  Beads mill, Dimethyl sulfoxide, DNA denaturation, DNA renaturation, Heat - ing, SonicationCorrespondence: Ahjeong Son, PhD  52 Ewhayeodae-gil, Seodaemun-gu, Seoul 120-750, Korea Tel: +82-2-3277-3339 Fax: +82-2-3277-3275 Email: ason@ewha.ac.kr Received:  June 12, 2014 Accepted:  August 8, 2014 Published online:  September 11, 2014 This article is available from: http://e-eht.org/",Non-OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
http://e-eht.org/ Page 2 of 8Environmental Health and Toxicology    2014;29:e2014007 this study will provide useful data to any DNA hybridization  based applications.,Non-OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
"http://e-eht.org/ Page 3 of 8X Wang, et al.",OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
http://e-eht.org/ Page 4 of 8Environmental Health and Toxicology    2014;29:e2014007 Final A 260 is the absorbance measured after the denatured DNA  being mixed with a hybridization buffer for a prolonged time.,Non-OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
"http://e-eht.org/ Page 5 of 8X Wang, et al.",OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
http://e-eht.org/ Page 6 of 8Environmental Health and Toxicology    2014;29:e2014007 Geiduschek [16] also observed the rapid DNA renaturation  when the temperature decreased below the T m. This problem  can be fixed by the more sophisticated setup of heating system  along with the elucidation of kinetics for this potentially rate-de - pendent reaction.,Non-OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
"http://e-eht.org/ Page 7 of 8X Wang, et al.",OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
http://e-eht.org/ Page 8 of 8Environmental Health and Toxicology    2014;29:e2014007 petitive polymerase chain reaction.,Non-OADS,/arxiv_data1/oa_pdf/c5/62/eht-29-e2014007.PMC4168728.pdf
"Copyright © 2014 The Korean Society of Environmental Health and Toxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8 http://e-eht.org/ Introduction The overuse of chemical pesticides for improving agricultural  productivity has created numerous problems, including the de - struction of natural ecosystems and pesticide-tolerant diseases  and insect pests.",Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
"In addition, even if used in an open field, they decompose Acute toxicity assessment of camphor in bio- pesticides by using Daphnia magna  and Danio rerio Eun-Chae Yim1, Hyeon-Joe Kim2, Seong-Jun Kim2 1Bioenergy and Biomaterials, Interdisciplinary Program of Graduate School for Chonnam National University, Gwangju;  2Department of Environmental and Energy Engineering, Chonnam National University, Gwangju, Korea• Original ArticleOpen Access Environmental Health and Toxicology Volume: 29, Article ID: e2014008, 8 pages http://dx.doi.org/10.5620/eht.2014.29.e2014008 eISSN: 2233-6567  Objectives  An ecofriendly alternative to chemical pesticides is bio-pesticides, which are  derived from natural sources.",Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
"Keywords  Acute toxicity, Bio-pesticides, Camphor, Danio rerio  embryo, Daphnia magna ,  Morphological abnormalitiesCorrespondence: Seong-Jun Kim, PhD 77 Yongbong-ro, Buk-gu,   Gwangju 500-757, Korea Tel: +82-62-530-1864 Fax: + 82-62-530-0864 E-mail: seongjun@jnu.ac.kr Received:  June 20, 2014 Accepted:  July 24, 2014 Published online:  September 19, 2014 This article is available from: http://e-eht.org/",Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
"http://e-eht.org/ Page 2 of 8Environmental Health and Toxicology    2014;29:e2014008 quickly, thereby minimizing the risk of environmental pollution  or residual toxicity [1].",Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
"http://e-eht.org/ Page 3 of 8E-C Yim, et al.",Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
"http://e-eht.org/ Page 4 of 8Environmental Health and Toxicology    2014;29:e2014008 the range of 395–1,580 μM after 96 hours, and above 1,580 μM,  the lethality was 100%.",Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
"http://e-eht.org/ Page 5 of 8E-C Yim, et al.",Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
"http://e-eht.org/ Page 6 of 8Environmental Health and Toxicology    2014;29:e2014008 A B Change in hatchability At 395 and 790 μM concentration, the hatchability after 96  hours was 83.3 and 53.3, respectively.",Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
"http://e-eht.org/ Page 7 of 8E-C Yim, et al.",Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
Available from:  http://www.oecd.org/chemicalsafety/testing/36817070.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
http://e-eht.org/ Page 8 of 8Environmental Health and Toxicology    2014;29:e2014008 7.,Non-OADS,/arxiv_data1/oa_pdf/c8/5b/eht-29-e2014008.PMC4168729.pdf
"Scott1, Alicia A. McNeely1, Courtney Berezuk1, Fuqiang Gao1, Gregory M. Szilagyi1,2, Sandra E. Black1,2 1LC Campbell Cognitive Neurology Research Unit, Heart & Stroke Foundation Canadian Partnership for Stroke Recovery, Brain Sciences Research Program, Sunnybrook Health Sciences Centre 2Department of Medicine (Neurology), Institute of Medical Science, University of Toronto Correspondence to: Joel Ramirez at joelr@sri.utoronto.ca URL: http://www.jove.com/video/50887 DOI: doi:10.3791/50887 Keywords: Medicine, Issue 86, Brain, Vascular Diseases, Magnetic Resonance Imaging (MRI), Neuroimaging, Alzheimer Disease, Aging, Neuroanatomy, brain extraction, ventricles, white matter hyperintensities, cerebrovascular disease, Alzheimer disease Date Published: 4/14/2014 Citation: Ramirez, J., Scott, C.J., McNeely, A.A., Berezuk, C., Gao, F., Szilagyi, G.M., Black, S.E.",Non-OADS,/arxiv_data1/oa_pdf/ff/87/jove-86-50887.PMC4168739.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/50887/ Introduction Brain image analysis is an emerging field of neuroscience requiring skilled operators with a high degree of computational and neuroanatomical competency.,Non-OADS,/arxiv_data1/oa_pdf/ff/87/jove-86-50887.PMC4168739.pdf
"To obtain an individual operator's inter-rater reliability test off-site, it is recommended to execute the full LE pipeline on the training set provided with the software (http://sabre.brainlab.ca).",Non-OADS,/arxiv_data1/oa_pdf/ff/87/jove-86-50887.PMC4168739.pdf
"Using the training set provided online ( http://sabre.brainlab.ca ), the following steps are recommended to assess inter-rater reliability for each of the processing stages after completion of LE.",Non-OADS,/arxiv_data1/oa_pdf/ff/87/jove-86-50887.PMC4168739.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseApril 2014 |  86  | e50887 | Page 11 of 12In conclusion, it is important to appreciate that this written component is meant to supplement a video-guided, standardized protocol publication in JoVE ( http://www.jove.com).",Non-OADS,/arxiv_data1/oa_pdf/ff/87/jove-86-50887.PMC4168739.pdf
"The primary purpose of our study was to investigate the  effectiveness of CsA in modulating functional and structural  responses to hRPCs in B6 mice, which will lay the ground - work for the further study of different genotypes of rhodopsin Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > Received 21 November 2013 | Accepted 17 September 2014 | Published 19 September 2014© 2014 Molecular Vision 1271Functional and morphological analysis of the subretinal injection  of human retinal progenitor cells under Cyclosporin A treatment Rui Huang,1,2 Petr Baranov,2 Kunbei Lai,1,2 Xinmei Zhang,2 Jian Ge,,1 Michael J. Young2 1Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun Yat-sen University, Guangzhou, China;  2Department of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston, MA Purpose:  The purpose of this study is to evaluate the functional and morphological changes in subretinal xenografts  of human retinal progenitor cells (hRPCs) in B6 mice treated with Cyclosporin A (CsA; 210 mg/l in drinking water).",Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > © 2014 Molecular Vision  1272mice.,Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
"Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > © 2014 Molecular Vision  1273dihydrochloride (DAPI), viewed under fluorescent illumina - tion, and examined with confocal microscopy (Leica SP2,  Leica Microsystems GmbH, Wetzlar, Germany).",Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > © 2014 Molecular Vision  1274bleb formation and retinal detachment due to the delivery of  the transplanted cells into the subretinal space.,Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > © 2014 Molecular Vision  1275 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
"Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > © 2014 Molecular Vision  1276both groups (p =0.04, p = 0.001, for the non-CsA and CsA,  respectively).",Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > © 2014 Molecular Vision  1277potential as a promising cell-based approach for photore - ceptor degeneration [ 20-22].,Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
"Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > © 2014 Molecular Vision  1278suppression in the recipient’s immune response, making it  possible to increase the survival rate after 3 weeks.",Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
"Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > © 2014 Molecular Vision  1279Therefore, improvement in the delivery methods, such as  seeding hRPCs on scaffolds, may cushion the stress placed  on the grafted cells and increase the survival rate.",Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
Molecular Vision  2014; 20:1271-1280 <http://www.molvis.org/molvis/v 20/1271 > © 2014 Molecular Vision  1280primates: Survival and intact retinal function.,Non-OADS,/arxiv_data1/oa_pdf/97/26/mv-v20-1271.PMC4168833.pdf
"Recently, several studies have  reported that TGF-β significantly enhances VEGF secretion, Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > Received 18 March 2014 | Accepted 17 September 2014 | Published 19 September 2014© 2014 Molecular Vision 1258Semaphorin 3A blocks the formation of pathologic choroidal  neovascularization induced by transforming growth factor beta Yujing Bai, Shuting Liang, Wenzhen Yu, Min Zhao, Lvzhen Huang, Mingwei Zhao, Xiaoxin Li (The first two authors contributed equally to this work) Key Laboratory of Vision Loss and Restoration, Ministry of Education; Beijing Key Laboratory for the Diagnosis and Treatment  of Retinal and Choroid Diseases; Department of Ophthalmology, Peking University People’ s Hospital, Beijing, 100044, China Objective:  Choroidal neovascularization (CNV) is a major cause of vision loss in retinal diseases such as age-related  macular degeneration (AMD).",Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
"Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1259vascular permeability, and extracellular matrix remodeling  on its own or in concert with other cytokines, such as tumor  necrosis factor alpha [ 10-13].",Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1260or 500 ng/ml Sema3A or Sema3A and TGF-β1 (10 ng/ml)  was placed in the bottom chamber.,Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
"Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1261electrophoresis (SDS–PAGE) and transferred electrophoreti - cally to polyvinylidene difluoride membranes (PVDF, Amer - sham, Little Chalfont, UK).",Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
"Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1262The numbers of cells that passed through the membrane  in the Sema3A-treated (250 ng/ml and 500 ng/ml) groups  were significantly lower than that in the control group (1%  FBS; Figure 3A,B,D,E, ** p<0.01, *** p<0.0001).",Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
"Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1263either the general culture medium or the TGF-β-containing  medium, and the lengths of the angiogenesis network differed  significantly from those of the controls (Figure 5A, *p<0.05,  ** p<0.01).",Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1264TGF-β was upregulated in the laser-induced CNV mouse  model:  Th e  T G F - β  c o n c e n tr a ti o n  in  th e  r e tin a -c h o r o i d   complexes was measured using ELISA.,Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
"Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1265day 14 after laser-induced CNV, hyperfluorescence leakage  was observed at the lesion sites in the mice.",Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1266 Figure 9.,Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
"Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1267Aflibercept, are used as the standard treatment for nAMD  and have been found to be a valuable adjunctive treatment  strategy for several other vascular retinal diseases [ 28].",Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
"Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  1268fibroblasts become more proliferative, leading to scar tissue  formation, in which collagen remodeling and scar contrac - tion are partially mediated by TGF-β [ 25].",Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  12697.,Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
Molecular Vision  2014; 20:1258-1270 <http://www.molvis.org/molvis/v 20/1258 > © 2014 Molecular Vision  127034.,Non-OADS,/arxiv_data1/oa_pdf/2e/4f/mv-v20-1258.PMC4168834.pdf
"Evidence for a major  gene has been identified for cortical [ 17] and nuclear [ 18,19] Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > Received 15 March 2012 | Accepted 17 September 2014 | Published 19 September 2014© 2014 Molecular Vision 1281Electronic medical records and genomics (eMERGE) network  exploration in cataract: Several new potential susceptibility loci Marylyn D. Ritchie,1 Shefali S. Verma,1 Molly A. Hall,1 Robert J. Goodloe,2 Richard L. Berg,3 Dave S. Carrell,4  Christopher S. Carlson,5 Lin Chen,6 David R. Crosslin,7,8 Joshua C. Denny,9,10 Gail Jarvik,7,11 Rongling Li,12  James G. Linneman,13 Jyoti Pathak,14 Peggy Peissig,13 Luke V .",Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
"Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1282cataract, with heritability estimates of 58% [ 20] and 48%  [21], respectively.",Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1283Table  1.,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
"Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1284Study sample Site Number Number Missing Total Median 4 IQR(25%,75%) (4,5) Range 1.000 - 6.000 Diabetes (p<0.0001) Cases Yes 921 2613 5503 No 1969 Controls Yes 306 323 1894 No 1265 ** Birthdate Year denotes decade of birth where 1=1910, 2=1920, 3=1930, 4=1940, 5=1950, 6=1960",Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1285and correct for population stratification in genome-wide asso - ciation studies.,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1286Table  2. pc aDjusTeD case -con Trol associa Tion analysis  resul Ts.,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1287CHR SNPReference  AlleleCase  MAFOR P value Gene Left Gene Right GeneType of  Variant 1 rs10746432 A 0.4345 0.8413 7.53E-05 HHAT LOC100129235 KCNH1 intron 5 rs160044 T 0.3105 1.232 7.62E-05 MEF2C LOC645323 LOC729011 intron 3 rs1447899 T 0.2838 1.246 0.00008 EIF4E3 FOXP1 GPR27 intron 12 rs4831958 T 0.0711 0.8469 8.04E-05 NA LOC100130336 LOC100131830 NA 4 rs6814129 G 0.4445 1.217 8.11E-05 NA MRPS36P2 LOC644325 NA 9 rs12347205 A 0.3934 1.21 8.47E-05 NA IL6RL1 OR7E31P NA 9 rs951611 T 0.0095 0.8008 9.12E-05 NA LOC286239 LOC401497 NA 1 rs4951508 T 0.2343 0.7486 9.58E-05 HHAT LOC100129235 KCNH1 intron 6 rs9379053 A 0.1076 0.7166 9.65E-05 NA LY86 RP11–320C15.1 NA 20 rs1337906 C 0.3422 1.179 9.84E-05 NA RPL41P1 ST13P NA 9 rs2148996 T 0.4654 0.8493 9.86E-05 NA LOC392358 GAS1 NA 19 rs7247032 T 0.3922 0.7675 9.91E-05 NA LOC100130084 USP29 NA 8 rs4268128 A 0.215 0.6761 9.97E-05 NA TNFRSF10B TNFRSF10C NA,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1288Table  3. pc aDjusTeD aGe-aT-DiaGnosis  associa Tion analysis  resul Ts.,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1289CHR SNPReference  AlleleCase MAF Beta P value Gene Left Gene Right GeneType of  Variant 20 rs6070943 A 0.1765 −0.6294 7.23E-05 PHACTR3 LOC645605 SYCP2 intron 1 rs991007 T 0.1118 0.656 7.26E-05 INADL TM2D1 L1TD1 intron 12 rs12099972 A 0.0821 1.132 7.71E-05 NA LOC100129881 LOC441644 NA 2 rs9309489 A 0.2321 −0.6522 7.86E-05 NA TACR1 FAM176A NA 14 rs1742707 A 0.4406 0.6657 7.97E-05 NA CPSF2 SLC24A4 NA 17 rs9908117 C 0.2586 −0.7235 8.27E-05 NA LOC100128284 WSCD1 NA 9 rs7874443 C 0.3182 −0.6617 8.34E-05 NA GOLM1 LOC100130433 NA 2 rs10195113 T 0.0657 −0.7182 8.41E-05 NA SLC8A1 LOC729984 NA 5 rs1472606 G 0.3331 −0.69 0.000085 NA SFXN1 HRH2 NA 18 rs7227421 G 0.0358 −1.679 9.02E-05 GNAL LOC729602 CHMP1B intron 10 rs4388822 T 0.0717 −0.7606 9.14E-05 NA LOC439992 GRID1 NA 5 rs2277939 A 0.3473 −0.8382 9.34E-05 SAP30L GALNT10 HAND1 intron,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1290 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1291 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
"Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1292set of patient samples has been genotyped on a genome-wide  association platform, those data can be reused for multiple  additional genotype-phenotype association studies.",OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  129318.,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  129443.,Non-OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
2011 Oct 30; Available from: http://www.ncbi.nlm.nih.gov/ pubmed/ 22037903 58.,OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
"Molecular Vision  2014; 20:1281-1295 <http://www.molvis.org/molvis/v 20/1281 > © 2014 Molecular Vision  1295using Biofilter, and gene-environment interactions using the PhenX Toolkit.",OADS,/arxiv_data1/oa_pdf/0d/36/mv-v20-1281.PMC4168835.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/10/d8/opth-8-1845.PMC4168849.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1845–1848Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1845Case repO rtopen access to scientific and medical research Open access Full text article http: //dx.doi.org/ 10.2147/OPTH.S6688 6Bilateral macular infarction as an ocular  manifestation of systemic lupus erythematosus (sLe) Chih-Ling Hu Kai-Ling peng Department of Ophthalmology, Chi  Mei Medical Center, tainan, taiwan,   republic of ChinaAbstract:  We report a rare case of bilateral macular infarction as an ocular presenting sign of  systemic lupus erythematosus (SLE).",Non-OADS,/arxiv_data1/oa_pdf/10/d8/opth-8-1845.PMC4168849.pdf
"According to the Correspondence: Kai-Ling peng   Department of Ophthalmology, Chi Mei  Medical Center, 901 Zhonghua road,  Yongkang District, tainan, taiwan 710,  republic of China   tel +886 6 281 2811 ext 57247   email caropkl65@gmail.co mJournal name: Clinical Ophthalmology Journal Designation: Case report Y ear: 2014 Volume: 8 Running head verso: Hu and Peng Running head recto: Bilateral macular infarction, systemic lupus erythematosus DOI: http://dx.doi.org/10.2147/OPTH.S66886",Non-OADS,/arxiv_data1/oa_pdf/10/d8/opth-8-1845.PMC4168849.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journalClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/10/d8/opth-8-1845.PMC4168849.pdf
"Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.Dove pres s Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.co m Dove press Dove press 1848Hu and p eng From our case, the perivascular hard exudation of both  eyes was partially resolved, with anti-dsDNA decreasing after  pulse therapy.",Non-OADS,/arxiv_data1/oa_pdf/10/d8/opth-8-1845.PMC4168849.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b1/97/ppa-8-1215.PMC4168850.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 1215–1221Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1215Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/PPA.S6961 9exploring motivations to seek and undergo  prosthodontic care: an empirical approach using  the Theory of Planned Behavior construct Antonio Hélio vieira Cláudio Rodrigues Leles Department of Prevention and Oral  Rehabilitation, School of Dentistry,  Federal University of Goias, Goiania,  Goias, BrazilAbstract:  Motivations for seeking and undergoing prosthodontic care are poorly understood and  are not often explored for clinical purposes when determining treatment need and understanding  the factors related to the demand for health care and effective use.",Non-OADS,/arxiv_data1/oa_pdf/b1/97/ppa-8-1215.PMC4168850.pdf
"Indeed, Correspondence: Cláudio Rodrigues  Leles Faculdade de Odontologia, Universidade  Federal de Goiás, Praça Universitária, s/n,  Setor Universitário, Goiânia, Goiás CeP  74.605-220, Brasil Tel +55 062 32096052 Fax +55 062 32096051 email claudio_leles@ufg.b r Journal name: Patient Preference and Adherence Journal Designation: Review Y ear: 2014 Volume: 8 Running head verso: Vieira and Leles Running head recto: Motivations to seek and undergo prosthodontic care DOI: http://dx.doi.org/10.2147/PPA.S69619",Non-OADS,/arxiv_data1/oa_pdf/b1/97/ppa-8-1215.PMC4168850.pdf
Available  from: http://www.dentalhealth.org/tell-me-about.,Non-OADS,/arxiv_data1/oa_pdf/b1/97/ppa-8-1215.PMC4168850.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/b1/97/ppa-8-1215.PMC4168850.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f9/e4/cmar-6-357.PMC4168851.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpCancer Management and Research 2014:6 357–363Cancer Management and Research Dove press submit your manuscript | www.dovepress.co m Dove press  357Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CMAR.S4723 8Dexrazoxane for the treatment of chemotherapy- related side effects Seppo w Langer Thoracic and Neuroendocrine  Section, Department of Oncology,   Copenhagen University Hospital,   Copenhagen, Denmark Correspondence: Seppo w Langer   Thoracic and Neuroendocrine Section,  Department of Oncology 5073,  Copenhagen University Hospital,  Rigshospitalet Blegdamsvej 9, DK-2100  Copenhagen, Denmark   email seppo.langer@regionh.d kAbstract:  For more than half a century, the different properties of dexrazoxane have captured  the attention of scientists and clinicians.",Non-OADS,/arxiv_data1/oa_pdf/f9/e4/cmar-6-357.PMC4168851.pdf
"Cancer Management and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/cancer-management-and-research-journa lCancer Management and Research is an international, peer-reviewed  open access journal focusing on cancer research and the optimal use of  preventative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/f9/e4/cmar-6-357.PMC4168851.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f9/e4/cmar-6-357.PMC4168851.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/78/48/copd-9-975.PMC4168852.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of COPD 2014:9 975–981International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  975OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S6356 8Systemic and pulmonary inflammation is   independent of skeletal muscle changes in patients   with chronic obstructive pulmonary disease Bethan l Barker1 susan McKenna1 Vijay Mistry1 Mitesh Pancholi1 hemu Patel2 Koirobi haldar3 Michael r Barer3 Ian D Pavord4 Michael C steiner1 Christopher e Brightling1 Mona Bafadhel4 1Institute for lung health, nIhr  respiratory Biomedical research Unit,   Department of Infection, Immunity  and Inflammation, University of  leicester, leicester, United Kingdom;   2Department of Clinical Microbiology,   University hospitals of leicester nhs   Trust, leicester, United Kingdom;   3Department of Infection, Immunity,   and Inflammation, University of  leicester, leicester, United Kingdom;   4respiratory Medicine Unit, nuffield  Department of Clinical Medicine,   University of Oxford, Old road  Campus, Oxford, United Kingdom Correspondence: Mona Bafadhel   respiratory Medicine Unit, nDM  Research Building, Nuffield Department  of Clinical Medicine, Old road Campus,  headington, Oxford, OX3 7FZ, UK   Tel +44 186 561 2898  email mona.bafadhel@ndm.ox.ac.u kBackground:  Nutritional depletion is an important manifestation of chronic obstructive   pulmonary disease (COPD), which has been related to systemic inflammation.",Non-OADS,/arxiv_data1/oa_pdf/78/48/copd-9-975.PMC4168852.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/78/48/copd-9-975.PMC4168852.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/78/48/copd-9-975.PMC4168852.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/85/a8/opth-8-1837.PMC4168853.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1837–1844Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1837Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/OPTH.S6761 9Favorable anatomic and visual outcomes with  25-gauge vitrectomy for myopic foveoschisis Mei Mii Masato Matsuoka Kayako Matsuyama Yayoi Otsu T etsuya nishimura Department of Ophthalmology, Kansai  Medical University, Takii hospital,   Osaka, JapanPurpose:  To report the surgical outcomes of 25-gauge vitrectomy in eyes with myopic  foveoschisis (MF).",Non-OADS,/arxiv_data1/oa_pdf/85/a8/opth-8-1837.PMC4168853.pdf
"The advantages of minimally invasive vitreous surgery are that no wound  suture is required because of the smaller incision size, less inflammation, less patient Correspondence: Masato Matsuoka   Department of Ophthalmology, Kansai  Medical University, 10-15 Fumizono-cho,  Moriguchi, Osaka 570-8507, Japan   Tel +81 6 6992 1001, ext 3322   Fax +81 6 6992 8263   email matsuokm@takii.kmu.ac.j pJournal name: Clinical Ophthalmology Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Mii et al Running head recto: Vitrectomy for myopic foveoschisis DOI: http://dx.doi.org/10.2147/OPTH.S67619",Non-OADS,/arxiv_data1/oa_pdf/85/a8/opth-8-1837.PMC4168853.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journalClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/85/a8/opth-8-1837.PMC4168853.pdf
Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.Dove pres s Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.co m Dove press Dove press 1844Mii et al,Non-OADS,/arxiv_data1/oa_pdf/85/a8/opth-8-1837.PMC4168853.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ba/b9/cia-9-1527.PMC4168854.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 1527–1537Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1527OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S6855 7Mariana g Figueiro1 Barbara A Plitnick1 Anna lok1 geoffrey e Jones1 Patricia higgins2,3 Thomas r hornick3,4 Mark s rea1 1lighting research Center, rensselaer  Polytechnic Institute, Troy, nY,   UsA; 2school of n ursing, 3school  of Medicine, Case Western reserve  University, 4geriatric research  education and Clinical Center, louis  stokes Cleveland Veterans Affairs  Medical Center, Cleveland, Oh, UsA Correspondence: Mariana g Figueiro   lighting research Center, rensselaer  Polytechnic Institute, 21 Union street,  3rd floor, Troy, NY 12180 USA   T el +1 518 687 7100   Fax +1 518 687 7120   email figuem@rpi.ed u Tailored lighting intervention improves measures  of sleep, depression, and agitation in persons   with Alzheimer’s disease and related dementia  living in long-term care facilities Background:  Light therapy has shown great promise as a nonpharmacological method to  improve symptoms associated with Alzheimer’s disease and related dementias (ADRD), with  preliminary studies demonstrating that appropriately timed light exposure can improve night - time sleep efficiency, reduce nocturnal wandering, and alleviate evening agitation.",Non-OADS,/arxiv_data1/oa_pdf/ba/b9/cia-9-1527.PMC4168854.pdf
"Keywords:  sleep disorders, light therapy, circadian rhythms, ADRD Introduction Alzheimer’s disease and related dementia (ADRD) is the most common mental disorder  diagnosed in elderly Americans, with an estimated 5.1 million people affected in 2010.1  Behavioral symptoms, such as disturbed sleep–wake patterns, nocturnal wandering,  agitation, and physical or verbal abuse, are among the most prevalent reasons that  individuals with ADRD transition to more controlled environments.Journal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Figueiro et al Running head recto: Tailored lighting intervention improves behavior in ADRD patients DOI: http://dx.doi.org/10.2147/CIA.S68557",Non-OADS,/arxiv_data1/oa_pdf/ba/b9/cia-9-1527.PMC4168854.pdf
Available from: http://www.nia.nih.,Non-OADS,/arxiv_data1/oa_pdf/ba/b9/cia-9-1527.PMC4168854.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/ba/b9/cia-9-1527.PMC4168854.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/ba/b9/cia-9-1527.PMC4168854.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/56/a4/ott-7-1601.PMC4168855.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 1601–1608OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1601Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6721 7Upregulation of micro-ribonucleic acid-128   cooperating with downregulation of PTen   confers metastatic potential and unfavorable  prognosis in patients with primary osteosarcoma Zheng Tian1,* Bin guo2,* Mei Yu3 chong Wang1 haoshaqiang Zhang4 Qingfu liang1 Kunli Jiang1 li cao5 1Bone neoplasms Department,   First affiliated hospital of Xinjiang  Medical University,  2Orthopedics  Department, central hospital,   3Ophthalmology Department, First  affiliated hospital of Xinjiang Medical  University,  4Orthopedics Department,   People’s hospital of Xinjiang Uygur  autonomous region,  5Department of  Joint surgery, First affiliated hospital  of Xinjiang Medical University,   Urumqi, People’s republic of china *These authors contributed equally to  this work correspondence: li cao   Department of Joint surgery,   First Affiliated Hospital of Xinjiang   Medical University,  137 liyushan   south road, Urumqi, Xinjiang  830054,   People’s republic of china   Tel +86 991 436 3406  Fax +86 991 436 3406  email tz4363406@126.co mObjective:  Abnormal expression of micro-ribonucleic acid (miRNA [miR])-128 has been  observed in various human cancer types, and its validated target genes are implicated in cancer- related cellular processes, such as cell proliferation, differentiation, and apoptosis.",Non-OADS,/arxiv_data1/oa_pdf/56/a4/ott-7-1601.PMC4168855.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/56/a4/ott-7-1601.PMC4168855.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/56/a4/ott-7-1601.PMC4168855.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5d/64/ceor-6-381.PMC4168856.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinicoEconomics and Outcomes Research 2014:6 381–388ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  381ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S6144 5Cost of tumor necrosis factor blockers   per patient with rheumatoid arthritis   in a multistate Medicaid population Machaon Bonafede1 george J Joseph2 neel shah2 nicole Princic1 David J harrison2 1Truven health analytics,    Cambridge, M a, 2amgen inc.,    Thousand Oaks, C a, Usa Correspondence: Machaon Bonafede   Truven health analytics,  77 Rowell Rd E,   Brentwood, nh  03833, Usa   Tel +1 603 580 5587  Fax +1 202 719 7801  Email machaon.bonafede@truvenhealth.",Non-OADS,/arxiv_data1/oa_pdf/5d/64/ceor-6-381.PMC4168856.pdf
Available from: http://www.cdc.gov/arthritis/basics/rheumatoid.htm.,Non-OADS,/arxiv_data1/oa_pdf/5d/64/ceor-6-381.PMC4168856.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/5d/64/ceor-6-381.PMC4168856.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/5d/64/ceor-6-381.PMC4168856.pdf
"Available from: http://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/PhysicianFeeSche d. Accessed   June 3, 2014.",Non-OADS,/arxiv_data1/oa_pdf/5d/64/ceor-6-381.PMC4168856.pdf
Available from: http://www.acog.,Non-OADS,/arxiv_data1/oa_pdf/5d/64/ceor-6-381.PMC4168856.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/89/3d/opth-8-1745.PMC4168860.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1745–1755Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1745Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S6773 0subconjunctival bevacizumab to augment  trabeculectomy with mitomycin C in the  management of failed glaucoma surgery  Correspondence: ahmed M saeed el-sherif Tower, 33rd el-horreya st,   el-Qanatir el-Khairiya, 13621,  al-Qalyubiyah, egypt Tel +20 122 746 8426 email a-saeed775@yahoo.co mahmed M saeed Tarek Tawfeek abouln asr Ophthalmology Department, Benha  University, egyptJournal name: Clinical Ophthalmology Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Saeed and AboulNasr Running head recto: Bevacizumab-augmented trabeculectomy DOI: http://dx.doi.org/10.2147/OPTH.S67730 Purpose:  To provide a feasible solution to the problem of failed glaucoma surgery.",Non-OADS,/arxiv_data1/oa_pdf/89/3d/opth-8-1745.PMC4168860.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/89/3d/opth-8-1745.PMC4168860.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.co m Dove press Dove press 1755Bevacizumab-augmented trabeculectomy  9.,Non-OADS,/arxiv_data1/oa_pdf/89/3d/opth-8-1745.PMC4168860.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/aa/e9/ccid-7-251.PMC4168861.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical, Cosmetic and Investigational Dermatology 2014:7 251–259Clinical, Cosmetic and Investigational Dermatology Dove press submit your manuscript | www.dovepress.co m Dove press  251RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CCID.S6753 4Targeting of interleukin-17 in the treatment   of psoriasis Ann Sophie Lønnberg Claus Zachariae Lone Skov Department of Dermato-Allergology,   Gentofte Hospital, University of  Copenhagen, Hellerup, Denmark Correspondence: Ann Sophie Lønnberg   Department of Dermato-Allergology,   Gentofte Hospital, Niels Andersens vej  65, DK-2900 Hellerup, Denmark   Tel +45 2814 0184  email ann_sophie_l@hotmail.co mAbstract:  “Psoriasis” is a chronic immune-mediated inflammatory disorder with epidermal  hyperplasia.",Non-OADS,/arxiv_data1/oa_pdf/aa/e9/ccid-7-251.PMC4168861.pdf
"Clinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journa lClinical, Cosmetic and Investigational Dermatology is an interna - tional, peer-reviewed, open access, online journal that focuses on  the latest clinical and experimental research in all aspects of skin  disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/aa/e9/ccid-7-251.PMC4168861.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/aa/e9/ccid-7-251.PMC4168861.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/94/97/imcrj-7-133.PMC4168866.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Medical Case Reports Journal 2014:7 133–137International Medical Case Reports Journal Dove press submit your manuscript | www.dovepress.co m Dove press  133Case Repo Rtopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/IMCRJ.S6720 3another cause of chest pain: Staphylococcus aureus   sternal osteomyelitis in an otherwise healthy adult thomas p Vacek shahnaz Rehman shipeng Yu ankush Moza Ragheb assaly  Department of Internal Medicine,    the University of toledo Medical  Center, toledo oH, Usa Correspondence: tp Vacek   Department of Internal Medicine,   the University of toledo Medical   Center,  3000 arlington ave, toledo,   oH 43614, Usa   email tpvace01@gmail.co mAbstract:  Chest pain requires a detailed differential diagnosis with good history-taking skills to  differentiate between cardiogenic and noncardiogenic causes.",Non-OADS,/arxiv_data1/oa_pdf/94/97/imcrj-7-133.PMC4168866.pdf
"International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-medical-case-reports-journal-journa lThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports  from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/94/97/imcrj-7-133.PMC4168866.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/94/97/imcrj-7-133.PMC4168866.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/.,Non-OADS,/arxiv_data1/oa_pdf/d7/70/jpr-7-555.PMC4168867.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Pain Research 2014:7 555–556Journal of Pain Research Dove press submit your manuscript | www.dovepress.com Dove press 555LetteRopen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/JPR.S7129 2Chronic pain, social withdrawal, and depression Rebecca Arden Harris Department of Family and Social  Medicine, Montefiore Medical Center/ Albert einstein College of Medicine,   Bronx, NY, USA Correspondence: Rebecca Arden Harris   Department of Family and Social  Medicine, Montefiore Medical Center/ Albert einstein College of Medicine,  Bronx, New Y ork, NY, USA   email rebecca.arden.harris@gmail.co mWallace et al1 used an effective combination of qualitative methods, ie, photographs  taken by patients with accompanying narratives, interviews, and focus group sessions,  to elicit descriptions of the daily realities of living with chronic pain from the patient  perspective.",Non-OADS,/arxiv_data1/oa_pdf/d7/70/jpr-7-555.PMC4168867.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journalThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/d7/70/jpr-7-555.PMC4168867.pdf
Visit  http://www.dovepress.com/testimonials.php to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d7/70/jpr-7-555.PMC4168867.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Multidisciplinary Healthcare 2014:7 389–400Journal of Multidisciplinary Healthcare Dove press submit your manuscript | www.dovepress.co m Dove press  389Original researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JMDH.S6734 8implementation of evidence-based stroke care:  enablers, barriers, and the role of facilitators Tara Purvis1,2 Karen Moss2 sonia Denisenko3  chris Bladin2,5 Dominique a cadilhac1,2,4 1Translational Public Health Unit,   stroke and ageing research centre,   Department of Medicine, Monash  Medical centre, school of clinical  sciences at Monash Health, Monash  University, clayton, Vic , australia;   2stroke Division, Florey institute of  neuroscience and Mental Health,   Melbourne Brain centre, Heidelberg,   Vic, australia; 3commission for  Hospital improvement, Department  of Health Victoria, Vic , australia;   4Department of Medicine, University  of Melbourne, Parkville, Vic , australia;   5eastern Health clinical school,   Monash University, Box Hill, Vic ,   australia correspondence: Dominique a cadilhac   level 1/43–51 Kanooka grove clayton,  Vic 3168, australia   Tel +61 3 9594 7583   Fax +61 3 9594 6258   email dominique.cadilhac@monash.ed uAbstract:  A stroke care strategy was developed in 2007 to improve stroke services in Victoria,  Australia.",Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
Available from: http://www.aihw.,Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
"Available from: http://strokefoundation.com.au/site/media/ NSF687.ClinicalServicesAudit2013.Final_.pd f. Accessed March 11,  2014.",Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
"Available from:  http://docs.health.vic.gov.au/docs/doc/63C0F126DF44F8BDCA257 981000511B0/$FILE/stroke_care_strategy.pd f. Accessed March 11,  2014.",Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
Available from: http://www.aihw.,Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
"Available from: http://www.nhmrc.gov.au/_files_nhmrc/ publications/attachments/e46.pd f. Accessed March 11, 2014.",Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
"Journal of Multidisciplinary Healthcare Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-multidisciplinary-healthcare-journa lThe Journal of Multidisciplinary Healthcare is an international, peer- reviewed open-access journal that aims to represent and publish research  in healthcare areas delivered by practitioners of different disciplines.",Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
Visit http://www.dove - press.com/testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
"Available from: http://strokefoundation.com.au/ site/media/Clinical_Guidelines_Acute_Management_Recommenda - tions_2010.pd f. Accessed March 12, 2013.",Non-OADS,/arxiv_data1/oa_pdf/3d/f6/jmdh-7-389.PMC4168868.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/df/8f/ijn-9-4317.PMC4168869.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4317–4330International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4317OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S6868 5Overendocytosis of gold nanoparticles increases  autophagy and apoptosis in hypoxic human renal  proximal tubular cells Fengan Ding1 Yiping li1 Jing liu1 lei liu1 Wenmin Yu1 Zhi Wang1 haifeng Ni2 Bicheng liu2 Pingsheng chen1,2 1school of Medicine, southeast  University, Nanjing, People’s republic  of china; 2Institute of Nephrology, The  affiliated Zhongda hospital, southeast  University, Nanjing, People’s republic  of chinaBackground:  Gold nanoparticles (GNPs) can potentially be used in biomedical fields ranging  from therapeutics to diagnostics, and their use will result in increased human exposure.",Non-OADS,/arxiv_data1/oa_pdf/df/8f/ijn-9-4317.PMC4168869.pdf
"These extraordinary features have made them  to be widely applied in biomedicine for diagnostic and therapeutic purposes in the  recent past, particularly for biosensors, biomarkers, molecular imaging, photothermal  therapy, and targeted delivery of drugs and antigens.1,2 Due to the rapid development  of GNP applications, human safety concerns are gaining increased attention, which  makes it necessary to better understand the biodistribution and circulation of GNPs in correspondence: Pingsheng chen school of Medicine, southeast University,  Nanjing, 210009, People’s republic  of china Tel +86 25 8327 2507 Fax +86 25 8379 0575 email chenpsh@sina.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Ding et al Running head recto: Overendocytosis of GNPs increases autophagy, apoptosis in hypoxic HK-2 DOI: http://dx.doi.org/10.2147/IJN.S6868 5",Non-OADS,/arxiv_data1/oa_pdf/df/8f/ijn-9-4317.PMC4168869.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/df/8f/ijn-9-4317.PMC4168869.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/df/8f/ijn-9-4317.PMC4168869.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d5/d7/mder-7-305.PMC4168870.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pMedical Devices: Evidence and Research 2014:7 305–318Medical Devices: Evidence and Research Dove press submit your manuscript | www.dovepress.co m Dove press  305REviEwopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S6733 8Surgical stapling device–tissue interactions:   what surgeons need to know to improve   patient outcomes Edward Chekan1 Richard L whelan2 1Ethicon inc., Cincinnati, OH, USA;    2St Luke’s Roosevelt Hospital,    New Y ork, NY, USA Correspondence: Edward Chekan   Ethicon inc.,  4545 Creek Road,   Cincinnati, OH  45242, USA   Tel +1 513 337 8160  Fax +1 513 337 2780  Email edchekan@its.jnj.co mAbstract:  The introduction of both new surgical devices and reengineered existing devices  leads to modifications in the way traditional tasks are carried out and allows for the develop - ment of new surgical techniques.",Non-OADS,/arxiv_data1/oa_pdf/d5/d7/mder-7-305.PMC4168870.pdf
Available from: http://www.sages.org/meetings/ annual-meeting/abstracts-archive/impact-of-gastro-jejunostomy- diameter-on-complications-and-weight-loss-after-roux-en-y-gastric- bypass-over-a-5-year-period /.,Non-OADS,/arxiv_data1/oa_pdf/d5/d7/mder-7-305.PMC4168870.pdf
"Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/medical-devices-evidence-and-research-journa lMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology,  research, and expert opinion supporting the use and application of  medical devices in the diagnosis, treatment and management of clini - cal conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/d5/d7/mder-7-305.PMC4168870.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b6/b4/ndt-10-1743.PMC4168871.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1743–1751Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1743Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/NDT .S6844 3Cognitive assessments for the early diagnosis  of dementia after stroke Noor Kamal Al-Qazzaz1,2 Sawal Hamid Ali1 Siti Anom Ahmad3 Shabiul islam4 1Department of electrical, electronic  and Systems engineering, Faculty of  engineering and Built environment,   Universiti Kebangsaan Malaysia (UKM),   Bangi, Selangor, Malaysia; 2Department  of Biomedical engineering,   Al-Khwarizmi College of engineering,   Baghdad University, Baghdad, iraq;  3Department of electrical and  electronic engineering, Faculty of  engineering, Universiti Putra Malaysia  (UPM), Serdang, Selangor, Malaysia;   4institute of Microengineering and  Nanoelectronics (iM eN), UKM, Bangi,   Selangor, MalaysiaAbstract:  The early detection of poststroke dementia (PSD) is important for medical practi - tioners to customize patient treatment programs based on cognitive consequences and disease  severity progression.",Non-OADS,/arxiv_data1/oa_pdf/b6/b4/ndt-10-1743.PMC4168871.pdf
"Stroke survivors more prone to develop dementia, of which 20%–25%  are diagnosed with vascular dementia (VaD), approximately 30% with degenera - tive dementia (particularly AD), and 10%–15% with a combination of AD and VaD  (mixed dementia).4–6 Approximately 1%–4% of elderly people aged 65 years suffer  from VaD, and the prevalence doubles every 5–10 years after this age.5,7 However,  cognitive impairment and dementia following a stroke diagnosis may involve multiple  functions, and the most affected domains are attention, executive function, memory,  visuospatial ability, and language, as shown in Table 1.1,8,9Correspondence: Noor Kamal Al-Qazzaz Department of electrical, electronic  and Systems engineering, Faculty of  engineering and Built environment,  Universiti Kebangsaan Malaysia, UKM,  Bangi, Selangor 43600, Malaysia email noorbmemsc@siswa.ukm.edu.m y Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2014 Volume: 10 Running head verso: Al-Qazzaz et al Running head recto: Early diagnosis of dementia after stroke DOI: http://dx.doi.org/10.2147/NDT.S68443",Non-OADS,/arxiv_data1/oa_pdf/b6/b4/ndt-10-1743.PMC4168871.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/b6/b4/ndt-10-1743.PMC4168871.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/b6/b4/ndt-10-1743.PMC4168871.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e9/db/ndt-10-1727.PMC4168872.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1727–1742Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1727Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/NDT .S6525 7Y okukan-san: a review of the evidence for use   of this Kampo herbal formula in dementia   and psychiatric conditions Hideki Okamoto1,2 Masaomi iyo2 Keigo Ueda1 Cheolsun Han1 Y oshiro Hirasaki1 Takao Namiki1 1Department of Japanese-Oriental  (Kampo) Medicine, 2Department of  Psychiatry, Chiba University Graduate  School of Medicine, Chiba City, Japan Correspondence: Hideki Okamoto   Department of Japanese-Oriental  (Kampo) Medicine, Chiba University  Graduate School of Medicine,   1-8-1 inohana, Chuo-ku, Chiba-shi,   Chiba 260-8670, Japan   T el +81 43 226 2984   Fax +81 43 226 2985   email bon@sa2.so-net.ne.j pJournal name: Neuropsychiatric Disease and Treatment Journal Designation: Review Y ear: 2014 Volume: 10 Running head verso: Okamoto et al Running head recto: A review of the evidence for use of Y okukan-san DOI: http://dx.doi.org/10.2147/NDT.S65257 Abstract:  Japanese traditional herbal medicine (Kampo) has its origins in traditional   Chinese medicine (TCM).",Non-OADS,/arxiv_data1/oa_pdf/e9/db/ndt-10-1727.PMC4168872.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/e9/db/ndt-10-1727.PMC4168872.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1742Okamoto et al  67.,Non-OADS,/arxiv_data1/oa_pdf/e9/db/ndt-10-1727.PMC4168872.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/6d/1d/ijn-9-4347.PMC4168873.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4347–4355International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4347OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/IJN.S6652 6Biodegradable drug-eluting nanofiber-enveloped  implants for sustained release of high bactericidal  concentrations of vancomycin and ceftazidime:   in vitro and in vivo studies correspondence: shih-Jung liu   Biomaterials lab, Mechanical   engineering, chang gung University,   259 Wen-hwa 1st road, Kwei-san,   Tao-Yuan 333, Taiwan   email shihjung@mail.cgu.edu.t wYung-heng hsu1,2 Dave Wei-chih chen1 chun-Der Tai3 Ying-chao chou1,2 shih-Jung liu2 steve Wen-Neng Ueng1 err-cheng chan4 1Department of Orthopedic surgery,   chang gung Memorial hospital,   guishan T ownship, 2Department  of Mechanical engineering, chang  gung University, guishan T ownship,   3graduate Institute of Medical  Mechatronics, chang gung University,   guishan T ownship, 4school of Medical  T echnology, chang gung University,   guishan T ownship, TaiwanJournal name: International Journal of Nanomedicine Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Hsu et al Running head recto: Antibiotic-eluting nanofiber-enveloped implants DOI: http://dx.doi.org/10.2147/IJN.S66526 Abstract:  We developed biodegradable drug-eluting nanofiber-enveloped implants that  provided sustained release of vancomycin and ceftazidime.",Non-OADS,/arxiv_data1/oa_pdf/6d/1d/ijn-9-4347.PMC4168873.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/6d/1d/ijn-9-4347.PMC4168873.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.co m Dove press Dove press 4355Antibiotic-eluting nanofiber-enveloped implants Acknowledgments The authors would like to thank the National Science  Council of Taiwan (Contract no.,Non-OADS,/arxiv_data1/oa_pdf/6d/1d/ijn-9-4347.PMC4168873.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ed/a0/oajsm-5-215.PMC4168877.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOpen Access Journal of Sports Medicine 2014:5 215–221Open Access Journal of Sports Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  215OriginAl reSeArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/OAJSM.S6407 8Rate of injury and subjective benefits   of gravitational wellness weightlifting David T Burke1 regina Bell1 Samir Al-Adawi2 Ariel Alexandroni1 Atsu Dorvlo3 Daniel P Burke4 1emory University School of Medicine,   Atlanta, emory University, gA, USA;   2Department of Behavioral Medicine,   college of Medicine and health  Sciences,  3Department of Mathematics  and Statistics, college of Science,   Sultan Qaboos University, Muscat,   Oman;  4georgia college and State  University, Milledgeville, gA, USA correspondence: David T Burke   emory University School of Medicine,   1441 clifton road, Atlanta,   gA 30322, USA   email db urke2@ emory.ed uBackground:  A preliminary study using the “gravitational wellness” weightlifting technique  demonstrated this to be a unique technique for loading the musculoskeletal system with extremely  high loads over short arcs.",Non-OADS,/arxiv_data1/oa_pdf/ed/a0/oajsm-5-215.PMC4168877.pdf
Available from: http://www.cdc.gov/nchs/fastats/obesity-overweight.,Non-OADS,/arxiv_data1/oa_pdf/ed/a0/oajsm-5-215.PMC4168877.pdf
"Open Access Journal of Sports Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/open-access-journal-of-sports-medicine-journa lOpen Access Journal of Sports Medicine is an international,  peer-reviewed, open access journal publishing original research,  reports, reviews and commentaries on all areas of sports  medicine.",Non-OADS,/arxiv_data1/oa_pdf/ed/a0/oajsm-5-215.PMC4168877.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ed/a0/oajsm-5-215.PMC4168877.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/24/f8/ndt-10-1763.PMC4168879.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1763–1767Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1763Case Repo RTopen access to scientific and medical research open access Full T ext article http: //dx.doi.org/ 10.2147/NDT .S7061 1Nobumasa ohara1  Hiroshi suzuki1  akiko suzuki1  Masanori Kaneko1  Masahiro Ishizawa1  Kazuo Furukawa1  Takahiro abe1  Yasuhiro Matsubayashi1  Takaho Yamada1  osamu Hanyu1  Takayoshi shimohata2 Hirohito sone1 1Department of Hematology,  endocrinology and Metabolism,  Faculty of Medicine, Niigata  University, Niigata, Japan;  2Department of Neurology, Brain  Research Institute, Niigata University,  Niigata, Japan Correspondence: Nobumasa ohara Department of Hematology,  endocrinology and Metabolism,  Faculty of Medicine, Niigata University,  1-757 asahimachi-dori, Chuo-ku,   Niigata 951-8510, Japan Tel +81 25 368 9026 Fax +81 25 368 9300 email oharan@med.niigata-u.ac.j p Reversible brain atrophy and cognitive impairment  in an adolescent Japanese patient with primary  adrenal Cushing’s syndrome Abstract:  Endogenous Cushing’s syndrome is an endocrine disease resulting from chronic  exposure to excessive glucocorticoids produced in the adrenal cortex.",Non-OADS,/arxiv_data1/oa_pdf/24/f8/ndt-10-1763.PMC4168879.pdf
"Studies have shown that many patients with  Cushing’s syndrome present with cognitive or psychological alterations.1,2,4 Further - more, several studies confirmed the occurrence of diffuse brain atrophy associated with  cognitive impairment in both children and adults with all types of Cushing’s syndrome.5−9  Journal name: Neuropsychiatric Disease and Treatment Journal Designation: Case Report Y ear: 2014 Volume: 10 Running head verso: Ohara et al Running head recto: Brain atrophy in Cushing’s syndrome DOI: http://dx.doi.org/10.2147/NDT.S70611",Non-OADS,/arxiv_data1/oa_pdf/24/f8/ndt-10-1763.PMC4168879.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/24/f8/ndt-10-1763.PMC4168879.pdf
"Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1767Brain atrophy in Cushing’s syndrome The pathogenesis of brain atrophy in Cushing’s syndrome  is thought to be multifactorial, and possible explanations  include loss of water content in brain tissue, catabolic effects  on proteins, reduction in glucose metabolism, synaptic  accumulation of glutamate, or neuronal cell death.6,9,15 The  present case did not provide information about the precise  mechanisms.",Non-OADS,/arxiv_data1/oa_pdf/24/f8/ndt-10-1763.PMC4168879.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/dd/4d/ijn-9-4331.PMC4168883.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4331–4346International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4331OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/IJN.S6540 8Journal name: International Journal of Nanomedicine Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Mahmood et al Running head recto: Raloxifene HCl-loaded nanotransfersomes for transdermal application DOI: http://dx.doi.org/10.2147/IJN.S65408 experimental design and optimization of raloxifene  hydrochloride loaded nanotransfersomes  for transdermal application syed Mahmood Muhammad Taher Uttam Kumar Mandal Department of Pharmaceutical  T echnology,  Kulliyyah of Pharmacy,   International Islamic University  Malaysia (IIUM), Pahang Darul  Makmur, Malaysia correspondence: Uttam Kumar Mandal   Department of Pharmaceutical  Technology, Kulliyyah of Pharmacy,   International Islamic University Malaysia,  Jalan sultan ahmad shah, Bandar Indera  Mahkota, 25200, Kuantan, Pahang Darul  Makmur, Malaysia   Tel +60 9571 4850   Fax +60 9571 6775   email mandalju2007@gmail.co m Abstract:  Raloxifene hydrochloride, a highly effective drug for the treatment of invasive  breast cancer and osteoporosis in post-menopausal women, shows poor oral bioavailability of  2%.",Non-OADS,/arxiv_data1/oa_pdf/dd/4d/ijn-9-4331.PMC4168883.pdf
"International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.co m Dove press Dove press International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/dd/4d/ijn-9-4331.PMC4168883.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s 4346Mahmood et al  26.,Non-OADS,/arxiv_data1/oa_pdf/dd/4d/ijn-9-4331.PMC4168883.pdf
"Submitted: 05/17/2014; Revised: 07/30/2014; Accepted: 08/04/2014; Published Online: 08/11/2014http://dx.doi.org/10.4161/epi.32252A pilot examination of the genome-wide DNA  methylation signatures of subjects entering   and exiting short-term alcohol dependence  treatment programs Robert a  Philibert1,2,*, Brandan Penaluna2, Teresa White2, Sarah Shires2, Tracy Gunter3, Jill Liesveld2, cheryl Erwin4,   Nancy h ollenbeck2, and Terry Osborn1 1Behavioral Diagnostics; Iowa c ity, I a US a; 2Department of Psychiatry; University of Iowa; Iowa c ity, I a US a; 3Department of Psychiatry; Indiana University School of Medicine;  Indianapolis, IN US a; 4Departments of Medical Education and Psychiatry; Texas Tech University h ealth Sciences c enter; Lubbock, TX US a Keywords:  Alcohol, DNA Methylation, Smoking, Abstinence alcoholism has a profound impact on millions of people throughout the world.",Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Am J Prev Med  2011; 41:516-24;  PMID:22011424 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Curr Pharm Des 2011;  17:1323-32;  PMID :21524263 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Neuropsychobiology  2006; 54:100-6;  PMID:17108710 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Am J Med Genet B Neuropsychiatr Genet 2012; 159B:141- 51; PMID:22232023 ; http://dx.doi.org/10.1002/ ajmg.b.32021 11.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Epigenetics  2012; 7:1331-8;  PMID:23070629 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
BMC Genomics  2014 ; 15:151;  PMID:24559495 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Environ Health Perspect 2012; 120:1425-31;  PMID:22851337 ; http://dx.doi.org/10.1289/ ehp.1205412 17.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Front  Genet 2012; 3:54; PMID:22514556 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Am J Med Genet B Neuropsychiatr Genet  2008; 147B:543-9;  PMID:17987668 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Am J Med Genet B Neuropsychiatr Genet 2008; 147B:565- 70; PMID:18454435 ; http://dx.doi.org/10.1002/ ajmg.b.30778 21.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Neuroreport  2005; 16:167-70;  PMID:15671870 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Cancer 2004; 101:125-32;  PMID:15221997 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Nat Rev Genet 2012; 13:705-19;  PMID:22986265 ; http://dx.doi.org/10.1038/ nrg3273 27.,OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Gastroenterology 2003; 124:1488-99;  PMID:12730887 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Alcohol  Clin Exp Res 2001; 25:726-33; PMID:11371722 ;  http://dx.doi.org/10.1111/j.1530-0277.2001.tb02273.x 31.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Biochemistry 2007; 46:4348-59;  PMID:17371052 ;  http://dx.doi.org/10.1021/bi700091r 32.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Drug  Metab Dispos 2007; 35:2262-9; PMID:17890447 ;  http://dx.doi.org/10.1124/dmd.107.016253 34.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Arch Toxicol 2012;  86:1323-9;  PMID:22371237 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Thorax 2010; 65:930-6; PMID:20627907 ;  http://dx.doi.org/10.1136/thx.2009.130260 36.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Epigenetics 2012; 7:225-9; PMID:22430798 ; http://dx.doi.org/10.4161/ epi.7.3.19284 38.,Non-OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Genome Biol 2003; 4:R28; PMID:12702209 ;  http://dx.doi.org/10.1186/gb-2003-4-4-r28 40.,OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
Nucleic Acids Res 2004; 32:D258-61; PMID:14681407 ; http://dx.doi.org/10.1093/nar/ gkh036,OADS,/arxiv_data1/oa_pdf/32/29/epi-9-1212.PMC4169013.pdf
"17-21 Currently, the major focus of epigenetic therapy  efforts is to develop and refine inhibitors of two families of epi - genetic silencing factors, the histone deacetylases (HDACs) and  *Correspondence to: Richard A Katz; Email; Richard.Katz@fccc.edu Submitted: 05/30/2014; Revised: 07/16/2014; Accepted: 07/21/2014; Published Online: 08/04/2014 http://dx.doi.org/10.4161/epi.32088Human factors and pathways essential   for mediating epigenetic gene silencing andrey Poleshko,1 andrew V Kossenkov2, Natalia Shalginskikh,1 anna Pecherskaya,1 Margret B Einarson,1 anna Marie Skalka,1  and Richard a Katz1* 1Fox c hase c ancer c enter; Philadelphia, P a US a; 2center for Systems and computational Biology; The Wistar Institute; Philadelphia, P a US a Keywords:  epigenetics; siRNA screen; gene silencing; SUMO pathway; integrins; epigenetic therapy Abbreviations:  GFP, Green Fluorescent Protein; SUMO, small ubiquitin-like modifier; HDAC, histone deacetylase; DNMT,   DNA methyltransferase; CMV, Cytomegalovirus; siRNA, small interfering RNA; GO, Gene Ontology; AML, acute myeloid  leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; FBS, fetal bovine serum; DMEM, Dulbecco’s  modified Eagle’s medium; ECM, extracellular matrix; HBSS, Hank’s Balanced Salt Solution; HAT, Histone acetyltransferase cellular identity in both normal and disease processes is determined by programmed epigenetic activation or silenc - ing of specific gene subsets.",Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
"), http://cgap.nci.nih.gov/Chromosomes/Mitelman).",Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nat Biotechnol 2010; 28:1079-88;  PMID:20944600 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nat Rev Genet 2013;  14:204-20;  PMID:23400093 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Cell Res 2011; 21:381- 95; PMID:21321607 ; http://dx.doi.org/10.1038/ cr.2011.22 6.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Trends Biochem Sci  2006; 31:89-97;  PMID:16403636 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nature  2013; 502:472-9;  PMID:24153300 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Science 2010; 330:612-6;  PMID:21030644 ; http://dx.doi.org/10.1126/ science.1191078 10.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Bioessays 2014; 36:75-83; PMID:24272858 ;  http://dx.doi.org/10.1002/bies.201300138 13.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nature 2007; 447:407- 12; PMID:17522673 ; http://dx.doi.org/10.1038/ nature05915 14.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nat  Rev Genet 2009; 10:295-304; PMID:19308066 ;  http://dx.doi.org/10.1038/nrg2540 15.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nat Biotechnol 2010; 28:817- 25; PMID:20657582 ; http://dx.doi.org/10.1038/ nbt.1662 16.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Mol Biol 2011; 409:36-46; PMID:21272588 ;  http://dx.doi.org/10.1016/j.jmb.2011.01.040 17.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Cell  2007; 128:683-92;  PMID:17320506 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
CA Cancer J Clin  2010; 60:376-92;  PMID:20959400 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Expert Opin Investig Drugs 2010; 19:1049-66;  PMID:20687783 ; http://dx.doi.org/10.1517/135437 84.2010.510514 21.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Expert Rev Anticancer Ther  2010; 10:9-22;  PMID:20014881 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Cell Stem Cell 2009; 4:301-12;  PMID:19341620 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Biol Chem 2010; 285:422-33; PMID:19880521 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
PLoS One  2009; 4:e7339;  PMID:19802393 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nucleic Acids Res 2013; 41:D808-15;  PMID:23203871 ; http://dx.doi.org/10.1093/nar/ gks1094 26.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Mol Cell 2004; 15:595-605; PMID:15327775 ;  http://dx.doi.org/10.1016/j.molcel.2004.06.043 29.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Cancer Res 2010; 70:6968-77;  PMID:20713525 ; http://dx.doi.org/10.1158/0008- 5472.CAN-09-4474 31.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Biomed Biotechnol 2011;  2011:690848;  PMID:21197454 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nat Struct Mol Biol 2007; 14:240-2; PMID:17310255 ; http://dx.doi.org/10.1038/ nsmb1200 34.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Mol Cell 2003; 11:1043-54;  PMID:12718889 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Mol Cell Biol 2001; 21:7065-77;  PMID:11564889 ; http://dx.doi.org/10.1128/ MCB.21.20.7065-7077.2001 36.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Biol Chem 2009; 284:3012-20; PMID:19049982 ;  http://dx.doi.org/10.1074/jbc.M806163200 38.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Cell 2012;  149:1474-87;  PMID:22726435 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Biol Chem 2002;  277:23658-63;  PMID:11960997 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nature  2010; 464:1192-5;  PMID:20414307 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Biol Chem 2005; 280:13928-35;  PMID :15691849 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Genes Dev 2006; 20:966- 76; PMID:16598039 ; http://dx.doi.org/10.1101/ gad.1404206 45.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Biol Chem 2014;In press;  PMID:24692537 ; http://dx.doi.org/10.1074/ jbc.M114.558197 47.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
N  Engl J Med 2009; 360:470-80; PMID:19129520 ;  http://dx.doi.org/10.1056/NEJMoa0808253 48.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Clin Genet 2010; 77:511-24; PMID:20236126 ;  http://dx.doi.org/10.1111/j.1399-0004.2010.01392.x 49.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Biol Chem 2002;  277:25026-31;  PMID:11978794 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Hematol Oncol 2009; 2:3; PMID:19166587 ;  http://dx.doi.org/10.1186/1756-8722-2-3 52.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nat Rev Mol Cell Biol 2014; 15:273- 88; PMID :24651544 ; http://dx.doi.org/10.1038/ nrm3769 54.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Gene 2009; 428:20- 4; PMID:18976699 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Cell Rep  2013; 5:292-301;  PMID:24209742 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nature  2008; 452:243-7;  PMID:18272965 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
J Virol  2008; 82:2313-23;  PMID:18094192 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Nat Protoc 2009; 4:44-57;  PMID:19131956 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
Biotechniques 2008; 45:81-94;  PMID:18611170 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8e/25/epi-9-1280.PMC4169020.pdf
"5Monoclonal antibodies targeting CD20 ch ien- hs ing ch ang, Edmund A. ro ssi and da vid M. Goldenberg* im munomedics, in c.; Morris Plains, nJ UsA *Correspondence to: David M. Goldenberg; Email: dmg.gscancer@att.net Submitted: 01/31/13; Accepted: 01/31/13http://dx.doi.org/10.4161/mabs.24106The ultimate test of a new agent is its clinical performance,  and it is therefore disappointing that Klein et al.",Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
MAbs 2013; 5:22-33; PMID:23211638; http://dx.doi.org/10.4161/mabs.22771 2.,OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
Drugs 2010; 70:1445-76; PMID:20614951; http://dx.doi.org/10.2165/11201110-000000000-00000 3.,Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
N Engl J Med 2012;  366:2008-16; PMID:22621628; http://dx.doi.org/10.1056/NEJMct1114348 4.,Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
Semin Arthritis Rheum 2009; 38:265-80; PMID:18336874; http://dx.doi.org/10.1016/j.semarthrit.2008.01.001 5.,Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
Blood 2009; 113:1062-70; PMID:18941114; http://dx.doi.org/10.1182/blood-2008-07-168146 6.,Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
Blood 2012; 119:5126-32; PMID:22431570; http://dx.doi.org/10.1182/blood-2012-01-4043687.,Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
Blood 2012; 119:5118-25; PMID:22438256; http://dx.doi.org/10.1182/blood-2012-02-408773 8.,Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
J Clin Oncol 2010; 28:1749-55; PMID:20194866; http://dx.doi.org/10.1200/JCO.2009.25.3187 9.,Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
J Clin Oncol 2009; 27:3346-53; PMID:19451441; http://dx.doi.org/10.1200/JCO.2008.19.9117 10.,Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
Haematologica 2011; 96:567-73; PMID:21173095; http://dx.doi.org/10.3324/haematol.2010.037390 11.,Non-OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
T rends Pharmacol Sci 2012; 33:474-81; PMID:22739259; http://dx.doi.org/10.1016/j.tips.2012.06.001,OADS,/arxiv_data1/oa_pdf/95/60/mabs-5-335.PMC4169026.pdf
"We believe that it is not justified to claim clinical superiority  of the 80 mg (for the subcutaneous formulation) or 80 mg/m2 (for intravenous infusions) weekly ×4 doses of veltuzumab over Response to:   Monoclonal antibodies targeting CD20 chr istian Klein,1,* Alfred Lammens,2 Wolfgang sc häfer,4 Guy Georges,4 Manfred sc hwaiger,3 Ekkehard Mössner,1  Karl-Peter  hopf ner,2 Pablo Umaña1 and Gerhard ni ederfellner3 1di scovery on cology; Pharma re search and Early de velopment (p rEd) ; ro che Glycart AG; sc hlieren, sw itzerland; 2dep artment of ch emistry and Biochemistry; Gene cen ter;  Ludwig-Maximilians University Munich; Munich, Germany; 3di scovery on cology; Pharma re search and Early de velopment (p rEd) ; ro che di agnostics Gmb h; P enzberg,  Germany; 4Large Molecule re search; Pharma re search and Early de velopment (p rEd) ; ro che di agnostics Gmb h; P enzberg, Germany *Correspondence to: Christian Klein; Email: christian.klein.ck1@roche.com Submitted: 02/12/13; Accepted: 02/12/13http://dx.doi.org/10.4161/mabs.24108",Non-OADS,/arxiv_data1/oa_pdf/60/71/mabs-5-337.PMC4169027.pdf
Expert  Opin Biol Ther 2011; 11:623-40; PMID:21395497; http://dx.doi.org/10.1517/14712 598.2011.560569 2.,Non-OADS,/arxiv_data1/oa_pdf/60/71/mabs-5-337.PMC4169027.pdf
"Expert Opin Biol Ther 2013; 13:169-182; PMID:23256681; http://dx.doi.org/ 10.1517/14712598.2012.735655 3.  v an Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibod- ies.",Non-OADS,/arxiv_data1/oa_pdf/60/71/mabs-5-337.PMC4169027.pdf
Semin Hematol 2010; 47:199-210; PMID:20350667; http://dx.doi.org/10.1053/j.seminhematol.2010.01.007 4.,Non-OADS,/arxiv_data1/oa_pdf/60/71/mabs-5-337.PMC4169027.pdf
Blood 2009; 113:1062-70; PMID:18941114; http://dx.doi.org/10.1182/blood-2008-07-168146 5.,Non-OADS,/arxiv_data1/oa_pdf/60/71/mabs-5-337.PMC4169027.pdf
J Clin Oncol 2009; 27:3346-53; PMID:19451441; http://dx.doi.org/10.1200/JCO.2008.19.9117 6.,Non-OADS,/arxiv_data1/oa_pdf/60/71/mabs-5-337.PMC4169027.pdf
Haematologica 2011; 96:567-73; PMID:21173095; http://dx.doi.org/10.3324/haematol.2010.037390 7.,Non-OADS,/arxiv_data1/oa_pdf/60/71/mabs-5-337.PMC4169027.pdf
Blood 2010; 115:4393-402; PMID:20194898; http://dx.doi.org/10.1182/blood-2009-06-225979 8.,Non-OADS,/arxiv_data1/oa_pdf/60/71/mabs-5-337.PMC4169027.pdf
"*Correspondence to: Alain Beck; Email: alain.beck@pierre-fabre.com Submitted: 02/24/13; Accepted: 02/24/13http://dx.doi.org/10.4161/mabs.24105th e 8th eu ropean Antibody Congress ( eA C), organized  by  te rrapin Ltd., was again held in  ge neva, Switzerland,  following on the tradition established with the 4th  eA C.  th e  new agenda format for 2012 included three parallel tracks on:  (1) naked antibodies; (2) antibody drug conjugates (ADCs); and (3) bispecific antibodies and alternative scaffolds.",Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
MAbs 2011; 3:415-6; PMID:21785279; http://dx.doi.org/10.4161/ mabs.3.5.17334 2.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
MAbs 2012; 4:419-25; PMID:22699226; http://dx.doi.org/10.4161/mabs.20996 3.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat  Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761 5.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216 6.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
N Engl J Med 2012; 367:1783-91; PMID:23020162; http://dx.doi.org/10.1056/NEJMoa1209124 7.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
MAbs 2012; 4:185- 97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000 8.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nature 1983; 305:537-40; PMID:6137772; http://dx.doi.org/10.1038/305537a0 9.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Mol Biol 1997; 270:26-35; PMID:9231898; http://dx.doi.org/10.1006/jmbi.1997.1116 10.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617 11.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat Biotechnol 1998; 16:677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677 12.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat Rev  Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155 13.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Methods 2005; 36:3- 10; PMID:15848070; http://dx.doi.org/10.1016/j.ymeth.2005.01.001 14.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat Rev  Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804 15.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Cancer Sci 2009; 100:1566-72; PMID:19538497; http://dx.doi.org/10.1111/j.1349-7006.2009.01222.x 16.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Anal Biochem 2013; 432:82-9; PMID:23026777; http://dx.doi.org/10.1016/j.ab.2012.09.032 17.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
PLoS One 2012; 7:e30295; PMID:22272329; http://dx.doi.org/10.1371/journal.pone.0030295 18.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Identification of  potential sites for tryptophan oxidation in recombinant antibodies using tert-butylhy-droperoxide and quantitative LC-MS. PLoS One 2011; 6:e17708; PMID:21390239; http://dx.doi.org/10.1371/journal.pone.0017708 19.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200 20.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Biotechnol Prog 2012; 28:608-22; PMID:22473974; http://dx.doi.org/10.1002/btpr.1548 21.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
AAPS J 2008; 10:268-76; PMID:18465252; http://dx.doi.org/10.1208/s12248-008-9026-7 22.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Mol Biol 2011; 413:261-78; PMID:21856311; http://dx.doi.org/10.1016/j.jmb.2011.08.01223.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
"Artif Cells Blood Substit Immobil Biotechnol 1999; 27:23-41; PMID:10063436; http://dx.doi.org/10.3109/10731199909117481 November 27, 2012: Day 1, Track B  Antibody Drug Conjugates:   Middle and Late-Stage ADC Progresses Hans- pe ter  gerb er Hans-Peter Gerber (Pfizer Oncology Research) pointed out that  ADC research and development (R&D) is undergoing a substan - tial transformation based on novel insights into biological mech - anism controlling safety and efficacy of ADCs.",Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Expert Opin Investig Drugs 2011; 20:1131-49; PMID:21599617;  http://dx.doi.org/10.1517/13543784.2011.582866 2.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Clin Oncol 2010; 28:2085-93; PMID:20308665; http://dx.doi.org/10.1200/JCO.2009.25.1900 3.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Mol Cancer Ther 2013; 12:38-47; PMID:23223830; http://dx.doi.org/10.1158/1535-7163.MCT-12-0603 4.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Clin Oncol 2010; 28:2698-704; PMID:20421541; http://dx.doi.org/10.1200/JCO.2009.26.2071 5.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Clin Oncol 2011; 29:398-405; PMID:21172893; http://dx.doi.org/10.1200/JCO.2010.29.5865 6.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Cancer 2012; 118:5733-40; PMID:22648179; http://dx.doi.org/10.1002/cncr.27622 7.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
"J Clin Oncol 2012; 30:2190-6; PMID:22614995; http://dx.doi.org/10.1200/JCO.2011.38.0402November 27, 2012: Day 1, Track C  Bispecific and Alternatives:   Exploring Bispecific Formats Alexey A. Lugovskoy The first session in the bispecific and alternative proteins track  of the 2012 European Antibody Congress was dedicated to case studies of bispecific antibody formats.",Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
"MAbs 2012; 4:653-63; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379 November 28, 2012: Day 2, Track A  Monoclonal Antibodies th ierry  w urch The second day of the ‘Monoclonal Antibody’ track, chaired by  Steve Coats  (MedImmune/AstraZeneca), addressed three major  topics: (1) the influence of collaborations on the R&D process; (2) three case studies of clinical success stories; and (3) the identi - fication and validation of novel targets with a particular emphasis on antibodies targeting immune check-point modulators.",Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
PLoS One 2010; 5:e9106; PMID:20161706; http://dx.doi.org/10.1371/journal.pone.0009106 3.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Science 2009; 324:246-51; PMID:19251591; http://dx.doi.org/10.1126/science.1171491 4.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Science 2011; 333:843-50; PMID:21737702; http://dx.doi.org/10.1126/science.1204839 5.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Science 2012; 337:1343-8; PMID:22878502; http://dx.doi.org/10.1126/science.12229086.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Int J Cancer 2005; 113:316-28; PMID:15386423; http://dx.doi.org/10.1002/ijc.20543 7.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Eur J Cancer 2007; 43:1318-27; PMID:17451939; http://dx.doi.org/10.1016/j.ejca.2007.03.009 8.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Natl  Cancer Inst 2012; 104:975-81; PMID:22761272; http://dx.doi.org/10.1093/jnci/djs258 10.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat Rev Drug Discov 2012; 11:17-8;  PMID:22212671; http://dx.doi.org/10.1038/nrd3630 11.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat Med 2009; 15:1088-92; PMID:19684583; http://dx.doi.org/10.1038/nm.1966 13.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Biomol Screen 2011; 16:744-54; PMID:21593485; http://dx.doi.org/10.1177/1087057111407067 14.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Methods Mol Biol 2011; 681:383-401; http://dx.doi.org/10.1007/978-1-60761-913-0_21; PMID:20978977 15.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Biol Chem 2012; 287:44425-34; PMID:23148212; http://dx.doi.org/10.1074/jbc.M112.415935 16.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Blood 2011; 118:6387-91; PMID:22031859; http://dx.doi.org/10.1182/blood-2011-06-360255 17.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Blood 2012; 120:4317-23; PMID:23002117; http://dx.doi.org/10.1182/blood-2012-06-437558 18.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Blood 2012; 120:4324-33; PMID:23033266; http://dx.doi.org/10.1182/blood-2012-06-438028 19.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Clin Cancer Res 2012; 18:3834-45; PMID:22615450; http://dx.doi.org/10.1158/1078-0432.CCR-12-0715 20.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Cancer Res 2007; 67:8882-90; PMID:17875730; http://dx.doi.org/10.1158/0008-5472.CAN-07-0696 21.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
T rends Biotechnol 2012; 30:575-82; PMID:22944617; http://dx.doi.org/10.1016/j.tibtech.2012.07.006 22.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Mol Biol 2010; 399:436-49; PMID:20382161; http://dx.doi.org/10.1016/j.jmb.2010.04.001 23.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Blood 2011; 117:4542-51; PMID:21300981; http://dx.doi.org/10.1182/blood-2010-09-306449 24.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Blood 2010; 116:926-34; PMID:20439625; http://dx.doi.org/10.1182/blood-2009-10-248609 25.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Cancer Cell 2010; 18:160-70; PMID:20708157; http://dx.doi.org/10.1016/j.ccr.2010.06.014,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Arthritis Res Ther 2009; 11:R142; PMID:19781067; http://dx.doi.org/10.1186/ar2814 3.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Nucl Med 2012; 53:922-7; PMID:22577235; http://dx.doi.org/10.2967/jnumed.111.101006 4.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
J Surg Oncol 2013; 107:173-9; PMID:22674435; http://dx.doi.org/10.1002/jso.23168 5.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Protein Sci 2005; 14:2436-46; PMID:16081651; http://dx.doi.org/10.1110/ps.051478705 6.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Bioconjug Chem 2005; 16:1282-90; PMID:16173809; http://dx.doi.org/10.1021/bc050201y 7.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat Biotechnol 2008; 26:925-32; PMID:18641636; http://dx.doi.org/10.1038/nbt.1480 8.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Clin Cancer Res 2010; 16:4769-78; PMID:20805300; http://dx.doi.org/10.1158/1078-0432.CCR-10-0987 9.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat Biotechnol 2012; 30:184-9; PMID:22267010; http://dx.doi.org/10.1038/nbt.2108 10.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Bioconjug Chem 2002; 13:729-36; PMID:12121127; http://dx.doi.org/10.1021/bc025517+ 11.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Int J Cancer 2008; 122:2405-13; PMID:18271006; http://dx.doi.org/10.1002/ijc.23408 12.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Br J Cancer 2011; 104:1106-15; PMID:21386847; http://dx.doi.org/10.1038/bjc.2011.78 13.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Angew Chem Int Ed Engl 2012; 51:941-4; PMID:22173886; http://dx.doi.org/10.1002/anie.201106527 14.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
"Clin Cancer Res 2004; 10:7063-70; PMID:15501986; http://dx.doi.org/10.1158/1078-0432.CCR-04-0789 November 28, 2012: Day 2, Track C  Bispecific and Alternatives: Morning session ro land Kontermann Robert Mabry  (Adimab) described the company platform tech - nology for rapid identification of bispecific antibodies utilizing  the IgG-scFv format, especially regarding stability influenced by linker length, orientation of variable domains and the formation of disulfide bonds.",Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Future Oncol 2012; 8:73-85; PMID:22149036; http://dx.doi.org/10.2217/fon.11.138 3.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Blood 2012; 120:5185-7; PMID:23024237; http://dx.doi.org/10.1182/blood-2012-07-441030 4.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Cancer Immunol Immunother 2012; PMID:23263452; http://dx.doi.org/10.1007/s00262-012-1384-4 5.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
"Expert Rev Clin Immunol 2007; 3:491-501; PMID:20477155; http://dx.doi.org/10.1586/1744666X.3.4.491November 28, 2012: Day 2, Track C  Bispecific and Alternatives: Afternoon session rob ert Mabry The afternoon session of the second day, chaired by Tariq Ghayur   (AbbVie), comprised three presentations on therapeutic leads in  different bispecific formats.",Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Eur J Cancer  2009; 45:1067-79; PMID:19131242; http://dx.doi.org/10.1016/j.ejca.2008.11.034 2.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
N Engl J Med 2012; 366:883-92; PMID:22397650; http://dx.doi.org/10.1056/NEJMoa1113205 6.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Cell 2012; 149:994-1007; PMID:22608083; http://dx.doi.org/10.1016/j.cell.2012.04.023 7.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat Rev Genet 2012; 13:795- 806; PMID:23044827; http://dx.doi.org/10.1038/nrg3317 8.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nat Med 2012; 18:221-3; PMID:22270724; http://dx.doi.org/10.1038/nm.2609 11.,OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nature 2012; 487:505-9; PMID:22763448; http://dx.doi.org/10.1038/nature11249 12.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
Nature 2012; 487:500-4; PMID:22763439; http://dx.doi.org/10.1038/nature11183 Note Summaries were prepared from PDFs of the presentations pro - vided by speakers after the meeting.,Non-OADS,/arxiv_data1/oa_pdf/59/80/mabs-5-339.PMC4169028.pdf
"Do not distribute.mAbs 5:3, 384–396; May/June 2013; © 2013 Landes Bioscience Repo Rt 384 mA bs  V olume 5 Issue 3*Correspondence to: David E. Szymkowski; Email david.szymkowski@xencor.com Submitted: 12/07/12; Revised: 02/08/13; Accepted: 02/12/13http://dx.doi.org/10.4161/mabs.23976Introduction Inhibition of costimulatory signals required for T cell activation  is now a clinically validated immunosuppressive strategy, with abatacept and belatacept now marketed for rheumatoid arthritis (RA) and kidney transplantation, respectively.",Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Annu Rev Immunol 2001; 19:565-94; PMID:11244047; http://dx.doi.org/10.1146/annurev.immunol.19.1.565 2.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Annu Rev Immunol 1983; 1:143-73; PMID:6443557; http://dx.doi.org/10.1146/annurev.iy.01.040183.0010433.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Immunol Rev 1977; 35:231-62; PMID:330389; http://dx.doi.org/10.1111/j.1600-065X.1977.tb00241.x 4.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Nat Rev Immunol 2011; 11:852-63; PMID:22116087; http://dx.doi.org/10.1038/nri31085.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
T rends Immunol 2011; 32:428-33; PMID:21723783; http://dx.doi.org/10.1016/j.it.2011.06.002 6.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
J Exp Med 1991; 174:561-9; PMID:1714933; http://dx.doi.org/10.1084/jem.174.3.561,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Arthritis Rheum 2011; 63:2854-64; PMID:21618201; http://dx.doi.org/10.1002/art.30463 27.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Arthritis Rheum 2002; 46:1470-9; PMID:12115176; http://dx.doi.org/10.1002/art.10294 30.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Nat Protoc 2007; 2:1269-75; PMID:17546023; http://dx.doi.org/10.1038/nprot.2007.17316.,OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
J Immunol 2012; 189:4470-7; PMID:23018459; http://dx.doi.org/10.4049/jimmunol.1201813 17.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Nature 2001; 410:604-8; PMID:11279501; http://dx.doi.org/10.1038/35069112 18.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Nature 2001; 410:608-11; PMID:11279502; http://dx.doi.org/10.1038/35069118 19.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
J Autoimmun 2005; 25:165-71; PMID:16256307; http://dx.doi.org/10.1016/j.jaut.2005.09.020 20.,OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
J Clin Invest 1995; 96:987-93; PMID:7543497; http://dx.doi.org/10.1172/JCI118146 21.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Science 1994; 265:1225-7; PMID:7520604; http://dx.doi.org/10.1126/sci-ence.7520604 22.,OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
"J Allergy Clin Immunol 2008; 121:299-306, quiz 307-8; PMID:18269922; http://dx.doi.org/10.1016/j.jaci.2008.01.002 8.",OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Am J T ransplant 2005; 5:443-53; PMID:15707398; http://dx.doi.org/10.1111/j.1600-6143.2005.00749.x 9.,OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155 13.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Nat Biotechnol 2010; 28:157-9; PMID:20081867; http://dx.doi.org/10.1038/nbt.1601 14.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
MAbs 2011; 3:422-30; PMID:22048693; http://dx.doi.org/10.4161/mabs.3.5.16983 15.,Non-OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
Immunity 1994; 1:793-801; PMID:7534620; http://dx.doi.org/10.1016/S1074-7613(94)80021-9,OADS,/arxiv_data1/oa_pdf/07/5e/mabs-5-384.PMC4169032.pdf
"Do not distribute.mAbs 5:3, 418–431; May/June 2013; © 2013 Landes Bioscience Repo Rt 418 mA bs  V olume 5 Issue 3*Correspondence to: Yang Shen; Email: yang.shen@imclone.com Submitted: 01/24/13; Revised: 03/11/13; Accepted: 03/13/13http://dx.doi.org/10.4161/mabs.24291Introduction In human serum, immunoglobulin 1 (IgG1) is the most abun- dant subclass among all IgGs.",Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Supplemental Material Supplemental materials may be found here:http://www.landesbioscience.com/journals/mabs/article/24218penicillin and streptomycin.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Virchows Arch A Pathol Anat Histopathol 1988; 412:591-4; PMID:3129870; http://dx.doi.org/10.1007/BF00844295 2.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nat Biotechnol 2006; 24:1241-52; PMID:17033665; http://dx.doi.org/10.1038/nbt1252 3.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nat Biotechnol 2008; 26:985-90; PMID:18779806; http://dx.doi.org/10.1038/nbt0908-985 4.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nat Rev Drug Discov 2007; 6:349-56; PMID:17431406; http://dx.doi.org/10.1038/nrd22415.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nat Biotechnol 2009; 27:331-7; PMID:19352366; http://dx.doi.org/10.1038/nbt0409-331 6.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804 7.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nat Rev Immunol 2006; 6:343-57; PMID:16622479; http://dx.doi.org/10.1038/nri1837 8.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747 9.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.1993110.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
http://www.immunologylink.com/FDA-APP-Abs.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Mol Immunol 1987; 24:751-7; PMID:3116408; http://dx.doi.org/10.1016/0161-5890(87)90058-7 12.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nat Biotechnol 2012; 30:69-77; PMID:22231104; http://dx.doi.org/10.1038/nbt.2076,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Protein Eng Des Sel 2010; 23:221-8; PMID:20019028; http://dx.doi.org/10.1093/protein/gzp077 44.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
J Mol Biol 2012; 422:532-44; PMID:22706026; http://dx.doi.org/10.1016/j.jmb.2012.06.014 45.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
J Cell Biol 1990; 111:829-37; PMID:2118144; http://dx.doi.org/10.1083/jcb.111.3.829 46.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nature 1994; 372:379-83; PMID:7969498; http://dx.doi.org/10.1038/372379a0 48.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
J Biol Chem 2006; 281:23514-24; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200 49.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Int Immunol 2006; 18:1759-69; PMID:17077181; http://dx.doi.org/10.1093/intimm/dxl110 51.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Arch Biochem Biophys 1978; 185:584-91; PMID:626512; http://dx.doi.org/10.1016/0003-9861(78)90204-7 53.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Bioinformatics 2007; 23:2947-8; PMID:17846036; http://dx.doi.org/10.1093/bioinfor-matics/btm404 54.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Bioinformatics 2000; 16:566-7; PMID:10980157; http://dx.doi.org/10.1093/bioinfor-matics/16.6.56628.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
J Biol Chem 2012; 287:5891-7; PMID:22203673; http://dx.doi.org/10.1074/jbc.M111.311811 29.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
J Biol Chem 2006; 281:15829-36; PMID:16597622; http://dx.doi.org/10.1074/jbc.M600697200 32.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Immunotechnology 1998; 3:253-70; PMID:9530559; http://dx.doi.org/10.1016/S1380-2933(97)10003-3 33.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Mol Immunol 2011; 48:1586-8; PMID:21605907; http://dx.doi.org/10.1016/j.molimm.2011.04.020 34.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
J Thromb Haemost 2010; PMID:20456749; http://dx.doi.org/10.1111/j.1538-7836.2010.03894.x 35.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
J Mol Biol 2009; 386:662-74; PMID:19154741; http://dx.doi.org/10.1016/j.jmb.2008.12.078 36.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
BMC Struct Biol 2007; 7:49; PMID:17640393; http://dx.doi.org/10.1186/1472-6807-7-49 37.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Acta Crystallogr D Biol Crystallogr 2010; 66:486-501; PMID:20383002; http://dx.doi.org/10.1107/S0907444910007493 38.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
IUBMB Life 2002; 53:85-98; PMID:12049200; http://dx.doi.org/10.1080/15216540211468 40.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Mol Immunol 1992; 29:1487-91; PMID:1454066; http://dx.doi.org/10.1016/0161-5890(92)90222-J14.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Anal Chem 2010; 82:5219-26; PMID:20491447; http://dx.doi.org/10.1021/ac100575n 15.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
PLoS One 2011; 6:e18615; PMID:21494600; http://dx.doi.org/10.1371/journal.pone.0018615 17.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt.1553 19.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Mol Immunol 2001; 38:1-8; PMID:11483205; http://dx.doi.org/10.1016/S0161-5890(01)00050-5 20.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Electrophoresis 2008; 29:2550-6; PMID:18494039; http://dx.doi.org/10.1002/elps.200800083 21.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
J Biol Chem 2008; 283:16194-205; PMID:18339624; http://dx.doi.org/10.1074/jbc.M709987200 22.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Biochemistry 2008; 47:7496-508; PMID:18549248; http://dx.doi.org/10.1021/bi800576c 23.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Anal Chem 2010; 82:1090-9; PMID:20039682; http://dx.doi.org/10.1021/ac902466z 24.,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
J Pharm Sci 2009; 98:3013-30; PMID:18680168; http://dx.doi.org/10.1002/jps.21514 26.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Adv Immunol 1973; 16:1-59; PMID:4125921; http://dx.doi.org/10.1016/S0065-2776(08)60295-3 27.,Non-OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
Anal Biochem 2011; 408:277-83; PMID:20869344; http://dx.doi.org/10.1016/j.ab.2010.09.025,OADS,/arxiv_data1/oa_pdf/19/15/mabs-5-418.PMC4169035.pdf
"Do not distribute.www.landesbioscience.com  mAbs  1mA bs 5:3, 1–12; May/June 2013; © 2013 Landes Bioscience Repo Rt Repo Rt *Correspondence to: Yannis-Nicolas François; Email: yfrancois@unistra.fr Submitted: 01/10/13; Revised: 02/11/13; Accepted: 02/13/13http://dx.doi.org/10.4161/mabs.23995Introduction Since 1986 and the approbation of muromonab-CD3 by the US  Food and Drug Administration (FDA), monoclonal antibodies (mAbs) have taken a major market share in the pharmaceutical industry and their development is constantly increasing.",Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747 2.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931 3.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
MAbs 2012; 4:1-9; PMID:22327425; http://dx.doi.org/10.4161/mabs.216144.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
MAbs 2011; 3:209-17; PMID:21441787; http://dx.doi.org/10.4161/mabs.3.2.150057.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
MAbs 2009; 1:394-416; PMID:20065643; http://dx.doi.org/10.4161/mabs.1.5.9630 8.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Mass Spectrom Rev 2009; 28:147-76; PMID:18720354; http://dx.doi.org/10.1002/mas.20190 9.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872:23-37; PMID:18672411; http://dx.doi.org/10.1016/j.jchromb.2008.03.032,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Biochem 2006; 355:249-58; PMID:16712766; http://dx.doi.org/10.1016/j.ab.2006.04.002 30.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Chem 2012; 84:4637-46; PMID:22510259; http://dx.doi.org/10.1021/ac3002885 31.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Mol Cell Proteomics 2010; 9:1716-28; PMID:20103567; http://dx.doi.org/10.1074/mcp.M900540-MCP200 32.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
J Pharm Sci 2008; 97:2426-47; PMID:17828757; http://dx.doi.org/10.1002/jps.21180 33.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Biotechnol Prog 2005; 21:11-6; PMID:15903235; http://dx.doi.org/10.1021/bp040016j 34.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
MAbs 2012; 4:1-7; PMID:22327425; http://dx.doi.org/10.4161/mabs.20996 35.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Curr Pharm Biotechnol 2008; 9:482-501; PMID:19075687; http://dx.doi.org/10.2174/138920108786786411 36.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Expert Opin Drug Discov 2010; 5:95-111; PMID:22823974; http://dx.doi.org/10.1517/17460440903413504 37.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Int J Mass Spectrom Ion Process 1994; 136:167-80; http://dx.doi.org/10.1016/0168-1176(94)04024-920.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Chem 2010; 82:9476-83; PMID:21028888; http://dx.doi.org/10.1021/ac102159d 21.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Chem 2012; 84:885-92; PMID:22148170; http://dx.doi.org/10.1021/ac202407v 22.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Chim Acta 2011; 698:77-83; PMID:21645662; http://dx.doi.org/10.1016/j.aca.2011.04.050 23.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Electrophoresis 2012; 33:1550-6; PMID:22736356; http://dx.doi.org/10.1002/elps.201200066 24.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
MAbs 2009; 1:142-50; PMID:20061815; http://dx.doi.org/10.4161/mabs.1.2.7632 25.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/NEJMra043186 26.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
J Chromatogr B Biomed Sci Appl 2001; 752:233-45; PMID:11270864; http://dx.doi.org/10.1016/S0378-4347(00)00548-X 28.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Biochem 2009; 392:145-54; PMID:19497295; http://dx.doi.org/10.1016/j.ab.2009.05.04311.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819:203-18; PMID:15833284; http://dx.doi.org/10.1016/j.jchromb.2004.06.052 12.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Biochem 2011; 419:17-25; PMID:21867674; http://dx.doi.org/10.1016/j.ab.2011.07.033 14.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Chem 2012; 84:5380-6; PMID:22663182; http://dx.doi.org/10.1021/ac3008847 15.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Biochem 2011; 417:256-63; PMID:21756870; http://dx.doi.org/10.1016/j.ab.2011.06.024 16.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Electrophoresis 2011; 32:3078-84; PMID:22145164; http://dx.doi.org/10.1002/elps.201100186 17.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Chem 2007; 79:4241-6; PMID:17447730; http://dx.doi.org/10.1021/ac0704560 18.,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
J Chromatogr A 2010; 1217:7605-11; PMID:20970804; http://dx.doi.org/10.1016/j.chroma.2010.10.006 19.,OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
Anal Chem 2011; 83:7297-305; PMID:21848273; http://dx.doi.org/10.1021/ac2010372,Non-OADS,/arxiv_data1/oa_pdf/4b/a9/mabs-5-479.PMC4169039.pdf
"Do not distribute.www.landesbioscience.com  mAbs  491mA bs 5:3, 491–500; May/June 2013; © 2013 Landes Bioscience Repo Rt Repo Rt *Correspondence to: Tudor Arvinte; Email: tudor.arvinte@unibas.ch Submitted: 02/14/13; Revised: 03/06/13; Accepted: 03/08/13http://dx.doi.org/10.4161/mabs.24245Introduction With numerous monoclonal antibodies (mAbs) already on the  market and many more in the development, the progress in understanding of the factors that affect their safety and efficacy becomes increasingly important.",Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
"Clin Ther  2002; 24:1720-40, discussion 1719; PMID:12501870; http://dx.doi.org/10.1016/S0149-2918(02)80075-3 2.",Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Nat Rev Drug Discov 2002; 1:457-62; PMID:12119747; http://dx.doi.org/10.1038/nrd818 3.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Curr Opin Nephrol Hypertens 2007; 16:585-8; PMID:18089975; http://dx.doi.org/10.1097/MNH.0b013e3282f0c4bf 4.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
J Immunotoxicol 2006; 3:123-30; PMID:18958692; http://dx.doi.org/10.1080/15476910600845567 5.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
J Phys Chem B 2010; 114:6614-24; PMID:20411962; http://dx.doi.org/10.1021/jp911706q 6.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Clin Immunol 2007; 124:26-32; PMID:17490912; http://dx.doi.org/10.1016/j.clim.2007.03.544 7.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
J Pharm Sci 2010; 99:3302-21; PMID:20310025; http://dx.doi.org/10.1002/jps.22097 8.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
J Pharm Sci 2009; 98:1201-5; PMID:18704929; http://dx.doi.org/10.1002/jps.21530 9.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Int J Pharm 2008; 358:1-15; PMID:18485634; http://dx.doi.org/10.1016/j.ijpharm.2008.03.04110.,OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
J Pharm Sci 2009; 98:2909-34; PMID:18823031; http://dx.doi.org/10.1002/jps.21566 11.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
J Pharm Sci 2008; 97:4219-27; PMID:18240303; http://dx.doi.org/10.1002/jps.21322 12.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
MAbs 2009; 1:142-50; PMID:20061815; http://dx.doi.org/10.4161/mabs.1.2.7632 13.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Int J Pharm 2007; 329:37-45; PMID:17005340; http://dx.doi.org/10.1016/j.ijpharm.2006.08.024 14.,OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Biochim Biophys Acta 2007; 1774:146-53; PMID:17142116; http://dx.doi.org/10.1016/j.bbapap.2006.10.010 15.,OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
J Pharm Sci 2005; 94:1928-40; PMID:16052543; http://dx.doi.org/10.1002/jps.20347 17.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
AAPS PharmSciTech 2004; 5:e47; PMID:15760080; http://dx.doi.org/10.1208/pt050347 18.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Mol Biotechnol 1997; 8:105-22; PMID:9406181; http://dx.doi.org/10.1007/BF02752255 19.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Eur J Pharm Biopharm 2007; 65:131-48; PMID:17107777; http://dx.doi.org/10.1016/j.ejpb.2006.09.00920.,OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Anal Biochem 2009; 388:279-87; PMID:19289095; http://dx.doi.org/10.1016/j.ab.2009.03.012 21.,OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Pharm Res 2012; 29:2202-12; PMID:22467219; http://dx.doi.org/10.1007/s11095-012-0749-x 22.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Curr Opin Chem Biol 1997; 1:378-83; PMID:9667873; http://dx.doi.org/10.1016/S1367-5931(97)80077-4 26.,OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
Anal Biochem 2000; 278:1-13; PMID:10640347; http://dx.doi.org/10.1006/abio.1999.4406 27.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
J Mol Recognit 1998; 11:204-10; PMID:10076841; http://dx.doi.org/10.1002/(SICI)1099-1352(199812)11:1/6<204::AID-JMR424>3.0.CO;2-T 28.,OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
J Clin Oncol 2011; 29:1757-64; PMID:21422411; http://dx.doi.org/10.1200/JCO.2010.32.322035.,Non-OADS,/arxiv_data1/oa_pdf/f4/81/mabs-5-491.PMC4169040.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"The grids were exposed to the primaryanti-CD63 antibody for 20 minutes, followed by sec-ondary antibody to rabbit anti-mouse IgG (Zymed,San Francisco, CA, USA) for 20 minutes and proteinImpact of EV isolation methods on RNA profiling Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858 3 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
MASS SIEVE was used to calculate percentage coverage for each protein identification (http://www.ncbi.nlm.nih.,OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"The concentrated conditioned medium (CCM) was equally divided over 4 isolation methods: ultracentrifugation (UC), OptiPrepTMdensity gradient centrifugation (ODG), ExoQuick-TCTMprecipitation (EQ) and Total Exosome IsolationTMprecipitation (TEI).Impact of EV isolation methods on RNA profiling Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"Total particle number, mean particle size and modus are shown for each preparation.Impact of EV isolation methods on RNA profiling Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858 7 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"(b) Gene Set Enrichment Analysis of UC versus ODG.Impact of EV isolation methods on RNA profiling Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858 9 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"10 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"Plotted values represent 3 replicates for each method.Impact of EV isolation methods on RNA profiling Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858 11 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"12 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"2013;2:19861, doi: http://dx.doi.org/10.3402/jev.v2i0.19861 12.",Non-OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"2007;5:1945 /C155.Impact of EV isolation methods on RNA profiling Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858 13 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"2013;2:20360, doi: http://dx.doi.org/10.3402/jev.v2i0.20360 20.",Non-OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"2012;1:18704, doi: http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"2013;2:19671, doi:http://dx.doi.org/10.3402/jev.v2i0.19671 28.",Non-OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"2013;2:22859, doi: http://dx.doi.org/10.3402/jev.v2i0.22859 31.",Non-OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"2014;3:23111, doi: http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"2013;2:20167, doi:http://dx.doi.org/10.3402/jev.v2i0.20167 45.",Non-OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"14 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24858 - http://dx.doi.org/10.3402/jev.v3.24858",OADS,/arxiv_data1/oa_pdf/1b/4c/JEV-3-24858.PMC4169610.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits  non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/54/66/cmu041.PMC4169669.pdf
https://www.gov.uk/government/uploads/system/uploads/   attachment_data/file/216424/dh_132086.pdf  (accessed on 14 July  2014).,OADS,/arxiv_data1/oa_pdf/54/66/cmu041.PMC4169669.pdf
https://www.gov.uk/government/collections/ english-indices-of-deprivation  (accessed on 26 April 2012).,Non-OADS,/arxiv_data1/oa_pdf/54/66/cmu041.PMC4169669.pdf
http://www.quali  tative-research.net/index.php/fqs/article/view/1428/3028  (accessed on  14 July 2014).,Non-OADS,/arxiv_data1/oa_pdf/54/66/cmu041.PMC4169669.pdf
"This is an Open Access article distributed under the terms of the Creative Commons   Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits   non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9b/f7/dxu057.PMC4169672.pdf
"Results showed that these con - ventional αβ T cells expressed Trav6, 8D-1 and 10 located  upstream of V α14 (Trav11 according to the nomenclature  by IMGT, the international ImMunoGeneTics information  system, http://www.imgt.org ) but did not express Trav1 and  Trav2 ( Supplementary Figure  2 , available at International  Immunology  Online).",OADS,/arxiv_data1/oa_pdf/9b/f7/dxu057.PMC4169672.pdf
"Since emmetropization is driven  by a sharp, in-focus image to the retina [ 14], abnormalities  in visual transmission through ON and OFF cone pathways  could potentially influence normal refractive development in  mammals [ 15].Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > Received 16 August 2014 | Accepted 18 September 2014 | Published 20 September 2014© 2014 Molecular Vision 1318Comparison of refractive development and retinal dopamine in  OFF pathway mutant and C57BL/6J wild-type mice Ranjay Chakraborty,1,4 Han na Park,1,4 Moe H. Aung,1,2 Christopher C. Tan,1 Curran S. Sidhu,1 P. Michael  Iuvone,1,2,3 Machelle T. Pardue1,2,4 (The first two authors contributed equally to this work.)",Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
"Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > © 2014 Molecular Vision  1319Although a few studies have reported abnormalities in  visual transmission through the ON pathway [ 16-20] are  associated with myopia in humans [ 21], and an increased  susceptibility to form-deprivation myopia in a mutant mouse  carrying a null mutation in Nyx [22], no previous study has  examined the refractive state associated with an OFF visual  pathway defect in mammals.",Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
"Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > © 2014 Molecular Vision  1320mice were given yohimbine (2.1 mg/kg) to reverse the effects  of anesthesia and reduce the development of corneal lesions  [39], and placed on a warming pad to recover.",Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
"Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > © 2014 Molecular Vision  1321flattening, 0.17±0.001, 0.18±0.001, and 0.15±0.007 mm for  Vsx1−/− , Vsx1+/+ , and C57BL/6J, respectively; Figure 1B;  two-way repeated-measures ANOVA main effect of age,  F(8,171)=281.95, p<0.001).",Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
"Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > © 2014 Molecular Vision  1322length or corneal curvature of the goggled mice compared to  the untreated naïve controls for any genotype or strain (two- way repeated-measures ANOVA, p>0.05; data not shown).",Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
"Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > © 2014 Molecular Vision  1323the Vsx1−/−  mice were also unresponsive to imposed form  deprivation, as were the Vsx1+/+  controls on the same genetic  background.",Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
"Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > © 2014 Molecular Vision  1324ages, and became significantly hyperopic with increasing  age (Figure 1A).",Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > © 2014 Molecular Vision  1325essential for determining the predisposition of the mouse eye  to form deprivation myopia than changes in DA with FD.,Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > © 2014 Molecular Vision  1326mutation responsible for the mouse nob phenotype.,Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
Molecular Vision  2014; 20:1318-1327 <http://www.molvis.org/molvis/v 20/1318 > © 2014 Molecular Vision  1327type 3a mouse retinal bipolar cell terminal differentiation.,Non-OADS,/arxiv_data1/oa_pdf/3e/11/mv-v20-1318.PMC4169773.pdf
"METHODS Patients and clinical examinations:  This study adhered to the  ARVO statement on human subjects and was approved by the  Institutional Review Board of the Xinhua Hospital affiliated  with the Shanghai Jiao Tong University School of Medicine Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > Received 30 March 2014 | Accepted 18 September 2014 | Published 20 September 2014© 2014 Molecular Vision 1296Novel mutations in the TSPAN12  gene in Chinese patients with  familial exudative vitreoretinopathy Yu Xu,1 Lulin Huang,2,3,4 Jing Li,1 Qi Zhang,1 Ping Fei,1 Xiong Zhu,2,3,4 Zhengfu Tai,2,4 Shi Ma,2,3 Bo Gong,2,3  Yun Li,5 Weizhou Zang,6 Xianjun Zhu,2,3,4 Peiquan Zhao,1 Zhenglin Yang2,3,4 (The first two authors contributed equally to this work.)",Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
"Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  1297and the Institutional Review Board of the Sichuan Academy  of Medical Sciences and Sichuan Provincial People’s Hospital,  China.",Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  1298CA).,Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  1299atmosphere.,Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  1300 Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  1301 Figure 4.,Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  1302 Figure 5.,Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  1303 Figure 7.,Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
"Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  1304Defective Norrin signaling mediated by mutant TSPAN12   proteins in vitro: To determine the effect of the TSPAN12   mutants on its biologic activity in Norrin/β-catenin signaling,  we performed luciferase assays in STF cells using wild-type  and three mutant TSPAN12  cDNAs.",Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  1305patients with FEVR with retina angiography and clinical  treatment.,Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
Molecular Vision  2014; 20:1296-1306 <http://www.molvis.org/molvis/v 20/1296 > © 2014 Molecular Vision  130611.,Non-OADS,/arxiv_data1/oa_pdf/dc/d1/mv-v20-1296.PMC4169774.pdf
"Herein we report the unusual Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > Received 6 July 2014 | Accepted 18 September 2014 | Published 20 September 2014© 2014 Molecular Vision 1307Severe retinal degeneration in women with a c.2543del mutation  in ORF15 of the RPGR  gene Bohdan Kousal,1,2 Pavlina Skalicka,1 Lucie Valesova,1 Tracy Fletcher,3 Niki Hart-Holden,3 Anna O’Grady,3  Christina F. Chakarova,4 Michel Michaelides,4,5 Alison J. Hardcastle,4 Petra Liskova1,2,4 1Department of Ophthalmology, First Faculty of Medicine, Charles University in Prague and General University Hospital in  Prague, Czech Republic; 2Laboratory of the Biology and Pathology of the Eye, Institute of Inherited Metabolic Disorders; First  Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic; 3Regional  Molecular Genetics Service, St Mary’ s Hospital, Manchester, United Kingdom; 4UCL Institute of Ophthalmology, London, United  Kingdom; 5Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom Purpose:  To describe the genotype-phenotype correlation and serial observations in a five-generation Czech family with  X-linked retinitis pigmentosa (XLRP) associated with severe visual impairment in women.",Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1308severe phenotype associated with a c.2543del ORF15 RPGR   mutation with profound visual loss in female carriers.,Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
"Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1309subcapsular cataracts) in at least one eye were found in female  individuals II:5, III:1, III:4, and III:9.",Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1310Table  1.,Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
"Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1311Individual/genderAge  (yrs)BCVA Subjective refraction (DS/DC)Pigmentary  depositsColor Vision DeficienciesMutation RE LE RE LE RE LE RE LE V:1/M 4 UA UA −2.5/-2.5 −2.5/-2.5 N N Not tested 6.5 1.0 0.5 −2.5/-2.5 −2.5/-2.5 N N 10 0.5 0.5 −3.0/-2.5 −3.0/-3.0 N N BCV A: best corrected visual acuity, DS: diopter sphere, DC: diopter cylinder, F: female, HM: hand movement, M: male, LE: left eye, RE: right eye, N: No, Y: yes, yrs: years,  TB: total blindness, UA: unavailable data.",Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1312individuals affected in four consecutive generations including  several severely affected women favored autosomal dominant  inheritance.,Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1313 Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
"Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1314that contribute to inter-individual phenotypic heterogeneity  remain elusive, but include skewed inactivation in women and  other genetic modifiers [ 5,12,25].",Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1315 Figure 4.,Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
"Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1316by a Foundation Fighting Blindness Career Development  Award, CC by The US Foundation Fighting Blindness, and  MM and AJH are supported by the National Institute for  Health Research Biomedical Research Centre at Moorfields  Eye Hospital NHS Foundation Trust and UCL Institute of  Ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
Molecular Vision  2014; 20:1307-1317 <http://www.molvis.org/molvis/v 20/1307 > © 2014 Molecular Vision  1317diagnosis of autosomal dominant retinitis pigmentosa.,Non-OADS,/arxiv_data1/oa_pdf/71/2f/mv-v20-1307.PMC4169777.pdf
"The mAChRs are G-protein coupled Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > Received 22 January 2014 | Accepted 18 September 2014 | Published 20 September 2014© 2014 Molecular Vision 1328Acetylcholine receptors in the retinas of the α7 nicotinic  acetylcholine receptor knockout mouse Marci L. Smith,1 Fred G. Oliveira Souza,1 Kady S. Bruce,1 Christianne E. Strang,1 Barbara J. Morley,2 Kent  T. Keyser1 1Department of Vision Sciences, University of Alabama at Birmingham, Birmingham, AL; 2Boys Town National Research  Hospital, Omaha, NE Purpose:  The α7 nicotinic acetylcholine receptor (nAChR) is widely expressed in the nervous system, including in the  inner retinal neurons in all species studied to date.",Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
"Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1329receptors of which there are five subtypes, m1–m5, each  encoded by a specific gene.",Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
"Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1330Inc., Lyon Cedex, France).",Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1331of the mean (SEM) was calculated by dividing the total SD  by the square root of the sample size.,OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1332Table  1.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
"Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1333Target Description Fold change Clcn6 chloride channel 6, brain −1.07 Gabra1 λ-aminobutyric acid (GABA-A) receptor, subunit α 1 1.02 Gabra2 λ-aminobutyric acid (GABA-A) receptor, subunit α 2 −1.10 Gabra3 λ-aminobutyric acid (GABA-A) receptor, subunit α 3 −1.07 Gabra4 λ-aminobutyric acid (GABA-A) receptor, subunit α 4 1.15 Gabra5 λ-aminobutyric acid (GABA-A) receptor, subunit α 5 1.08 Gabra6 λ-aminobutyric acid (GABA-A) receptor, subunit α 6 NA Gabrb2 λ-aminobutyric acid (GABA-A) receptor, subunit β 2 1.19* Gabrb3 λ-aminobutyric acid (GABA-A) receptor, subunit β 3 1.07 Gabrd λ-aminobutyric acid (GABA-A) receptor, subunit Δ 1.03 Gabrg2 λ-aminobutyric acid (GABA-A) receptor, subunit λ 2 1.16 Gabrp λ-aminobutyric acid (GABA-A) receptor, π −1.36 Gabrq λ-aminobutyric acid (GABA-A) receptor, subunit θ −1.04 Gabrr1 λ-aminobutyric acid (GABA-C) receptor, subunit ρ 1 −1.09 Gabrr2 λ-aminobutyric acid (GABA-A) receptor, subunit ρ 2 1.10 Gabrr3 λ-aminobutyric acid (GABA-A) receptor, subunit ρ 3 1.07 Glra1 glycine receptor α 1 1.09 Glra2 glycine receptor, α 2 subunit 1.15 Glra3 glycine receptor, α 3 subunit −1.20 Glra4 glycine receptor, α 4 1.01 Glrb glycine receptor, β subunit −1.06 Kcna2 potassium voltage-gated channel, shaker-related, brain and spinal cord 1.02 Kcna6 potassium voltage-gated channel, shaker-related, brain −1.04 Kcnc4 potassium voltage gated channel, Shaw-related, neurotransmitter release 1.06 Kcnd1 potassium voltage-gated channel, Shal, brain −1.01 Kcnh2 potassium voltage-gated channel, subfamily H, brain, ear −1.03 Kcnj3 potassium inwardly-rectifying channel, subfamily J, spinal interneurons −1.09 Kcnj4 frontal cortex pyramidal neurons HCN, Kir2, and Kleak -1.98* Kcnj6 potassium inwardly-rectifying channel, subfamily J, brain 1.01 Kcnn2 potassium channel calcium-activated, subfamily N, synaptic plasticity 1.21 Kcnn3 potassium intermediate/small conductance, Ca2+ activated, N type, brain −1.28 Kcnq2 potassium voltage-gated channel, subfamily Q, hippocampus 1.02 Kcnq3 potassium voltage-gated channel, subfamily Q, member 3, brain 1.18 Ryr3 ryanodine receptor 3 1.22",Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
"Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1334Target Description Fold change Scn1a sodium channel, voltage-gated, type I, brain 1.08 Scn1b sodium channel, voltage-gated, type I, β brain & cardiac −1.12 Scn5a sodium channel, voltage-gated, type V, cardiac and brain 1.29 Scn7a sodium channel, voltage-gated, type VII, sodium concentration sensor, taste 1.07 Slc5a7 solute carrier family 5 (high affinity choline transporter), member 7 −1.01 Gria1 AMPA 1 cerebllum 1.03 Gria2 AMPA 2 synaptic 1.14 Gria3 AMPA 3, als 1.14 Gria4 AMPA 4 alcohol use 1.19 Grik1 kainate 1 presynaptic 1.06 Grik2 kainate 2 mossy fiber, synaptic plasticity 1.11 Grik5 kainate 5 mossy fiber 1.15 Grin1 NMDA NR1 brain −1.05 Grin2a NMDA NR2a brain −1.08 Grin2b NMDA NR2b brain 1.17 Grin2c NMDA NR2c brain 1.13 Grin2d NMDA NR2d brain −1.16 Grin3a NMDA NR3a 1.04 Grin3b NMDA3b motor neurons 1.09 Vdac1 voltage-dependent anion channel 1 1.02 Hsp90ab1 heat shock protein 90 α (cytosolic), class B member 1 1.16 Actb actin, β Avg Ct=22.3 Gapdh glyceraldehyde-3-phosphate dehydrogenase Avg Ct=23.4 Gusb glucuronidase, β Avg Ct=32.6 Hprt1 hypoxanthine guanine phosphoribosyl transferase 1 Avg Ct=23.8 MGDC mouse genomic DNA contamination No amp RTC reverse transcription control No amp PPC positive PCR control Avg Ct=18 * p<0.05 ***p<0.001",Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1335Table  2. a CeTylCholine  reCepTor primer  pair S. Subunit Accession  number Primer (5′-3′)Product   (bp)Temp  (C°)Primer  ratio (nmol)Product homology to  mouse sequence α2 nAChR NM_144803 F- GTGCCCAACACTTCCGATG 126 55.8 F400:R600 92% R-TGTAGTCATTCCATTCCTGCTTT α3 nAChR NM_145129 F- CCAGTTTGAGGTGTCTATGTC 198 55.8 F300:R200 99% R- TCGGCGTTGTTGTAAAGC α4 nAChR NM_015730 F-CTCAGATGTGGTCCTTGTC 178 62.6 F500:R400 95% R- GAGTTCAGATGGGATGCG α5 nAChR NM_176844 F- CATCGTTTTGTTTGATAATGC 90 55.8 F500:R300 84% R- TGCGTCCAAGTGACAGTG α6 nAChR NM_021369 F- TGTCTCCGATCCCGTCAC 213 62.6 F600:R500 98% R TTGTTATACAGAACGATGTCAGG α7 nAChR NM_007390 F-GGTCATTTGCCCACTCTG 130 57.6 F500:R500 99% R- GACAGCCTATCGGGTGAG α9 nAChR NM_001081104 F- ACAAGGCCACCAACTCCA 152 54.0 F400:R400 81% R- ACCAACCCACTCCTCCTCTT α10 nAChR NM_001081424 F- TCTGACCTCACAACCCACAA 168 54.0 F500:R400 94% R- TCCTGTCTCAGCCTCCATGT β2 nAChR NM_009602 F-CCGGCAAGAAGCCGGGACCT 152 62.6 F300:R400 97% R- CTCGCTGACACAAGGGCTGCG β3 nAChR NM_173212 F- AAGAAGCAGACTCCTACC 123 62.6 F200:R600 90% R- AACAACCTGACTGATGAAG β4 nAChR NM_148944 F- CTACAGGAAGCATTAGAGG 146 50.0 F300:R200 84% R- CAGAATACACACAATCACG m1 mAChR NM_007698 F-GACCCTACAGACCCCTCTCC 165 66.2 F600:R500 93% R- CCCTTCCTCCAGTCACAAGA m2 mAChR NM_203491 F-CGGCTTTCTATCTGCCTGTC 169 50.0 F100:R400 96% R- GGCATGTTGTTGTTGTTTGG m3 mAChR NM_033269 F-GTACAACCTCGCCTTTGTTTCC 244 62.6 F400:R200 99% R- GACAAGGATGTTGCCGATGATG m4 mAChR NM_007699 F-GCCTTCATCCTCACCTGGAC 146 62.6 F400:R200 99% R- AGTGGCATTGCAGAGTGCAT m5 mAChR NM_205783 F- CCATGGACTGTGGGAAGTCA 215 62.6 F300:R200 99% R- CAGCGTCCCATGAGGATGTA,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1336Subunit Accession  number Primer (5′-3′)Product   (bp)Temp  (C°)Primer  ratio (nmol)Product homology to  mouse sequence RyR3 NM_177652 F- AAGGTCATACTCCATCAGG 110 50.0 F400:R200 98% R- AATAAGGCGGTTGTGTTC,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1337final elongation cycle.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1338and incubated in a primary antibody overnight at 4 °C.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1339overnight in a primary antibody at 4  °C (Table 3).,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1340GCL is composed of ganglion and displaced amacrine cell  populations.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1341 Figure 4.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1342subunit in the whole retina.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1343 Figure 5.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1344 Figure 6.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1345whole mouse retinas.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1346 Figure 7.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1347 Figure 8.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
"Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1348for mAb210 were broadly distributed through the IPL and  overlapped the ChAT immunoreactive processes in sublamina  2 and sublamina 4, suggesting that α3 and α5 nAChRs are  distributed on processes within the ON and OFF pathways.",OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1349the ChAT (green) immunoreactive bands.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
"Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1350processes at sublamina 2 and sublamina 4, as well as diffuse  labeling throughout the IPL in the α7 nAChR KO mouse  retinas.",Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1351DISCUSSION We wanted to understand why the elimination of a receptor  subunit that is implicated in the development of the nervous  system and that plays a role in normal vision resulted in  a phenotype without significant observable phenotypic  dysfunction.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
"Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1352specific to particular cell types of the retina, and the combined  effect rises to significance.",Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
"Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1353In general, nAChRs are activated by ACh and nicotine  but blocked by curare, while mAChRs are activated by  ACh and muscarine but blocked by atropine.",Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1354ganglion cells of the rabbit retina.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  135534.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
Molecular Vision  2014; 20:1328-1356 <http://www.molvis.org/molvis/v 20/1328 > © 2014 Molecular Vision  1356A receptors.,Non-OADS,/arxiv_data1/oa_pdf/48/92/mv-v20-1328.PMC4169779.pdf
"ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionNon-CommercialLicense(http://creativecommons.org/licenses/by-nc/.0/),which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/bc/db/ehu214.PMC4169872.pdf
"In this study,  SRF samples of cases that underwent conventional retinal Molecular Vision  2014; 20:1357-1365 <http://www.molvis.org/molvis/v 20/1357 > Received 3 April 2014 | Accepted 19 September 2014 | Published 21 September 2014© 2014 Molecular Vision 1357Amino acid and vascular endothelial growth factor levels in  subretinal fluid in rhegmatogenous retinal detachment Ozgur Yalcinbayir,1 Rifat Levent Buyukuysal,2 Oner Gelisken,3 Cagatay Buyukuysal,4 Basak Can5 1Department of Ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/57/4e/mv-v20-1357.PMC4169890.pdf
Molecular Vision  2014; 20:1357-1365 <http://www.molvis.org/molvis/v 20/1357 > © 2014 Molecular Vision  1358detachment surgery were used and compared with samples of  vitreous from non-RRD cases.,Non-OADS,/arxiv_data1/oa_pdf/57/4e/mv-v20-1357.PMC4169890.pdf
"Molecular Vision  2014; 20:1357-1365 <http://www.molvis.org/molvis/v 20/1357 > © 2014 Molecular Vision  1359and post-column reaction temperatures were adjusted to  40 °C and 45 °C, respectively.",Non-OADS,/arxiv_data1/oa_pdf/57/4e/mv-v20-1357.PMC4169890.pdf
Molecular Vision  2014; 20:1357-1365 <http://www.molvis.org/molvis/v 20/1357 > © 2014 Molecular Vision  1360Table  1.,Non-OADS,/arxiv_data1/oa_pdf/57/4e/mv-v20-1357.PMC4169890.pdf
"Molecular Vision  2014; 20:1357-1365 <http://www.molvis.org/molvis/v 20/1357 > © 2014 Molecular Vision  1361of DRD, we observed that the levels of leucine, tyrosine,  phenylalanine, and valine steadily declined with time (Table  2).",Non-OADS,/arxiv_data1/oa_pdf/57/4e/mv-v20-1357.PMC4169890.pdf
Molecular Vision  2014; 20:1357-1365 <http://www.molvis.org/molvis/v 20/1357 > © 2014 Molecular Vision  1362We believe that the high concentrations of glutamate  and aspartate in this study represent the excitotoxic state of  the retinal neurons and photoreceptors.,Non-OADS,/arxiv_data1/oa_pdf/57/4e/mv-v20-1357.PMC4169890.pdf
Molecular Vision  2014; 20:1357-1365 <http://www.molvis.org/molvis/v 20/1357 > © 2014 Molecular Vision  1363showed that SRF concentrations of VEGF increased signifi - cantly in cases with RRD.,Non-OADS,/arxiv_data1/oa_pdf/57/4e/mv-v20-1357.PMC4169890.pdf
Molecular Vision  2014; 20:1357-1365 <http://www.molvis.org/molvis/v 20/1357 > © 2014 Molecular Vision  1364REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/57/4e/mv-v20-1357.PMC4169890.pdf
Molecular Vision  2014; 20:1357-1365 <http://www.molvis.org/molvis/v 20/1357 > © 2014 Molecular Vision  1365neurodegenerative disorders.,Non-OADS,/arxiv_data1/oa_pdf/57/4e/mv-v20-1357.PMC4169890.pdf
"Two adjacent 14 bp linker  tails from separate Z probes are required for the binding of Molecular Vision  2014; 20:1366-1373 <http://www.molvis.org/molvis/v 20/1366 > Received 4 September 2013 | Accepted 19 September 2014 | Published 21 September 2014© 2014 Molecular Vision 1366Simultaneous visualization and cell-specific confirmation of RNA  and protein in the mouse retina Andrew J. Stempel,1 Catherine W. Morgans,2 J. Timothy Stout,3 Binoy Appukuttan1 1Eye and Vision Health, Flinders University, Adelaide, South Australia, Australia; 2Department of Physiology & Pharmacology,  Oregon Health & Science University, Portland, OR; 3Cullen Eye Institute, Baylor College of Medicine, Houston, TX Purpose:  Simultaneous dual labeling to visualize specific RNA and protein content within the same formalin-fixed  paraffin embedded (FFPE) section can be technically challenging and usually impossible, because of variables such as  tissue fixation time and pretreatment methods to access the target RNA or protein.",Non-OADS,/arxiv_data1/oa_pdf/09/7f/mv-v20-1366.PMC4169891.pdf
Molecular Vision  2014; 20:1366-1373 <http://www.molvis.org/molvis/v 20/1366 > © 2014 Molecular Vision  1367a preamplifier.,Non-OADS,/arxiv_data1/oa_pdf/09/7f/mv-v20-1366.PMC4169891.pdf
Molecular Vision  2014; 20:1366-1373 <http://www.molvis.org/molvis/v 20/1366 > © 2014 Molecular Vision  1368a.,Non-OADS,/arxiv_data1/oa_pdf/09/7f/mv-v20-1366.PMC4169891.pdf
Molecular Vision  2014; 20:1366-1373 <http://www.molvis.org/molvis/v 20/1366 > © 2014 Molecular Vision  1369keep the oven or chamber humidified and to ensure that the  tissue section contained within the hydrophobic barrier is  completely covered with probe solution.],Non-OADS,/arxiv_data1/oa_pdf/09/7f/mv-v20-1366.PMC4169891.pdf
Molecular Vision  2014; 20:1366-1373 <http://www.molvis.org/molvis/v 20/1366 > © 2014 Molecular Vision  1370tissue with Slowfade.,Non-OADS,/arxiv_data1/oa_pdf/09/7f/mv-v20-1366.PMC4169891.pdf
Molecular Vision  2014; 20:1366-1373 <http://www.molvis.org/molvis/v 20/1366 > © 2014 Molecular Vision  1371be visualized fluorescently [ 8].,Non-OADS,/arxiv_data1/oa_pdf/09/7f/mv-v20-1366.PMC4169891.pdf
Molecular Vision  2014; 20:1366-1373 <http://www.molvis.org/molvis/v 20/1366 > © 2014 Molecular Vision  137272 h) and Pretreatment 2 and Pretreatment 3 incubation times  should be the first steps altered for optimization.,Non-OADS,/arxiv_data1/oa_pdf/09/7f/mv-v20-1366.PMC4169891.pdf
Molecular Vision  2014; 20:1366-1373 <http://www.molvis.org/molvis/v 20/1366 > © 2014 Molecular Vision  1373be directly attributed to mRNA abundance [ 9].,Non-OADS,/arxiv_data1/oa_pdf/09/7f/mv-v20-1366.PMC4169891.pdf
"4: 345-353, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.345 ▣MINI-REVIEW •Received 4 March 2014, revised 29 April 2014, accepted 24 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/f7/ad/kjp-52-345.PMC4170030.pdf
"*Corresponding author (gen@obihiro.ac.jp) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.New Molecules in Babesia gibsoni  and Their Application  for Diagnosis, Vaccine Development, and Drug Discovery Youn-Kyoung Goo1,2 and Xuenan Xuan1,*  1National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan;  2Department of Parasitology and Tropical Medicine, Kyungpook National University School of Medicine, Daegu, Korea Abstract:  Babesia gibsoni is an intraerythrocytic apicomplexan parasite that causes piroplasmosis in dogs.",Non-OADS,/arxiv_data1/oa_pdf/f7/ad/kjp-52-345.PMC4170030.pdf
doi: http://dx.doi.org/10.1645/13-278.1.,OADS,/arxiv_data1/oa_pdf/f7/ad/kjp-52-345.PMC4170030.pdf
"4: 355-365, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.355 ▣ORIGINAL ARTICLE •Received 19 April 2014, revised 29 May 2014, accepted 4 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/fb/7a/kjp-52-355.PMC4170031.pdf
"*Corresponding author (myeong@yuhs.ac) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Amoebic PI3K and PKC Is Required for Jurkat T Cell Death  Induced by Entamoeba histolytica Young Ah Lee, Kyeong Ah Kim, Arim Min, Myeong Heon Shin * Department of Environmental Medical Biology and Institute of Tropical Medicine, Yonsei University College of Medicine, Seoul 120-752, Korea Abstract:  The enteric protozoan parasite Entamoeba histolytica  is the causative agent of human amebiasis.",Non-OADS,/arxiv_data1/oa_pdf/fb/7a/kjp-52-355.PMC4170031.pdf
"4: 367-376, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.367 ▣ORIGINAL ARTICLE •Received 17 April 2014, revised 10 June 2014, accepted 15 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/ff/e7/kjp-52-367.PMC4170032.pdf
"*Corresponding author (howoo@catholic.ac.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.High Expression of Water-Soluble Recombinant Antigenic  Domains of Toxoplasma gondii Secretory Organelles Zhaoshou Yang, Hye-Jin Ahn, Ho-Woo Nam * Department of Parasitology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea Abstract:  Recombinant antigenic proteins of Toxoplasma gondii  are alternative source of antigens which are easily ob - tainable for serodiagnosis of toxoplasmosis.",Non-OADS,/arxiv_data1/oa_pdf/ff/e7/kjp-52-367.PMC4170032.pdf
Transmembrane regions of those proteins  were predicted by DAS server (http://www.sbc.su.se/~miklos/ DAS/maindas.html).,OADS,/arxiv_data1/oa_pdf/ff/e7/kjp-52-367.PMC4170032.pdf
"4: 377-381, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.377 ▣ORIGINAL ARTICLE •Received 21 April 2014, revised 17 June 2014, accepted 24 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/79/c7/kjp-52-377.PMC4170033.pdf
"*Corresponding author (kesaratmu@yahoo.com) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Nested-PCR and a New ELISA-Based NovaLisa Test Kit  for Malaria Diagnosis in an Endemic Area of Thailand Pimwan Thongdee1,2, Wanna Chaijaroenkul1,3, Jiraporn Kuesap1, Kesara Na-Bangchang1,3,* 1Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand; 2Graduate  Program in Biomedical Sciences, Thammasat University, Pathumthani, Thailand; 3Center of Excellence in Pharmacology and Molecular Biology of  Malaria and Cholangiocarcinoma, Thammasat University, Pathumthani, Thailand Abstract:  Microscopy is considered as the gold standard for malaria diagnosis although its wide application is limited by  the requirement of highly experienced microscopists.",Non-OADS,/arxiv_data1/oa_pdf/79/c7/kjp-52-377.PMC4170033.pdf
http://www.boe.moph.go.th/ Annual/AESR201 1/index.html.,Non-OADS,/arxiv_data1/oa_pdf/79/c7/kjp-52-377.PMC4170033.pdf
"4: 383-389, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.383 ▣ORIGINAL ARTICLE •Received 21 March 2014, revised 15 May 2014, accepted 26 May 2014.",Non-OADS,/arxiv_data1/oa_pdf/f6/03/kjp-52-383.PMC4170034.pdf
"*Corresponding author (bkna@gnu.ac.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Molecular Analysis of Anisakis  Type I Larvae in Marine Fish  from Three Different Sea Areas in Korea Woon-Mok Sohn, Jung-Mi Kang, Byoung-Kuk Na * Department of Parasitology and Tropical Medicine, and Institute of Health Sciences, Gyeongsang National University School of Medicine,   Jinju 660–751, Korea Abstract:  Anisakiasis, a human infection of Anisakis  L3 larvae, is one of the common foodborne parasitic diseases in Ko - rea.",Non-OADS,/arxiv_data1/oa_pdf/f6/03/kjp-52-383.PMC4170034.pdf
"4: 391-397, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.391 ▣ORIGINAL ARTICLE •Received 16 May 2014, revised 29 June 2014, accepted 15 July 2014.",Non-OADS,/arxiv_data1/oa_pdf/6a/7d/kjp-52-391.PMC4170035.pdf
"*Corresponding author (yhalee@cnu.ac.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Prevalence and Risk Factors of Clonorchiasis among  Residents of Riverside Areas in Muju-gun,   Jeollabuk-do, Korea Do-Soon Park1,†, Sung-Jin Na2,†, Shin Hyeong Cho3, Kyung Ja June4, Young-Chae Cho1, Young-Ha Lee2,*  1Graduate School of Public Health, Chungnam National University, Daejeon 301-131, Korea; 2Department of Infection Biology, School of Medicine,  Chungnam National University, Daejeon 301-131, Korea; 3Division of Malaria and Parasitic Diseases, Korea National Institute of Health,   Osong 363-951, Korea; 4Department of Nursing, Soonchunhyang University, Chonan 330-090, Korea  Abstract:  We evaluated the status of Clonorchis sinensis  infection and potential risk factors among residents of riverside  areas (Geumgang) in Muju-gun, Jeollabuk-do (Province), Korea.",Non-OADS,/arxiv_data1/oa_pdf/6a/7d/kjp-52-391.PMC4170035.pdf
"4: 399-412, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.399 ▣ORIGINAL ARTICLE •Received 17 April 2014, revised 16 May 2014, accepted 26 May 2014.",Non-OADS,/arxiv_data1/oa_pdf/90/a4/kjp-52-399.PMC4170036.pdf
"*Corresponding author (wmsohn@gnu.ac.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Prevalence of Zoonotic Trematode Metacercariae in  Freshwater Fish from Gangwon-do, Korea Shin-Hyeong Cho1, Won-Ja Lee1, Tong-Soo Kim2, Won-Seok Seok3, Taejoon Lee3, Kyungjin Jeong3,   Byoung-Kuk Na4, Woon-Mok Sohn4,* 1Division of Malaria and Parasitic Diseases, National Institute of Health, Centers for Disease Control and Prevention, Osong 363-951, Korea;  2Department of Parasitology and Inha Research Institute for Medical Sciences, Inha University College of Medicine, Incheon 400-103, Korea;  3Infection Disease Intelligence Division, Gangwon Institute of Health and Environment, Chuncheon  200-822, Korea; 4Department of Parasitology  and Tropical Medicine, and Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 660-751, Korea Abstract:  The infection status of zoonotic trematode metacercariae was investigated in a total of 2,293 freshwater fish  collected from 11 rivers or streams in 9 administrative regions of Gangwon-do, Korea for 5 years (2009-2013).",Non-OADS,/arxiv_data1/oa_pdf/90/a4/kjp-52-399.PMC4170036.pdf
Gangwon Province (South Korea) in Wikipedia - The free ency - clopedia: http://en.wikipedia.org 12.,Non-OADS,/arxiv_data1/oa_pdf/90/a4/kjp-52-399.PMC4170036.pdf
"4: 413-418, August 2014  http://dx.doi.org/ 10.3347/kjp.2014.52.4.413 ▣ORIGINAL ARTICLE •Received 7 December 2013, revised 30 April 2014, accepted 22 May 2014.",Non-OADS,/arxiv_data1/oa_pdf/6e/7f/kjp-52-413.PMC4170037.pdf
"*Corresponding author (Hosseinisafa_ahmad@hotmail.com) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Genetic Diversity of Echinococcus granulosus  in Center   of Iran Nader Pestechian1, Ahmad Hosseini Safa1,*, Mohammadhasan Tajedini2,3, Mohammad Rostami-Nejad4,  Mohammad Mousavi1, Hosseinali Yousofi1, Shaghayegh Haghjooy Javanmard3 1Department of Medical Parasitology and Mycology Isfahan University of Medical Sciences, Isfahan, Iran; 2Department of Clinical Biochemistry,  School of Pharmacy and Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; 3Physiology  Research Center, Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran; 4Gastroenterology and Liver Disease Research  Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Abstract:  Hydatid cyst caused by Echinococcus granulosus  is one of the most important parasitic diseases around the  world and many countries in Asia, including Iran, are involved with this infection.",Non-OADS,/arxiv_data1/oa_pdf/6e/7f/kjp-52-413.PMC4170037.pdf
"4: 419-423, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.419 ▣ORIGINAL ARTICLE •Received 23 February 2014, revised 14 May 2014, accepted 24 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/7f/da/kjp-52-419.PMC4170038.pdf
"†Present address: Department of Clinical Pathology, Gwangju Health University,  Gwangju 506-701, Korea *Corresponding author (wmsohn@gnu.ac.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Intestinal Helminthic Infections in Striped Field Mice,  Apodemus agrarius , from Two Southern Regions of Korea Woon-Mok Sohn1,*, Byoung-Kuk Na1, Hyeon-Je Song2,†, Chung-Mo Kim2, Gi-Jin Nam3 1Department of Parasitology and Tropical Medicine, and Institute of Health Science, Gyeongsang National University School of Medicine,   Jinju 660-751, Korea; 2Department of Microbiology, Jeollanam-do Institute of Health and Environment, Gwangju 502-810, Korea;   3Department of Microbiology, Gyeongsangnam-do Institute of Health and Environment, Changwon 641-825, Korea  Abstract:  The present study was performed to know the infection status of intestinal helminths in a most common spe - cies of field mice, Apodemus agrarius , from 2 southern regions of Korea.",Non-OADS,/arxiv_data1/oa_pdf/7f/da/kjp-52-419.PMC4170038.pdf
"4: 425-428, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.425 ▣CASE REPORT •Received 19 March 2014, revised 15 May 2014, accepted 24 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/df/f0/kjp-52-425.PMC4170039.pdf
"*Corresponding author (infection@korea.ac.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Pulmonary Toxocariasis Mimicking Invasive Aspergillosis  in a Patient with Ulcerative Colitis Eun Jin Park1, Joon Young Song1,2,*, Min Ju Choi1, Ji Ho Jeon1, Jah-yeon Choi1, Tae Un Yang1, Kyung Wook Hong1,  Ji Yun Noh1,2, Hee Jin Cheong1,2, Woo Joo Kim1,2 1Department of Internal Medicine, Korea University College of Medicine, Seoul 136-705, Korea; 2Asian Pacific Influenza Institute (APII), Korea  University College of Medicine, Seoul 136-705, Korea Abstract:  A 45-year-old-male who had underlying ulcerative colitis and presented with fever and dry cough.",Non-OADS,/arxiv_data1/oa_pdf/df/f0/kjp-52-425.PMC4170039.pdf
"4: 429-433, August 2014  http://dx.doi.org/ 10.3347/kjp.2014.52.4.429 ▣BRIEF COMMUNICATION •Received 20 September 2013, revised 28 May 2014, accepted 4 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/f7/ee/kjp-52-429.PMC4170040.pdf
"*Corresponding author (enedina@servidor.unam.mx) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.The MAK16  Gene of Entamoeba histolytica  and Its  Identification in Isolates from Patients  María del Pilar Crisóstomo-Vázquez, Víctor Alberto Marevelez-Acosta, Andrés Flores-Luna,   Enedina Jiménez-Cardoso * Hospital Infantil de México Federico Gómez, Laboratory of Parasitology Research, Dr. Márquez #162 Col. Doctores, 06720, México, D.F.",Non-OADS,/arxiv_data1/oa_pdf/f7/ee/kjp-52-429.PMC4170040.pdf
"Oli - gonucleotides were designed to amplify the mak16  gene using  the PRIMER3 program (http://www-genome.wi.mit.edu/cgi- bin/primer/primer3_www.cgi): F, 5 ´-CGAATGGCCAAACTT - GATTT-3 ´; R, 5 ´-CAAACGTT CTGCCCAATCTT-3 ´.",OADS,/arxiv_data1/oa_pdf/f7/ee/kjp-52-429.PMC4170040.pdf
"4: 435-438, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.435 ▣BRIEF COMMUNICATION •Received 24 December 2013, revised 15 May 2014, accepted 24 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/28/9d/kjp-52-435.PMC4170041.pdf
"*Corresponding author (tick@chonbuk.ac.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Suppression of Eimeria tenella  Sporulation by Disinfectants Myung-Jo You * Laboratory of Veterinary Parasitology, College of Veterinary Medicine and Biosafety Research Center, Chonbuk National University,   Jeonju 561-756, Korea Abstract:  The disinfectant effects (DEs) of 10 types of chemicals, defined by their ability to destroy or inhibit oocysts and  consequently prevent sporulation of Eimeria tenella  field isolate, were evaluated in vitro.",Non-OADS,/arxiv_data1/oa_pdf/28/9d/kjp-52-435.PMC4170041.pdf
"4: 439-441, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.439 ▣BRIEF COMMUNICATION •Received 17 March 2014, revised 14 May 2014, accepted 24 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/bb/93/kjp-52-439.PMC4170042.pdf
"*Corresponding author (howoo@catholic.ac.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Gefitinib Inhibits the Growth of Toxoplasma gondii  in   HeLa Cells Zhaoshou Yang, Hye-Jin Ahn, Ho-Woo Nam * Department of Parasitology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea Abstract:  Toxoplasma gondii  is the causative agent of toxoplasmosis with symptoms of congenital neurological and ocu - lar diseases and acquired lymphadenitis, retinochoroiditis, and meningoencephalitis.",Non-OADS,/arxiv_data1/oa_pdf/bb/93/kjp-52-439.PMC4170042.pdf
"4: 443-447, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.443 ▣BRIEF COMMUNICATION •Received 13 November 2013, revised 21 May 2014, accepted 24 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/67/74/kjp-52-443.PMC4170043.pdf
"*Corresponding author (ondalgl@cdc.go.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Molecular Detection and Seroprevalence of Babesia  microti  among Stock Farmers in Khutul City, Selenge  Province, Mongolia Sung-Hee Hong1, Davaasuren Anu2, Young-Il Jeong1, Davaajav Abmed2, Shin-Hyeong Cho1, Won-Ja Lee1,   Sang-Eun Lee1,* 1Division of Malaria &Parasitic Diseases, Korea National Institute of Health, Korea Centers for Disease Control and Prevention, Osong 363-951, Korea;   2Laboratory of Parasitology, National Center for Communicable Diseases, Ministry of Health, Ulaanbaator-210648, Mongolia Abstract:  Babesiosis is an emerging tick-borne disease in humans worldwide; however, little is known about the frequen - cy of infection or prevalence of this disease in other parts of the world, excluding North America.",Non-OADS,/arxiv_data1/oa_pdf/67/74/kjp-52-443.PMC4170043.pdf
"4: 449-451, August 2014   http://dx.doi.org/ 10.3347/kjp.2014.52.4.449 ▣BRIEF COMMUNICATION •Received 12 May 2014, revised 24 June 2014, accepted 24 June 2014.",Non-OADS,/arxiv_data1/oa_pdf/25/b4/kjp-52-449.PMC4170044.pdf
"*Corresponding author (gmpark@kd.ac.kr) © 2014, Korean Society for Parasitology and Tropical Medicine This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Karyological Studies of Biomphalaria tenagophila   (d’Orbigny, 1835) (Gastropoda: Planobidae) from   Rio de Janeiro, Brazil Gab Man Park1,* and Tai-Soon Yong2 1Department of Environmental Medical Biology, Kwandong University College of Medicine, Gangneung 210-701, Korea; 2Department of  Environmental Medical Biology and Institute of Tropical Medicine, Yonsei University College of Medicine, Seoul 120-752, Korea Abstract:  The karyotypes of Biomphalaria tenagophila  collected from Rio de Janeiro, Brazil were studied using the air- drying method.",Non-OADS,/arxiv_data1/oa_pdf/25/b4/kjp-52-449.PMC4170044.pdf
"http://e-jbm.org/   163Copyright © 2014 The Korean Society for Bone and  Mineral Research This is an Open Access article distributed under the terms  of the Creative Commons Attribution Non-Commercial Li - cense (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribu - tion, and reproduction in any medium, provided the original  work is properly cited.J Bone Metab 2014;21:163-167 http://dx.doi.org/10.11005/jbm.2014.21.3.163 pISSN 2287-6375 eISSN 2287-7029 Factors and Mechanisms Involved in the Coupling  from Bone Resorption to Formation: How  Osteoclasts Talk to Osteoblasts Kyoji Ikeda, Sunao Takeshita Department of Bone and Joint Disease, National Center for Geriatrics and Gerontology, Obu, Japan Bone remodeling is the fundamental means by which the quality as well as quantity of  the skeleton is maintained throughout adult life.",Non-OADS,/arxiv_data1/oa_pdf/d3/b9/jbm-21-163.PMC4170079.pdf
"164  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.163tial coupling factors, including two secretory products that  were recently identified in our laboratory (Fig.",OADS,/arxiv_data1/oa_pdf/d3/b9/jbm-21-163.PMC4170079.pdf
Coupling Factors http://dx.doi.org/10.11005/jbm.2014.21.3.163  http://e-jbm.org/   165identified as a factor present in the conditioned medium  of osteoclast-like cells generated from a RAW264.7 macro - phage cell line with receptor activator of nuclear factor-kap - pa B ligand (RANKL) that inhibited ALP activity in a mouse  osteoblastic cell line (MC3T3-E1) preosteoblastic cell line;  the inhibitory activity contained in the conditioned medi - um was abrogated by a neutralizing anti-PDGF-BB anti - body.,Non-OADS,/arxiv_data1/oa_pdf/d3/b9/jbm-21-163.PMC4170079.pdf
166  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.163tion remains to be determined.,Non-OADS,/arxiv_data1/oa_pdf/d3/b9/jbm-21-163.PMC4170079.pdf
Coupling Factors http://dx.doi.org/10.11005/jbm.2014.21.3.163  http://e-jbm.org/   1676.,OADS,/arxiv_data1/oa_pdf/d3/b9/jbm-21-163.PMC4170079.pdf
"http://e-jbm.org/   169Copyright © 2014 The Korean Society for Bone and  Mineral Research This is an Open Access article distributed under the terms  of the Creative Commons Attribution Non-Commercial Li - cense (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribu - tion, and reproduction in any medium, provided the original  work is properly cited.J Bone Metab 2014;21:169-188 http://dx.doi.org/10.11005/jbm.2014.21.3.169 pISSN 2287-6375 eISSN 2287-7029 Microarray Analysis of Gene Expression Reveals that  Cyclo-oxygenase-2 Gene Therapy Up-regulates  Hematopoiesis and Down-regulates Inflammation  During Endochondral Bone Fracture Healing K.-H. William Lau1,2, Nicoleta L. Popa1, Charles H. Rundle1,2 1Research Service (151), Jerry L. Pettis Memorial Veterans Administration Medical Center, Loma Linda, CA; 2Department of Medicine, Loma  Linda University School of Medicine, Loma Linda, CA, USA Background:  Cyclo-oxygenase-2 (Cox-2) is an inflammatory mediator that is necessary  for the tissue repair, including bone fracture healing.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"170  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.169and ossify to bridge the injury with woven bone that is even - tually remodeled to cortical bone, a sequence of healing  stages that facilitates the evaluation of bone repair and the  efficacy of therapeutic approaches.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
Gene Expression in Cox-2 Fracture Therapy http://dx.doi.org/10.11005/jbm.2014.21.3.169  http://e-jbm.org/   171current study has confirmed significant expression of the  hCox-2 transgene in the Cox-2-treated fracture tissues used  in this study by microarray and real-time RT-PCR (data not  shown).,OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
172  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.169from that GO category on the chip.,Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
Gene Expression in Cox-2 Fracture Therapy http://dx.doi.org/10.11005/jbm.2014.21.3.169  http://e-jbm.org/   173Fig.,OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
174  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.169Table 3.,Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"Gene Expression in Cox-2 Fracture Therapy http://dx.doi.org/10.11005/jbm.2014.21.3.169  http://e-jbm.org/   175Positively enriched gene setsTotal   entities# of measured  entitiesNormalized  ESMedian  changeP-value Lymphocyte differentiation 13 7 1.9 1.2 0.00 Purine ribonucleoside monophosphate biosynthetic process 21 15 1.9 1.1 0.00 Positive regulation of protein serine-threonine kinase activity 16 11 1.9 1.1 0.00 Cell aging 41 32 1.9 1.1 0.00 Toll-like receptor 1 signaling pathway 71 65 1.9 1.1 0.00 Nerve growth factor receptor signaling pathway 224 201 1.9 1.1 0.00 Mitotic metaphase-anaphase transition 16 13 1.9 1.1 0.00 MyD88-dependent toll-like receptor signaling pathway 80 70 1.9 1.1 0.00 Actin filament capping 23 18 1.9 1.0 0.00 Attachment of spindle microtubules to kinetochore 9 6 1.8 1.3 0.00 Microtubule nucleation 18 11 1.8 1.1 0.00 G2-M transition DNA damage checkpoint 19 17 1.8 1.1 0.00 Toll-like receptor 4 signaling pathway 83 72 1.8 1.1 0.00 Stress-activated MAPK cascade 54 47 1.8 1.1 0.00 ATP biosynthetic process 74 56 1.8 1.0 0.00 Toll-like receptor signaling pathway 92 72 1.8 1.1 0.00 Small GTPase mediated signal transduction 375 290 1.7 1.1 0.00 MyD88-independent toll-like receptor signaling pathway 69 63 1.7 1.1 0.00 Pyrimidine nucleotide biosynthetic process 13 8 1.7 1.1 0.00 Intracellular signal transduction 388 309 1.7 1.1 0.00 Toll-like receptor 3 signaling pathway 66 59 1.7 1.1 0.00 Alpha-beta T cell differentiation 16 7 1.7 1.0 0.00 Induction of apoptosis by extracellular signals 118 94 1.7 1.1 0.00 Microtubule-based movement 121 82 1.6 1.0 0.00 Cell morphogenesis 64 54 1.6 1.0 0.00 Toll signaling pathway 80 72 1.6 1.1 0.00 Regulation of cell shape 76 67 1.6 1.1 0.00 Metabolic process 2,421 2,156 1.6 1.0 0.00 Integrin-mediated signaling pathway 103 93 1.6 1.0 0.00 Platelet degranulation 80 74 1.6 1.0 0.00 Cell proliferation 429 359 1.6 1.0 0.00 Intracellular protein kinase cascade 125 105 1.5 1.1 0.00 Cell surface receptor linked signaling pathway 259 218 1.4 -1.0 0.00 Anti-apoptosis 243 207 1.4 1.0 0.00 Viral reproduction 362 267 1.4 1.0 0.00 Transmembrane transport 831 695 1.3 -1.0 0.00 Regulation of transcription, DNA-dependent 2,872 1,888 1.1 1.0 0.00 Negatively enriched gene setsTotal   entities# of measured  entitiesNormalized  ESMedian  changeP-value Proteolysis 657 470 -1.3 -1.0 0.03 Detection of chemical stimulus involved in sensory perception of smell 1,100 773 -2.3 -1.1 0.00 Spermatogenesis 423 336 -1.3 -1.0 0.03 Multicellular organismal development 1,146 985 -1.3 -1.0 0.00 Ion transport 693 595 -1.3 -1.0 0.01 Cell differentiation 735 585 -1.3 -1.0 0.01Table 3.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
176  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.169Table 3.,Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"Gene Expression in Cox-2 Fracture Therapy http://dx.doi.org/10.11005/jbm.2014.21.3.169  http://e-jbm.org/   177Negatively enriched gene setsTotal   entities# of measured  entitiesNormalized  ESMedian  changeP-value Inhibition of adenylate cyclase activity by metabotropic glutamate receptor      signaling pathway9 6 -1.5 -1.2 0.03 Fertilization 36 30 -1.5 -1.0 0.03 Positive regulation of leukocyte chemotaxis 17 8 -1.5 -1.1 0.05 Thyroid gland development 20 19 -1.5 -1.1 0.05 Forebrain dorsal-ventral pattern formation 6 5 -1.5 -1.3 0.03 Chemotaxis 153 113 -1.5 -1.1 0.02 Insulin secretion 43 36 -1.5 -1.1 0.03 Positive regulation of tissue remodeling 8 6 -1.6 -1.2 0.01 Mating behavior 10 9 -1.6 -1.1 0.03 Thyroid hormone generation 10 10 -1.6 -1.1 0.04 Cellular response to gonadotropin stimulus 11 9 -1.6 -1.2 0.05 Organic acid metabolic process 14 9 -1.6 -1.1 0.04 Behavioral response to ethanol 6 6 -1.6 -1.1 0.05 Phenol-containing compound metabolic process 11 6 -1.6 -1.2 0.04 Retinoid metabolic process 19 14 -1.6 -1.1 0.03 Bile acid biosynthetic process 25 22 -1.6 -1.1 0.03 Myoblast differentiation 18 13 -1.6 -1.1 0.04 Calcium ion-dependent exocytosis 25 18 -1.6 -1.1 0.03 Positive regulation of immunoglobulin secretion 7 7 -1.6 -1.2 0.02 Cardiac muscle cell differentiation 20 16 -1.6 -1.0 0.05 Positive regulation of circadian sleep-wake cycle, non-REM sleep 6 5 -1.6 -1.2 0.02 Calcium-independent cell-cell adhesion 27 24 -1.6 -1.1 0.02 Steroid metabolic process 120 91 -1.6 -1.0 0.01 Gamma-aminobutyric acid signaling pathway 25 24 -1.6 -1.1 0.03 Forebrain anterior-posterior pattern formation 6 5 -1.6 -1.2 0.00 Response to vitamin A 27 20 -1.6 -1.0 0.03 Retrograde axon cargo transport 6 6 -1.6 -1.0 0.03 Sensory perception of sound 126 105 -1.6 -1.1 0.00 Peptide hormone processing 26 16 -1.6 -1.1 0.02 Biphenyl metabolic process 10 8 -1.6 -1.1 0.02 Glucocorticoid metabolic process 14 7 -1.6 -1.2 0.03 Maternal process involved in parturition 7 5 -1.6 -1.0 0.03 Sensory perception of taste 106 51 -1.6 -1.1 0.01 Rhodopsin mediated phototransduction 6 6 -1.6 -1.2 0.02 Maintenance of gastrointestinal epithelium 8 5 -1.6 -1.2 0.02 Maternal behavior 8 6 -1.6 -1.2 0.03 Regulation of cytoskeleton organization 13 7 -1.6 1.0 0.03 Negative regulation of secretion 19 5 -1.6 -1.2 0.03 Axis specification 22 15 -1.6 -1.2 0.02 Adult heart development 15 15 -1.6 -1.2 0.02 Intermediate filament cytoskeleton organization 13 9 -1.6 -1.1 0.02 Phthalate metabolic process 7 7 -1.6 -1.2 0.03 Adenohypophysis development 11 11 -1.6 -1.2 0.02 Estrogen biosynthetic process 10 10 -1.6 -1.1 0.03Table 3.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"178  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.169Negatively enriched gene setsTotal   entities# of measured  entitiesNormalized  ESMedian  changeP-value Pattern specification process 115 93 -1.6 -1.0 0.00 Sensory perception of chemical stimulus 33 27 -1.6 -1.1 0.02 Positive regulation of glycolysis 9 9 -1.6 -1.2 0.01 Central nervous system development 137 126 -1.6 -1.1 0.00 Neuron fate commitment 36 29 -1.6 -1.2 0.01 Inner ear development 34 32 -1.6 -1.0 0.00 Response to bacterium 42 36 -1.6 -1.0 0.01 piRNA metabolic process 10 8 -1.6 -1.2 0.01 Suckling behavior 13 11 -1.6 -1.0 0.04 Regulation of heart contraction 48 39 -1.6 -1.1 0.02 G-protein signaling, coupled to cyclic nucleotide second messenger 43 40 -1.6 -1.1 0.01 Positive regulation of receptor internalization 9 8 -1.6 -1.2 0.03 Sarcomere organization 22 15 -1.6 -1.2 0.02 Glucocorticoid biosynthetic process 13 9 -1.6 -1.1 0.03 Regulation of alternative nuclear mRNA splicing, via spliceosome 11 9 -1.6 -1.2 0.04 Behavioral response to nicotine 8 7 -1.6 -1.2 0.02 Intermediate filament organization 15 11 -1.6 -1.2 0.00 Regulation of calcium ion-dependent exocytosis 14 11 -1.6 -1.2 0.03 Sensory perception of light stimulus 14 11 -1.6 -1.2 0.01 Cellular response to transforming growth factor beta stimulus 21 18 -1.7 -1.1 0.03 Neutrophil chemotaxis 37 30 -1.7 -1.0 0.01 Regulation of ion transmembrane transport 177 165 -1.7 -1.1 0.00 Spinal cord association neuron differentiation 10 9 -1.7 -1.2 0.01 Cerebral cortex GABAergic interneuron migration 5 5 -1.7 -1.2 0.02 Positive regulation of tyrosine phosphorylation of Stat5 protein 18 15 -1.7 -1.1 0.02 Intermediate filament-based process 10 8 -1.7 -1.2 0.02 Positive regulation of neuron differentiation 60 56 -1.7 -1.1 0.00 Muscle organ development 115 102 -1.7 -1.0 0.00 Response to stilbenoid 14 13 -1.7 -1.2 0.01 Phototransduction, visible light 9 8 -1.7 -1.2 0.02 Excretion 46 38 -1.7 -1.1 0.00 Plasma membrane repair 6 5 -1.7 -1.3 0.00 Behavior 67 40 -1.7 -1.1 0.01 Anatomical structure morphogenesis 166 96 -1.7 -1.1 0.00 Sodium ion transmembrane transport 29 28 -1.7 -1.1 0.00 Visual perception 230 198 -1.7 -1.1 0.00 Bile acid and bile salt transport 24 22 -1.7 -1.1 0.02 Cartilage condensation 24 21 -1.7 -1.0 0.00 Dibenzo-p-dioxin metabolic process 12 11 -1.7 -1.2 0.01 Forebrain neuron differentiation 11 10 -1.7 -1.2 0.01 Cytolysis 31 22 -1.7 -1.1 0.02 Positive regulation of heart rate 12 9 -1.7 -1.2 0.01 Inner ear morphogenesis 68 65 -1.8 -1.1 0.00 Grooming behavior 14 13 -1.8 -1.2 0.02Table 3.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"Gene Expression in Cox-2 Fracture Therapy http://dx.doi.org/10.11005/jbm.2014.21.3.169  http://e-jbm.org/   179Negatively enriched gene setsTotal   entities# of measured  entitiesNormalized  ESMedian  changeP-value Neuron fate specification 11 8 -1.8 -1.1 0.00 Camera-type eye development 65 51 -1.8 -1.1 0.01 Positive regulation of insulin-like growth factor receptor signaling pathway 13 11 -1.8 -1.2 0.01 Detection of light stimulus involved in visual perception 8 7 -1.8 -1.2 0.00 Digestion 69 43 -1.8 -1.2 0.00 Cytosolic calcium ion homeostasis 20 14 -1.8 -1.1 0.01 Peripheral nervous system development 43 34 -1.8 -1.1 0.00 Complement activation, classical pathway 59 26 -1.8 -1.1 0.00 Positive regulation of T cell chemotaxis 8 7 -1.8 -1.0 0.00 Feeding behavior 48 37 -1.8 -1.1 0.00 Synaptic transmission, cholinergic 23 17 -1.8 -1.2 0.00 Positive regulation of phagocytosis 37 27 -1.8 -1.2 0.00 Regulation of muscle contraction 32 24 -1.8 -1.1 0.01 Hormone biosynthetic process 72 61 -1.9 -1.1 0.00 Keratinocyte proliferation 17 14 -1.9 -1.1 0.00 Macrophage chemotaxis 16 11 -1.9 -1.2 0.00 Aromatic amino acid family metabolic process 18 9 -1.9 -1.2 0.00 Neurotransmitter secretion 73 61 -2.0 -1.1 0.00 Positive regulation of nitric oxide biosynthetic process 36 33 -2.0 -1.0 0.00 Regulation of membrane potential 58 44 -2.0 -1.2 0.00 Chemokine-mediated signaling pathway 7 5 -2.0 -1.4 0.00 Epidermis development 102 77 -2.0 -1.1 0.00 Lymphocyte chemotaxis 14 10 -2.1 -1.3 0.00 Cellular response to interferon-beta 15 11 -2.2 -1.8 0.00 Muscle contraction 126 105 -2.2 -1.1 0.00 Muscle filament sliding 41 35 -2.3 -1.2 0.00 Cellular response to interferon-gamma 25 23 -2.3 -1.2 0.00 ES, enrichment score; GTPase, guanosine triphosphatase; ARF, ADP-ribosylation factor; MAPK,mitogen-activated protein kinase; ATP , adenosine triphos - phate; REM, rapid eye movement; GABA, gamma-aminobutyric acid.Table 3.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
180  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.169Table 4.,Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"Gene Expression in Cox-2 Fracture Therapy http://dx.doi.org/10.11005/jbm.2014.21.3.169  http://e-jbm.org/   1811.5-Fold up-regulated      gene symbolDescriptionGenbank   accessionFold-change Orc1l Origin recognition complex, subunit 1-like (S.cerevisiae) NM_011015 2.0 Epor Erythropoietin receptor NM_010149 2.0 Gata1 GATA binding protein 1 NM_008089 2.0 Fcrla Fc receptor-like A NM_145141 1.9 F2rl2 Coagulation factor II (thrombin) receptor-like 2 NM_010170 1.9 Fcna Ficolin A NM_007995 1.9 Gp9 Glycoprotein 9 (platelet) NM_018762 1.9 Prtn3 Proteinase 3 NM_011178 1.9 Cd79b CD79B antigen NM_008339 1.9 Spnb1 Spectrin beta 1 NM_013675 1.9 Hist1h1a Histone cluster 1, H1a NM_030609 1.9 IL-1a Interleukin-1 alpha NM_010554 1.9 Car2 Carbonic anhydrase 2 NM_009801 1.9 Trim58 Tripartite motif-containing 58 NM_001039047 1.9 Nfe2 Nuclear factor, erythroid derived 2 NM_008685 1.9 Acss1 Acyl-CoA synthetase short-chain family member 1 NM_080575 1.9 Bcl11a B-cell CLL/lymphoma 11A (zinc finger protein) NM_016707 1.8 Hbq1 Hemoglobin, theta 1 NM_175000 1.8 Gp5 Glycoprotein 5 (platelet) NM_008148 1.8 E2f2 E2F transcription factor 2 NM_177733 1.8 Lrmp Lymphoid-restricted membrane protein NM_008511 1.8 Nup210 Nucleoporin 210 NM_018815 1.8 Alas2 Aminolevulinic acid synthase 2, erythroid NM_009653 1.8 Tmcc2 Transmembrane and coiled-coil domains 2 NM_178874 1.8 Tac2 Tachykinin 2 NM_009312 1.8 Ikzf3 IKAROS family zinc finger 3 NM_011771 1.8 Itga2b Integrin alpha 2b NM_010575 1.8 IRF4 Interferon regulatory factor 4 NM_013674 1.8 Slc25a37 Solute carrier family 25, member 37 NM_026331 1.8 Gcet2 Germinal center expressed transcript 2 NM_008099 1.8 Dntt Deoxynucleotidyltransferase, terminal NM_009345 1.8 Bpgm 2,3-bisphosphoglycerate mutase NM_007563 1.8 Cecr2 Cat eye syndrome chromosome region, candidate 2 homolog (human) NM_001128151 1.8 Siglecg Sialic acid binding Ig-like lectin G NM_172900 1.8 Zfpm1 Zinc finger protein, multitype 1 NM_009569 1.8 Pou2af1 POU domain, class 2, associating factor 1 NM_011136 1.8 Xk Kell blood group precursor (McLeod phenotype) homolog NM_023500 1.8 Chst3 Carbohydrate (chondroitin 6/keratan) sulfotransferase 3 NM_016803 1.8 Epb4.9 Erythrocyte protein band 4.9 NM_013514 1.8 Mup2 Major urinary protein 2 NM_008647 1.8 Art4 ADP-ribosyltransferase 4 NM_026639 1.8 Abcb10 ATP-binding cassette, sub-family B (MDR/TAP), member 10 NM_019552 1.8 Kcnj5 Potassium inwardly-rectifying channel, subfamily J, member 5 NM_010605 1.8 Slamf1 Signaling lymphocytic activation molecule family member 1 NM_013730 1.7Table 4.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"182  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.1691.5-Fold up-regulated      gene symbolDescriptionGenbank   accessionFold-change Cdc6 Cell division cycle 6 homolog (S. cerevisiae) NM_011799 1.7 Slc43a1 Solute carrier family 43, member 1 NM_001081349 1.7 Fhdc1 FH2 domain containing 1 NM_001033301 1.7 Snca Synuclein, alpha NM_001042451 1.7 Bard1 BRCA1 associated RING domain 1 NM_007525 1.7 Prg4 Proteoglycan 4 (megakaryocyte stimulating factor, articular superficial zone protein) NM_021400 1.7 Stab2 Stabilin 2 NM_138673 1.7 Mpo Myeloperoxidase NM_010824 1.7 Uhrf1 Ubiquitin-like, containing PHD and RING finger domains, 1 NM_010931 1.7 Rasgrp2 RAS, guanyl releasing protein 2 NM_011242 1.7 Ms4a3 Membrane-spanning 4-domains, subfamily A, member 3 NM_133246 1.7 Cd5l CD5 antigen-like NM_009690 1.7 Ppbp Pro-platelet basic protein NM_023785 1.7 Clec1b C-type lectin domain family 1, member b NM_019985 1.7 Kif14 Kinesin family member 14 NM_001081258 1.7 Gnaz Guanine nucleotide binding protein, alpha z subunit NM_010311 1.7 Atp2a3 ATPase, Ca++ transporting, ubiquitous NM_016745 1.7 Tmc8 Transmembrane channel-like gene family 8 NM_181856 1.7 Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 NM_008830 1.7 Abcg4 ATP-binding cassette, sub-family G (WHITE), member 4 NM_138955 1.7 CXCR5 Chemochine (C-X-C motif) receptor 5 NM_007551 1.7 Slc6a4 Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 NM_010484 1.6 Ctsg Cathepsin G NM_007800 1.6 Ly6d Lymphocyte antigen 6 complex, locus D NM_010742 1.6 Fbxo5 F-box protein 5 NM_025995 1.6 Depdc1b DEP domain containing 1B NM_178683 1.6 IL7r Interleukin 7 receptor NM_008372 1.6 Blnk B-cell linker NM_008528 1.6 Cdc25b Cell division cycle 25 homolog B (S. pombe) NM_023117 1.6 Alad Aminolevulinate, delta-, dehydratase NM_008525 1.6 Kcnn4 Potassium intermediate/small conductance calcium-activated channel, subfamily N,      member 4NM_008433 1.6 Mns1 Meiosis-specific nuclear structural protein 1 NM_008613 1.6 Hmbs Hydroxymethylbilane synthase NM_013551 1.6 Slc16a10 Solute carrier family 16 (monocarboxylic acid transporters), member 10 NM_001114332 1.6 Cpox Coproporphyrinogen oxidase NM_007757 1.6 Slc15a2 Solute carrier family 15 (H+/peptide transporter), member 2 NM_021301 1.6 Pdia2 Protein disulfide isomerase associated 2 NM_001081070 1.6 Pkd2l2 Polycystic kidney disease 2-like 2 NM_016927 1.6 Slc14a1 Solute carrier family 14 (urea transporter), member 1 NM_028122 1.6 Ypel4 Yippee-like 4 (Drosophila) NM_001005342 1.6 Rbm38 RNA binding motif protein 38 NM_019547 1.6 Tspan32 Tetraspanin 32 NM_020286 1.6 Btk Bruton agammaglobulinemia tyrosine kinase NM_013482 1.6 Ela2 Elastase 2, neutrophil NM_015779 1.6Table 4.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"Gene Expression in Cox-2 Fracture Therapy http://dx.doi.org/10.11005/jbm.2014.21.3.169  http://e-jbm.org/   1831.5-Fold up-regulated      gene symbolDescriptionGenbank   accessionFold-change Grap2 GRB2-related adaptor protein 2 NM_010815 1.6 Muc13 Mucin 13, epithelial transmembrane NM_010739 1.6 Klhl6 Kelch-like 6 (Drosophila) NM_183390 1.6 Treml1 Triggering receptor expressed on myeloid cells-like 1 NM_027763 1.6 Ccnf Cyclin F NM_007634 1.6 Mkrn1 Makorin, ring finger protein, 1 NM_018810 1.6 E2f8 E2F transcription factor 8 NM_001013368 1.6 Fcho1 FCH domain only 1 NM_028715 1.6 Gdpd2 Glycerophosphodiester phosphodiesterase domain containing 2 NM_023608 1.6 Cenpk Centromere protein K NM_021790 1.5 Gch1 GTP cyclohydrolase 1 NM_008102 1.5 Pip5k1b Phosphatidylinositol-4-phosphate 5-kinase, type 1 beta NM_008846 1.5 Prg2 Proteoglycan 2, bone marrow NM_008920 1.5 Mup5 Major urinary protein 5 NM_008649 1.5 Kif22 Kinesin family member 22 NM_145588 1.5 Slc9a7 Solute carrier family 9 (sodium/hydrogen exchanger), member 7 NM_177353 1.5 Dyrk3 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 NM_145508 1.5 Fn3k Fructosamine 3 kinase NM_001038699 1.5 Prkar2b Protein kinase, cAMP dependent regulatory, type II beta NM_011158 1.5 Slc22a23 Solute carrier family 22, member 23 NM_001033167 1.5 Casc5 Cancer susceptibility candidate 5 NM_029617 1.5 Tal1 T-cell acute lymphocytic leukemia 1 NM_011527 1.5 Mup2 Major urinary protein 2 NM_001045550 1.5 Rad54l RAD54 like (S. cerevisiae) NM_009015 1.5 PF-4 Platelet factor-4 NM_019932 1.5 Ufsp1 UFM1-specific peptidase 1 NM_027356 1.5 Ces2 Carboxylesterase 2 NM_145603 1.5 Gclc Glutamate-cysteine ligase, catalytic subunit NM_010295 1.5 1.5-Fold down-regulated      gene symbolDescription Genbank accession Fold-change Pcp4 Purkinje cell protein 4 NM_008791 0.7 IL-33 Interleukin-33 NM_133775 0.7 Phf11 PHD finger protein 11 NM_172603 0.6 Lmod2 leiomodin 2 (cardiac) NM_053098 0.6 EG620915 Predicted gene, EG620915 XR_030718 0.6 Tnnc1 Troponin C, cardiac/slow skeletal NM_009393 0.6 EG408196 Predicted gene, EG408196 NM_001082542 0.6 Nudt10 Nudix (nucleoside diphosphate linked moiety X)-type motif 10 NM_001031664 0.6 Scn7a Sodium channel, voltage-gated, type VII, alpha NM_009135 0.6 Omt2a Oocyte maturation, alpha NM_001111286 0.6 Tnni1 Troponin I, skeletal, slow 1 NM_021467 0.6 Chrna1 Cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) NM_007389 0.6 Tnnt2 Troponin T2, cardiac NM_011619 0.6 Klra5 Killer cell lectin-like receptor, subfamily A, member 5 NM_008463 0.6 CCL7 Chemokine (C-C motif) ligand 7 NM_013654 0.6Table 4.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
184  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.169Table 4.,Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"Gene Expression in Cox-2 Fracture Therapy http://dx.doi.org/10.11005/jbm.2014.21.3.169  http://e-jbm.org/   185genes displayed increased expression in response to Cox-2  transgene expression, notably PF-4 (Table 4).",OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"186  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.169The expression of the Cox-2 transgene has been estab - lished to up-regulate PGE 2 production,[12] whose effects  are mediated through the 4 PTGER receptors.",Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
Gene Expression in Cox-2 Fracture Therapy http://dx.doi.org/10.11005/jbm.2014.21.3.169  http://e-jbm.org/   187CONFLICT OF INTEREST KHWL and CHR are co-inventors on a U.S. patent applica - tion filed for Cox-2 gene therapy for bone repair.,OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
188  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.169Pharm Bull 2013;36:481-4.,Non-OADS,/arxiv_data1/oa_pdf/9c/d0/jbm-21-169.PMC4170080.pdf
"http://e-jbm.org/   189Copyright © 2014 The Korean Society for Bone and  Mineral Research This is an Open Access article distributed under the terms  of the Creative Commons Attribution Non-Commercial Li - cense (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribu - tion, and reproduction in any medium, provided the original  work is properly cited.J Bone Metab 2014;21:189-194 http://dx.doi.org/10.11005/jbm.2014.21.3.189 pISSN 2287-6375 eISSN 2287-7029 High Dietary Sodium Intake Assessed by 24-hour  Urine Specimen Increase Urinary Calcium Excretion  and Bone Resorption Marker Sun Mi Park1, Jaehwan Jee2, Ji Young Joung1, Yoon Young Cho1, Seo Young Sohn1, Sang-Man Jin1, Kyu Yeon Hur1,  Jae Hyeon Kim1, Sun Wook Kim1, Jae Hoon Chung1, Moon Kyu Lee1, Yong-Ki Min1 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School     of Medicine, Seoul;   2Health Promotion Center, Samsung Medical Center, Seoul, Korea Background:  The average dietary sodium intake of Koreans is 2.6 times higher than the  World Health Organization’s recommended amount.",Non-OADS,/arxiv_data1/oa_pdf/a0/0c/jbm-21-189.PMC4170081.pdf
190  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.189be excessive dietary sodium intake.,Non-OADS,/arxiv_data1/oa_pdf/a0/0c/jbm-21-189.PMC4170081.pdf
Dietary Sodium and Bone Metabolism  http://dx.doi.org/10.11005/jbm.2014.21.3.189  http://e-jbm.org/   191off point to evaluation of the subjects’ 24-hour urinary so - dium excretion amount.,Non-OADS,/arxiv_data1/oa_pdf/a0/0c/jbm-21-189.PMC4170081.pdf
"192  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.189modified FFQ, low sodium intake group ( <2 g/day) includ - ed 15 subjects; the high sodium intake group ( ≥2 g/day)  included 71 subjects.",Non-OADS,/arxiv_data1/oa_pdf/a0/0c/jbm-21-189.PMC4170081.pdf
"Dietary Sodium and Bone Metabolism  http://dx.doi.org/10.11005/jbm.2014.21.3.189  http://e-jbm.org/   193measures were significantly and positively correlated, which  has been proven as the quantity of sodium in a 24-hour  urine specimen is almost the same as the quantity of sodi - um ingested in the absence of hydration disorders or large  change of volume load.",Non-OADS,/arxiv_data1/oa_pdf/a0/0c/jbm-21-189.PMC4170081.pdf
"194  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.189that in order to accurately estimate sodium intake, multi - ple specimens of 24-hour urine sodium is needed to reflect  their usual diet.",Non-OADS,/arxiv_data1/oa_pdf/a0/0c/jbm-21-189.PMC4170081.pdf
Available from: http://www.cdc.gov/nchs/ data/databriefs/db93.pdf 3.,OADS,/arxiv_data1/oa_pdf/a0/0c/jbm-21-189.PMC4170081.pdf
"http://e-jbm.org/   195Copyright © 2014 The Korean Society for Bone and  Mineral Research This is an Open Access article distributed under the terms  of the Creative Commons Attribution Non-Commercial Li - cense (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribu - tion, and reproduction in any medium, provided the original  work is properly cited.J Bone Metab 2014;21:195-203 http://dx.doi.org/10.11005/jbm.2014.21.3.195 pISSN 2287-6375 eISSN 2287-7029 Nutrient Intake and Bone Mineral Density by  Nutritional Status in Patients with Inflammatory  Bowel Disease Heesook Lim1, Hwa Jong Kim2, Su Jin Hong2, Soonkyung Kim3* 1Department of Nutrition, 2Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital,    Bucheon;   3Department of Food Sciences & Nutrition, Soonchunhyang University, Asan, Korea Background:  Malnutrition among inflammatory bowel disease (IBD) may arise from fac - tors including inadequate dietary intake, malabsorption, and progression of disease.",Non-OADS,/arxiv_data1/oa_pdf/0e/8f/jbm-21-195.PMC4170082.pdf
196  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.195Bone density generally varies according to genetics or  ethnicity.,Non-OADS,/arxiv_data1/oa_pdf/0e/8f/jbm-21-195.PMC4170082.pdf
Nutritional status and BMD in IBD http://dx.doi.org/10.11005/jbm.2014.21.3.195  http://e-jbm.org/   197the subject’s lumber spine and femoral neck.,Non-OADS,/arxiv_data1/oa_pdf/0e/8f/jbm-21-195.PMC4170082.pdf
198  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.195Table 1.,Non-OADS,/arxiv_data1/oa_pdf/0e/8f/jbm-21-195.PMC4170082.pdf
Nutritional status and BMD in IBD http://dx.doi.org/10.11005/jbm.2014.21.3.195  http://e-jbm.org/   199Table 3.,Non-OADS,/arxiv_data1/oa_pdf/0e/8f/jbm-21-195.PMC4170082.pdf
200  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.195Table 4.,Non-OADS,/arxiv_data1/oa_pdf/0e/8f/jbm-21-195.PMC4170082.pdf
Nutritional status and BMD in IBD http://dx.doi.org/10.11005/jbm.2014.21.3.195  http://e-jbm.org/   201decrease the performance of routine activities and lower  quality of life.,Non-OADS,/arxiv_data1/oa_pdf/0e/8f/jbm-21-195.PMC4170082.pdf
202  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.195REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/0e/8f/jbm-21-195.PMC4170082.pdf
Nutritional status and BMD in IBD http://dx.doi.org/10.11005/jbm.2014.21.3.195  http://e-jbm.org/   20329.,Non-OADS,/arxiv_data1/oa_pdf/0e/8f/jbm-21-195.PMC4170082.pdf
"http://e-jbm.org/   205Copyright © 2014 The Korean Society for Bone and  Mineral Research This is an Open Access article distributed under the terms  of the Creative Commons Attribution Non-Commercial Li - cense (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribu - tion, and reproduction in any medium, provided the original  work is properly cited.J Bone Metab 2014;21:205-212 http://dx.doi.org/10.11005/jbm.2014.21.3.205 pISSN 2287-6375 eISSN 2287-7029 Efficacy of Dual Energy X-ray Absorptiometry for  Evaluation of Biomechanical Properties:   Bone Mineral Density and Actual Bone Strength Sung Hwa Seo1, Joomi Lee2, Il Hyung Park3 1Department of Medical and Health Science, Gyeongju University, Gyeongju;   2Department of Biomedical Sciences, Kyungpook National University, Daegu;   3Department of Orthopaedic Surgery, Kyungpook National University School of Medicine, Daegu, Korea Introduction:  Bone mineral density (BMD) is an important index in diagnosis of osteo - porosis and other metabolic bone diseases, prediction of fractures, and monitoring  treatment.",Non-OADS,/arxiv_data1/oa_pdf/96/96/jbm-21-205.PMC4170083.pdf
"206  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.205result, prevention and treatment of osteoporosis has emerg- ed as a serious social and financial.",Non-OADS,/arxiv_data1/oa_pdf/96/96/jbm-21-205.PMC4170083.pdf
"Bone Mineral Density and Actual Bone Strength http://dx.doi.org/10.11005/jbm.2014.21.3.205  http://e-jbm.org/   207conduct of DXA, QCT, and biomechanical studies.",Non-OADS,/arxiv_data1/oa_pdf/96/96/jbm-21-205.PMC4170083.pdf
208  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.205between BMDs using DXA and QCT.,OADS,/arxiv_data1/oa_pdf/96/96/jbm-21-205.PMC4170083.pdf
Bone Mineral Density and Actual Bone Strength http://dx.doi.org/10.11005/jbm.2014.21.3.205  http://e-jbm.org/   209Table 2.,Non-OADS,/arxiv_data1/oa_pdf/96/96/jbm-21-205.PMC4170083.pdf
210  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.205lar bone.,Non-OADS,/arxiv_data1/oa_pdf/96/96/jbm-21-205.PMC4170083.pdf
Bone Mineral Density and Actual Bone Strength http://dx.doi.org/10.11005/jbm.2014.21.3.205  http://e-jbm.org/   211tion of severe osteoporosis.,Non-OADS,/arxiv_data1/oa_pdf/96/96/jbm-21-205.PMC4170083.pdf
212  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.205dependence on anatomic location and function.,OADS,/arxiv_data1/oa_pdf/96/96/jbm-21-205.PMC4170083.pdf
"http://e-jbm.org/   213Copyright © 2014 The Korean Society for Bone and  Mineral Research This is an Open Access article distributed under the terms  of the Creative Commons Attribution Non-Commercial Li - cense (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribu - tion, and reproduction in any medium, provided the original  work is properly cited.J Bone Metab 2014;21:213-216 http://dx.doi.org/10.11005/jbm.2014.21.3.213 pISSN 2287-6375 eISSN 2287-7029 Bone Health and Clinical Results after Hip Fracture  Surgery in Patients with Subclinical Hypothyroidism Ki-Choul Kim1*, Young-Kyun Lee2*, You Jin Lee3, Yong-Chan Ha4, Kyung-Hoi Koo2 1Department of Orthopedic Surgery, Dankook University School of Medicine, Cheonan;   2Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seongnam;   3Department of Internal Medicine, Center for Thyroid Cancer, National Cancer Center, Goyang;   4Department of Orthopaedic Surgery, Chung-Ang University College of Medicine, Seoul, Korea Background:  Subclinical thyroid dysfunction might influence a bone health.",Non-OADS,/arxiv_data1/oa_pdf/72/4f/jbm-21-213.PMC4170084.pdf
"214  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.213ing BMD, vitamin D, and bone turnover marker in elderly  patients with hip fracture.",Non-OADS,/arxiv_data1/oa_pdf/72/4f/jbm-21-213.PMC4170084.pdf
Bone Health in Subclinical Hypothyroidism http://dx.doi.org/10.11005/jbm.2014.21.3.213  http://e-jbm.org/   215BMD of femur and the level of 25-(OH)D were similar in the  two groups.,Non-OADS,/arxiv_data1/oa_pdf/72/4f/jbm-21-213.PMC4170084.pdf
216  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.21387:489-99.,Non-OADS,/arxiv_data1/oa_pdf/72/4f/jbm-21-213.PMC4170084.pdf
"http://e-jbm.org/   217Copyright © 2014 The Korean Society for Bone and  Mineral Research This is an Open Access article distributed under the terms  of the Creative Commons Attribution Non-Commercial Li - cense (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribu - tion, and reproduction in any medium, provided the original  work is properly cited.J Bone Metab 2014;21:217-222 http://dx.doi.org/10.11005/jbm.2014.21.3.217 pISSN 2287-6375 eISSN 2287-7029 Increase in the Serum Parathyroid Hormone Level  During a Bisphosphonate Drug Holiday Yoon Kyung Song1, Jeong Min Kim1, Sun Jin Park1, Seong-Kyu Lee2,3 1Department of Internal Medicine, Nowon Eulji Hospital, Seoul; 2Department of Internal Medicine, Eulji University Hospital, Daejeon;  3Department of Biochemistry-Molecular Biology, School of Medicine, Eulji University, Daejeon, Korea  After discontinuation of bisphosphonate therapy, an antiresorptive effect and antifrac - ture protection persist for an undefined period.",Non-OADS,/arxiv_data1/oa_pdf/d1/f1/jbm-21-217.PMC4170085.pdf
"218  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.217are gradually released over years,[2,5,6] and therefore, dis - continuation of bisphosphonate therapy is associated with  an antiresorptive effect and antifracture protection persist - ing for an undefined period, and results in a minimization  of the potential risks of adverse events.",Non-OADS,/arxiv_data1/oa_pdf/d1/f1/jbm-21-217.PMC4170085.pdf
"Serum PTH during A Bisphosphonate Drug Holiday http://dx.doi.org/10.11005/jbm.2014.21.3.217  http://e-jbm.org/   219score -3.6) and femoral neck (BMD 0.634 g/cm2, T-score  -2.4, Z-score -2.4).",Non-OADS,/arxiv_data1/oa_pdf/d1/f1/jbm-21-217.PMC4170085.pdf
"220  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.217clast Health Outcomes and Reduced Incidence with Zole - dronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT)  extension, and the Actonel Vertebral Efficacy with Risedro - nate Therapy-Multinational Trial (VERT-MN) extension.",Non-OADS,/arxiv_data1/oa_pdf/d1/f1/jbm-21-217.PMC4170085.pdf
"Serum PTH during A Bisphosphonate Drug Holiday http://dx.doi.org/10.11005/jbm.2014.21.3.217  http://e-jbm.org/   221bone turnover, approximately 500 mg of calcium per day is  released from bone and an equivalent amount is accreted  to bone daily.",Non-OADS,/arxiv_data1/oa_pdf/d1/f1/jbm-21-217.PMC4170085.pdf
222  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.217in healthy older women receiving calcium supplementa - tion: randomised controlled trial.,Non-OADS,/arxiv_data1/oa_pdf/d1/f1/jbm-21-217.PMC4170085.pdf
"http://e-jbm.org/   223Copyright © 2014 The Korean Society for Bone and  Mineral Research This is an Open Access article distributed under the terms  of the Creative Commons Attribution Non-Commercial Li - cense (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribu - tion, and reproduction in any medium, provided the original  work is properly cited.J Bone Metab 2014;21:223-226 http://dx.doi.org/10.11005/jbm.2014.21.3.223 pISSN 2287-6375 eISSN 2287-7029 Intravenous Zoledronate for a Patient with Paget’s  Disease Ki-Choul Kim Department of Orthopedic Surgery, Dankook University School of Medicine, Cheonan, Korea Paget’s disease (PD) of bone is characterized by increase of bone resorption by atypical  osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic  bone.",Non-OADS,/arxiv_data1/oa_pdf/e4/2f/jbm-21-223.PMC4170086.pdf
Ki-Choul Kim 224  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.223diograph obtained at our hospital revealed a typical mosa - ic pattern of PD in her pubic and left ilium (Fig.,Non-OADS,/arxiv_data1/oa_pdf/e4/2f/jbm-21-223.PMC4170086.pdf
Intravenous Zoledronate for a Patient with PD http://dx.doi.org/10.11005/jbm.2014.21.3.223  http://e-jbm.org/   225and limping gait disappeared.,Non-OADS,/arxiv_data1/oa_pdf/e4/2f/jbm-21-223.PMC4170086.pdf
Ki-Choul Kim 226  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.223had been treated unsuccessfully with oral bisphosphonates  was effectively treated with a 5 mg infusion of zoledronate.,Non-OADS,/arxiv_data1/oa_pdf/e4/2f/jbm-21-223.PMC4170086.pdf
"http://e-jbm.org/   227Copyright © 2014 The Korean Society for Bone and  Mineral Research This is an Open Access article distributed under the terms  of the Creative Commons Attribution Non-Commercial Li - cense (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribu - tion, and reproduction in any medium, provided the original  work is properly cited.J Bone Metab 2014;21:227-232 http://dx.doi.org/10.11005/jbm.2014.21.3.227 pISSN 2287-6375 eISSN 2287-7029 A Case of Cavernous Sinus Thrombophlebitis and  Meningitis as a Complication in Osteopetrosis Hyun Chul Chung1, So Hyun Park1, Eun Sook Kim1, Young Il Kim1, Sun Ho Lee2, Il Seong Nam-Goong1  1Departments of Internal Medicine and 2Laboratory Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan,  Korea Osteopetrosis is a rare genetic bone disease characterized by increased bone density  but prone to breakage due to defective osteoclastic function.",Non-OADS,/arxiv_data1/oa_pdf/e8/10/jbm-21-227.PMC4170087.pdf
228  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.227ous sinus thrombophlebitis and meningitis.,Non-OADS,/arxiv_data1/oa_pdf/e8/10/jbm-21-227.PMC4170087.pdf
 Cavernous Sinus Thrombophlebitis and Memingitis in Osteopetrosis http://dx.doi.org/10.11005/jbm.2014.21.3.227  http://e-jbm.org/   229infection.,Non-OADS,/arxiv_data1/oa_pdf/e8/10/jbm-21-227.PMC4170087.pdf
"230  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.227For etiologic evaluation, we tested further examination  for diffuse sclerosing bony structure.",Non-OADS,/arxiv_data1/oa_pdf/e8/10/jbm-21-227.PMC4170087.pdf
 Cavernous Sinus Thrombophlebitis and Memingitis in Osteopetrosis http://dx.doi.org/10.11005/jbm.2014.21.3.227  http://e-jbm.org/   231our patient has severe disease.,Non-OADS,/arxiv_data1/oa_pdf/e8/10/jbm-21-227.PMC4170087.pdf
232  http://e-jbm.org/  http://dx.doi.org/10.11005/jbm.2014.21.3.227teopetrosis.,Non-OADS,/arxiv_data1/oa_pdf/e8/10/jbm-21-227.PMC4170087.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Microbial Ecology in Health & Disease 2014, 25: 25817 - http://dx.doi.org/10.3402/mehd.v25.25817 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/1c/55/MEHD-25-25817.PMC4170109.pdf
"2 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2014, 25: 25817 - http://dx.doi.org/10.3402/mehd.v25.25817",Non-OADS,/arxiv_data1/oa_pdf/1c/55/MEHD-25-25817.PMC4170109.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and re production in any medium, provided the original work is properly cited.1 Citation: Infection Ecology and Epidemiology 2014, 4: 24553 - http://dx.doi.org/10.3402/iee.v4.24553 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a9/46/IEE-4-24553.PMC4170111.pdf
"2 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2014, 4: 24553 - http://dx.doi.org/10.3402/iee.v4.24553",Non-OADS,/arxiv_data1/oa_pdf/a9/46/IEE-4-24553.PMC4170111.pdf
"aeruginosa in Egyptian vultures Citation: Infection Ecology and Epidemiology 2014, 4: 24553 - http://dx.doi.org/10.3402/iee.v4.24553 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a9/46/IEE-4-24553.PMC4170111.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"Helium was used as the carrier gas at a constant flow rateMohamed Nadjib Boukhatem 2 (page number not for citation purpose)Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431",Non-OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"Determination of the diameter of zone inhibition by (A) the disc diffusion method and (B) the vapor diffusion method (19).Antifungal and anti-inflammatory activities of lemon grass oil Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"For morphological assessment ofcutaneous inflammation, biopsies from control and treatedears of mice were collected at the end of the experiment.Samples were fixed in 10% neutral buffered formalin, rou- tinely processed, sectioned at 6 mmu s i n gam i c r o t o m eMohamed Nadjib Boukhatem 4 (page number not for citation purpose)Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431",Non-OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"bRI (retention index) calculated on the HP-5MS column relative to C8-C24n-alkanes.Antifungal and anti-inflammatory activities of lemon grass oil Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"/C28/C30 no activity; LGEO /C30lemon grass essential oil; HEX /C30hexomedine solution (1%); AmB /C30amphotericin B.Mohamed Nadjib Boukhatem 6 (page number not for citation purpose)Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431",Non-OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"DGIZ: Diameter of growth inhibition zone; LGEO: lemon grass essential oil.Antifungal and anti-inflammatory activities of lemon grass oil Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"Means within the same column followed by the different letter are significantly different ( PB0.05) according to ANOVA one- way analysis followed by Tukey’s post hoc multiple comparison test.Mohamed Nadjib Boukhatem 8 (page number not for citation purpose)Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431",Non-OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"Ke: keratin; Ep: epidermal layer; De: dermal layer; Mu: muscle; Ca: cartilage layer; Od: edema; Pc: PMN cells inﬁltration.Antifungal and anti-inflammatory activities of lemon grass oil Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"2008; 99: 8783 /C17.Mohamed Nadjib Boukhatem 10 (page number not for citation purpose)Citation: Libyan J Med 2014, 9: 25431 - http://dx.doi.org/10.3402/ljm.v9.25431",Non-OADS,/arxiv_data1/oa_pdf/2a/bd/LJM-9-25431.PMC4170112.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/ by-nc-nd/3.0/ATRA’s effect on MMPs JM Kim et al 153 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/0a/05/ijos201363a.PMC4170145.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/ by-nc-nd/3.0/A massive fibrous epulis GM Fonseca et al 184 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/4c/a4/ijos201375a.PMC4170146.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/Compensation trends of first molar angulation HS u et al 181 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/1e/d8/ijos201415a.PMC4170147.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/Anti-proteolytic characterisation of biomodified dentin RR Liu et al 174 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/23/ff/ijos201422a.PMC4170148.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/ by-nc-nd/3.0/Mesenchymal stem cells migrate to salivary glands S Schwarz et al 161 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/58/81/ijos201423a.PMC4170149.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/ by-nc-nd/3.0/Responsive genes and pathways to 17- bestradiol in MC3T3-E1 cells ZZ Shang et al 149 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/f2/07/ijos20142a.PMC4170150.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/ by-nc-nd/3.0/Non-invasive oral lesions detection device DV Messadi et al 167 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/4e/4b/ijos201439a.PMC4170151.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/Oral spindle cell lipoma MA Al Sheddi et al 187 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/e0/4d/ijos20143a.PMC4170152.pdf
Available at https://iadr.confex.,Non-OADS,/arxiv_data1/oa_pdf/e5/d6/ijos201444a.PMC4170153.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information for this article can be found on International Journal of Oral Science ’s website (http://www.nature.com/ijos).Nuclear expression of DMP1 in odontogenesis SX Lin et al 141 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/e5/d6/ijos201444a.PMC4170153.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/ by-nc-nd/3.0/The mucosal immune system in oral cavity RQ Wu et al 132 International Journal of Oral Science",Non-OADS,/arxiv_data1/oa_pdf/b2/60/ijos201448a.PMC4170154.pdf
"• Tel: (65) 91786039  • Fax: (65) 6225 6283 • E-mail: bab_nazir@hotmail.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/37/89/kjr-15-543.PMC4170156.pdf
http://dx.doi.org/10.3348/kjr.2014.15.5.543 pISSN 1229-6929  · eISSN 2005-8330Review Article  | Genitourinary Imaging,Non-OADS,/arxiv_data1/oa_pdf/37/89/kjr-15-543.PMC4170156.pdf
"• Tel: (822) 440-6187  • Fax: (822) 440-6932 • E-mail: ghjahng@gmail.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/54/2f/kjr-15-554.PMC4170157.pdf
Korean J Radiol 2014;15(5):554-577http://dx.doi.org/10.3348/kjr.2014.15.5.554 pISSN 1229-6929  · eISSN 2005-8330Review Article | Neuroimaging and Head & Neck INTRODUCTION Magnetic resonance techniques have been powerful in  visualizing tissue perfusion in the brain and other parts  of body.,Non-OADS,/arxiv_data1/oa_pdf/54/2f/kjr-15-554.PMC4170157.pdf
"• Tel: (8231) 920-2184  • Fax: (8231) 920-2189 • E-mail: jkjun@ncc.re.kr This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e1/22/kjr-15-578.PMC4170158.pdf
"Because mammograms in the NCSP should be  interpreted by radiologists, their performance may be the  most important factor in improving the quality of breast http://dx.doi.org/10.3348/kjr.2014.15.5.578 pISSN 1229-6929  · eISSN 2005-8330",Non-OADS,/arxiv_data1/oa_pdf/e1/22/kjr-15-578.PMC4170158.pdf
http://www.mw.go.kr/front_new/al/sal0101vw.,Non-OADS,/arxiv_data1/oa_pdf/e1/22/kjr-15-578.PMC4170158.pdf
http://www.bokjiro.go.kr/policy/legislationView.do?board_ sid=300&data_sid=151815&searchGroup=AR01&searchSort=R EG_DESC&pageIndex=1&searchWrd=%EA%B2%80%EC%A7%84 &searchCont=&pageUnit=10&searchProgrYn=.,Non-OADS,/arxiv_data1/oa_pdf/e1/22/kjr-15-578.PMC4170158.pdf
http://www.mw.go.kr/front_new/jb/sjb0402vw.jsp?PAR_ MENU_ID=03&MENU_ID=030402&BOARD_ID=220&BOARD_ FLAG=03&CONT_SEQ=22366&page=1.,Non-OADS,/arxiv_data1/oa_pdf/e1/22/kjr-15-578.PMC4170158.pdf
http://www.acr.org/ Meetings-Events/EC-BIBC.,Non-OADS,/arxiv_data1/oa_pdf/e1/22/kjr-15-578.PMC4170158.pdf
http://www.acr.org/~/media/ACR/ Documents/Accreditation/Mammography/Requirements.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e1/22/kjr-15-578.PMC4170158.pdf
Annual report of cancer statistics in  Korea in 2010. http://ncc.re.kr/manage/manage03_033_list.,Non-OADS,/arxiv_data1/oa_pdf/e1/22/kjr-15-578.PMC4170158.pdf
"• Tel: (822) 2072-1862  • Fax: (822) 743-6385  • E-mail: river7774@gmail.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a5/4f/kjr-15-586.PMC4170159.pdf
"During the surveillance period, core biopsies were  performed six times, followed by US-guided vacuum-assisted  core needle excisions or surgical excisions of lesions with http://dx.doi.org/10.3348/kjr.2014.15.5.586 pISSN 1229-6929  · eISSN 2005-8330Case Report | Breast Imaging",Non-OADS,/arxiv_data1/oa_pdf/a5/4f/kjr-15-586.PMC4170159.pdf
Korean J Radiol 2014;15(5):591-604http://dx.doi.org/10.3348/kjr.2014.15.5.591 pISSN 1229-6929  · eISSN 2005-8330Original Article  | Experimental and Others,Non-OADS,/arxiv_data1/oa_pdf/81/fa/kjr-15-591.PMC4170160.pdf
"• Tel: (8261) 379-7102  • Fax: (8261) 379-7133 • E-mail: yjeong@jnu.ac.kr This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f1/4d/kjr-15-605.PMC4170161.pdf
"However, adequate quality of arterial-phase images  is also crucial to the detection and characterization of http://dx.doi.org/10.3348/kjr.2014.15.5.605 pISSN 1229-6929  · eISSN 2005-8330Original Article  | Gastrointestinal Imaging",Non-OADS,/arxiv_data1/oa_pdf/f1/4d/kjr-15-605.PMC4170161.pdf
"• Tel: (8232) 890-2769  • Fax: (8232) 890-2743 • E-mail: radjeon@inha.ac.kr This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9f/98/kjr-15-613.PMC4170162.pdf
Korean J Radiol 2014;15(5):613-621http://dx.doi.org/10.3348/kjr.2014.15.5.613 pISSN 1229-6929  · eISSN 2005-8330Original Article  | Intervention INTRODUCTION Endovascular aneurysm repair (EVAR) is generally a safe  and efficient treatment (1-3).,Non-OADS,/arxiv_data1/oa_pdf/9f/98/kjr-15-613.PMC4170162.pdf
"• Tel: (822) 870-2534  • Fax: (822) 870-3863 • E-mail: cyho50168@naver.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/21/1d/kjr-15-622.PMC4170163.pdf
Endovascular repair  with stent grafts for aortic aneurysms does not cause any  significant difference in endothelialization of the luminal http://dx.doi.org/10.3348/kjr.2014.15.5.622 pISSN 1229-6929  · eISSN 2005-8330Original Article  | Intervention,Non-OADS,/arxiv_data1/oa_pdf/21/1d/kjr-15-622.PMC4170163.pdf
"• Tel: (822) 2072-2584  • Fax: (822) 743-7418 • E-mail: angiointervention@gmail.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6b/bd/kjr-15-630.PMC4170164.pdf
"Otherwise, a recanalized paraumbilical http://dx.doi.org/10.3348/kjr.2014.15.5.630 pISSN 1229-6929  · eISSN 2005-8330Brief Communication  | Intervention",Non-OADS,/arxiv_data1/oa_pdf/6b/bd/kjr-15-630.PMC4170164.pdf
"• Tel: (8262) 220-3773  • Fax: (8262) 222-3858  • E-mail: dhchoi@chosun.ac.kr This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/aa/5b/kjr-15-637.PMC4170165.pdf
Laboratory tests  were normal except for elevated N-terminal B-type http://dx.doi.org/10.3348/kjr.2014.15.5.637 pISSN 1229-6929  · eISSN 2005-8330Case Report | Cardiovascular Imaging,Non-OADS,/arxiv_data1/oa_pdf/aa/5b/kjr-15-637.PMC4170165.pdf
"• Tel: (8620) 87755766-8471  • Fax: (8620) 87615805 • E-mail: canhuisun@sina.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9a/c0/kjr-15-641.PMC4170166.pdf
"The mass  was poorly defined with fascial thickening, which represents http://dx.doi.org/10.3348/kjr.2014.15.5.641 pISSN 1229-6929  · eISSN 2005-8330Case Report | Pediatric Imaging",Non-OADS,/arxiv_data1/oa_pdf/9a/c0/kjr-15-641.PMC4170166.pdf
"• Tel: (822) 3410-2502  • Fax: (822) 3410-2559 • E-mail: hoyunlee96@gmail.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/07/d7/kjr-15-646.PMC4170167.pdf
"Based  on CT imaging findings, the tumors were interpreted as  a squamous cell carcinoma (tumor 1), invasive mucinous http://dx.doi.org/10.3348/kjr.2014.15.5.646 pISSN 1229-6929  · eISSN 2005-8330Case Report  | Thoracic Imaging",Non-OADS,/arxiv_data1/oa_pdf/07/d7/kjr-15-646.PMC4170167.pdf
"• Tel: (8264) 717-1373  • Fax: (8264) 717-1377  • E-mail: sy7728.jeong@gmail.com This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/77/a5/kjr-15-651.PMC4170168.pdf
These imaging http://dx.doi.org/10.3348/kjr.2014.15.5.651 pISSN 1229-6929  · eISSN 2005-8330Case Report | Thoracic Imaging,Non-OADS,/arxiv_data1/oa_pdf/77/a5/kjr-15-651.PMC4170168.pdf
"• Tel: (39) 633775989 • Fax: (39) 633775322 • E-mail: aresedo1992@yahoo.it This is an Open Access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fe/92/kjr-15-655.PMC4170169.pdf
Korean J Radiol 2014;15(5):655-656http://dx.doi.org/10.3348/kjr.2014.15.5.655 pISSN 1229-6929 · eISSN 2005-8330 Fig.,OADS,/arxiv_data1/oa_pdf/fe/92/kjr-15-655.PMC4170169.pdf
Dr. Kim had a particularly great influence on the field of http://dx.doi.org/10.3348/kjr.2014.15.5.657 pISSN 1229-6929  · eISSN 2005-8330In Memoriam,Non-OADS,/arxiv_data1/oa_pdf/66/2e/kjr-15-657.PMC4170170.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6392 | DOI: 10.1038/srep06392 7",Non-OADS,/arxiv_data1/oa_pdf/fe/73/srep06392.PMC4170193.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/7d/dd/srep06434.PMC4170195.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6434 | DOI: 10.1038/srep06434 9",Non-OADS,/arxiv_data1/oa_pdf/7d/dd/srep06434.PMC4170195.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/be/81/srep06433.PMC4170196.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6433 | DOI: 10.1038/srep06433 7",Non-OADS,/arxiv_data1/oa_pdf/be/81/srep06433.PMC4170196.pdf
Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/d4/50/srep06432.PMC4170197.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6432 | DOI: 10.1038/srep06432 12",Non-OADS,/arxiv_data1/oa_pdf/d4/50/srep06432.PMC4170197.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2014-005992).,Non-OADS,/arxiv_data1/oa_pdf/ab/9f/bmjopen-2014-005992.PMC4170202.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/ab/9f/bmjopen-2014-005992.PMC4170202.pdf
2013. http://media.wix.com/ugd/dded87_951541699e9edc71ce66c9bac4734c69.pdf (accessed24 May 2014).,Non-OADS,/arxiv_data1/oa_pdf/ab/9f/bmjopen-2014-005992.PMC4170202.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 005914).,Non-OADS,/arxiv_data1/oa_pdf/4f/53/bmjopen-2014-005914.PMC4170203.pdf
"Washington, DC: National Academies Press, 2003.http://www.iom.edu/Reports/2002/Unequal-Treatment-Confronting-Racial-and-Ethnic-Disparities-in-Health-Care.aspx#sthash.PZGdD8ZA.dpuf 40.",Non-OADS,/arxiv_data1/oa_pdf/4f/53/bmjopen-2014-005914.PMC4170203.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 005878).,Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
"London: The Government Office for Science, 2008. http://www.bis.gov.uk/assets/BISCore/corporate/MigratedD/ec_group/116 –08-FO_b.pdf 16.",Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
2010. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216096/dh_127424.pdf 17.,Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
2011. https://www.gov.uk/government/uploads/system/ uploads/attachment_data/file/213761/dh_124058.pdf 18.,Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
http://www.dh.,Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
http://www.healthscotland.,Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
2007. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_075218 (accessed1 Oct 2011).,Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
"Washington, DC: US Government Printing Office, 2010. http://health.gov/dietaryguidelines/dga2010/DietaryGuidelines2010.pdf (accessed 1 Oct 2011).",Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
http://www2.warwick.ac.uk/fac/med/research/platform/wemwbs/ development/papers/donatella_bianco-thesis.pdf 33.,Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
http://www.ic.nhs.uk/pubs/35.,Non-OADS,/arxiv_data1/oa_pdf/98/0b/bmjopen-2014-005878.PMC4170205.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 005680).,Non-OADS,/arxiv_data1/oa_pdf/f1/fd/bmjopen-2014-005680.PMC4170206.pdf
Available: http://www.who.int/hiv/topics/mtct/grc_handbook_mar2010_1.pdf (aaccessed 10 Sep 2013).,Non-OADS,/arxiv_data1/oa_pdf/f1/fd/bmjopen-2014-005680.PMC4170206.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2014-005065).,Non-OADS,/arxiv_data1/oa_pdf/42/cd/bmjopen-2014-005065.PMC4170207.pdf
2012. http://webqa.phac-aspc.gc.ca/aids-sida/publication/survreport/estimat2011-eng.php 11.,Non-OADS,/arxiv_data1/oa_pdf/42/cd/bmjopen-2014-005065.PMC4170207.pdf
http://ottawa.ca/calendar/ottawa/citycouncil/obh/2011/11-21/F%205794%20OPH%20Sexual%20Health%20Report%20Eng%20WEB%20Tagged% 20Nov14-11.pdf 12.,Non-OADS,/arxiv_data1/oa_pdf/42/cd/bmjopen-2014-005065.PMC4170207.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 006258).,Non-OADS,/arxiv_data1/oa_pdf/83/fb/bmjopen-2014-006258.PMC4170208.pdf
Data sourced from https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml(accessed June 2014).,OADS,/arxiv_data1/oa_pdf/83/fb/bmjopen-2014-006258.PMC4170208.pdf
"Canberra: National Heart Foundation of Australia, 2008. http://www.heartfoundation.org.au/SiteCollectionDocuments/Reduce-risk-in-heart-disease-guideline.pdf 6.",Non-OADS,/arxiv_data1/oa_pdf/83/fb/bmjopen-2014-006258.PMC4170208.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2014-005848).,Non-OADS,/arxiv_data1/oa_pdf/ac/38/bmjopen-2014-005848.PMC4170209.pdf
"Institut de Veille Sanitaire, Saint Denis, 2012. http://www.invs.sante.fr/content/download/83774/306579/version/1/file/TR13G263_%28resultats_Epac2012%29.pdf (accessed 10 Jul 2014).",Non-OADS,/arxiv_data1/oa_pdf/ac/38/bmjopen-2014-005848.PMC4170209.pdf
"Institut national de la statistique et des études économiques, 2011. http://www.insee.fr/fr/themes/tableau.asp?ref_id=NATCCJ06206&reg_id=0 (accessed 10 Jul 2014).",Non-OADS,/arxiv_data1/oa_pdf/ac/38/bmjopen-2014-005848.PMC4170209.pdf
"Influenza at the human-animal interface ,http://www.who.int/influenza/ human_animal_interface/HAI_Risk_Assessment/en/ .Date of access: 27/06/ 2014 (2014a).",Non-OADS,/arxiv_data1/oa_pdf/1e/f2/srep06345.PMC4170210.pdf
"Human infections with avian influenza A(H7N9) virus ,http://www.who.int/influenza/human_animal_interface/ influenza_h7n9/en/ .Date of access: 27/06/2014 (2014b).",Non-OADS,/arxiv_data1/oa_pdf/1e/f2/srep06345.PMC4170210.pdf
http://dx.doi.org/10.3201/ eid2012.140911 (2014).46.,Non-OADS,/arxiv_data1/oa_pdf/1e/f2/srep06345.PMC4170210.pdf
Primary and processed data are deposited at the Data Coordinating Center (https://tcga-data.nci.nih.gov/tcga/tcgaDownload.,OADS,/arxiv_data1/oa_pdf/ea/76/41586_2014_Article_BFnature13480.PMC4170219.pdf
jsp); primary sequence files are deposited in CGHub (https://cghub.ucsc.edu/).,OADS,/arxiv_data1/oa_pdf/ea/76/41586_2014_Article_BFnature13480.PMC4170219.pdf
"Sample lists, and supporting data can be found at (https://tcga-data.nci.nih.gov/ docs/publications/stad_2014/).",OADS,/arxiv_data1/oa_pdf/ea/76/41586_2014_Article_BFnature13480.PMC4170219.pdf
"IARC CancerBase 11, http://globocan.iarc.fr, accessed on January 15, 2014 (2013).",Non-OADS,/arxiv_data1/oa_pdf/ea/76/41586_2014_Article_BFnature13480.PMC4170219.pdf
All of the primary sequence files are deposited in CGHub and all other data are deposited at the Data Coordinating Center (DCC) for public access (http://cancergenome.nih.gov/) and (https://cghub.ucsc.,OADS,/arxiv_data1/oa_pdf/ea/76/41586_2014_Article_BFnature13480.PMC4170219.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/75/62/PCR-5-143.PMC4170529.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.,Non-OADS,/arxiv_data1/oa_pdf/75/62/PCR-5-143.PMC4170529.pdf
The application can be downloaded from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/7c/65/PCR-5-145.PMC4170530.pdf
The application can be downloaded from http://itunes.apple.com/us/app/medknow-journals/id458064375?ls=1&mt=8.,Non-OADS,/arxiv_data1/oa_pdf/07/76/PCR-5-159.PMC4170533.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/56/ce/PCR-5-184.PMC4170537.pdf
"Perspectives in Clinical Research | October-December 2014 | Vol 5 | Issue 4 195Indian Regulatory Update: June-August 2014 • Order speci ﬁ es that design of  the placebo-controlled  studies needs to be appropriate, ef ﬁ cient and ethical • The detailed order can be accessed at following URL:  http://www.cdsco.nic.in/writereaddata/oo11.pdf.",Non-OADS,/arxiv_data1/oa_pdf/62/3b/PCR-5-195.PMC4170539.pdf
OFFICE ORDER ON ANCILLARY CARE TO  CLINICAL TRIAL SUBJECTS • The CDSCO has issued an of ﬁ ce order specifying that the  sponsor should make a provision for providing ancillary care to the clinical trial subjects for any other illnesses; such care needs to be provided at the same institute • The detailed order can be accessed at following URL:  http://www.cdsco.nic.in/writereaddata/oo5.pdf.,Non-OADS,/arxiv_data1/oa_pdf/62/3b/PCR-5-195.PMC4170539.pdf
DEPARTMENT OFFICER TO BE AVAILABLE  FOR CLARIFICATIONS/GRIEVANCES/STATUS OF APPLICATION • Central Drugs Standard Control Organization  (CDSCO) has issued an office order to ensure availability of  DDC or representative for discussion with stakeholder on status of  the application and to provide clari ﬁ cations and address grievances if  any • Such of ﬁ cer will be available between 3 pm and 4 pm  every day for different divisions and for global clinical trials the of ﬁ cer will be available on Friday at CHEB  men’s hostel • Details of  the order can be read at following URL:  http://www.cdsco.nic.in/writereaddata/Of ﬁ ce%20 Order%20dated%2027 th%20June%202014.pdf.,Non-OADS,/arxiv_data1/oa_pdf/62/3b/PCR-5-195.PMC4170539.pdf
"CLINICAL TRIAL WITH MEDICAL DEVICES  TO FOLLOW SAME APPROVAL PROCESS AS CLINICAL TRIALS WITH DRUGS • Central Drugs Standard Control Organization  has issued an of ﬁ ce order specifying the approval  procedure to be followed for clinical trials with devices would remain same as that followed for approval of  clinical trials with drugs and vaccines • Order further speci ﬁ es that the requirements for EC  registrations, accreditation of  investigator, etc., will also be same as clinical trials with drugs • Ofﬁ ce order is available at: http://www.cdsco.nic.in/ writereaddata/oo3.pdf.",Non-OADS,/arxiv_data1/oa_pdf/62/3b/PCR-5-195.PMC4170539.pdf
"PROPOSAL FOR CREATION OF IT ENABLED  SYSTEM • With the aim to bring complete transparency and  accountability in functioning, CDSCO has proposed IT enabled system• In the ﬁ rst phase, CDSCO has proposed to create an  IT enabled system for online submission of  various information on clinical trials to streamline the process of  approval, maintaining comprehensive database and monitoring of  clinical trials for ensuring the protection of  rights, safety and well beings of  trial subjects and authenticity of  the data generated • Proposal has been released for commenting by all  the stakeholders and can be accessed at following URL: http://www.cdsco.nic.in/writereaddata/PROPOSAL%20FOR%20CREATION%20OF%20IT%20ENABLED%20SYSTEM.pdf.",Non-OADS,/arxiv_data1/oa_pdf/62/3b/PCR-5-195.PMC4170539.pdf
"OFFICE ORDER TO LIMIT NUMBER CLINICAL  TRIALS AN INVESTIGATOR CAN UNDERTAKE AT A TIME • Central Drugs Standard Control Organization has  issued an of ﬁ ce order limiting the number of  clinical  trials an investigator can undertake at a time • The maximum trials, which can be undertaken by any  investigator at a time is capped at 3 • Of ﬁ ce order is available at: http://www.cdsco.nic.in/ writereaddata/of ﬁ cer%20order%202.pdf.",Non-OADS,/arxiv_data1/oa_pdf/62/3b/PCR-5-195.PMC4170539.pdf
• The of ﬁ ce memorandum can be accessed at following  URL: http://www.cdsco.nic.in/writereaddata/Extension%20of%20Expert%20Committee%20.pdf.,Non-OADS,/arxiv_data1/oa_pdf/62/3b/PCR-5-195.PMC4170539.pdf
Available from: http://www.ada.org/1761.aspx.,OADS,/arxiv_data1/oa_pdf/0c/00/JISPCD-4-129.PMC4170546.pdf
[37]  A comparative assessment of ‘meta-analysis’ software  programs was done by using uniform resource locator  address http://www.meta-analysis.com/pages/comparisons.,OADS,/arxiv_data1/oa_pdf/17/56/TI-21-140.PMC4170554.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/a5/84/TI-21-148.PMC4170555.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/a5/84/TI-21-148.PMC4170555.pdf
The  application can be downloaded from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/bc/03/TI-21-167.PMC4170558.pdf
Available	 from:	http://www.who.int/whosis	 [Last	accessed on	 2014 Jan 22].,OADS,/arxiv_data1/oa_pdf/42/8f/TI-21-179.PMC4170560.pdf
The application can be downloaded from http://itunes.apple.com/us/app/medknow-journals/ id458064375?ls=1&mt=8.,Non-OADS,/arxiv_data1/oa_pdf/5f/c5/TI-21-196.PMC4170563.pdf
"156pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.3.156 Annals of Surgical Treatment and ResearchCASE REPORT Synchronous multiple colonic adenocarcinomas arising  in patient with neurofibromatosis type 1 Ik Yong Kim, Mee Yon Cho1, Young Wan Kim Departments of Surgery and 1Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea INTRODUCTION Neurofibromatosis type 1 (NF1) is an autosomal dominant  inherited disorder and patients with NF1 have high risk for  both benign and malignant tumors in their lifetime.",Non-OADS,/arxiv_data1/oa_pdf/98/a1/astr-87-156.PMC4170576.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.We report a case of synchronous multiple colon adenocarcinomas in a patient with neurofibromatosis type 1 (NF1).",Non-OADS,/arxiv_data1/oa_pdf/98/a1/astr-87-156.PMC4170576.pdf
" Annals of Surgical Treatment and Research 139pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.3.139 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Comparison of the surgical outcomes of laparoscopic  versus open surgery for colon perforation during  colonoscopy Jeongsoo Kim, Gil Jae Lee1, Jeong-Heum Baek1, Won-Suk Lee1 Gachon University School of Medicine, Incheon, 1Department of Surgery, Gachon University Gil Medical Center, Gachon  University Shcool of Medicine, Incheon, Korea INTRODUCTION Colonoscopy is a safe and common means of screening for  colon cancer, but sometimes a major complication, such as,  colonic perforation or hemorrhage, is encountered during the procedure.",Non-OADS,/arxiv_data1/oa_pdf/df/08/astr-87-139.PMC4170577.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose:  Colonoscopy is a safe and commonly used method for the screening of colon cancer, but sometimes major  complications, such as, colonic perforation or hemorrhage occur during the procedure.",Non-OADS,/arxiv_data1/oa_pdf/df/08/astr-87-139.PMC4170577.pdf
" Annals of Surgical Treatment and Research 123pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.3.123 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE hMLH1  promoter methylation and BRAF mutations in  high-frequency microsatellite instability colorectal  cancers not fulfilling the revised Bethesda guidelines Sang Jin Kim, Hyoung Ran Kim, Seok Hyung Kim1, Ji Hye Han2, Yong Beom Cho, Seong Hyeon Yun, Woo Yong  Lee, Hee Cheol Kim Departments of Surgery and 1Pathology, Samsung Medical Center, Seoul, 2Center for Clinical Research, Samsung Biomedical  Research Institute, Seoul, Korea INTRODUCTION Microsatellite instability (MSI) is one of the main colorectal  carcinogenic mechanisms.",Non-OADS,/arxiv_data1/oa_pdf/18/f5/astr-87-123.PMC4170578.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose: Sporadic colorectal cancers with high-frequency microsatellite instability (MSI-H) are related to hypermethylation  of mismatch repair ( MMR ) genes and a higher frequency of BRAF mutations than Lynch syndrome.",Non-OADS,/arxiv_data1/oa_pdf/18/f5/astr-87-123.PMC4170578.pdf
" Annals of Surgical Treatment and Research 161pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.3.161 Annals of Surgical Treatment and ResearchCASE REPORT Metachronous schwannoma in the colon with vestibular  schwannoma Eun-Joo Jung, Hye Seung Han1, Young-Cho Koh2, Joon Cho2, Chun-Geun Ryu, Jin Hee Paik, Dae-Yong Hwang Departments of Surgery, 1Pathology, and 2Neurosurgery, Colorectal Cancer Center, Konkuk University Medical Center, Konkuk  University School of Medicine, Seoul, Korea INTRODUCTION Schwannoma is a benign tumor arising from Schwann cells  that form the neural sheath [1-7].",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/astr-87-161.PMC4170579.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.We experienced a case of vestibular schwannoma and metachronous schwannoma in the colon.",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/astr-87-161.PMC4170579.pdf
"144pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.3.144 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Endometriosis of the appendix Jiho Yoon, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea INTRODUCTION Endometriosis is defined as functioning endometrial tissue  in a location outside of the uterus.",Non-OADS,/arxiv_data1/oa_pdf/6a/3f/astr-87-144.PMC4170580.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose:  Endometriosis is defined as functioning endometrial tissue outside of the uterus.",Non-OADS,/arxiv_data1/oa_pdf/6a/3f/astr-87-144.PMC4170580.pdf
" Annals of Surgical Treatment and Research 131pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.3.131 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Single incision laparoscopic colectomy for colorectal  cancer: comparison with conventional laparoscopic  colectomy  Sang Woo Lim, Hyeong Rok Kim, Young Jin Kim Department of Colon and Rectal Surgery, Chonnam National University Hwasun Hospital, Gwangju, Korea INTRODUCTION Laparoscopic surgery has gained wide acceptance in colon  cancer treatment, and its oncologic outcomes have been shown  to be at least equivalent to those of conventional open surgery.",Non-OADS,/arxiv_data1/oa_pdf/b5/40/astr-87-131.PMC4170581.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose:  The aim of this retrospective study was to evaluate the feasibility of single incision laparoscopic surgery (SILS),  and to compare the short-term surgical outcomes with those of conventional laparoscopic surgery for colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/b5/40/astr-87-131.PMC4170581.pdf
" Annals of Surgical Treatment and Research 113pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.3.113 Annals of Surgical Treatment and ResearchREVIEW ARTICLE The clinical features and optimal treatment of anorectal  malignant melanoma Soomin Nam, Chang Woo Kim, Se Jin Baek, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Nam Kyu Kim Division of Colon and Rectal Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul,  Korea INTRODUCTION Anorectal malignant melanoma (AMM), which has rare  incidence, is as less than 0.05%–4.6% of anorectal malignancies  [1,2].",Non-OADS,/arxiv_data1/oa_pdf/13/0b/astr-87-113.PMC4170582.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Anorectal malignant melanoma (AMM) is a very rare and aggressive disease.",Non-OADS,/arxiv_data1/oa_pdf/13/0b/astr-87-113.PMC4170582.pdf
Available from:  http://ganjoho.jp/pro/statistics/en/table_ download.html.,OADS,/arxiv_data1/oa_pdf/13/0b/astr-87-113.PMC4170582.pdf
"118pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.3.118 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Clinical application of sentinel lymph node mapping in  colon cancer: in vivo  vs. ex vivo techniques Seung Yeop Oh, Do Yoon Kim, Young Bae Kim1, Kwang Wook Suh Departments of Surgery and 1Pathology, Ajou University School of Medicine, Suwon, Korea INTRODUCTION Accurate pathologic staging is important for improving the  long-term survival in patients with colorectal cancer because  administration of adjuvant chemotherapy can improve the survival [1].",Non-OADS,/arxiv_data1/oa_pdf/e7/dd/astr-87-118.PMC4170583.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose: Clinical usefulness of sentinel lymph node (SLN) mapping in colorectal cancer remains controversial.",Non-OADS,/arxiv_data1/oa_pdf/e7/dd/astr-87-118.PMC4170583.pdf
"148pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.87.3.148 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Evaluating the efficacy of the current diagnosis-related  group reimbursement system for laparoscopic  appendectomy at a single institute in Korea Ri Na Yoo, Chul-Woon Chung1, Jong-Woo Kim Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, 1Department of Surgery, International St.  Mary’s Hospital, Incheon, Korea INTRODUCTION Superfluous medical cost has been the greatest issue in  public health in modern era.",Non-OADS,/arxiv_data1/oa_pdf/96/fd/astr-87-148.PMC4170584.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose:  The diagnosis-related group (DRG) system has been adapted to reduce overall medical costs by grouping and  classifying relatively homogenous patients based on similar resource consumption patterns in the treatment.",Non-OADS,/arxiv_data1/oa_pdf/96/fd/astr-87-148.PMC4170584.pdf
"Cases of fatality after ORIGINAL ARTICLE Young-Soo Jung Department of Oral and Maxillofacial Surgery, Oral Science Research Institute,  College of Dentistry, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul  120-752, Korea TEL: +82-2-2228-3139   FAX: +82-2-2227-8022 E-mail: ysjoms@yuhs.ac    This is an open-access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.CC Copyright ⃆ 2014 The Korean Association of Oral and Maxillofacial Surgeons.",Non-OADS,/arxiv_data1/oa_pdf/c1/ef/jkaoms-40-169.PMC4170657.pdf
http://dx.doi.org/10.5125/jkaoms.2014.40.4.169 pISSN 2234-7550 ·eISSN 2234-5930,OADS,/arxiv_data1/oa_pdf/c1/ef/jkaoms-40-169.PMC4170657.pdf
"For	patients	with	TMD,	the	aim	of	clinical	management	 is	to	relieve	the	symptoms	(pain	with	mandibular	function,	EDITORIALhttp://dx.doi.org/10.5125/jkaoms.2014.40.4.153 pISSN 2234-7550 ·eISSN 2234-5930",Non-OADS,/arxiv_data1/oa_pdf/71/52/jkaoms-40-153.PMC4170658.pdf
"A buccal fat pad is an autogenous graft CASE SERIES STUDY Su-Gwan Kim Department of Oral and Maxillofacial Surgery, School of Dentistry, Chosun  University, 309 Pilmun-daero, Dong-gu, Gwangju 501-759, Korea TEL: +82-62-220-3819   FAX: +82-62-228-7316 E-mail: sgckim@chosun.ac.kr    This is an open-access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.CC Copyright ⃆ 2014 The Korean Association of Oral and Maxillofacial Surgeons.",Non-OADS,/arxiv_data1/oa_pdf/3d/6e/jkaoms-40-188.PMC4170659.pdf
http://dx.doi.org/10.5125/jkaoms.2014.40.4.188 pISSN 2234-7550 ·eISSN 2234-5930,OADS,/arxiv_data1/oa_pdf/3d/6e/jkaoms-40-188.PMC4170659.pdf
"This is an open-access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.CC Copyright ⃆ 2014 The Korean Association of Oral and Maxillofacial Surgeons.",Non-OADS,/arxiv_data1/oa_pdf/55/ca/jkaoms-40-160.PMC4170660.pdf
http://dx.doi.org/10.5125/jkaoms.2014.40.4.160 pISSN 2234-7550 ·eISSN 2234-5930,OADS,/arxiv_data1/oa_pdf/55/ca/jkaoms-40-160.PMC4170660.pdf
"204Corrigendum: Evaluation of soft tissue asymmetry using cone-beam  computed tomography after open reduction and internal fixation of  zygomaticomaxillary complex fracture  Dong Hyuck Kim1,3, Rae Hyong Kim3, Jun Lee1,2, Young Deok Chee1,2, Kyung Hwan Kwon1,2 1Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University, 2Wonkwang Dental Research Institute,  3Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Wonkwang University, Iksan, Korea J Korean Assoc Oral Maxillofac Surg 2014;40:103-110.    http://dx.doi.org/10.5125/jkaoms.2014.40.3.103 This correction is being published to correct the author’s name.",Non-OADS,/arxiv_data1/oa_pdf/18/57/jkaoms-40-204.PMC4170661.pdf
"Before correction Dong Hyuck Kim1,3, Rae Hyong Kim3, Jun Lee1,2, Young Deok Chee1,2, Kyoung-Hwan Kwon1,2 After correction Dong Hyuck Kim1,3, Rae Hyong Kim3, Jun Lee1,2, Young Deok Chee1,2, Kyung Hwan Kwon1,2    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.CCCORRECTION Copyright ⃆ 2014 The Korean Association of Oral and Maxillofacial Surgeons.",Non-OADS,/arxiv_data1/oa_pdf/18/57/jkaoms-40-204.PMC4170661.pdf
http://dx.doi.org/10.5125/jkaoms.2014.40.4.204 pISSN 2234-7550 ·eISSN 2234-5930,OADS,/arxiv_data1/oa_pdf/18/57/jkaoms-40-204.PMC4170661.pdf
"Numerous studies have ORIGINAL ARTICLE Seung Il Song Division of Oral and Maxillofacial Surgery, Department of Dentistry, Ajou  University Hospital, 164 WorldCup-ro, Yeongtong-gu, Suwon 443-380, Korea TEL: +82-31-219-5328   FAX: +82-31-219-5329 E-mail: seungilsong@hanmail.net    This is an open-access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.CC Copyright ⃆ 2014 The Korean Association of Oral and Maxillofacial Surgeons.",Non-OADS,/arxiv_data1/oa_pdf/f0/21/jkaoms-40-155.PMC4170662.pdf
http://dx.doi.org/10.5125/jkaoms.2014.40.4.155 pISSN 2234-7550 ·eISSN 2234-5930,OADS,/arxiv_data1/oa_pdf/f0/21/jkaoms-40-155.PMC4170662.pdf
"The authors present a case in which mis- diagnosis and inappropriate treatment of a buccal cheek lac- eration due to an ill-fitting denture resulted in a buccal space  abscess that progressed into CST.CASE REPORT Hwi-Dong Jung Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei  University, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea TEL: +82-2-2228-3138   FAX: +82-2-2227-8022 E-mail: cancer7@yuhs.ac    This is an open-access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.CC Copyright ⃆ 2014 The Korean Association of Oral and Maxillofacial Surgeons.",Non-OADS,/arxiv_data1/oa_pdf/83/a4/jkaoms-40-195.PMC4170663.pdf
http://dx.doi.org/10.5125/jkaoms.2014.40.4.195 pISSN 2234-7550 ·eISSN 2234-5930,OADS,/arxiv_data1/oa_pdf/83/a4/jkaoms-40-195.PMC4170663.pdf
"This is an open-access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.CC Copyright ⃆ 2014 The Korean Association of Oral and Maxillofacial Surgeons.",Non-OADS,/arxiv_data1/oa_pdf/91/f6/jkaoms-40-181.PMC4170664.pdf
http://dx.doi.org/10.5125/jkaoms.2014.40.4.181 pISSN 2234-7550 ·eISSN 2234-5930,OADS,/arxiv_data1/oa_pdf/91/f6/jkaoms-40-181.PMC4170664.pdf
"This is an open-access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.CC Copyright ⃆ 2014 The Korean Association of Oral and Maxillofacial Surgeons.",Non-OADS,/arxiv_data1/oa_pdf/0a/de/jkaoms-40-199.PMC4170665.pdf
http://dx.doi.org/10.5125/jkaoms.2014.40.4.199 pISSN 2234-7550 ·eISSN 2234-5930,OADS,/arxiv_data1/oa_pdf/0a/de/jkaoms-40-199.PMC4170665.pdf
"Stem cells ORIGINAL ARTICLE Byoung Moo Seo Department of Oral and Maxillofacial Surgery, School of Dentistry, Seoul  National University, 101 Daehak-ro, Jongno-gu, Seoul 110-749, Korea TEL: +82-2-2072-3369   FAX: +82-2-766-4948 E-mail: seobm@snu.ac.kr    This is an open-access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.CC Copyright ⃆ 2014 The Korean Association of Oral and Maxillofacial Surgeons.",Non-OADS,/arxiv_data1/oa_pdf/ea/0c/jkaoms-40-173.PMC4170666.pdf
http://dx.doi.org/10.5125/jkaoms.2014.40.4.173 pISSN 2234-7550 ·eISSN 2234-5930 This work was supported by grant No.,Non-OADS,/arxiv_data1/oa_pdf/ea/0c/jkaoms-40-173.PMC4170666.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/.0/),whichpermitsnon-commercialre-use,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.",Non-OADS,/arxiv_data1/oa_pdf/77/96/ddu124.PMC4170716.pdf
"*Correspondence to: Leonor Kremer; Email: lkremer@cnb.csic.es Submitted: 03/12/2014; Revised: 04/25/2014; Accepted: 04/29/2014; Published Online: Published Online: 05/07/2014http://dx.doi.org/10.4161/mabs.29063Antitumor effects of a monoclonal antibody   to human CCR9 in leukemia cell xenografts Sonia Chamorro1, Maria Vela1,‡, Ana Franco-Villanueva1,‡, Laura Carramolino1,†, Julio Gutiérrez1, Lucio Gómez1,2, María Lozano1,2,  Beatriz Salvador3, Mónica García-Gallo2, Carlos Martínez-A1, and Leonor Kremer1,2,* 1Department of Immunology and o ncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain; 2Protein Tools Unit;  Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain; 3Department of Plant Molecular Genetics; Centro Nacional de  Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain †Current Affiliation: Centro Nacional de Investigaciones Cardiovasculares; Instituto de Salud Carlos III (CNIC/ISCIII); Madrid, Spain ‡These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Immunol Rev 2003;  195:5-14;  PMID:12969306 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Nat Rev Immunol 2011 ; 11:597-606;  PMID:21866172 ; http://dx.doi.org/10.1038/ nri3049 3.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Cancer Metastasis Rev  2010 ; 29:709- 22; PMID:20839032 ; http://dx.doi.org/10.1007/ s10555-010-9256-x 4.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Clin  Exp Metastasis  2008 ; 25:345-56; PMID:17891505 ;  http://dx.doi.org/10.1007/s10585-007-9097-3 5.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
J Invest Dermatol  2004 ;  122:685-90; PMID:15086554 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Clin Cancer Res 2008 ; 14:621-3;  PMID:18245518 ; http://dx.doi.org/10.1158/1078- 0432.CCR-07-2235 7.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Clin Cancer Res 2008 ; 14:638-45;  PMID:18245522 ; http://dx.doi.org/10.1158/1078- 0432.CCR-07-20258.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Eur J Immunol  2000 ; 30:262-71; PMID:10602049 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Blood  2001 ; 97:850-7;  PMID:11159507 ; http://dx.doi.org/10.1182/blood.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
J Exp Med 2000 ; 192:761- 8; PMID:10974041 ; http://dx.doi.org/10.1084/ jem.192.5.76113.,OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
J Exp Med 1999 ; 190:1241 - 56; PMID:10544196 ; http://dx.doi.org/10.1084/ jem.190.9.1241 14.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Proc Natl Acad Sci U S A 2007 ; 104:6347 - 52; PMID:17404233 ; http://dx.doi.org/10.1073/ pnas.0609180104 15.,OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Immunity   1997 ; 7:291-301; PMID:9285413 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Clin Cancer Res  2004 ; 10:8743 -50; PMID :15623660 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Int  J Cancer 2010 ; 127:2020 -30; PMID:20127861 ;  http://dx.doi.org/10.1002/ijc.25219 21.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
J Ovarian  Res 2010 ; 3:15; PMID:20565782 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Cancer Res 2004 ; 64:7579 -87;  PMID:15492285 ; http://dx.doi.org/10.1158/0008- 5472.CAN-04-0641 23.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
J Pathol  2012 ; 226:713- 22; PMID:21984373 ; http://dx.doi.org/10.1002/ path.3015 24.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Leuk Res  2011 ; 35:1254 -60; PMID:21295855 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Nat Rev Immunol 2010 ; 10:317- 27 ; PMID:20414205 ; http://dx.doi.org/10.1038/ nri2744 26.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Nat Rev Cancer 2012 ; 12:278-87;  PMID:22437872 ; http://dx.doi.org/10.1038/ nrc3236 27.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Drug Discov Today 2012 ; 17:954- 63; PMID:22561895 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
J Natl Cancer Inst 1990 ;  82:4-6; PMID:1688381 ; http://dx.doi.org/10.1093/ jnci/82.1.4 29.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Nature  2000 ; 407:249-57; PMID:11001068 ;  http://dx.doi.org/10.1038/35025220 30.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Front Immunol  2013 ; 4:76; PMID:23543707 ;  http://dx.doi.org/10.3389/fimmu.2013.00076 32.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Nat Med  2000 ; 6:443-6;  PMID:10742152 ; http://dx.doi.org/10.1038/74704 33.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
"J Gastrointest Surg 2009 ;  13:1955 -62, discussion 1962 ; PMID:19756884 ;  http://dx.doi.org/10.1007/s11605-009-1002-8 35.",Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Biochem Pharmacol   2012 ; 84:1366 -80; PMID:22935450 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Biosci Rep   2006 ; 26:325-39; PMID:17024562 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Cell 1992 ;  68:855-67; PMID :1547487 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
"Blood  2003 ; 101:949- 54; PMID:12393572 ; http://dx.doi.org/10.1182/ blood-2002-02-0469 42. van Meerten  T, van Rijn  RS, Hol S, Hagenbeek  A,  Ebeling  SB.",OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Clin Cancer Res 2006 ; 12:4027 -35;  PMID:16818702 ; http://dx.doi.org/10.1158/1078- 0432.CCR-06-0066 43.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Clin Cancer Res 2013 ; 19:357-66;  PMID:23213054 ; http://dx.doi.org/10.1158/1078- 0432.CCR-12-2333 45.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Bone Marrow Transplant   2013 ; 48:998-9; PMID:23292237 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
Blood   2010 ; 115:5366 -75; PMID:20357241 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7f/c7/mabs-6-1000.PMC4171004.pdf
"7 An increased  EpCAM expression is a poor prognostic marker in breast and gallbladder carcinomas, 8,9 and EpCAM is overexpressed in cancer  *Correspondence to: Kaja Lund; Email: Kaja.Lund@rr-research.no and Pål K Selbo; Email: Selbo@rr-research.no Submitted: 01/09/2014; Revised: 02/11/2014; Accepted: 02/13/2014; Published Online: 02/18/2014http://dx.doi.org/10.4161/mabs.28207The novel EpCAM-targeting monoclonal antibody  3–17I linked to saporin is highly cytotoxic after  photochemical internalization in breast, pancreas  and colon cancer cell lines Kaja Lund1,2,3*, Monica Bostad2,4, ellen Skarpen5, Michael Braunagel1, Sergej Kiprijanov1,† Stefan Krauss2,3, Alex Duncan1,   Anders Høgset2,6 and Pål K Selbo2,4,6,* 1Affitech r esearch AS; o slo, Norway; 2Cancer Stem Cell Innovation Center (SFI-CAST); o slo University Hospital; o slo, Norway; 3Section for Cellular and Genetic Therapy;  Institute of Microbiology; o slo University Hospital; o slo, Norway; 4Department of r adiation Biology; Institute for Cancer r esearch; Norwegian r adium Hospital; o slo  University Hospital; o slo, Norway; 5Confocal Microscopy Core Facility; Department of Biochemistry; Institute for Cancer r esearch; Norwegian r adium Hospital; o slo University  Hospital; o slo, Norway; 6PCI Biotech AS; Lysaker, Norway †Current address: BerGenBio AS; Bergen, Norway Keywords:  EpCAM, drug delivery, cancer, antibody drug conjugate, antitumor, monoclonal antibody, antibody therapeutics,  photochemical internalization.",Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Br J Cancer 2007; 96:417- 23; PMID:17211480 ; http://dx.doi.org/10.1038/ sj.bjc.6603494 2.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
J Cell Biol  1994; 125:437-46;  PMID:8163559 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
J Clin Pathol  2011; 64:415-20;  PMID :21415054 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Hum Pathol  2004; 35:122-8;  PMID:14745734 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Front Biosci 2008; 13:3096-100;  PMID:17981779 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Clin Cancer Res 2004; 10:3131-6; PMID :15131054 ;  http://dx.doi.org/10.1158/1078-0432.CCR-03-0528 9.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Lancet 2000; 356:1981- 2; PMID:11130529 ; http://dx.doi.org/10.1016/ S0140-6736(00)03312-2 10.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Proc Natl Acad Sci U S A 2007;  104:10158-63;  PMID:17548814 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Cancer Cell Int 2010; 10:44; PMID:21044305 ;  http://dx.doi.org/10.1186/1475-2867-10-44 14.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
J Natl Cancer Inst 2012; 104:622-34;  PMID:22457476 ; http://dx.doi.org/10.1093/jnci/ djs140 15.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
CA Cancer J Clin 2011; 61:250- 81; PMID :21617154 ; http://dx.doi.org/10.3322/ caac.20114 18.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
J  Control Release 2010; 148:2-12; PMID:20600406 ;  http://dx.doi.org/10.1016/j.jconrel.2010.06.008 19.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Int J Cancer 2001;  92:761-6;  PMID:11340584 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Clin  Cancer Res 2005; 11:8476-85; PMID:16322311 ;  http://dx.doi.org/10.1158/1078-0432.CCR-05-1245 21.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Photochem Photobiol Sci 2011; 10:1637-51; PMID:21773635 ; http://dx.doi.org/10.1039/ c1pp05128h 22.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Int J Cancer 2000; 87:853-9;  PMID:10956397 ; http://dx.doi.org/10.1002/1097- 0215(20000915)87:6<853::AID-IJC15>3.0.CO;2-0 26.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Cancer 2001; 91:1-8;  PMID:11148553 ; http://dx.doi.org/10.1002/1097- 0142(20010101)91:1<1::AID-CNCR1>3.0.CO;2-Pless than 10% across the illumination area (765 cm2) with an  output of ~13.5 mW/cm2.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
J Control Release 2012;  161:175-87;  PMID:21945285 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Adv Drug Deliv Rev 1998; 31:53- 88; PMID:10837618 ; http://dx.doi.org/10.1016/ S0169-409X(97)00094-X 31.,Non-OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
Methods Mol Biol 2010; 635:133-45;  PMID:20552345 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
J Control Release 2013; 168:317- 26; PMID:23567040 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/04/12/mabs-6-1038.PMC4171007.pdf
"In the mammalian immune system, progenitor B cells (pro-B  cells) and precursor B cells (pre-B cells) in the bone marrow undergo V-D-J gene segment rearrangement at the heavy chain locus and then V L gene rearrangement at the light chain loci to  generate the primary B cell receptor repertoire.7 Contact of B  cells with cognate antigen in germinal centers along with both membrane-bound and secreted signals provided by T follicular helper cells leads to somatic hypermutation (SHM) by induc - tion of activation-induced cytidine deaminase (AID) dependent deamination of cytidine, followed by error-prone DNA repair  *Correspondence to: Steve Roffler; Email: sroff@ibms.sinica.edu.tw Submitted: 03/18/2014; Revised: 05/05/2014; Accepted: 05/05/2014http://dx.doi.org/10.4161/mabs.29124Mimicking the germinal center reaction in  hybridoma cells to isolate temperature-selective  anti-PEG antibodies yu-Cheng Su1, 2, Talal S al-Qaisi2, 3, Hsin- yi Tung2, 3, Tian-Lu Cheng4, Kuo-Hsiang Chuang5, Bing-Mae Chen2 and Steve r r offler2,* 1Program in Molecular Medicine; National y ang-Ming University and a cademia Sinica; Taipei, Taiwan; 2Institute of Biomedical Sciences; a cademia Sinica; Taipei, Taiwan;  3Taiwan International Graduate Program; National y ang-Ming University; Taipei, Taiwan; 4Faculty of Biomedical Science and e nvironmental Biology; MedicoGenomic r esearch  Center; Kaohsiung Medical University; Kaohsiung, Taiwan; 5Graduate Institute of Pharmacognosy; Taipei Medical University; Taipei, Taiwan Keywords:  germinal center reaction, somatic hypermutation, class switch recombination, AID, activation-induced cytidine  deaminase, affinity maturation, polyethylene glycol, PEG, temperature-dependent binding, hybridoma, temperature-selective  antibody, anti-PEG Abbreviations: AID, activation-induced cytidine deaminase; CDR, complementarity-determining region; CSR, class switch  recombination; eGFP, enhanced green fluorescent protein; FACS, fluorescence-activated cell sorting; FR1, framework one of the  variable region gene segment; HA, hemagglutinin; HEL, hen egg white lysozyme; mAbs, monoclonal antibodies; MFI, mean  fluorescence intensity; PEG, polyethylene glycol; pre-B cells, precursor B cells; pro-B cells, progenitor B cells; pCMV-AID-loxP,  lentiviral vector for stoppable expression of AID; pTetOn-AID, lentiviral vector for tetracycline-inducible expression of AID; SHM,  somatic hypermutation; V-D-J, heavy chain variable, diverse and joining gene segments; VL, light chain variable region Modification of antibody class and binding properties typically requires cloning of antibody genes, antibody library  construction, phage or yeast display and recombinant antibody expression.",Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
a ntibody framework regions and CD rs were  assigned according to the Kabat numbering system61  using the website http://www.bioinf.org.uk/abysis.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Biotechnol 2000; 18:852-6;  PMID:10932154 ; http://dx.doi.org/10.1038/78458 2.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat  Biotechnol 2005; 23:344-8; PMID:15723048 ;  http://dx.doi.org/10.1038/nbt1067 3.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Proc Natl Acad Sci U S A 2000; 97:2029- 34; PMID:10688877 ; http://dx.doi.org/10.1073/ pnas.0305275974.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Med 1996; 2:100-2; PMID:8564822 ;  http://dx.doi.org/10.1038/nm0196-100 5.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Proc Natl Acad Sci U S A 2011; 108:20455-60; PMID :22158898 ; http://dx.doi.org/10.1073/ pnas.1114010108 7.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Curr Opin Immunol 1997; 9:114- 20; PMID:9039786 ; http://dx.doi.org/10.1016/ S0952-7915(97)80167-78.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Exp Med  2007; 204:1145-56;  PMID:17452520 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Rev Immunol 2006; 6:573- 83; PMID:16868548 ; http://dx.doi.org/10.1038/ nri1896 10.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Immunol Methods 2006; 316:59-66;  PMID:16997317 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Rev Drug Discov 2003; 2:214- 21; PMID:12612647 ; http://dx.doi.org/10.1038/ nrd1033 14.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Phys Chem 1991; 95:6706-9; http://dx.doi.org/10.1021/j100170a060 15.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Langmuir 2010; 26:4048-56;  PMID:19928841 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nucleic Acids Res 2005; 33:e63; PMID :15809225 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Gene Ther  2010; 17:14-25;  PMID:19727135 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Immunol Methods 2005; 300:47-62;  PMID :15936027 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Structure 1999; 7:1517- 26; PMID:10647182 ; http://dx.doi.org/10.1016/ S0969-2126(00)88342-2 20.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Mol Biol 2001; 310:1167-76; PMID :11502003 ;  http://dx.doi.org/10.1006/jmbi.2001.4816 21.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Clin Exp Metastasis 2003;  20:103-9;  PMID:12705631 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Bioconjug Chem 2010; 21:1264-70;  PMID:20536171 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Protein Eng Des Sel 2013; 26:151- 64; PMID:23173178 ; http://dx.doi.org/10.1093/ protein/gzs090 26.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Biol Chem 2013; 288:7688-96;  PMID:23355464 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Cell  1980; 20:293-301;  PMID:6771018 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Cell 1980; 21:393-406;  PMID:6773668 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Cell 1980; 20:303-12;  PMID:6771019 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Immunol Methods 2009; 343:28-41; PMID:19187782 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Bioconjug Chem 1999; 10:520-8; PMID:10346886 ;  http://dx.doi.org/10.1021/bc980143z 32.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Bioconjug Chem 2005; 16:1225- 31; PMID:16173802 ; http://dx.doi.org/10.1021/ bc050133f 33.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Expert Opin Drug Deliv 2009;  6:1-16;  PMID:19236204 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Bioconjug Chem 2012; 23:881-99; PMID:22242549 ;  http://dx.doi.org/10.1021/bc200478w 35.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Science 2002; 296:2198-200;  PMID:12077410 ;  http://dx.doi.org/10.1126/science.1071396 36.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Am Chem Soc 2009;  131:14075-80;  PMID:19739626 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Mater 2010; 9:101- 13; PMID:20094081 ; http://dx.doi.org/10.1038/ nmat261438.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Chem Soc Rev 2010; 39:3394-412; PMID:20523948 ; http://dx.doi.org/10.1039/ b914342b 39.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Mater 2010; 9:101- 13; PMID:20094081 ; http://dx.doi.org/10.1038/ nmat2614 40.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Biotechnol Prog  1998; 14:55-62;  PMID:10858036 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Annu Rev Immunol 2002; 20:165-96;  PMID:11861601 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Eur J Immunol 2005; 35:2949-55; PMID:16180247 ;  http://dx.doi.org/10.1002/eji.200425719 44.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Exp Med  1996; 184:1651-61;  PMID:8920855 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Exp Med 1993; 177:1031-7;  PMID:8459202 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Exp Med 1989; 170:1415- 20; PMID:2677210 ; http://dx.doi.org/10.1084/ jem.170.4.1415 47.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nature 2008; 455:532-6; PMID:18716625 ;  http://dx.doi.org/10.1038/nature07231 49.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Rev  Immunol 2012; 12:786-98;  PMID:23059428 ;  http://dx.doi.org/10.1038/nri3311 50.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
PLoS One  2010; 5:e13137;  PMID:20957227 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Cancer Gene Ther 2007; 14:187-200;  PMID:16977328 ; http://dx.doi.org/10.1038/ sj.cgt.7700999 53.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Clin Exp Metastasis 2003;  20:103-9;  PMID:12705631 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Biotechnol 1997; 15:871-5; PMID:9306402 ; http://dx.doi.org/10.1038/ nbt0997-871 55.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Virol 2004; 78:1421-30; PMID:14722297 ;  http://dx.doi.org/10.1128/JVI.78.3.1421-1430.200456.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Biotechnol  2005; 23:584-90;  PMID:15834403 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
J Nucl Med 2010; 51:933- 41; PMID:20484433 ; http://dx.doi.org/10.2967/ jnumed.109.071977 58.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nucleic Acids Res 2000; 28:E78; PMID:10931937 ;  http://dx.doi.org/10.1093/nar/28.16.e78 59.,OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
Nat Biotechnol 2011; 29:73-8; PMID:21151124 ; http://dx.doi.org/10.1038/ nbt.1717 61.,Non-OADS,/arxiv_data1/oa_pdf/53/13/mabs-6-1069.PMC4171010.pdf
"Evolocumab, a human IgG 2 antibody that targets proprotein  convertase subtilisin/kexin type 9 (PCSK9) is currently in  *Correspondence to: Susan Pederson; Email: pederson@amgen.com Submitted: 02/24/2014; Revised: 03/28/2014; Accepted: 03/31/2014http://dx.doi.org/10.4161/mabs.28719 Characterization of a quantitative method   to measure free proprotein convertase   subtilisin/kexin type 9 in human serum alexander Colbert, a mber Umble- romero, Samantha Prokop, r en Xu, John Gibbs and Susan Pederson* Department of Pharmacokinetics and Drug Metabolism; a mgen Inc.; Seattle, W a US a Keywords:  monoclonal antibody (mAb), PCSK9, pharmacokinetic, pharmacodynamic, ligand, ex vivo, biomarker,   fit-for-purpose, bioanalytical Abbreviations: ambient room temperature, ART; minimum required dilution, MRD; gain-of-function, GOF; low density  lipoprotein cholesterol, LDL-C; LDL receptor, LDLR; loss-of-function, LOF; proprotein convertase subtilisin/kexin type 9,  PCSK9; recombinant human PCSK9, rhPCSK9 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that plays an important role in the regulation  of serum low-density lipoprotein (LDL) cholesterol by downregulation of LDL receptor, and as such is considered a novel  target in cholesterol lowering therapy.",Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Curr Pharm Biotechnol 2008;  9:423-30;  PMID:19075682 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Bioanalysis  2010 ; 2:1125 -40; PMID:21083212 ;  http://dx.doi.org/10.4155/bio.10.64 4.,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Amercian Journal  of Biochemistry and Biotechnology  2013 ; 9:206-18;  http://dx.doi.org/10.3844/ajbbsp.2013.206.218 5.,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Clin Pharmacol Ther 2008 ; 84:548-58;  PMID:18784655 ; http://dx.doi.org/10.1038/ clpt.2008.170 6.,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Bioanalysis  2011 ; 3:659-75; PMID:21417734 ;  http://dx.doi.org/10.4155/bio.11.28 8.,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Lipids Health Dis  2011 ; 10:38; PMID:21352602 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Proc Natl Acad Sci U S A  2009 ; 106:9820 -5; PMID:19443683 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Curr Cardiol  Rep 2013 ; 15:345; PMID:23338726 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
J Lipid  Res 2009 ; 50(Suppl ):S172 -7; PMID:19020338 ;  http://dx.doi.org/10.1194/jlr.R800091-JLR200 14.,OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
J Lipid Res 2008 ; 49:394-8; PMID:18033751 ;  http://dx.doi.org/10.1194/jlr.M700437-JLR200 16.,OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
MAbs   2013 ; 5:288-96; PMID:23396084 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
AAPS J 2011 ; 13:99- 110; PMID:21240643 ; http://dx.doi.org/10.1208/ s12248-011-9251-318.,OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Pharm Res 2003 ;  20:1885 -900; PMID:14661937 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
Bioanalysis  2009 ; 1:1461 - 74; PMID:21083095 ; http://dx.doi.org/10.4155/ bio.09.130 22.,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
J Am  Coll Cardiol  2012 ; 60:1888 -98; PMID:23083772 ;  http://dx.doi.org/10.1016/j.jacc.2012.08.986,Non-OADS,/arxiv_data1/oa_pdf/18/99/mabs-6-1103.PMC4171013.pdf
"; Can ani - mal models help us to answer these questions, and, if so, which  *Correspondence to: André Pèlegrin; Email: andre.pelegrin@inserm.fr; Hervé Watier; Email: herve.watier@univ-tours.fr Submitted: 05/15/14; Accepted: 05/15/14; Published Online: 05/16/2014http://dx.doi.org/10.4161/mabs.29262MAbImprove A French “Laboratoire d’excellence” (LabEx) dedicated   to therapeutic antibodies andré Pèlegrin1,*, arnaud d aguet2 and Hervé Watier2,3,* 1irCM; i nstitut de r echerche en Cancérologie de Montpellier; i NSerM, U896; Université Montpellier; i nstitut régional du Cancer Montpellier; Montpellier, France; 2Université  François r abelais de Tours; CN rS, UM r 7292; Tours, France; 3CHr U de Tours; Service d’immunologie; Tours, France",Non-OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
Science 2009; 326:1613;  PMID:20019265 ; http://dx.doi.org/10.1126/ science.326.5960.1613-a 2.,Non-OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
gdraccith.fr/index.php?page=en ; PMID:20035704 ;  http://dx.doi.org/10.1051/medsci/200925121189 .,OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
Institut de Recherche en Cancérologie de Montpellier  http://www.ircm.fr/index.php?locale=en5.,Non-OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
MAbs 2011; 3:1-2; http://www.imgt.org/ ; PMID:21099347 ; http:// dx.doi.org/10.4161/mabs.3.1.14151 .,OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
MAbs 2011; 3:417-21;  PMID:21857165 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
MAbs 2013; 5:626-32;  http://taid.fr/?lang=en ; PMID:23883703 ; http:// dx.doi.org/10.4161/mabs.25300 .8.,OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
MAbs 2014; 6:805-9;  PMID:24714167 ; http://dx.doi.org/10.4161/ mabs.28831 .,Non-OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
http://www.mabdosing.fr/en/index.,Non-OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
http://www.icm.,Non-OADS,/arxiv_data1/oa_pdf/76/05/mabs-6-803.PMC4171014.pdf
"MAbImprove is not only a research tool (with 200 researchers working on monoclonal therapeutic antibodies in Tours and Montpellier), but also a support for biopharmaceutical  *Correspondence to: Hervé Watier; Email: watier@med.univ-tours.fr Submitted: 04/03/14; Accepted: 04/03/14; Published Online: 04/08/2014http://dx.doi.org/10.4161/mabs.28831Antibody biosimilars: Fears or opportunities?",Non-OADS,/arxiv_data1/oa_pdf/1a/a0/mabs-6-805.PMC4171015.pdf
Laboratoire d’Excellence MAbImprove http://mabimprove.univ-tours.fr/?lang=en 3.,Non-OADS,/arxiv_data1/oa_pdf/1a/a0/mabs-6-805.PMC4171015.pdf
Nat Biotechnol  2011; 29:310-2;  PMID:21478841 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1a/a0/mabs-6-805.PMC4171015.pdf
Ann Rheum Dis  2013; 72:1605-12;  PMID:23687259 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1a/a0/mabs-6-805.PMC4171015.pdf
"The chapter properly notes that  Correspondence to: Michiel E Ultee;   Email: Michiel.Ultee@gallusbiopharma.comSubmitted: 04/07/14; Accepted: 04/07/14; Published Online: 04/08/2014http://dx.doi.org/10.4161/mabs.28832Therapeutic Fc-Fusion Proteins Edited by Steven M Chamow, Thomas Ryll, Henry B Lowman  and Deborah Farson Michiel e  Ultee Chief Scientific o fficer; Gallus Biopharmaceuticals; Princeton, NJ USA Keywords: fusion protein, Enbrel, Orencia, therapeutic protein, biopharmaceutical, Fc-fusion, biotherapeutic, Eylea",Non-OADS,/arxiv_data1/oa_pdf/b8/5e/mabs-6-810.PMC4171016.pdf
http://www.casss.org/displaycommon.,Non-OADS,/arxiv_data1/oa_pdf/b8/5e/mabs-6-810.PMC4171016.pdf
"4,10  In antibody therapeutics, a novel genera - tion of products is on its way, many of Opening the door to innovation Janine Schuurman, Yvo F Graus, Aran F Labrijn, Sigrid R Ruuls, and Paul WHI Parren* Genmab; Utrecht, The Netherlands Keywords:  Open innovation,  immunotherapy, Fab-arm exchange, bispecific antibodies, DuoBody technology, drug development, technology platform *Correspondence to: Paul WHI Parren;   Email: p.parren@genmab.com Submitted: 04/23/2014Accepted: 04/23/2014Published Online: 04/24/2014http://dx.doi.org/10.4161/mabs.29004",Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
"Forbes, 2012: http://www.forbes.com/sites/matthewherper/2012/02/10/ the-truly-staggering-cost-of-inventing-new-drugs/ .",Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Nat Rev Drug Discov 2012; 11:191-200;  PMID:22378269 ; http://dx.doi.org/10.1038/ nrd3681 6.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Nat Biotechnol  2011; 29:27-33;  PMID:21221096 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Nat Rev Drug Discov  2013; 12:489-92;  PMID:23812256 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Nat Rev Drug Discov 2013; 12:173-5;  PMID:23449292 ; http://dx.doi.org/10.1038/ nrd395610.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
MAbs  2014; 6:5-14;  PMID:24284914 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Science 2013; 342:1432- 3; PMID:24357284 ; http://dx.doi.org/10.1126/ science.342.6165.1432 13.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Proc Natl Acad Sci U S A  2003; 100:4712-7;  PMID:12682289 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
N Engl J Med 2010; 363:711-23;  PMID:20525992 ; http://dx.doi.org/10.1056/ NEJMoa1003466 15.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
N Engl J Med 2010; 363:1812- 21; PMID:21047225 ; http://dx.doi.org/10.1056/ NEJMoa1002965 16.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
J Nat Prod 1981; 44:482- 5; PMID:7288444 ; http://dx.doi.org/10.1021/ np50016a016 17.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Nat Biotechnol 2003; 21:778-84;  PMID:12778055 ; http://dx.doi.org/10.1038/nbt832 18.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Science  2007; 317:1554-7;  PMID:17872445 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Nat Biotechnol 2009; 27:767-71; PMID:19620983 ;  http://dx.doi.org/10.1038/nbt.1553 22.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
J Immunol 2011; 187:3238-46; PMID:21841137 ;  http://dx.doi.org/10.4049/jimmunol.1003336 23.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Structure 2011; 19:1274-82; PMID:21893287 ;  http://dx.doi.org/10.1016/j.str.2011.06.016 24.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
MAbs  2013; 5:917-24;  PMID :23995615 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Proc Natl Acad Sci U S A 2013;  110:5145-50;  PMID:23479652 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Immunology  2004; 111:66-74;  PMID:14678200 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Drug Discov Today 2011; 16:288- 92; PMID:21129498 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
"Annu Rev Immunol 1988; 6:535-54; PMID:3289577 ; http://dx.doi.org/10.1146/ annurev.iy.06.040188.002535 45. van der Zee JS, van Swieten P, Aalberse RC.",OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Immunology 1999; 97:693-8;  PMID:10457225 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Mol Immunol 1993; 30:105-8;  PMID:8417368 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Immunology 2002; 105:9-19; PMID:11849310 ;  http://dx.doi.org/10.1046/j.0019-2805.2001.01341.x 51.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
MAbs 2012; 4:636;  PMID:22955209 ; http://dx.doi.org/10.4161/ mabs.22075 52.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
J Am Chem Soc 2011; 133:10302- 11; PMID:21627172 ; http://dx.doi.org/10.1021/ ja203638y 55.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Mol Immunol 2013; 54:1-7; PMID:23164605 ;  http://dx.doi.org/10.1016/j.molimm.2012.10.029 56.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Ann N Y Acad Sci  2008; 1132:174-9;  PMID:18567867 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Mol Immunol 2010;  47:1592-4;  PMID:20299101 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
J Biol Chem 2014; 289:6098-109;  PMID:24425871 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Curr Opin Immunol 2008; 20:479-85; PMID:18577454 ;  http://dx.doi.org/10.1016/j.coi.2008.05.010 61.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
Mol Immunol 2013; 53:35-42;  PMID:22784992 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
J Immunol  2009; 182:4275-81;  PMID:19299726 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/61/1f/mabs-6-812.PMC4171017.pdf
"*Correspondence to: Mark Haverick and Alexandre Ambrogelly;   Email: marck.haverick@merck.com and alexandre.ambrogelly@gilead.com   Submitted: 02/20/2014; Revised: 03/27/2014;  Accepted: 03/27/2014; Published Online: 04/01/2014http://dx.doi.org/10.4161/mabs.28693Separation of mAbs molecular variants  by analytical hydrophobic interaction  chromatography HPLC Overview and applications Mark Haverick*, Selina Mengisen, Mohammed Shameem, and Alexandre Ambrogelly†,* BioProcess Development; Merck r esearch Laboratories; Kenilworth, NJ USA †Current address: Gilead Sciences Inc.; Oceanside, CA USA Keywords:  hydrophobic interaction chromatography, HIC-HPLC, Enbrel®, etanercept, biosimilar, tryptophan, oxidation,  deamidation, succinimide, formulation Hydrophobic interaction chromatography-high perfor - mance liquid chromatography (HIC-HPLC) is a powerful ana - lytical method used for the separation of molecular variants  of therapeutic proteins.",Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Nat Chem Biol 2007; 3:29- 35; PMID:17173027 ; http://dx.doi.org/10.1038/ nchembio847 2.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Nat Rev Drug Discov 2012; 11:527-40; http://dx.doi.org/10.1038/nrd3746 ; PMID:22743980 .,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Nat Biotechnol 2004; 22:1383-91; PMID:15529163 ; http://dx.doi.org/10.1038/ nbt1030 4.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
J Biotechnol  2001; 87:143-59;  PMID:11278038 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
J Chromatogr B Analyt Technol Biomed Life Sci 2008; 866:133-53; http://dx.doi.org/10.1016/j.jchromb.2008.01.041 ;  PMID:18294930 .,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:955-60;  http://dx.doi.org/10.1016/j.jchromb.2011.03.006 ;  PMID:21440514 .,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
J Chromatogr A 2008; 1214:81-9;  http://dx.doi.org/10.1016/j.chroma.2008.10.078 ;  PMID:19012891 .,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Anal Chem 2008; 80:3168-74; http://dx.doi.org/10.1021/ac702245c ; PMID:18355059 .9.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Glycobiology 2009; 19:144-52; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
MAbs 2013; 5:432- 44; PMID:23608772 ; http://dx.doi.org/10.4161/ mabs.24458 12.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Biochemistry  2007; 46:1534-44;  PMID:17279618 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Mol Immunol 1992; 29:751-8; PMID:1603094 ;  http://dx.doi.org/10.1016/0161-5890(92)90185-Z 14.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
J Biochem Biophys Methods  1993; 26:27-39;  PMID:8482788 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
MAbs 2011; 3:161-72; PMID:21441786 ; http://dx.doi.org/10.4161/ mabs.3.2.14960 17.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
BMC Struct  Biol 2004; 4:4; PMID :15113422 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
J  Chromatogr A 1986; 359:85-97; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Expert Opin Biol  Ther 2013; 13:153-6; http://dx.doi.org/10.1517/1471 2598.2012.758710 ; PMID:23286777 .,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
MAbs 2012; 4:578-85; http://dx.doi.org/10.4161/ mabs.21328 ; PMID:22820257 .,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
J Chromatogr A 2011; 1218:2091-7; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Protein Expr Purif 2007; 54:110-6;  PMID:17408966 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
MAbs 2013; 5:787-94; http://dx.doi.org/10.4161/mabs.25269 ;  PMID:23883920 .,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Pharm Res 2004; 21:897- 903; PMID :15212151 ; http://dx.doi.org/10.1023/ B:PHAM.0000029275.41323.a6 27.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Int J  Pharm 2011; 421:82-93; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
J Biol Chem 2011; 286:25118-33; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Aggregation-prone motifs in human  immunoglobulin G. J Mol Biol 2009; 391:404- 13; http://dx.doi.org/10.1016/j.jmb.2009.06.028 ;  PMID:19527731 .31.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Protein  Eng Des Sel 2012; 25:591-601; PMID:22843678 ;  http://dx.doi.org/10.1093/protein/gzs042 32.,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Protein Eng Des Sel 2010; 23:643-51; http://dx.doi.org/10.1093/protein/ gzq037 ; PMID:20543007 .,OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
MAbs 2011; 3:408- 11; PMID:21540645 ; http://dx.doi.org/10.4161/ mabs.3.4.15677 35.,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
Clin Cancer Res 2004; 10:7063-70; PMID:15501986 ; http://dx.doi.org/10.1158/1078- 0432.CCR-04-0789,Non-OADS,/arxiv_data1/oa_pdf/b3/80/mabs-6-852.PMC4171020.pdf
"Submitted: 04/09/2014; Revised: 05/13/2014; Accepted: 05/15/2014; Published Online: 05/21/2014http://dx.doi.org/10.4161/mabs.29242Evaluation of cardiovascular parameters   in cynomolgus monkeys following IV  administration of LBR-101, a monoclonal antibody  against calcitonin gene-related peptide Sarah Walter*, abbas a libhoy, r afael e scandon and Marcelo e .",Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Ann Neurol 1993; 33:48-56; PMID:8388188 ;  http://dx.doi.org/10.1002/ana.410330109 2.,OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Ann Neurol  1990; 28:183-7;  PMID:1699472 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Cephalalgia 2002;  22:54-61;  PMID:11993614 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Lancet 2008; 372:2115- 23; PMID:19036425 ; http://dx.doi.org/10.1016/ S0140-6736(08)61626-8 6.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Cephalalgia 2011; 31:712-22;  PMID:21383045 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
N Engl J Med  2004; 350:1104-10;  PMID :15014183 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Clin Pharmacol Ther  2013; 93:78-85;  PMID:23212108 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Curr Treat Options Neurol  2012; 14:50-9;  PMID:22090312 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Methods 2005; 36:1-2;  PMID :15848069 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
J Orthop Res 1997; 15:243-8; PMID:9167627 ;  http://dx.doi.org/10.1002/jor.1100150213 12.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Cardiovasc Res 1998; 38:493- 9; PMID:9709411 ; http://dx.doi.org/10.1016/ S0008-6363(98)00016-9 13.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
J Cardiovasc Pharmacol 2010; 56:518- 25; PMID:20729756 ; http://dx.doi.org/10.1097/ FJC.0b013e3181f5d41414.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Eur J Pharmacol 2009; 623:96-102; PMID:19766109 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Br  J Clin Pharmacol 2011; 71:708-17; PMID:21480950 ;  http://dx.doi.org/10.1111/j.1365-2125.2010.03869.x 18.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Headache  2013; 53:1230-44;  PMID:23848260 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Nat Rev Neurol 2010; 6:573-82; PMID:20820195 ; http://dx.doi.org/10.1038/ nrneurol.2010.127 21.,OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
CNS Drugs 2013; 27:717-29;  PMID:23839594 ; http://dx.doi.org/10.1007/ s40263-013-0090-x 22.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Eur J Immunol 1999; 29:2613-24; PMID:10458776 ; http://dx.doi.org/10.1002/ (SICI)1521-4141(199908)29:08<2613::AID- IMMU2613>3.0.CO;2-J 23.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Br J  Pharmacol 2008; 155:1093-103;  PMID:18776916 ;  http://dx.doi.org/10.1038/bjp.2008.334 24.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Toxicol Pathol  1999; 27:1-3;  PMID:10367664 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Cephalalgia  2013; 34:483-92;  PMID:24366980 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Mol Cell Neurosci  1999; 14:99-120;  PMID:10532808 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Circ Res  2001; 89:983-90;  PMID:11717154 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Endocrinology 2010; 151:4257-69;  PMID:20610563 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Ther Adv Neurol Disord 2010;  3:369-78;  PMID:21179597 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Expert Rev Mol Med 2011; 13:e36; PMID:22123247 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Nature 1983; 305:534-6;  PMID:6604878 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
J Exp Biol 2012; 215:1930- 7; PMID:22573772 ; http://dx.doi.org/10.1242/ jeb.070177 34.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
J Physiol 2012; 590:6321-6;  PMID:22988134 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Neurology  2000; 55:754-62;  PMID:10993991 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
Pacing Clin Electrophysiol 2011; 34:384-8;  PMID:21091739 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/42/mabs-6-871.PMC4171022.pdf
"Alterations of IgG N-glycosylation have been linked  *Correspondence to: Andreas Seidl; Email: andreas.seidl@sandoz.com Submitted: 03/31/2014; Revised: 05/12/2014; Accepted: 05/16/2014; Published Online: 05/21/2014http://dx.doi.org/10.4161/mabs.29263Small scale affinity purification and high  sensitivity reversed phase nanoLC-MS N-glycan  characterization of mAbs and fusion proteins Fabian Higel1, Andreas Seidl1,*, Uwe Demelbauer1, Fritz Sörgel2,3, Wolfgang Frieß4 1Sandoz Biopharmaceuticals; H eXAL AG; o berhaching, Germany; 2IBMP; Institute for Biomedical and Pharmaceutical r esearch; Nuernberg-Heroldsberg, Germany; 3Institute  of Pharmacology; Faculty of Medicine; University Duisburg- essen; e ssen, Germany; 4Department of Pharmacy; Pharmaceutical Technology and Biopharmaceutics; Ludwig  Maximilians-Universitaet Muenchen; Munich, Germany Keywords:  oligosaccharide, N-glycosylation, fusion protein, therapeutic antibody, mass spectrometry, nanoLC, biomarker discovery Abbreviations: 2-AA, Anthranilic acid or 2-Aminobenzoic acid; 2-AB, 2-Aminobenzamide; ACN, Acetonitrile; ADCC, Antibody- dependent cell-mediated cytotoxicity; CE, Capillary electrophoresis; CDC, Complement-dependent cytotoxicity; CID, Collision  induced dissociation; EIC, Extracted ion chromatogram; ESI, Electrospray Ionization; GlcNAc, N-acetylglucosamine; HILIC,  Hydrophilic liquid interaction chromatography; HPAEC-PAD, High-Performance Anion-Exchange Chromatography with  Pulsed Amperometric Detection; HPLC, High Performance Liquid Chromatography; IgG, Immunoglobulin G; LC-MS, Liquid  chromatography-Mass spectrometry; LLOQ, Lower Limit of Quantification; mAb, Monoclonal antibody; MALDI, Matrix  Assisted Laser Desorption Ionization; MS, Mass spectrometry; PGC, Porous graphitized carbon; PNGaseF, Peptide -N-Glycosidase  F; RNase B, Ribonuclease B; RP, Reversed phase; RPC, Reversed phase chromatography N-glycosylation is a complex post-translational modification with potential effects on the efficacy and safety of  therapeutic proteins and known influence on the effector function of biopharmaceutical monoclonal antibodies (mAbs).",Non-OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Nat Biotechnol 2010; 28:917-24; PMID:20829826 ;  http://dx.doi.org/10.1038/nbt0910-917 2.,Non-OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
J Biol Chem 2002 ;  277:26733 -40; PMID:11986321 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Nat Rev Drug Discov  2009 ; 8:226-34; PMID:19247305 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Autoimmun Rev  2009 ; 8:266-73; PMID:19022409 ;  http://dx.doi.org/10.1016/j.autrev.2008.11.002 8.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Glycobiology  2008 ;  18:1105 -18; PMID:18818422 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal Chem 2010 ; 82:10208 -15;  PMID:21073175 ; http://dx.doi.org/10.1021/ ac102860w 12.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
J Proteome Res  2011 ; 10:1667 -74; PMID:21184610 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Nat  Med 1995 ; 1:237-43; PMID:7585040 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Proteomics   2007 ; 7:4070 -81; PMID:17994628 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Glycoconj  J 2012 ; 29:57-66; PMID:22179780 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal Bioanal Chem 2013 ;  405:2481 -93; PMID:23371526 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Nat Chem Biol 2010 ; 6:713- 23; PMID:20852609 ; http://dx.doi.org/10.1038/ nchembio.437 19.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal Chem 2004 ; 76:833- 8; PMID:14750882 ; http://dx.doi.org/10.1021/ ac034936c 20.,Non-OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal Biochem   2012 ; 423:153-62; PMID:22330744 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal  Bioanal Chem  2013 ; 405:2469 -80; PMID:23307132 ;  http://dx.doi.org/10.1007/s00216-012-6680-5 22.,Non-OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal Chem 2010 ; 82:1498 -508;  PMID:20108906 ; http://dx.doi.org/10.1021/ ac902617t 23.,Non-OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal  Bioanal Chem  2013 ; 405:5825 -31; PMID:23670280 ;  http://dx.doi.org/10.1007/s00216-013-6988-9 24.,Non-OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Biol Pharm Bull 2000 ;  23:269-73; PMID:10726877 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal Biochem   1995 ; 230:229-38; PMID:7503412 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal Biochem  2007 ; 370:147- 61; PMID:17880905 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal Biochem   2013 ; 432:82-9; PMID:23026777 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Proteomics  2010 ; 10:2330 - 6; PMID :20391534 ; http://dx.doi.org/10.1002/ pmic.200900804 32.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Mol Immunol  2010 ;  47:2074 -82; PMID:20444501 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
J Biochem   2008 ; 143:725-9; PMID:18218651 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
Anal Chem 2013 ; 85:8841 - 9; PMID:23919734 ; http://dx.doi.org/10.1021/ ac402068r 35.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
J Chromatogr A 2013 ; 1307 :201- 6; PMID:23932029 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/99/9b/mabs-6-894.PMC4171024.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ) Correspondence to: P.D.,Non-OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
2010; 32(9) http://dx.doi.org/ 10.1080/13803391003662702 .,Non-OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
"2011. http://dx.doi.org/10.1155/2011/868305  (Epub 2010 Nov 24) Boyke J, Driemeyer J, Gaser C, Buechl C, May A.",OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
http://dx.doi.org/ 10.2975/28.2004.173.176.,Non-OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
http://dx.doi.org/10.1016/j.wpsyc.2012.05.004.,OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
"2011. http://dx.doi.org/10.1016/j.brs.2011.08.004 Hausdorff JM, Schweiger A, Herman T, Yogev-Seligmann G, Giladi N. Dual-task decrements in gait: contributing factors among healthy older adults.",OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
"2014. http://dx.doi.org/10.1111/acps.12245  (Epub ahead of print) Hlustík P, Solodkin A, Noll DC, Small SL.",Non-OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
2008; 6:45. http://dx.doi.org/ 10.1186/1477-7525-6-45 .,Non-OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
http://dx.doi.org/10.1126/stke.118pe19 .,Non-OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
2011a; 126(1–3) http://dx.doi.org/10.1016/ j.schres.2010.10.025 .,OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
2009; 8(3) http://dx.doi.org/ 10.1111/j.1474-9726.2009.00468.x .,Non-OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
2005; 187:489. http://dx.doi.org/101192/bjp.,Non-OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
http://dx.doi.org/ 10.1111/j.1600-0447.2010.01666.x .,Non-OADS,/arxiv_data1/oa_pdf/74/25/nihms627988.PMC4171045.pdf
"Brugger W. Phase II Study With Rituximab and Cyclophospha-mide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma, 2005; http://clinicaltrials.gov/ct2/show/NCT00204659.",Non-OADS,/arxiv_data1/oa_pdf/d6/7d/WO-18-22232.PMC4171466.pdf
"Dziennik Zachodni 23.10.2012: http://www.dziennikzachodni.pl/artykul/682867,prof-maciejewski-kazdy- rak-jest-inny-gdzie-powstana-breast,id,t.html.",Non-OADS,/arxiv_data1/oa_pdf/cd/aa/WO-18-22905.PMC4171469.pdf
"17.10.2012, gazeta.pl: http://pulsmedycyny.pl/2702367,64090,breast-unit-sa-niezbedne.",Non-OADS,/arxiv_data1/oa_pdf/cd/aa/WO-18-22905.PMC4171469.pdf
"Puls Medycyny 27.02.2013: http://pulsmedycyny.pl/3018391,18393,3.-onkolog-z-poczuciem-misji-prof.-jacek-jassem.",Non-OADS,/arxiv_data1/oa_pdf/cd/aa/WO-18-22905.PMC4171469.pdf
The way in which colorectal cancer affects the daily living abilities of the patients was assessed using the EasternCooperative Oncology Group (ECOG) performance status (Table 1)[ http://ecog.dfci.harvard.edu/general/perf_stat.,Non-OADS,/arxiv_data1/oa_pdf/5e/bf/40291_2014_Article_107.PMC4171587.pdf
"Box 10-254, Wellington, New Zealande-mail: scott.metcalfe@pharmac.govt.nzURL: http://www.pharmac.govt.nzPharmacoEconomics (2014) 32:1031–1033 DOI 10.1007/s40273-014-0208-0",Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://www.longwoods.com/content/ 16915 .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://www.legislation.govt.nz/act/public/2000/ 0091/latest/DLM80878.html .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
Wel- lington: PHARMAC; 2006. http://www.pharmac.govt.nz/2005/ 12/22/231205.pdf .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
2008. http://www.nice.org.uk/page.aspx?o=283494 .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://adisonline.com/ pharmacoeconomics/Abstract/2 004/22170/Reco nciliation_of_ Economic_Concerns_and_Health.1.aspx .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://adisonline.co m/pharmacoeconomics/ Abstract/2006/24090/The_Value_of_Thinly_Spread_QALYs.3.,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=5295600 .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
Wellington: PHARMAC; 2013. http://www.pharmac.,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 1376689/pdf/jmedeth00296-0016.pdf .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC1376690/pdf/jmedeth00296-0023.pdf .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
Wellington:PHARMAC; 2012. http://www.pharmac.govt.nz/2012/06/26/ PFPAFinal.pdf .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
Welling- ton: PHARMAC; 2011. http://www.pharmac.health.nz/assets/ annual-review-2011.pdf .,OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
"Methods of technology appraisal consultation, last updated 23 May 2014. https://www.nice.org.uk/Guidance/InConsultation/ GID-INCONSULTATION/html/p/methods-of-technology-appraisal-consultation?id=2cbiqn4bjozoxf4h6trcemndea .",Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
PHARMAC; 2007. http://www.pharmac.govt.nz/2012/06/26/ PFPAFinal.pdf .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
Wellington: PHARMAC; 2010. http://www.pharmac.health.nz/ assets/funding-applications-guidelines.pdf .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://informahealthcare.com/doi/abs/10.1586/ erp.09.2 .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://www.nzma.org.nz/journal/read- the-journal/all-issues/2010-2019/2013/vol-126-no-1378/5735 .,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
http://www.mdpi.com/1660-4601/7/4/1831 .Letter to the Editor 1033,Non-OADS,/arxiv_data1/oa_pdf/fb/62/40273_2014_Article_208.PMC4171589.pdf
"Registered in England and Wales, 3802726. http://www.worldobesity.org/aboutobesity/ world-map-obesity/ .",Non-OADS,/arxiv_data1/oa_pdf/4b/af/40262_2014_Article_166.PMC4171595.pdf
http://medicine.iupui.edu/ clinpharm/ddis/clinical-table/ .,Non-OADS,/arxiv_data1/oa_pdf/4b/af/40262_2014_Article_166.PMC4171595.pdf
Available from: http://www.ginasth- ma.com/ 5.,Non-OADS,/arxiv_data1/oa_pdf/96/4f/PDIA-31-23473.PMC4171677.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/89/05/bbt010.PMC4171678.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/81/4f/bbt021.PMC4171679.pdf
"http://yasara.org/ (13 February 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/81/4f/bbt021.PMC4171679.pdf
"2010. http://www.biotechniques.com/news/3- D-mitochondria-blockbuster-captivates-students/biotech niques-306309.html (29 October 2012, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/81/4f/bbt021.PMC4171679.pdf
"Methods Experimental details .Graphene films were purchased from the Graphene Supermarket [https://graphene-supermarket.com/], and they were grown on polycrystalline nickel substrates (10 mm 310 mm, 1 mm thick) using the chemical vapour deposition (CVD) method.",Non-OADS,/arxiv_data1/oa_pdf/07/79/srep06450.PMC4171696.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/07/79/srep06450.PMC4171696.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6450 | DOI: 10.1038/srep06450 9",Non-OADS,/arxiv_data1/oa_pdf/07/79/srep06450.PMC4171696.pdf
wrotethe first draft of the paper and all authors provided input and approved the final manuscript Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/d2/f6/srep06445.PMC4171697.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6445 | DOI: 10.1038/srep06445 9",Non-OADS,/arxiv_data1/oa_pdf/d2/f6/srep06445.PMC4171697.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/d2/7b/srep06444.PMC4171698.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/3c/0f/srep06443.PMC4171700.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6443 | DOI: 10.1038/srep06443 6",Non-OADS,/arxiv_data1/oa_pdf/3c/0f/srep06443.PMC4171700.pdf
Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/33/d1/srep06418.PMC4171701.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/c6/a1/srep06442.PMC4171702.pdf
All authors reviewed the manuscript Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/2a/cf/srep06454.PMC4171705.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6454 | DOI: 10.1038/srep06454 7",Non-OADS,/arxiv_data1/oa_pdf/2a/cf/srep06454.PMC4171705.pdf
http://dx.doi.org/10.1016/j.ymgmr.2014.08.002 2214-4269/© 2014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/9a/main.PMC4171744.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d1/9a/main.PMC4171744.pdf
Contents lists available at ScienceDirect Molecular Genetics and Metabolism Reports journal homepage: http://www.journals.elsevier.com/ molecular-genetics-and-metabolism-reports/,Non-OADS,/arxiv_data1/oa_pdf/d1/9a/main.PMC4171744.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d1/9a/main.PMC4171744.pdf
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ymgmr.2014.08.002 .,OADS,/arxiv_data1/oa_pdf/d1/9a/main.PMC4171744.pdf
(Available from: http://www.informatics.,Non-OADS,/arxiv_data1/oa_pdf/d1/9a/main.PMC4171744.pdf
(Available from: http://www.informatics.jax.org ).,OADS,/arxiv_data1/oa_pdf/d1/9a/main.PMC4171744.pdf
"[19] Ensembl Genome Server (EGS), The European Bioinformatics Institute (EBI) and the Welcome Trust Sanger Institute (WTSI), Release 75, Available from: http://www.ensembl.org 2014.",OADS,/arxiv_data1/oa_pdf/d1/9a/main.PMC4171744.pdf
"[30] Online Mendelian Inheritance in Man (OMIM), McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore MD), Available from: http://omim.org 2014.",Non-OADS,/arxiv_data1/oa_pdf/d1/9a/main.PMC4171744.pdf
"Patients with and without prior exposure to TNF inhibitors had similarbaseline characteristics (see Supplementary Table 1, avail-able in the online version of this article at http://onlinelibrary.wiley.com/doi/10.1002/acr.22256/abstract).",Non-OADS,/arxiv_data1/oa_pdf/3b/9c/acr0066-1085.PMC4171746.pdf
"Those patients with prior exposure to a TNF inhibitor had with- drawn from previous treatment primarily due to a lack ofresponse (see Supplementary Table 2, available in theonline version of this article at http://onlinelibrary.wiley.com/doi/10.1002/acr.22256/abstract).",Non-OADS,/arxiv_data1/oa_pdf/3b/9c/acr0066-1085.PMC4171746.pdf
"Moderate to high correlations ( /H110020.48 to /H110020.76) were observed between SF-36 and PsAQOL outcomes at base-line and week 12; conversely, poor correlations ( /H110020.18 to 0.46) were calculated between the DLQI and other health status/HRQOL measures (see Supplementary Table 3,available in the online version of this article at http://onlinelibrary.wiley.com/doi/10.1002/acr.22256/abstract).Poor correlations were observed between improvements in clinical outcomes and in HRQOL outcomes (see Supple- mentary Table 3, available in the online version of thisarticle at http://onlinelibrary.wiley.com/doi/10.1002/acr.22256/abstract).",Non-OADS,/arxiv_data1/oa_pdf/3b/9c/acr0066-1085.PMC4171746.pdf
Available at: http://www.ama-assn.org//ama/pub/about-ama/our-people/ama-councils/council-science-public-health/reports/reports-topic.page (accessed 14May 2014) (Archived at http://www.webcitation.org/6PZWdbC4p).,Non-OADS,/arxiv_data1/oa_pdf/03/4a/add0109-1482.PMC4171750.pdf
Available at: http://www.cdc.gov/homeandrecreationalsafety/rxbrief/ (accessed 14May 2014) (Archived at http://www.webcitation.org/6PZX251PF).,OADS,/arxiv_data1/oa_pdf/03/4a/add0109-1482.PMC4171750.pdf
Declaration of interests All authors have completed the Uniﬁed Competing Inter- est form at http://www.icmje.org/coi_disclosure.pdf(available on request from the corresponding author) anddeclare: JB’s post is funded by a fellowship from the UKSociety for the Study of Addiction; R.W .,Non-OADS,/arxiv_data1/oa_pdf/43/77/add0109-1531.PMC4171752.pdf
[Available at http://europepmc.org/abstract/MED/1864 3163.],Non-OADS,/arxiv_data1/oa_pdf/ca/46/wrcr0050-0661.PMC4171757.pdf
Atlantic salmon LG 24 (also denoted chromosome 7in http://www.asalbase.org) has been demonstrated toshow homology to both LG 10 (chromosome 9) and LG22 (chromosome 17; Danzmann et al.,Non-OADS,/arxiv_data1/oa_pdf/55/10/age0045-0709.PMC4171758.pdf
"URL http://www.lgcgenom- ics.com/genotyping/kaspgenotyping-reagents/kasp-overview/ Li X.H., Bai J.J., Ye X., Hu Y.C., Li S.J.",OADS,/arxiv_data1/oa_pdf/55/10/age0045-0709.PMC4171758.pdf
"Dalton is distributed at no cost from http://www.daltonprogram.org for a number of UNIX platforms.C/circlecopyrt2013 John Wiley & Sons, Ltd. H o wt oc i t et h i sa r t i c l e : WIREs Comput Mol Sci 2014, 4:269–284.",Non-OADS,/arxiv_data1/oa_pdf/1b/7b/wcms0004-0269.PMC4171759.pdf
"Information about patches, releases, and other updates are provided on the Dalton forum (http://daltonprogram.org/forum), where users can also exchange experiences, view tutorials and seek help on installing and using the Dalton programs.CONCLUSION We have presented the Dalton quantum chem- istry program system—a highly ﬂexible general- purpose code for molecular electronic-structure calculations.",Non-OADS,/arxiv_data1/oa_pdf/1b/7b/wcms0004-0269.PMC4171759.pdf
"FURTHER READING/RESOURCES Information about how to obtain a copy of Dalton, installation instructions, manuals, tutorials, and so on can be found on http://www.daltonprogram.org.",Non-OADS,/arxiv_data1/oa_pdf/1b/7b/wcms0004-0269.PMC4171759.pdf
Available at: http://www.blixassociates.,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://www.fas.,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://register.consilium.europa.eu/pdf/en/09/ st15/st15505-re01.en09.pdf (accessed on 5-9-2012).,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://www.australiagroup.net/en/animal.,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://www.australiagroup.net/en/biologi- cal_agents.html (accessed on 25-2-2011b).,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://uk.biosikring.dk/532/ (accessed on 19-7-2012).,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://archive.defra.gov.uk/foodfarm/farmanimal/diseases/vetsurveillance/documents/dst_summary.pdf (accessed on 25-2-2011).,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at:http://www.discontools.eu/upl/1/default/doc/1396_DISCON-TOOLSbrochureﬁnal.pdf.,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://ec.europa.eu/health/ph_threats/Bioterrorisme/keydo_bio_01_en.pdf(accessed on 25-2-2011).,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://www.etpgah.eu/action-plan.,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://www.iso.org/iso/iso_catalogue/catalogue_tc/cata-logue_detail.htm?csnumber=44651.,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://www.selectagents.gov/resources/List_of_Select_Agents_and_Toxins_2012-12-4.pdf (accessedon 6-12-2012).,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
"Available at: http://www.fas.org/bwc/agr/main.htmWorld Health Organization (WHO), 2006: Setting Priorities in communicable disease surveillance.",Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://www.who.int/csr/resources/publications/surveillance/WHO_CD-S_EPR_LYO_2006_3/en/index.html.,OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
Available at: http://www.oie.int/ﬁlead- min/Home/eng/Health_standards/tahc/2010/en_chapitre_1.2.,Non-OADS,/arxiv_data1/oa_pdf/f5/f1/zph0061-0157.PMC4171777.pdf
"Thecounty had 76,629 inhabitants at the beginning ofthe study period and covers an area of 48,617 km 2.14* *Statistics Norway, Table 07459. http://statbank.ssb.no/ statistikkbanken/?PLanguage =1 [Accessed November 2012] bs_bs_banner Acta Anaesthesiol Scand 2014; 58:726–732 Printed in Singapore.",OADS,/arxiv_data1/oa_pdf/ef/ac/aas0058-0726.PMC4171781.pdf
Available from: http://www.bmscanada.ca/static/products/en/pm_pdf/Plavix_EN_PM.pdf.,OADS,/arxiv_data1/oa_pdf/cd/98/IJPhS-76-281.PMC4171864.pdf
Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070107.pdf  [Last accessed on 2013 May 18].,Non-OADS,/arxiv_data1/oa_pdf/cd/98/IJPhS-76-281.PMC4171864.pdf
Available from: http://www.cofepris.gob.mx/TyS/Documents/TercerosAutorizados/ cvfq032011.pdf [Last accessed on 2013 May 18].,Non-OADS,/arxiv_data1/oa_pdf/cd/98/IJPhS-76-281.PMC4171864.pdf
Available from: http://www.sitio.farmacopea.org.mx/legisla/NOM-177PruebInter7may99.pdf.,Non-OADS,/arxiv_data1/oa_pdf/cd/98/IJPhS-76-281.PMC4171864.pdf
Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Advisory Committee for Pharmaceutical Scienceand Clinical Pharmacology/UCM178927.pdf.,Non-OADS,/arxiv_data1/oa_pdf/cd/98/IJPhS-76-281.PMC4171864.pdf
Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM209294.pdf.,Non-OADS,/arxiv_data1/oa_pdf/cd/98/IJPhS-76-281.PMC4171864.pdf
Available from: http://www.fda.gov/ohrms/dockets/ac/04/slides/4034S2_02_DiLiberti.ppt.,Non-OADS,/arxiv_data1/oa_pdf/cd/98/IJPhS-76-281.PMC4171864.pdf
Available  from: http://www.whocc.no/filearchive/publications/2010guidelines.pdf.,Non-OADS,/arxiv_data1/oa_pdf/39/f4/IJPhS-76-308.PMC4171867.pdf
Available from: http://www.who.int/ medicines/publications/08_ENGLISH_indexFINAL_EML15.pdf [Last accessed on 2013 Jan 01].,Non-OADS,/arxiv_data1/oa_pdf/39/f4/IJPhS-76-308.PMC4171867.pdf
Mean±SD from absolute data was calculated  using online calculator (http://easycalculation.com/ statistics/standard-deviation.php).,OADS,/arxiv_data1/oa_pdf/d0/99/IJPhS-76-364.PMC4171874.pdf
Available from: http://www.aseanbiodiversity.,Non-OADS,/arxiv_data1/oa_pdf/1a/e0/IJPhS-76-374.PMC4171876.pdf
Available from: http://www.nice.org.uk.,Non-OADS,/arxiv_data1/oa_pdf/01/dc/IJEM-18-593.PMC4171878.pdf
Available  from: http://www.cps.ca/en.,Non-OADS,/arxiv_data1/oa_pdf/01/dc/IJEM-18-593.PMC4171878.pdf
Available From: http://www.idf.,Non-OADS,/arxiv_data1/oa_pdf/54/9c/IJEM-18-600.PMC4171880.pdf
Available from:  http://www.apiindia.org/content_mu_2010.html [Last accessed on  2013 Aug 23].,OADS,/arxiv_data1/oa_pdf/81/8d/IJEM-18-642.PMC4171886.pdf
Available from: http://www.kidney.,Non-OADS,/arxiv_data1/oa_pdf/c9/38/IJEM-18-655.PMC4171888.pdf
Available from: http://www.iofbonehealth.,Non-OADS,/arxiv_data1/oa_pdf/c9/38/IJEM-18-655.PMC4171888.pdf
Available from: http://www.endotext.,Non-OADS,/arxiv_data1/oa_pdf/0c/67/IJEM-18-700.PMC4171895.pdf
"His facial features are not significantly  different to that of Shiva (right) and apparently there are no neuropsychiatric  or endocrinal stigmata memory  (apa = loss and smara  = remembrance), confusion  of  mind and Epilepsy  (http://www.spokensanskrit.de/).",Non-OADS,/arxiv_data1/oa_pdf/40/e7/IJEM-18-741.PMC4171905.pdf
Available from:  http://www.oriente‑e‑occidente.com/PDF/The_Dance_of_Siva.pdf   [Last accessed on 2014 Apr 14].,Non-OADS,/arxiv_data1/oa_pdf/40/e7/IJEM-18-741.PMC4171905.pdf
Available from: http://www.shaivam.org/ tamil/thiru07_1.pdf.,Non-OADS,/arxiv_data1/oa_pdf/40/e7/IJEM-18-741.PMC4171905.pdf
Available from:  http://www.oriente‑e‑occidente.com/PDF/The_Dance_of_Siva.pdf   [Last accessed on 2014 Apr 14].,Non-OADS,/arxiv_data1/oa_pdf/54/4b/IJEM-18-742.PMC4171906.pdf
Available from: http://www.shaivam.org/ tamil/thiru07_1.pdf.,Non-OADS,/arxiv_data1/oa_pdf/54/4b/IJEM-18-742.PMC4171906.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f1/b6/ceg-7-359.PMC4171998.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical and Experimental Gastroenterology 2014:7 359–367Clinical and Experimental Gastroenterology Dove press submit your manuscript | www.dovepress.co m Dove press  359REviEwopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEG.S4529 7Management of inflammatory bowel disease   in poor responders to infliximab iván Guerra Fernando Bermejo Gastroenterology Department,   Hospital Universitario de Fuenlabrada,   Madrid, Spain Correspondence: iván Guerra   Hospital Universitario de Fuenlabrada,  Camino del Molino  2, 28342 Fuenlabrada,  Madrid, Spain   Tel +34 91 600 6175  Email ivan.guerra@salud.madrid.or gAbstract:  Infliximab (IFX) is an effective treatment for inducing and maintaining response in  Crohn’ s disease and ulcerative colitis patients.",Non-OADS,/arxiv_data1/oa_pdf/f1/b6/ceg-7-359.PMC4171998.pdf
"Clinical and Experimental Gastroenterology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-and-experimental-gastroenterology-journa lClinical and Experimental Gastroenterology is an international, peer- reviewed, open access journal, publishing all aspects of gastroenterology  in the clinic and laboratory, including: Pathology, pathophysiology  of gastrointestinal disease; Investigation and treatment of gastointes - tinal disease; Pharmacology of drugs used in the alimentary tract; Immunology/genetics/genomics related to gastrointestinal disease.",Non-OADS,/arxiv_data1/oa_pdf/f1/b6/ceg-7-359.PMC4171998.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f1/b6/ceg-7-359.PMC4171998.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/66/a2/ceor-6-401.PMC4171999.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinicoEconomics and Outcomes Research 2014:6 401–407ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  401ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S6633 8adherence and resource use among   patients treated with biologic drugs:   findings from BEETLE study luca Degli Esposti1 Diego sangiorgi1 Valentina Perrone2 sonia Radice2 Emilio Clementi3,4 Francesco Perone4,5 Stefano Buda1 1CliCon srl health, Economics and  Outcomes Research, Ravenna, Italy;   2Unit of Clinical Pharmacology,   Department of Biomedical and  Clinical Sciences, L Sacco University  hospital, Università di Milano, Milan,   Italy; 3Unit of Clinical Pharmacology,   Department of Biomedical and  Clinical Sciences, CNR Institute of  Neuroscience, L Sacco University  hospital, Università di Milano, Milan,   Italy; 4Scientific Institute, IRCCS   E Medea, Lecco, Italy; 5local health  Unit, Caserta, Italy Correspondence: luca Degli Esposti   CliCon srl, health, Economics and   Outcomes Research, Via salara,   36 – 48100 Ravenna, Italy   Tel +39 544 38393   Fax +39 544 212699   Email luca.degliesposti@clicon.i tObjectives:  Systemic administration of anti-tumor necrosis factor alpha (anti-TNF alpha)  leads to an anti-inflammatory and joint protective effect in pathologies such as rheumatoid   arthritis, psoriasis, and Crohn’ s disease.",Non-OADS,/arxiv_data1/oa_pdf/66/a2/ceor-6-401.PMC4171999.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/66/a2/ceor-6-401.PMC4171999.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/66/a2/ceor-6-401.PMC4171999.pdf
Available at: http://www.ema.europa.eu/ema/index.,Non-OADS,/arxiv_data1/oa_pdf/66/a2/ceor-6-401.PMC4171999.pdf
Available at: http://www.ema.europa.eu/ema/index.,Non-OADS,/arxiv_data1/oa_pdf/66/a2/ceor-6-401.PMC4171999.pdf
Available at: http://www.ema.europa.eu/ema/index.,Non-OADS,/arxiv_data1/oa_pdf/66/a2/ceor-6-401.PMC4171999.pdf
"The initiation of necroptosis is associated with the  release of damage-associated molecular patterns (DAMPs) Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > Received 2 May 2014 | Accepted 22 September 2014 | Published 24 September 2014© 2014 Molecular Vision 1374Ischemia-reperfusion injury of the retina is linked to necroptosis  via the ERK1/2-RIP3 pathway Sheng Gao,1,2 Kalina Andreeva,2 Nigel G. F. Cooper2 (The first two authors contributed equally to this work) 1Department of Ophthalmology, West China Hospital of Sichuan University, Chengdu, China; 2Department of Anatomical  Sciences and Neurobiology, University of Louisville, School of Medicine, Louisville, KY Purpose:  Ischemia-reperfusion (IR) injury is involved in the pathology of many retinal disorders since it contributes to  the death of retinal neurons and the subsequent decline in vision.",Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1375that enhance innate inflammation and lead to tissue injury  and cell death [ 22-26].,Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
"Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1376Island, NY).",Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1377 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
"Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1378necrotic cell death [ 44,45]) were colocalized in cells within  the RGC layer (Figure 4D–F).",Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1379and total ERK protein (t-ERK) in the IR-injured rat retina  were measured with western blots.,Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1380post-ischemia in the IR-injured rat retina (Figure 9D–F).,Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1381 Figure 9.,Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1382time point in the retina and gradually returned to normal  levels in later reperfusion periods (Figure 7 and Figure 8).,Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1383some of the principal players involved in the necroptotic  signal transduction pathway and demonstrated that inhibi - tion of this pathway leads to increased retinal ganglion cell  survival.,OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
"Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1384form oligomers on cell membranes to increase the extracel - lular V-domains for higher ligand binding affinity [ 34,36].",Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1385REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  138624.,Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
Molecular Vision  2014; 20:1374-1387 <http://www.molvis.org/molvis/v 20/1374 > © 2014 Molecular Vision  1387structure of C-terminal rage (ctRAGE) and its binding to  mDia1.,Non-OADS,/arxiv_data1/oa_pdf/5c/da/mv-v20-1374.PMC4172004.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseApril 2014 |  86  | e51275 | Page 1 of 5Video Article Myelin Oligodendrocyte Glycoprotein (MOG 35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice Stefan Bittner1,2, Ali M. Afzali1, Heinz Wiendl1, Sven G. Meuth1,3 1Department of Neurology, University of Münster 2Interdisciplinary Center for Clinical Research (IZKF), Münster 3Institute of Physiology – Neuropathophysiology, University of Münster Correspondence to: Stefan Bittner at stefan-bittner@ukmuenster.de URL: http://www.jove.com/video/51275 DOI: doi:10.3791/51275 Keywords: Immunology, Issue 86, experimental autoimmune encephalomyelitis, EAE, multiple sclerosis, MS, animal model, Autoimmunity, neuroinflammation, central nervous system, pertussis Date Published: 4/15/2014 Citation: Bittner, S., Afzali, A.M., Wiendl, H., Meuth, S.G. Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice.",Non-OADS,/arxiv_data1/oa_pdf/0a/df/jove-86-51275.PMC4172026.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/51275/ Introduction Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system wherein the destruction of oligodendrocytes and neurons results in heterogenic and accumulating clinical symptoms.,Non-OADS,/arxiv_data1/oa_pdf/0a/df/jove-86-51275.PMC4172026.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseMay 2014 |  87  | e51401 | Page 1 of 8Video Article BEST: Barcode Enabled Sequencing of Tetrads Adrian C. Scott1, Catherine L. Ludlow1, Gareth A. Cromie1, Aimée M. Dudley1 1Pacific Northwest Diabetes Research Institute Correspondence to: Aimée M. Dudley at aimee.dudley@gmail.com URL: http://www.jove.com/video/51401 DOI: doi:10.3791/51401 Keywords: Genetics, Issue 87, Yeast, Tetrad, Genetics, DNA sequencing Date Published: 5/1/2014 Citation: Scott, A.C., Ludlow, C.L., Cromie, G.A., Dudley, A.M. BEST: Barcode Enabled Sequencing of Tetrads.",Non-OADS,/arxiv_data1/oa_pdf/8d/43/jove-87-51401.PMC4172027.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/51401/ Introduction Meiotic gene mapping, commonly known as tetrad analysis, is central to yeast genetics.",Non-OADS,/arxiv_data1/oa_pdf/8d/43/jove-87-51401.PMC4172027.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/eb/d5/tcrm-10-743.PMC4172031.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpTherapeutics and Clinical Risk Management 2014:10 743–752Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  743ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/TCRM.S6845 0Bloodstream infections in patients with  hematological malignancies: which is more  fatal – cancer or resistant pathogens?,Non-OADS,/arxiv_data1/oa_pdf/eb/d5/tcrm-10-743.PMC4172031.pdf
"Infection risk of hematological patients with neutropenia Correspondence: habip gedik İnfeksiyon Hastalıkları ve Klinik  Mikrobiyoloji Klini ği, Bakırköy Sadi  Konuk eğitim ve Araştırma Hastanesi,  İstanbul, Türkiye Tel +90 21 2314 5555 Fax +90 21 2221 7800 email habipgedik@yahoo.co m Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2014 Volume: 10 Running head verso: Gedik et al Running head recto: Bloodstream infections in hematology patients DOI: http://dx.doi.org/10.2147/TCRM.S68450",Non-OADS,/arxiv_data1/oa_pdf/eb/d5/tcrm-10-743.PMC4172031.pdf
"Available  from: http://www.cdc.gov./hai/organisms cre/cre-toolkit/index.htm l.  Accessed April 5, 2014.",OADS,/arxiv_data1/oa_pdf/eb/d5/tcrm-10-743.PMC4172031.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/eb/d5/tcrm-10-743.PMC4172031.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/eb/d5/tcrm-10-743.PMC4172031.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c2/4c/cia-9-1573.PMC4172032.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 1573–1579Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1573OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/CIA.S6631 0Wei-hsiu hsu1–3 Chi-lung Chen2 liang Tseng Kuo2 Chun-hao Fan1 Mel s lee2 robert Wen-Wei hsu2 1sports Medicine Center, Chang gung  Memorial hospital at Chia Yi, Chia Yi,  Taiwan; 2Division of sports Medicine,  Department of Orthopedic surgery,  Chang gung Memorial hospital at  Chia Yi, Chia Yi, Taiwan; 3Department  of Medicine, Chang gung University,  Tao Yuan, Taiwan Correspondence: Wei-hsiu hsu Department of Orthopedic surgery,  Chang gung Memorial hospital at Chia Yi,   no 6 West section, Chia Pu road, Puzih,  Chia Yi hsien 613, Taiwan Tel +886 5 362 1000 ext 2855 Fax +886 5 362 3002  email 7572@cgmh.org.t w Background:  Health-related fitness has been reported to be associated with improved quality  of life (QoL) in the elderly.",Non-OADS,/arxiv_data1/oa_pdf/c2/4c/cia-9-1573.PMC4172032.pdf
"The aging process  is typically characterized by a loss of muscular strength, reduction in joint mobility,  reduction in cardiovascular capacity, and a decline in cognitive capacity.1 These  physiological changes become more pronounced in postmenopausal women due to  the development of osteoporosis and sarcopenia.2–4 These age-related declines can be  assessed using health-related measures of fitness.5,6 Health-related fitness comprises  several dimensions, including body composition, cardiorespiratory endurance, mus - cular strength, muscle endurance, agility, balance, and flexibility.5,7 Each dimension  can be enhanced by using specific training regimens.8–13The relationship between health-related fitness  and quality of life in postmenopausal women  from southern TaiwanJournal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Hsu et al Running head recto: Health-related fitness and quality of life in postmenopausal women DOI: http://dx.doi.org/10.2147/CIA.S66310",Non-OADS,/arxiv_data1/oa_pdf/c2/4c/cia-9-1573.PMC4172032.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/c2/4c/cia-9-1573.PMC4172032.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/c2/4c/cia-9-1573.PMC4172032.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/72/a0/cia-9-1517.PMC4172033.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 1517–1525Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1517OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S6744 9heliodoro Alemán-Mateo1 Virginia ramírez Carreón1 liliana Macías1 humberto Astiazaran- garcía1 Ana Cristina gallegos- Aguilar1 José rogelio ramos  enríquez2 1Coordinación de nutrición, Centro  de Investigación en Alimentación y  Desarrollo, A.C., 2laboratorio de  Análisis Clínicos e Investigación,  Departamento de Ciencias Químico  Biológicas, Universidad de sonora,  hermosillo, Mexico Correspondence: heliodoro  Alemán-Mateo Coordinación de nutrición, Centro  de Investigación en Alimentación y  Desarrollo, A.C., Carretera a la Victoria  km 0.6, hermosillo, sonora 83304,  Mexico Tel +52 662 289 2400 ext 283 Fax +52 662 280 0094 email helio@ciad.m x Background:  At present, it is unknown whether the use of nutrient-rich dairy proteins improves  the markers of sarcopenia syndrome.",Non-OADS,/arxiv_data1/oa_pdf/72/a0/cia-9-1517.PMC4172033.pdf
"Keywords:  nutritional intervention, nutrient-rich dairy proteins, ricotta cheese, markers of  sarcopenia, elderly Introduction Sarcopenia is a syndrome characterized by the progressive, generalized loss of skeletal  muscle mass and strength, with a risk of such adverse outcomes as physical disabil - ity, poor quality of life, and even death.1 The causes of loss of skeletal muscle are  unclear, but may include a lower basal rate of protein synthesis in aged muscle and/or nutrient-rich dairy proteins improve appendicular  skeletal muscle mass and physical performance,  and attenuate the loss of muscle strength  in older men and women subjects: a single-blind  randomized clinical trialJournal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Alemán-Mateo et al Running head recto: Nutrient-rich dairy proteins offset age-related muscle loss DOI: http://dx.doi.org/10.2147/CIA.S67449",Non-OADS,/arxiv_data1/oa_pdf/72/a0/cia-9-1517.PMC4172033.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/72/a0/cia-9-1517.PMC4172033.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/72/a0/cia-9-1517.PMC4172033.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/72/69/oajsm-5-223.PMC4172046.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOpen Access Journal of Sports Medicine 2014:5 223–234Open Access Journal of Sports Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  223Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OAJSM.S4439 2Factors influencing pacing in triathlon Sam SX wu1 Jeremiah J Peiffer2 Jeanick Brisswalter3 Kazunori Nosaka1 Chris R Abbiss1 1Centre for exercise and Sports  Science Research, School of Exercise  and Health Sciences, Edith Cowan  University, Perth, WA, Australia;   2School of Psychology and Exercise  Science, Murdoch University, Perth,   WA, Australia; 3Laboratory of Human  Motricity, Education Sport and Health,   University of Nice Sophia Antipolis,   Nice, France Correspondence: Sam Shi Xuan Wu   School of Exercise and Health Sciences,  Edith Cowan University, 270 Joondalup  Drive, Joondalup, WA 6027, Australia   Tel +61 8 6304 5740   Fax +61 8 6304 5036   email s.goh@ecu.edu.a uAbstract:  Triathlon is a multisport event consisting of sequential swim, cycle, and run disci - plines performed over a variety of distances.",Non-OADS,/arxiv_data1/oa_pdf/72/69/oajsm-5-223.PMC4172046.pdf
"Open Access Journal of Sports Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/open-access-journal-of-sports-medicine-journa lOpen Access Journal of Sports Medicine is an international,  peer-reviewed, open access journal publishing original research,  reports, reviews and commentaries on all areas of sports  medicine.",Non-OADS,/arxiv_data1/oa_pdf/72/69/oajsm-5-223.PMC4172046.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/72/69/oajsm-5-223.PMC4172046.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/29/19/clep-6-301.PMC4172047.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Epidemiology 2014:6 301–308Clinical Epidemiology Dove press submit your manuscript | www.dovepress.co m Dove press  301REviEwopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CLEP .S6699 8The Danish Collaborative Bacteraemia   Network (DACOBAN) database Kim Oren Gradel1,2 Henrik Carl Schønheyder3,4 Magnus Arpi5 Jenny Dahl Knudsen6 Christian Østergaard6 Mette Søgaard7 For the Danish  Collaborative Bacteraemia  Network (DACOBAN) 1Center for Clinical Epidemiology,   Odense University Hospital,  2Research  Unit of Clinical Epidemiology, institute  of Clinical Research, University  of Southern Denmark, Odense,   Denmark;  3Department of Clinical  Microbiology, Aalborg University  Hospital,  4Department of Clinical  Medicine, Aalborg University, Aalborg,   5Department of Clinical Microbiology,   Herlev Hospital, Copenhagen  University Hospital, Herlev,   6Department of Clinical Microbiology,   Hvidovre Hospital, Copenhagen  University Hospital, Hvidovre,   7Department of Clinical Epidemiology,   institute of Clinical Medicine, Aarhus  University Hospital, Aarhus University,   Aarhus, Denmark Correspondence: Kim Oren Gradel  Center for Clinical Epidemiology, Odense  University Hospital, Entrance  101, 4th  floor,  29 Sønder Boulevard, Odense   5000, Denmark   Tel +45 21 158 085  Fax +45 65 917 264  Email kim.gradel@rsyd.d kAbstract:  The Danish Collaborative Bacteraemia Network (DACOBAN) research database  includes microbiological data obtained from positive blood cultures from a geographically and  demographically well-defined population serviced by three clinical microbiology departments  (1.7 million residents,  32% of the Danish population).",Non-OADS,/arxiv_data1/oa_pdf/29/19/clep-6-301.PMC4172047.pdf
"Table  1 Hospital and population data DCM at HospitalsaOne blood-   culture setBlood-culture   systemArea (years) Population  (year)b Aalborg Hospital 4 (1,347)cChildren:  1×10 mL   Adults:  3×10 mLBacT/Alert County of North Jutland (2000–2006)   North Denmark Region (2007–2011)494,153 (2000)   580,293 (2011)d Herlev Hospital 3 (1,587) Children:  1×10 mL   Adults:  2×10 mLBactec Copenhagen County (2000–2006)   Capital Region, corresponding to the   former Copenhagen County (2007–2011)613,444 (2000)   648,449 (2011)e Hvidovre Hospital 5 (1,639) Children:  1×10 mL       Adults:  2×10 mLBacT/Alert Copenhagen municipality, Frederiksberg  municipality, Bornholm regional   municipality (2000–2006)   Capital Region, corresponding to the   former Copenhagen, Frederiksberg, and   Bornholm municipalities (2007–2011)630,462 (2000)       690,146 (2011) Notes:  aHospitals submitting blood cultures to the DCM; bcompiled from http://www.statistikbanken.d k (accessed August  5, 2013); cnumber of hospitals in  2011 (beds in  the hospitals in  2009, compiled from http://www.ssi.dk/Sundhedsdataogit/Dataformidling/Sundhedsdata/Sengepladser.asp x [accessed September  4, 2013]); dservices from  DCM, Aalborg Hospital to Thy-Mors Hospital (catchment population  45,000,  146 beds) took effect in  2011; ethree municipalities (Søllerød, værløse, Ledøje-Smørum) in  Frederiksborg County before  2007 were merged with municipalities from Copenhagen County in  2007.",Non-OADS,/arxiv_data1/oa_pdf/29/19/clep-6-301.PMC4172047.pdf
"This reorganization had very little impact on  the background population of the DACOBAN database, and  almost none for the present Capital Region, but it led to a  17%  increase in the population when North Jutland County was  reorganized into the North Denmark Region.9 Population data  can be obtained from Statistics Denmark ( http://www.stat - bank.d k, in English) for the calculation of incidence data.",OADS,/arxiv_data1/oa_pdf/29/19/clep-6-301.PMC4172047.pdf
We plan to include micro - biological data from Rigshospitalet in the DACOBAN data - base after taking its different laboratory information system  (MADS [ http://www.madsonline.d k]) into account.,Non-OADS,/arxiv_data1/oa_pdf/29/19/clep-6-301.PMC4172047.pdf
Clinical Epidemiology 2014:6submit your manuscript | www.dovepress.co m Dove press Dove press 304Gradel et al External Quality Assessment Service ( http://www.ukneqas - micro.org.u k).,Non-OADS,/arxiv_data1/oa_pdf/29/19/clep-6-301.PMC4172047.pdf
"Clinical Epidemiology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-epidemiology-journa lClinical Epidemiology is an international, peer-reviewed, open access  journal focusing on disease and drug epidemiology, identification of  risk factors and screening procedures to develop optimal preventative  initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/29/19/clep-6-301.PMC4172047.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0c/ba/cia-9-1551.PMC4172048.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 1551–1561Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1551OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S6046 2Mohamad hasnan Ahmad1 suzana shahar2 nur Islami Mohd   Fahmi T eng2 Zahara Abdul Manaf2 noor Ibrahim Mohd sakian3 Baharudin Omar4 1Centre of nutrition epidemiology  research, Institute of Public health,   Ministry of health, Kuala lumpur,   Malaysia; 2Dietetics Program,   3Occupational Therapy Program,   4Department of Biomedical sciences,   Faculty of health sciences, Universiti  Kebangsaan Malaysia, Kuala lumpur,   Malaysia Correspondence: suzana shahar Dietetics Program, Faculty of health  sciences, Universiti Kebangsaan Malaysia,  Jalan raja Muda Abdul Aziz, 50300 Kuala  lumpur, Malaysia T el +60 392 897 667 Fax +60 326 947 621 email suzana.shahar@gmail.co mAbstract:  This study aimed to determine the factors associated with exercise behavior based  on the theory of planned behavior (TPB) among the sarcopenic elderly people in Cheras, Kuala   Lumpur.",Non-OADS,/arxiv_data1/oa_pdf/0c/ba/cia-9-1551.PMC4172048.pdf
Applying theory of planned behavior to predict  exercise maintenance in sarcopenic elderlyJournal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Ahmad et al Running head recto: Applied theory of planned behavior to predict exercise in sarcopenic elderly DOI: http://dx.doi.org/10.2147/CIA.S60462,Non-OADS,/arxiv_data1/oa_pdf/0c/ba/cia-9-1551.PMC4172048.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/0c/ba/cia-9-1551.PMC4172048.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/0c/ba/cia-9-1551.PMC4172048.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/40/62/dddt-8-1405.PMC4172049.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2014:8 1405–1418Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1405Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/DDDT .S6737 0studies of synthetic chalcone derivatives as  potential inhibitors of secretory phospholipase  a2, cyclooxygenases, lipoxygenase  and pro-inflammatory cytokines ibrahim Jantan1,* Syed Nasir Abbas Bukhari1,* Olayiwola  A Adekoya2 ingebrigt sylte3 1Drug and herbal research centre,   Faculty of Pharmacy, Universiti  Kebangsaan Malaysia, Kuala  lumpur,   Malaysia; 2Department of Pharmacy,   Faculty of health science, UiT The  arctic University of norway, Tromsø,   norway; 3Department of Medical  Biology, Faculty of health science,   UiT The arctic University of norway,   Tromsø, norway *These authors contributed equally  to this work correspondence: ibrahim Jantan; syed  Nasir Abbas Bukhari Drug and herbal research center,  Faculty of Pharmacy, Universiti  Kebangsaan Malaysia,  Jalan raja Muda abdul aziz, 50300  Kuala lumpur, Malaysia  Tel +60 3 9289 7315 Fax +60 3 2698 3271  email profibj@gmail.co m;  snab_hussaini@yahoo.co m Journal name: Drug Design, Development and Therapy Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Jantan et al Running head recto: Anti-inflammatory effects of chalcone derivatives DOI: http://dx.doi.org/10.2147/DDDT.S67370 Abstract:  Arachidonic acid metabolism leads to the generation of key lipid mediators which  play a fundamental role during inflammation.",Non-OADS,/arxiv_data1/oa_pdf/40/62/dddt-8-1405.PMC4172049.pdf
Structure  Analysis and Verification  (SAVS) server  at Ucla facility ( http://nihserver.mbi.ucla.edu/SAVES/ ).,OADS,/arxiv_data1/oa_pdf/40/62/dddt-8-1405.PMC4172049.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDove pres s Drug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/40/62/dddt-8-1405.PMC4172049.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/40/62/dddt-8-1405.PMC4172049.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/40/74/dddt-8-1391.PMC4172050.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2014:8 1391–1403Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1391Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/DDDT .S6863 6inhibition of urokinase plasminogen activator  “uPa” activity alters ethanol consumption  and conditioned place preference in mice elyazia al Maamari* Mouza al ameri shamma al Mansouri amine Bahi* Department of anatomy, college  of Medicine and health sciences,   United arab emirates University,   al ain, United arab emirates  *These authors contributed equally  to this work correspondence: amine Bahi Department of anatomy, college  of Medicine and health sciences, United  arab emirates University, PO Box 17666,  al ain, United arab emirates Tel +971 3 7137 516 Fax +971 3 7672 033 email amine.bahi@uaeu.ac.a e Journal name: Drug Design, Development and Therapy Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Al Maamari et al Running head recto: uPA inhibition modulates ethanol reward in mice DOI: http://dx.doi.org/10.2147/DDDT.S68636 Abstract:  Urokinase plasminogen activator, uPA, is a serine protease implicated in addiction  to drugs of abuse.",Non-OADS,/arxiv_data1/oa_pdf/40/74/dddt-8-1391.PMC4172050.pdf
Available from:  http://www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf.,OADS,/arxiv_data1/oa_pdf/40/74/dddt-8-1391.PMC4172050.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDove pres s Drug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/40/74/dddt-8-1391.PMC4172050.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/40/74/dddt-8-1391.PMC4172050.pdf
"Original Article http://mjiri.iums.ac.ir Medical Journal of the Islamic Republic of Iran (MJIRI) Iran University of Medical Sciences ____________________________________________________________________________________________________________________ 1.PhD Student of Biostatistics, Department of Biostatistics, Faculty of Medical Sciences , Tarbiat Modares University, Tehran, Iran.",Non-OADS,/arxiv_data1/oa_pdf/53/97/mjiri-28-28.PMC4172057.pdf
2 8.28.7 May2014http://mjiri.iums.ac.irand existential reactions to that enviro n- ment.,Non-OADS,/arxiv_data1/oa_pdf/53/97/mjiri-28-28.PMC4172057.pdf
2 8.28.7 May2014 http://mjiri.iums.ac.irMethods Questionnaire SF36 A new measure that consider as a mea s- ure of health status is the Short Form 36 (SF-36).,Non-OADS,/arxiv_data1/oa_pdf/53/97/mjiri-28-28.PMC4172057.pdf
2 8.28.7 May2014http://mjiri.iums.ac.irinstruments -tests or items or other stimuli - have been used.,Non-OADS,/arxiv_data1/oa_pdf/53/97/mjiri-28-28.PMC4172057.pdf
2 8.28.7 May2014 http://mjiri.iums.ac.irwith a high QoL show them.,Non-OADS,/arxiv_data1/oa_pdf/53/97/mjiri-28-28.PMC4172057.pdf
2 8.28.7 May2014http://mjiri.iums.ac.irDiscussion The purpose of the paper was to introduce the RM and to show an application of this model in estimating the latent variable in quality of life research.,Non-OADS,/arxiv_data1/oa_pdf/53/97/mjiri-28-28.PMC4172057.pdf
2 8.28.7 May2014 http://mjiri.iums.ac.irlongitudinal latent regression model (LLRM) to examine the effect of various factors on the quality of life of terminal cancer patients in Italy.,Non-OADS,/arxiv_data1/oa_pdf/53/97/mjiri-28-28.PMC4172057.pdf
2 8.28.7 May2014http://mjiri.iums.ac.irPersian] 9.Amini R. Health needs assessment report on blind survivors.,Non-OADS,/arxiv_data1/oa_pdf/53/97/mjiri-28-28.PMC4172057.pdf
"2 8.28.7 May2014 http://mjiri.iums.ac.ir38.TranBX,Ohinmaa A,DuongAT,Thi-Do, NguyenLT.Changes in drug use are associated with health -related quality of life improvements among methadone ma intenance patients with HIV/AIDS .",Non-OADS,/arxiv_data1/oa_pdf/53/97/mjiri-28-28.PMC4172057.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d0/00/cia-9-1563.PMC4172068.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 1563–1571Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1563RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/CIA.S6726 3Xue-Song Mi1,2 Ti-Fei Yuan3,4 Kwok-Fai So2,4,5 1Department of Ophthalmology,   The First Affiliated Hospital of Jinan  University, Guangzhou, People’s  Republic of China; 2Department   of Anatomy, Li Ka Shing Faculty   of Medicine, The University of Hong  Kong, Hong Kong, People’s Republic   of China; 3School of Psychology,   Nanjing Normal University,   Nanjing, People’s Republic of China;   4Department of Ophthalmology,    Li Ka Shing Faculty of Medicine, The  University of Hong Kong, Hong Kong,   People’s Republic of China; 5GHM  Institute of CNS Regeneration, Jinan  University, Guangzhou, People’s  Republic of China Correspondence: Kwok-Fai So   GHM Institute of CNS Regeneration,  Jinan University, Huang Pu Road west  601, Guangzhou, 510632, People’s  Republic of China   email hrmaskf@hku.h k The current research status of normal tension  glaucoma Abstract:  Normal tension glaucoma (NTG) is a progressive optic neuropathy that mimics  primary open-angle glaucoma, but lacks the findings of elevated intraocular pressure or other  mitigating factors that can lead to optic neuropathy.",Non-OADS,/arxiv_data1/oa_pdf/d0/00/cia-9-1563.PMC4172068.pdf
"The third step in diagnosis is to  perform visual field (VF) testing to confirm whether there are specific glaucomatous  VF defects.7  For the management of NTG, the initial approach is to observe if there is any docu - mented progression of the disease, which includes the following  indications: 1) signs Journal name: Clinical Interventions in Aging Journal Designation: Review Y ear: 2014 Volume: 9 Running head verso: Mi et al Running head recto: The current research status of normal tension glaucoma DOI: http://dx.doi.org/10.2147/CIA.S67263",Non-OADS,/arxiv_data1/oa_pdf/d0/00/cia-9-1563.PMC4172068.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/d0/00/cia-9-1563.PMC4172068.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/d0/00/cia-9-1563.PMC4172068.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/2e/40/cpaa-6-127.PMC4172069.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Pharmacology: Advances and Applications 2014:6 127–137Clinical Pharmacology: Advances and Applications Dove press submit your manuscript | www.dovepress.co m Dove press  127Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CPAA.S3660 0Melatonergic drugs in development Alessia Carocci1 Alessia Catalano1 Maria Stefania Sinicropi2 1Department of Pharmacy–Drug  Sciences, University of Bari Aldo  Moro, Bari,  2Department of Pharmacy,   Health and Nutritional Sciences,   University of Calabria, Cosenza, italy Correspondence: Alessia Carocci   Department of Pharmacy – Drug   Sciences, University of Bari Aldo   Moro, via Orabona,  4.",Non-OADS,/arxiv_data1/oa_pdf/2e/40/cpaa-6-127.PMC4172069.pdf
"Clinical Pharmacology: Advances and Applications Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-pharmacology-advances-and-applications-journa lClinical Pharmacology: Advances and Applications is an international,  peer-reviewed, open access journal publishing original research, reports,  reviews and commentaries on all areas of drug experience in humans.",Non-OADS,/arxiv_data1/oa_pdf/2e/40/cpaa-6-127.PMC4172069.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/2e/40/cpaa-6-127.PMC4172069.pdf
http://dx.doi.org/10.1126/science.1104816 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1136/gutjnl-2012-303249 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1053/ j.gastro.2011.06.072 .,OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1136/gutjnl-2012-303954 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1136/ gut.2005.073817 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1053/gast.2002.30294 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/ 10.1038/nature11552 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1053/j.gastro.2010.08.049 .,OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1126/science.1208344 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1371/ journal.pone.0026988 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1371/journal.pone.0020338 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/ 10.1371/journal.ppat.1000711 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1371/ journal.pone.0020953 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/ 10.1371/journal.pone.0035988 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
69:405– 411. http://dx.doi.org/10.1017/ S0022172400021653 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1371/ journal.pone.0002836 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1371/journal.ppat.1002995 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1136/ gutjnl-2012-304119 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1093/cid/cit715 .,OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.3201/ eid1902.121147 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
93:33– 41. http://dx.doi.org/10.1016/j.prevetmed.2009.09.015 .,OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/ 10.1038/ismej.2011.41 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/10.1007/s10875-011-9572-0 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
http://dx.doi.org/ 10.1093/nar/gkp353 .,Non-OADS,/arxiv_data1/oa_pdf/12/39/mBio.01212-14.PMC4172070.pdf
Oncogene 25:6347– 6360. http://dx.doi.org/10.1038/sj.onc.1209885 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
9:860 – 875. http://dx.doi.org/10.1038/ nrmicro2655 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/ j.cell.2004.09.038 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1073/ pnas.75.6.2732 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
18: 660 – 672. http://dx.doi.org/10.1101/gad.1185304 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
79:8057– 8064. http://dx.doi.org/ 10.1128/JVI.79.13.8057-8064.2005 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1371/ journal.ppat.1000562 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1128/MCB.01631-07 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1126/ science.1184939 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/j.mib.2012.04.009 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1017/ S1355838201010330 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1074/jbc.M610258200 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/ 0042-6822(62)90125-3 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1073/ pnas.72.2.742 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/ 10.1016/0042-6822(71)90282-0 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
84: 867– 882. http://dx.doi.org/10.1128/JVI.01571-09 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1007/s00418-012-1063-8 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1083/jcb.201112145 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
76: 4483– 4496. http://dx.doi.org/10.1128/JVI.76.9.4483-4496.2002 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/ 10.1016/0042-6822(70)90171-6 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/S0022 -2836(03)00668-5 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
Virology120:399 – 411. http://dx.doi.org/10.1016/0042-6822(82)90040-X .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
162: 459 – 471. http://dx.doi.org/ 10.1084/jem.162.2.459 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/ j.molcel.2009.03.006 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1101/cshperspect.a013706 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1038/nrm2838 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/ j.tibs.2006.08.005 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1002/elps.1150110305 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/0042-6822(71)90058-4 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
Virology 47:797– 806. http://dx.doi.org/10.1016/0042-6822(72)90571-5 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
76:8285– 8297. http://dx.doi.org/10.1128/JVI.76.16.8285 -8297.2002 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/ j.virol.2007.03.037 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1006/viro.1997.8531 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1128/JVI.74.13.5939-5948.2000 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1128/JVI.00276-06 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1128/JVI.75.3.1459 -1475.2001 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
94:4957– 4970. http://dx.doi.org/10.1529/ biophysj.107.120345 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
mBio 5(1):e00931- 13.http://dx.doi.org/10.1128/mBio.00931-13 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/j.semcdb.2004.11.004 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1128/JVI.01239-09 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/ j.virol.2012.11.017 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/j.virol.2013.10.009 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/ j.tim.2012.02.001 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/ 10.1371/journal.pone.0004772 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/ 10.1016/j.virol.2008.04.015 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/j.cell.2009.01.042 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
Virology 70: 411– 424. http://dx.doi.org/10.1016/0042-6822(76)90282-8 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1038/emboj.2009.256 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1016/j.virol.2010.06.043 .,OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1006/viro.1996.0059 .,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
http://dx.doi.org/10.1128/JVI.77.24.13361-13375.2003 .Reovirus Retargets Translation to Viral Factories September/October 2014 Volume 5 Issue 5 e01463-14®mbio.asm.org 11,Non-OADS,/arxiv_data1/oa_pdf/84/e5/mBio.01463-14.PMC4172071.pdf
9:32.http://dx.doi.org/ 10.1186/1741-7015-9-32 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1371/journal.pgen.1003741 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1111/j.1462-2920.2011.02483.x .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
6:31– 45. http://dx.doi.org/10.1038/ismej.2011.83 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1164/ rccm.201009-1430OC .,OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1371/journal.pone.0060225 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
194: 4857– 4866. http://dx.doi.org/ 10.1128/JB.01050-12 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
46:82– 87. http://dx.doi.org/10.1038/ng.2848 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1128/AAC.01371-12 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1099/ mic.0.033993-0 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/ 10.1128/IAI.01282-06 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1093/molbev/mss075 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1126/ science.288.5469.1251 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1136/thx.47.1.6 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1128/JB.01581-07 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1016/j.jcf.2008.09.006 .,OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1089/mdr.2011.0019 .,OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1038/27900 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1371/ journal.pgen.1000713 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
6:471– 474. http://dx.doi.org/ 10.1038/ismej.2011.104 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1002/ppul.21011 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1126/science.1082240 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
Thorax 65:57– 62. http://dx.doi.org/10.1136/ thx.2009.114512 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1016/ j.jcf.2012.04.011 .,OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1016/ S0169-5347(00)01994-7 .,OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1038/ nrg1046 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1111/j.1574- 6976.2008.00149.x .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1038/35037572 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
http://dx.doi.org/10.1186/gb-2004-5-10-r80 .,Non-OADS,/arxiv_data1/oa_pdf/a2/21/mBio.01592-14.PMC4172072.pdf
"TheAPH1 gene (CNAG_02944 in the C. neoformans H99 se- rotype A genome database; http://www.broadinstitute.org/annotation/ genome/cryptococcus_neoformans/MultiHome.html) deletion con- struct was created by fusing genomic sequence upstream of APH1 (5= ﬂank; 787 bp), the neomycin resistance (Neor) cassette (ampliﬁed from pJAF vector), and genomic sequence downstream of APH1 (3=ﬂank; 952 bp) by overlap PCR.",OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
The position of the motif wasdetermined by using the BIG-PI fungal predictor (http://mendel.im-p.ac.at/sat/gpi/fungi_server.html).,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1046/j.1365-2958.2001.02236.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1074/ jbc.M707913200 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
Cell5:488 – 498. http://dx.doi.org/10.1128/EC.5.3.488-498.2006 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1128/ IAI.01351-06 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1128/ IAI.69.9.5589-5596.2001 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1016/S1130 -1406(06)70047-X .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
7:621– 628. http://dx.doi.org/10.1111/j.1567-1364.2007.00223.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1371/journal.pone.0070514 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1016/0003-9861(88)90375-X .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1074/jbc.M200114200 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1111/ j.1567-1364.2006.00105.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
Genetics 186:885– 895. http://dx.doi.org/10.1534/genetics.110.120824 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.3109/ 13693786.2011.653835 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1099/mic.0.27405-0 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1266/ggs.72.323 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1111/j.1365-2958.1990.tb00560.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
Mycopathologia 173: 407– 418. http://dx.doi.org/10.1007/s11046-011-9468-9 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
Cell 7:58 – 67. http://dx.doi.org/10.1128/EC.00370-07 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
Yeast 27:661– 672. http://dx.doi.org/10.1002/yea.1775 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1371/ journal.pone.0052470 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1111/j.1365 -2958.2011.07632.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
6:645– 651. http://dx.doi.org/10.1111/j.1567 -1364.2006.00043.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1042/ BJ20071097 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1083/jcb.200109077 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1007/s00408-004-2511-6 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1016/S1286-4579(03)00028-5 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
Cell 6:855– 867. http://dx.doi.org/10.1128/ EC.00399-06 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1111/j.1365-2958.2006.05551.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1016/0008-6215(90)84273-W .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1111/j.1365-2958.2010.07119.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1074/jbc.275.20.14882 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
Genomics 272:639 – 650. http://dx.doi.org/10.1007/ s00438-004-1085-6 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1111/j.1365-2958.2004.04474.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1093/infdis/jit029 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1093/jb/mvj128 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1371/journal.pone.0011113 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1016/ j.micinf.2006.05.001 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1007/s00203-006-0100-1 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1247/csf.23.333 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1016/j.plantsci.2010.04.005 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1104/pp.110.153270 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1111/j.1365-2958.2010.07254.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
"http://dx.doi.org/10.1242/jcs.060210 .59.Vida TA, Emr SD.",OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1016/0006-291X(90)90990-5 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1111/j.1699 -0463.1999.tb01507.x .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
41:469 – 477. http://dx.doi.org/ 10.1080/10683160310001615399 .,Non-OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/ 10.1016/S1286-4579(02)00024-2 .,OADS,/arxiv_data1/oa_pdf/89/29/mBio.01649-14.PMC4172073.pdf
http://dx.doi.org/10.1128/ CMR.13.3.470-511.2000 .,OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
Laryngoscope 107: 640 – 647. http://dx.doi.org/10.1097/00005537-199705000-00016 .SLO and NADase Promote S. pyogenes Survival in Macrophages September/October 2014 Volume 5 Issue 5 e01690-14®mbio.asm.org 9,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
25:880 – 883. http://dx.doi.org/10.1097/ 01.inf.0000238136.63851.4a .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1007/82_2012_281 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1128/ IAI.71.9.5376-5380.2003 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1371/ journal.pmed.0030053 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1128/IAI.72.5.2956-2963.2004 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
187:6022– 6031. http://dx.doi.org/10.4049/jimmunol.1101385 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/ 10.1159/000317635 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
2:75– 84. http://dx.doi.org/ 10.2217/17460913.2.1.75 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1385/1-59259-052-7:1 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1016/S0041- 0101(01)00155-6 .,OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.2174/156652408785747924 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1128/ mBio.00394-12 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1111/j.1462-5822.2008.01245.x .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
284:862– 871. http://dx.doi.org/10.1074/jbc.M804632200 .,OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1111/j.1574- 6968.1995.tb07538.x .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1074/jbc.M506879200 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1371/ journal.ppat.0010035 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1016/S0092- 8674(01)00198-2 .,OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1126/ science.1103966 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1371/ journal.ppat.1003394 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
281:8216 – 8223. http://dx.doi.org/10.1074/jbc.M511674200 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/ 10.1016/0140-6736(92)90339-5 .,OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1074/jbc.M113.481556 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
Streptococcus pyo- genes cytolysin-mediated translocation does not require pore formationby streptolysin O. EMBO Rep. 11:400 – 405. http://dx.doi.org/10.1038/ embor.2010.37 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1038/nrmicro2128 .,OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1146/ annurev-pathol-011811-132445 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1128/mBio.00332-10 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
Immunity 23: 409 – 417. http://dx.doi.org/10.1016/j.immuni.2005.09.007 .,OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
Nature 482: 414 – 418. http://dx.doi.org/ 10.1038/nature10744 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1111/j.1365-2958.2006.05430.x .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1371/ journal.ppat.1000832 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1371/ journal.ppat.1002361 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/ 10.1128/IAI.01560-08 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1371/journal.ppat.1000145 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/ 10.1172/JCI3065 .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
http://dx.doi.org/10.1046/j.1365- 2958.2001.02635.x .,Non-OADS,/arxiv_data1/oa_pdf/18/d2/mBio.01690-14.PMC4172074.pdf
"National Center for Biotechnology Information (NCBI) databases for genome, gene, and nucleotide accessions were que-ried (http://www.ncbi.nlm.nih.gov/pubmed) for all taxonomy virus an-notations and for accessions from prokaryotic and eukaryotic humanpathogen lists compiled by literature searches and web resources (http://www.niaid.nih.gov: Emerging and Re-emerging Infectious Diseases, Cat-egory A, B, and C Priority Pathogens).",OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
"masked using mdust (http://doc.bioperl.org/bioperl-run/lib/Bio/Tools/ Run/Mdust.html) followed by BLASTN 2.0MP-WashU (Advanced Bio-computing, LLC, St. Louis, MO) identiﬁcation of unique regions in viralaccessions (36).",OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
Probes and accession annotations are avail- able in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/).,OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
Oropharyngeal squamous cell carcinoma tumor samples were ob- tained from the Abramson Cancer Center’s Tumor Tissue and Biospeci-men Bank (https://somapps.med.upenn.edu/pbr/portal/tumor/).,OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1038/486194a .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1038/nature11234 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
13:467– 471. http://dx.doi.org/ 10.1016/j.autrev.2014.01.029 .,OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1097/MED.0000000000000032 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/ 10.1371/journal.pone.0086708 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
10:3– 4. http://dx.doi.org/10.1016/ j.ddtec.2012.10.014 .,OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1513/ AnnalsATS.201306-204AW .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1513/AnnalsATS.201310- 339FR .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1513/ AnnalsATS.201306-198MG .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.2217/imt.13.130 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1016/ j.freeradbiomed.2013.11.008 .,OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1126/science.1240527 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1371/journal.pone.0083744 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
88: 4786 – 4797. http://dx.doi.org/10.1128/JVI.00093-14 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
72: 6288 – 6298. http://dx.doi.org/10.1128/AEM.00246-06 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
50:2536. http://dx.doi.org/10.3791/2536 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1111/1755-0998.12239 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1186/gb-2007-8-5-r93 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
2008:4920. http://dx.doi.org/ 10.1101/pdb.prot4920 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1002/gcc.21937 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1007/s12105-012-0370-7 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1073/ pnas.0601180103 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1002/ cncr.23764 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1042/BST0360522 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1016/j.virol.2008.11.014 .,OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1016/ j.virol.2013.07.008 .,OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1186/gb-2009-10-3- r25.,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1093/bib/ bbs017 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1086/ 507896 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1371/journal.ppat.0020025 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/ 10.1128/JCM.00364-07 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
196: 817– 825. http://dx.doi.org/10.1086/520816 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1073/ pnas.0805968105 .,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
5:88. http://dx.doi.org/10.1186/1743-422X- 5-88 .PathoChip Metagenomic Proﬁling of Human Cancers September/October 2014 Volume 5 Issue 5 e01714-14®mbio.asm.org 13,Non-OADS,/arxiv_data1/oa_pdf/03/74/mBio.01714-14.PMC4172075.pdf
http://dx.doi.org/10.1128/ mBio.01206-14 .,Non-OADS,/arxiv_data1/oa_pdf/47/31/mBio.01717-14.PMC4172076.pdf
http://dx.doi.org/10.1093/qjmed/ hcg150 .,OADS,/arxiv_data1/oa_pdf/47/31/mBio.01717-14.PMC4172076.pdf
http://dx.doi.org/ 10.1097/MAJ.0b013e31824ba6e0 .,Non-OADS,/arxiv_data1/oa_pdf/47/31/mBio.01717-14.PMC4172076.pdf
"KEGG, Kyoto Encyclopedia of Genes and Genomes ( http://www.genome.jp/kegg/ ); TCA, tricarboxylic acid./H9252-Lactam Resistance Mechanisms in M. tuberculosis September/October 2014 Volume 5 Issue 5 e01767-14®mbio.asm.org 3",Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
48: 77– 84. http://dx.doi.org/10.1046/j.1365-2958.2003.03425.x .Lun et al.,OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
Cancer 5:689 – 698. http://dx.doi.org/ 10.1038/nrc1691 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
22:56 – 63. http://dx.doi.org/ 10.1016/j.tig.2005.11.003 .,OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1128/AAC.39.12.2692 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1128/JB.187.6.1892-1900.2005 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1128/ AAC.39.12.2620 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1099/mic.0.27629-0 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1128/AAC.05690-11 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
26:874 – 877. http://dx.doi.org/10.1086/513945 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.5588/ijtld.11.0414 .,OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
16:466 – 469. http://dx.doi.org/10.1038/nm.2120 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
56:4189 – 4195. http://dx.doi.org/10.1128/AAC.00665-12 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1128/AAC.01663-13 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/ 10.1016/j.diagmicrobio.2004.04.003 .,OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1099/ mic.0.037507-0 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
72:819 – 825. http://dx.doi.org/10.1128/ AEM.72.1.819-825.2006 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1074/jbc.M111.239988 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/ 10.1002/bip.22447 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
191:625– 631. http://dx.doi.org/10.1128/JB.00932-08 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1128/ AAC.00298-08 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1016/j.tube.2008.08.003 .,OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/ 10.1371/journal.pone.0102135 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1128/AAC.00037-14 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/ 10.1074/jbc.M113.538959 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
279: 40174 – 40184. http://dx.doi.org/10.1074/ jbc.M406796200 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1016/ j.celrep.2013.10.031 .,OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/ 10.1074/jbc.M700035200 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1128/AAC.47.10.3053- 3060.2003 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1183/ 09031936.00124312 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1177/ 108705719900400206 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1038/31159 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
4:2907. http://dx.doi.org/10.1038/ncomms3907 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/ 10.1128/AAC.00918-13 .,Non-OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
BMC Bioinformatics 14:244. http://dx.doi.org/10.1186/1471- 2105-14-244 .Lun et al.,OADS,/arxiv_data1/oa_pdf/3e/45/mBio.01767-14.PMC4172077.pdf
http://dx.doi.org/10.1016/ j.vaccine.2006.05.111 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/JVI.01631-08 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/JVI.75.3.1565-1570.2001 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/JVI.02190-08 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1074/jbc.274.9.5810 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1016/j.virol.2009.08.034 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/ JVI.77.24.12961-12967.2003 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/JVI.77.6.3531-3541.2003 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1074/ jbc.M208691200 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1371/journal.ppat.1000524 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1097/MJT.0b013e3181754134 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/ 10.1016/S0042-6822(02)00143-5 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
7:2.http://dx.doi.org/10.1186/1743-422X-7-2 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
Virology227:474 – 483. http://dx.doi.org/10.1006/viro.1996.8348 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1371/journal.ppat.1002657 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/JVI.01014-08 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1006/viro.2001.1493 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1111/j.1742- 4658.2009.07400.x .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1371/journal.ppat.1004162 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1371/ journal.ppat.1000318 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/JVI.00980-12 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/ 10.1128/JVI.03222-12 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1016/j.virol.2014.04.024 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1016/j.advenzreg.2009.10.002 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/ 10.1101/cshperspect.a016865 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
86:4169 – 4181. http://dx.doi.org/10.1128/ JVI.05493-11 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
Trafﬁc 13:455– 467. http://dx.doi.org/10.1111/ j.1600-0854.2011.01320.x .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/JVI.80.2.759- 768.2006 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1007/s00705-009-0310-3 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1016/ j.virol.2013.04.017 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1016/ j.virol.2010.09.002 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/JVI.01081-10 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
1195: 289. http://dx.doi.org/10.1007/ 7651_2013_65 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.3233/ JAD-2011-101065 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1016/j.cell.2007.09.038 .,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/mBio.00101-11 .Zhang et al.,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1038/416031a .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1007/s00412-012-0388-3 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1128/JVI.00731-09 .,Non-OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/10.1016/j.virol.2004.02.011 ./H9253-Secretase Blocks Golgi Apparatus Trafﬁcking of HPV September/October 2014 Volume 5 Issue 5 e01777-14®mbio.asm.org 11,OADS,/arxiv_data1/oa_pdf/ea/2e/mBio.01777-14.PMC4172078.pdf
http://dx.doi.org/ 10.1128/mBio.00360-12 .,Non-OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
http://dx.doi.org/10.1128/mBio.00358-12 .,Non-OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
http://dx.doi.org/10.1128/IAI.01530-13 .8.Rosenberg A.,Non-OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
http://dx.doi.org/10.1128/MMBR.00007-10 .,Non-OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
http://dx.doi.org/10.1038/nrmicro799 .,OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
http://dx.doi.org/ 10.1093/cid/10.Supplement_2.S274 .,OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
Science 335:660 – 661. http://dx.doi.org/10.1126/science.1217994 .,Non-OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
http://dx.doi.org/10.1128/IAI.00623-09 .,Non-OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
http://dx.doi.org/ 10.1126/science.1213362 .,Non-OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
Nature 486:420 – 428. http://dx.doi.org/10.1038/nature10831 .,Non-OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
http://dx.doi.org/10.1016/ j.cell.2013.05.035 .,OADS,/arxiv_data1/oa_pdf/16/ae/mBio.01875-14.PMC4172079.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5c/e2/prom-5-105.PMC4172080.pdf
"Information on how to request permission may be found at: http://www.dovepress.com/permissions.ph pPatient Related Outcome Measures 2014:5 105–110Patient Related Outcome Measures Dove press submit your manuscript | www.dovepress.co m Dove press  105ORiginal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/PROM.S6673 7assessment of patient satisfaction   with the preoperative anesthetic evaluation endale gebreegziabher  gebremedhn Vidhya nagaratnam Department of anesthesia, school of  Medicine, gondar college of Medicine  and health sciences, University of  gondar, gondar, ethiopia correspondence: endale gebreegziabher  gebremedhn   Department of anesthesia,   school of Medicine, gondar college   of Medicine and health sciences,   University of gondar, PO Box 196,   gondar, ethiopia   T el +251910880117   email endalege@yahoo.co mBackground:  The evaluation of patient satisfaction is a core aspect of the continuous quality  improvement in anesthesia service that can be affected by the preoperative anesthetist visit.",Non-OADS,/arxiv_data1/oa_pdf/5c/e2/prom-5-105.PMC4172080.pdf
"Available from: http://www.aagbi.org/sites/default/files/ preoperativeass01.pd f. Accessed September 4, 2014.",OADS,/arxiv_data1/oa_pdf/5c/e2/prom-5-105.PMC4172080.pdf
"Patient Related Outcome Measures Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-related-outcome-measures-journa lPatient Related Outcome Measures is an international, peer-reviewed,  open access journal focusing on treatment outcomes specifically  relevant to patients.",Non-OADS,/arxiv_data1/oa_pdf/5c/e2/prom-5-105.PMC4172080.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/5c/e2/prom-5-105.PMC4172080.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e0/fa/ott-7-1609.PMC4172081.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 1609–1617OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1609Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6234 9isolation, detection, and immunomorphological  characterization of circulating tumor cells (cTcs)  from patients with different types of sarcoma  using isolation by size of tumor cells: a window   on sarcoma-cell invasion ludmilla T Domingos  chinen1 celso a lopes Mello2 emne ali abdallah1 luciana MM Ocea1 Marcilei e Buim1 natália M Breve1 José luiz gasparini Junior1 Marcello F Fanelli2 Patrizia Paterlini-Bréchot3 1international research center,   2Department of clinical Oncology,   ac camargo cancer center, são  Paulo, Brazil; 3Unité inserM U807,   Université Paris Descartes, Paris,   France correspondence: ludmilla T Domingos  chinen   international research center, ac  camargo cancer center, rua Taguá,   440 são Paulo, 01508-010, Brazil   Tel +55 11 2189 2993   email ludmilla.chinen@cipe.accamargo.",Non-OADS,/arxiv_data1/oa_pdf/e0/fa/ott-7-1609.PMC4172081.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/e0/fa/ott-7-1609.PMC4172081.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e0/fa/ott-7-1609.PMC4172081.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a5/0d/ppa-8-1229.PMC4172082.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 1229–1237Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1229OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/PPA.S6665 5An evaluation of patients’ adherence with  hypoglycemic medications among Papua new  Guineans with type 2 diabetes: influencing factors stella Tilu Pihau-T ulo richard W Parsons Jeffery D hughes chiri and school of Pharmacy,    curtin University, Perth, WA, Australia correspondence: Jeffery D hughes   school of Pharmacy, curtin University,  gPO Box U1987, Perth, WA 6845,  Australia   Tel +61 8 9266 7367   Fax +61 8 9266 2769   email j .d.hughes@curtin.edu.au  Purpose:  The aims of this study were to evaluate the extent of adherence to hypoglycemic  medications, assess the relationship between adherence and glycemic control, and evaluate  factors affecting adherence.",Non-OADS,/arxiv_data1/oa_pdf/a5/0d/ppa-8-1229.PMC4172082.pdf
"The earliest report of diabetes in PNG was in 1963, where 10 cases  were seen at the Port Moresby General Hospital (PMGH) over a 3-year period.2  The first survey of diabetes in 1962 found no cases in a rural district and a 0.2%  prevalence in four suburban communities in Port Moresby.3 The diabetes prevalence  in various coastal population groups in PNG have been reported to range from 0.2%  in the 1960s to 33.0% in the 1990s.3–7 A survey in two highlands populations in  1983 and 1985 reported a complete absence of diabetes as well as impaired glu - cose tolerance prevalence rates ranging from 1.7%–2.7%.6,8 The WHO reported Journal name: Patient Preference and Adherence Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Pihau-Tulo et al Running head recto: Adherence with hypoglycemic medications in Papua New Guinea DOI: http://dx.doi.org/10.2147/PPA.S66655",Non-OADS,/arxiv_data1/oa_pdf/a5/0d/ppa-8-1229.PMC4172082.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/a5/0d/ppa-8-1229.PMC4172082.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/af/80/opth-8-1869.PMC4172083.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1869–1875Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1869Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/OPTH.S6980 4Differentiation between chalazion and sebaceous  carcinoma by noninvasive meibography Yuji nemoto1 reiko arita2,3 atsushi Mizota1 Yuko sasajima4 1Department of Ophthalmology,   T eikyo University school of Medicine,   T okyo, 2itoh Clinic, saitama,   3Department of Ophthalmology,   The University of T okyo, T okyo,   4Department of Pathology, Teikyo  University school of Medicine,   T okyo, JapanBackground:  Sebaceous carcinoma is notorious for masquerading clinically as other benign  lesions such as chalazion.",Non-OADS,/arxiv_data1/oa_pdf/af/80/opth-8-1869.PMC4172083.pdf
"This aggressive neoplasm can exhibit local recurrence as well Correspondence: reiko arita itoh Clinic, 626-11, Minaminakano,  Minuma-ku, saitama City, saitama  337-0042, Japan Tel +81 486 86 5588 Fax +81 486 86 8485 email ritoh@za2.so-net.ne.j p Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Nemoto et al Running head recto: Application of meibography for eyelid tumors DOI: http://dx.doi.org/10.2147/OPTH.S69804",Non-OADS,/arxiv_data1/oa_pdf/af/80/opth-8-1869.PMC4172083.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/af/80/opth-8-1869.PMC4172083.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/af/80/opth-8-1869.PMC4172083.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/88/18/ijn-9-4421.PMC4172084.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4421–4435International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4421RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/IJN.S6586 6Nanotubular surface modification of metallic  implants via electrochemical anodization  technique Correspondence: Lu-Ning wang  School of Materials Science and  engineering, University of Science and  T echnology Beijing, No.",Non-OADS,/arxiv_data1/oa_pdf/88/18/ijn-9-4421.PMC4172084.pdf
"30, Xueyuan Road,  Hai-Dian District, Beijing, 100083,   People’s Republic of China   T el +86 10 6233 2184   Fax +86 10 6233 2184   email luning.wang@ustb.edu.c n     Jing-Li Luo   Department of Chemical and Materials  engineering, University of Alberta,   9107 - 116 Street, edmonton,   AB, T6G 2v4, Canada   T el +1 780 492 2232   Fax +1 780 492 2880   email luoj@ualberta.c aLu-Ning wang1 Ming Jin1 Yudong Zheng1 Yueping Guan1 Xin Lu1 Jing-Li Luo2 1School of Materials Science and  engineering, University of Science   and T echnology Beijing, Beijing,   People’s Republic of China;   2Department of Chemical and  Materials engineering, University   of Alberta, edmonton, AB, CanadaJournal name: International Journal of Nanomedicine Journal Designation: Review Y ear: 2014 Volume: 9 Running head verso: Wang et al Running head recto: Nanotubular surface modification of metallic implants DOI: http://dx.doi.org/10.2147/IJN.S65866 Abstract:  Due to increased awareness and interest in the biomedical implant field as a result  of an aging population, research in the field of implantable devices has grown rapidly in the  last few decades.",Non-OADS,/arxiv_data1/oa_pdf/88/18/ijn-9-4421.PMC4172084.pdf
Available from:  http://www.sciencenewsline.com/articles/2012021012390001.html/.,Non-OADS,/arxiv_data1/oa_pdf/88/18/ijn-9-4421.PMC4172084.pdf
"International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.co m Dove press Dove press International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/88/18/ijn-9-4421.PMC4172084.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s 4435Nanotubular surface modification of metallic implants  64.,Non-OADS,/arxiv_data1/oa_pdf/88/18/ijn-9-4421.PMC4172084.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8f/1d/mder-7-319.PMC4172085.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pMedical Devices: Evidence and Research 2014:7 319–324Medical Devices: Evidence and Research Dove press submit your manuscript | www.dovepress.co m Dove press  319ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S6775 6Impact of the shape of the implantable ports   on their efficiency of flow (injection and flushing) Gérard Guiffant1 Patrice Flaud1 Jean Jacques Durussel1 Jacques Merckx1,2 1Université Paris Diderot, Paris,   France; 2University Teaching Hospital  Necker-Enfants Malades, Paris, France Correspondence: Gérard Guiffant   Université Paris Diderot,   Centre National de la Recherche  Scientifique (CNRS) 7057, 10 rue Alice   Domon et Léonie Duquet, 75205 Paris,  CEDEX 13, France   Fax +33 01 5727 6211   Email gerard.guiffant@univ-paris-diderot.",Non-OADS,/arxiv_data1/oa_pdf/8f/1d/mder-7-319.PMC4172085.pdf
"Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/medical-devices-evidence-and-research-journa lMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology,  research, and expert opinion supporting the use and application of  medical devices in the diagnosis, treatment and management of clini - cal conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/8f/1d/mder-7-319.PMC4172085.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseMay 2014 |  87  | e51547 | Page 1 of 13Video Article Preparation and Use of Photocatalytically Active Segmented Ag|ZnO and Coaxial TiO2-Ag Nanowires Made by Templated Electrodeposition A. Wouter Maijenburg1, Eddy J.B. Rodijk1, Michiel G. Maas1, Johan E. ten Elshof1 1MESA+ Institute for Nanotechnology, University of Twente Correspondence to: Johan E. ten Elshof at j.e.tenelshof@utwente.nl URL: http://www.jove.com/video/51547 DOI: doi:10.3791/51547 Keywords: Physics, Issue 87, Multicomponent nanowires, electrochemistry, sol-gel processes, photocatalysis, photochemistry, H2 evolution Date Published: 5/2/2014 Citation: Maijenburg, A.W., Rodijk, E.J., Maas, M.G., ten Elshof, J.E.",Non-OADS,/arxiv_data1/oa_pdf/9b/6b/jove-87-51547.PMC4172098.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/51547/ Introduction Owing to their small dimensions and large surface-to-volume ratio, nanowires are very promising one-dimensional objects that can be used in a wide range of biomedical and nanotechnological applications1.",Non-OADS,/arxiv_data1/oa_pdf/9b/6b/jove-87-51547.PMC4172098.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/aa/61/dmso-7-409.PMC4172102.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 409–420Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  409Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DMSO.S5130 1Sex differences in type  2 diabetes: focus on  disease course and outcomes Lisa Arnetz1,2 Neda Rajamand ekberg1,2 Michael Alvarsson1,2 1Department of Molecular   Medicine and Surgery, Karolinska   institutet,  2Department of   endocrinology, Metabolism and   Diabetes, Stockholm, Sweden Correspondence: Michael Alvarsson   Department of endocrinology,   Diabetes and Metabolism, D2:04,   Karolinska University Hospital Solna,   17176 Stockholm, Sweden   Tel +46 8 5177 2862  Fax +46 8 5177 3096  email m ichael.",Non-OADS,/arxiv_data1/oa_pdf/aa/61/dmso-7-409.PMC4172102.pdf
"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journa lDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy is  an international, peer-reviewed open-access journal committed to  the rapid publication of the latest laboratory and clinical findings  in the fields of diabetes, metabolic syndrome and obesity research.",Non-OADS,/arxiv_data1/oa_pdf/aa/61/dmso-7-409.PMC4172102.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/aa/61/dmso-7-409.PMC4172102.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f3/96/ijn-9-4387.PMC4172103.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4387–4398International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4387REVIEWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJN.S4929 7Thermosensitive liposomal drug delivery  systems: state of the art review Barbara Kneidl1,2 Michael Peller3 Gerhard Winter2 Lars H Lindner1 Martin Hossann1 1Department of Internal Medicine  III, University Hospital Munich,   2Department of Pharmacy,   Pharmaceutical Technology and  Biopharmaceutics, 3Institute for  Clinical Radiology, University  Hospital Munich, Ludwig-Maximilians  University, Munich, Germany Correspondence: Martin Hossann   Medizinische Klinik und Poliklinik III,  Klinikum der Universität München,  Marchioninistrasse 15, D-81377 München,  Germany   T el +49 89 4400 73153   Fax +49 89 4400 78694   Email martin.hossann@med.",Non-OADS,/arxiv_data1/oa_pdf/f3/96/ijn-9-4387.PMC4172103.pdf
uni-muenchen.d eJournal name: International Journal of Nanomedicine Journal Designation: REVIEW Y ear: 2014 Volume: 9 Running head verso: Kneidl et al Running head recto: Thermosensitive liposomal drug delivery systems DOI: http://dx.doi.org/10.2147/IJN.S49297 Abstract:  Thermosensitive liposomes are a promising tool for external targeting of drugs to solid  tumors when used in combination with local hyperthermia or high intensity focused ultrasound.,Non-OADS,/arxiv_data1/oa_pdf/f3/96/ijn-9-4387.PMC4172103.pdf
"International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.co m Dove press Dove press International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/f3/96/ijn-9-4387.PMC4172103.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s 4398Kneidl et al 83.,Non-OADS,/arxiv_data1/oa_pdf/f3/96/ijn-9-4387.PMC4172103.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b6/f6/ndt-10-1799.PMC4172104.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1799–1805Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1799OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/NDT .S6956 2sleep and cognitive problems in patients  with attention-deficit hyperactivity disorder hae Kook lee Jong-hyun Jeong Na-Y oung Kim Min-hyeon Park Tae-Won Kim ho-Jun seo hyun-Kook lim seung-chul hong Jin-hee han Department of Psychiatry, college  of Medicine, The catholic University  of Korea, seoul, KoreaObjectives:  Attention-deficit hyperactivity disorder (ADHD) is characterized by inattentive  and impulsive behavior.",Non-OADS,/arxiv_data1/oa_pdf/b6/f6/ndt-10-1799.PMC4172104.pdf
"In addition to these symptoms,  children and adolescents with ADHD are highly sensitive to stimuli and often have  unstable responses.2correspondence: Jong-hyun Jeong Department of Psychiatry, st Vincent  hospital, college of Medicine,   catholic University of Korea,  93, Jungbu-daero, Paldal-gu,   suwon, Korea Tel +82 31 249 7150 Fax +82 31 248 6758 email anton3@catholic.ac.k r Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2014 Volume: 10 Running head verso: Lee et al  Running head recto: Sleep and cognitive dysfunction in ADHD DOI: http://dx.doi.org/10.2147/NDT.S69562",Non-OADS,/arxiv_data1/oa_pdf/b6/f6/ndt-10-1799.PMC4172104.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/b6/f6/ndt-10-1799.PMC4172104.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/b6/f6/ndt-10-1799.PMC4172104.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pPsychology Research and Behavior Management 2014:7 251–259Psychology Research and Behavior Management Dove press submit your manuscript | www.dovepress.co m Dove press  251ORiginal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/PRBM.S6856 6Perceived parenting and social support: can they  predict academic achievement in argentinean  college students?,Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
"Available from: http://www.clarin.com/educacion/Decanos- rectores-reconocen-desercion-punto_0_542945805.htm l. Accessed  December 10, 2012.",Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
Available from: http://www.clarin.com/opinion/Necesitamos- graduados- universitarios_0_815318529.html.,Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
"Available from: http://www.clarin.com/educacion/Polemica-cantidad- graduados-universidades_0_542945804.htm l. Accessed August  6, 2014.",Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
Available from: http://www.clarin.com/sociedad/sinonimo-exito-   academico_0_461354029.html.,Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
"Available from: http://www.hfrp.org/family-involvement/ publications-resources/perceived-academic-support-from-parents- teachers-and-peers-relation-to-hong-kong-adolescents-academic- behavior-and-achievemen t. Accessed December 10, 2012.",Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
"Available from: http://www.uba.ar/institucional/censos/ Estudiantes2011/ estudiantes%202011.pd f. Accessed August  6, 2014.",Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
Available from:  http://diniece.me.gov.ar/images/stories/diniece/evaluacion_ educativa/ nacionales/r e sultados/Resultados%20Censo%20ONE%202010.pdf.,Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
"Available from: http://iaqse.caib.es/documents/aval2009-10/ pisa2009-informe-espanol.pd f. Accessed August  6, 2014.",Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
"Psychology Research and Behavior Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/psychology-research-and-behavior-management-journa lPsychology Research and Behavior Management is an international, peer- reviewed, open access journal focusing on the science of psychology and  its application in behavior management to develop improved outcomes  in the clinical, educational, sports and business arenas.",Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/db/85/prbm-7-251.PMC4172105.pdf
Available from: http://www.cpa.,Non-OADS,/arxiv_data1/oa_pdf/46/75/0036-4665-rimtsp-56-05-369.PMC4172106.pdf
[cited 2013 Jan 28]  Available from: http://www.cve.saude.sp.gov.br/htm/zoo/Den_dir06.htm  12.,Non-OADS,/arxiv_data1/oa_pdf/46/75/0036-4665-rimtsp-56-05-369.PMC4172106.pdf
Available from: http://www2.paho.org/hq/ dmdocuments/2011/epi_alerts_March_18_2011_dengue_update1.pdf   22.,Non-OADS,/arxiv_data1/oa_pdf/46/75/0036-4665-rimtsp-56-05-369.PMC4172106.pdf
Available from: http://www.who.int/mediacentre/factsheets/fs117/ en/   29.,Non-OADS,/arxiv_data1/oa_pdf/46/75/0036-4665-rimtsp-56-05-369.PMC4172106.pdf
Available from: http://dtr2004.saude.gov.br/ sinanweb/tabnet/dh?sinan/lta/bases/ltabr.def  9.,OADS,/arxiv_data1/oa_pdf/74/1a/0036-4665-rimtsp-56-05-375.PMC4172107.pdf
Available  from: http://www.who.int/neglected_diseases/en/ Received: 3 October 2013 Accepted: 25 February 2014,Non-OADS,/arxiv_data1/oa_pdf/06/09/0036-4665-rimtsp-56-05-381.PMC4172108.pdf
Available from: http://goo.gl/mPcbz.,Non-OADS,/arxiv_data1/oa_pdf/41/03/0036-4665-rimtsp-56-05-391.PMC4172109.pdf
Available from: http://goo.gl/PiM9n.,Non-OADS,/arxiv_data1/oa_pdf/41/03/0036-4665-rimtsp-56-05-391.PMC4172109.pdf
Available from:  ftp://ftp.cve.saude.sp.gov.br/doc_tec/outros/bol_bepa5608.pdf  6.,Non-OADS,/arxiv_data1/oa_pdf/ac/dc/0036-4665-rimtsp-56-05-403.PMC4172111.pdf
Available from: http://www.seade.gov.br/produtos/perfil/ perfil.php  33.,OADS,/arxiv_data1/oa_pdf/ac/dc/0036-4665-rimtsp-56-05-403.PMC4172111.pdf
The specificity of primers was verified by the software  BLAST (http://blast.ncbi.nlm.gov/Blast.cgi).,OADS,/arxiv_data1/oa_pdf/29/13/0036-4665-rimtsp-56-05-411.PMC4172112.pdf
Dimer formation was  predicted with OPERON (http://www.operon.com/technical/toolkit.,OADS,/arxiv_data1/oa_pdf/29/13/0036-4665-rimtsp-56-05-411.PMC4172112.pdf
Available from: http://www.dsmz.,Non-OADS,/arxiv_data1/oa_pdf/47/9e/0036-4665-rimtsp-56-05-427.PMC4172115.pdf
Available  from: < http://www.cfsan.fda.gov/~ebam/bam-9.html >.,OADS,/arxiv_data1/oa_pdf/47/9e/0036-4665-rimtsp-56-05-427.PMC4172115.pdf
Available from: http://trisul.com.br/arquivos/dengue_ (bula).pdf  9.,Non-OADS,/arxiv_data1/oa_pdf/8b/fc/0036-4665-rimtsp-56-05-447.PMC4172119.pdf
Available from: https://www.bio-rad.com/webroot/web/pdf/inserts/ CDG/pt/72830_12-2008.pdf  21.,Non-OADS,/arxiv_data1/oa_pdf/8b/fc/0036-4665-rimtsp-56-05-447.PMC4172119.pdf
Available from:  http://www.zoologia.hu/qp.html   17.,Non-OADS,/arxiv_data1/oa_pdf/e3/0a/0036-4665-rimtsp-56-05-455.PMC4172121.pdf
Available from: http://www.webmd.com/ children/tc/fifth-disease-topic-overview  2.,Non-OADS,/arxiv_data1/oa_pdf/a9/dc/0036-4665-rimtsp-56-05-458.PMC4172122.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/fd/0e/ijn-9-4375.PMC4172124.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4375–4386International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4375OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/IJN.S6568 9comparison of process parameter optimization  using different designs in nanoemulsion-based  formulation for transdermal delivery of fullerene cheng loong Ngan1 Mahiran Basri1,2 Fui Fang lye1 hamid reza Fard Masoumi1 Minaketan Tripathy3,4 roghayeh abedi Karjiban1 emilia abdul-Malek1  1Department of chemistry, Faculty  of science, 2halal Products research  Institute, Universiti Putra Malaysia,   selangor, Malaysia; 3laboratory  of Fundamentals of Pharmaceutics,   Faculty of Pharmacy, Puncak alam  campus, Universiti T eknologi M ara,   selangor, Malaysia; 4Brain and  Neuroscience communities   of research, Universiti T eknologi  Mara, selangor, Malaysia correspondence: Mahiran Basri;   cheng loong Ngan   Department of chemistry, Faculty   of science, Universiti Putra Malaysia,  43400 UPM serdang, selangor, Malaysia   T el +60 389 467 266   Fax +60 389 466 997   email mahiran@upm.edu.m y;   clngan88@yahoo.co m Abstract:  This research aims to formulate and to optimize a nanoemulsion-based formulation  containing fullerene, an antioxidant, stabilized by a low amount of mixed surfactants using high  shear and the ultrasonic emulsification method for transdermal delivery.",Non-OADS,/arxiv_data1/oa_pdf/fd/0e/ijn-9-4375.PMC4172124.pdf
"Hence,  efforts to modify the surface of the molecules into functionalized fullerene have  been reported.10 However, engineered fullerene derivatives can be highly toxic.6  Journal name: International Journal of Nanomedicine Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Ngan et al Running head recto: Comparison of process parameter optimization DOI: http://dx.doi.org/10.2147/IJN.S65689",Non-OADS,/arxiv_data1/oa_pdf/fd/0e/ijn-9-4375.PMC4172124.pdf
"International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.co m Dove press Dove press International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/fd/0e/ijn-9-4375.PMC4172124.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s 4386Ngan et al 14.,Non-OADS,/arxiv_data1/oa_pdf/fd/0e/ijn-9-4375.PMC4172124.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8c/b0/ijn-9-4399.PMC4172125.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4399–4409International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4399OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/IJN.S6600 0Nanouric acid or nanocalcium phosphate as  central nidus to induce calcium oxalate stone  formation: a high-resolution transmission electron  microscopy study on urinary nanocrystallites Jie gao1 Jun-Fa Xue2 Meng Xu2 Bao-song gui1 Feng-Xin Wang2 Jian-Ming Ouyang2 1Department of Nephrology,  the second hospital of Xi’an  Jiaotong University, Xi’an, People’s  republic of china; 2Institute of  Biomineralization and lithiasis  research, Jinan University,  guangzhou, People’s republic  of china correspondence: Bao-song gui Department of Nephrology, the second  hospital of Xi’an Jiaotong University,  Western number 5, Xi’an 710004,  People’s republic of china email guibsdoctor@sina.co m  Jian-Ming Ouyang Institute of Biomineralization and lithiasis  research, Jinan University, 601 Western  huangpu avenue, guangzhou 510632,  People’s republic of china email toyjm@jnu.edu.c n Purpose:  This study aimed to accurately analyze the relationship between calcium oxalate  (CaOx) stone formation and the components of urinary nanocrystallites.",Non-OADS,/arxiv_data1/oa_pdf/8c/b0/ijn-9-4399.PMC4172125.pdf
"A previous study has  shown that calcium oxalate monohydrate (COM) formation was closely related with  hyperoxaluria, whereas calcium oxalate dihydrate (COD) formation was closely related  with hypercalciuria.4  The formation process of CaOx stones involves nucleation, growth, agglomeration,  and cell adhesion.5,6 The properties of urinary crystallites were found to be closely  related to renal stone formation in the urine.7–9 In addition, COM content was found to  be greater in urinary crystallites of patients with renal stones, while COD was found  to be greater in control subjects.Journal name: International Journal of Nanomedicine Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Gao et al Running head recto: Nano-UA or nano-CaP to induce CaOx stone formation DOI: http://dx.doi.org/10.2147/IJN.S66000",Non-OADS,/arxiv_data1/oa_pdf/8c/b0/ijn-9-4399.PMC4172125.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/8c/b0/ijn-9-4399.PMC4172125.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.co m Dove press Dove press 4409Nano-U a or nano-caP to induce caOx stone formation  32.,Non-OADS,/arxiv_data1/oa_pdf/8c/b0/ijn-9-4399.PMC4172125.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/40/2d/ott-7-1619.PMC4172128.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2014:7 1619–1624OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1619Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S6739 3Nanotetrac targets integrin αvβ3 on tumor cells  to disorder cell defense pathways and block  angiogenesis Paul J Davis1,2 Hung-Yun Lin2,3 Thangirala Sudha2 Murat Yalcin2,4 Heng-Yuan Tang2 Aleck Hercbergs5 John T Leith6 Mary K Luidens1 Osnat Ashur-Fabian7,8 Sandra incerpi9 Shaker A Mousa2 1Department of Medicine, Albany  Medical College, Albany, NY, USA;   2Pharmaceutical Research institute,   Albany College of Pharmacy and  Health Sciences, Albany, NY, USA;   3PhD Program for Cancer Biology   and Drug Discovery, College of  Medical Science and Technology, Taipei  Medical University, Taipei, Taiwan;   4Department of Physiology, veterinary  Medicine Faculty, Uludag University,   Gorukle, Bursa, T urkey;  5Radiation  Oncology, Cleveland Clinic, Cleveland,   OH, USA;  6Rhode island Nuclear  Science Center, Narragansett, Ri,   USA;  7Translational Hemato-oncology  Laboratory, Hematology institute   and Blood Bank, Meir Medical Center,   Kfar-Saba, israel;  8Department of  Human Molecular Genetics and  Biochemistry, Sackler Faculty of  Medicine, Tel Aviv University, Tel  Aviv, israel;  9Department of Sciences,   University of Roma Tre, Rome, italy Correspondence: Paul J Davis   Pharmaceutical Research institute,   One Discovery Drive, Rensselaer,   NY 12144, USA   T el +1 518 428 7848  Fax +1 518 694 7567  email pdavis.ordwayst@gmail.co mAbstract:  The extracellular domain of integrin αvβ3 contains a receptor for thyroid hormone  and hormone analogs.",Non-OADS,/arxiv_data1/oa_pdf/40/2d/ott-7-1619.PMC4172128.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/40/2d/ott-7-1619.PMC4172128.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/40/2d/ott-7-1619.PMC4172128.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/92/42/ijn-9-4357.PMC4172146.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4357–4373International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4357RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJN.S4690 0Nanopharmaceuticals (part 1): products   on the market volkmar weissig1 Tracy K Pettinger2 Nicole Murdock3 1Department of Pharmaceutical  Sciences, Midwestern University  College of Pharmacy Glendale,   Glendale, AZ, USA; 2Department of  Pharmacy Practice and Administrative  Sciences, College of Pharmacy, Idaho  State University, Pocatello, ID, USA;   3Department of Pharmacy Practice,   Midwestern University College  of Pharmacy Glendale, Glendale,   AZ, USAAbstract:  In 2000, the National Institute of Health launched the National Nanotechnology  Initiative to support, coordinate, and advance research and development of nanoscale projects.",Non-OADS,/arxiv_data1/oa_pdf/92/42/ijn-9-4357.PMC4172146.pdf
"Colloidal gold, a  traditional alchemical preparation, was turned into a suspension of gold nanoparticles,  and colloidal drug-delivery systems1 became nanodrug delivery systems.2 The exploration of colloidal systems, ie, systems containing nanometer sized com - ponents, for biomedical research was, however, launched already more than 50 years  ago3–5 and efforts to explore colloidal (nano) particles for drug delivery date back  about 40 years.6 For example, efforts to reduce the cardiotoxicity of anthracyclines  via encapsulation into nanosized phospholipid vesicles (liposomes) began at the end  of the 1970s.7,8 During the 1980s, three liposome-dedicated US start-up companies  (Vestar in Pasadena, CA, USA, The Liposome Company in Princeton, NJ, USA, and Correspondence: volkmar weissig Midwestern University College  of Pharmacy Glendale, Department  of Pharmaceutical Sciences,   19555 N 59th Avenue, Glendale,   AZ 85308, USA Tel +1 623 572 3574 Fax +1 623 572 3565 email vweiss@midwestern.ed u Journal name: International Journal of Nanomedicine Article Designation: Review Y ear: 2014 Volume: 9 Running head verso: Weissig et al Running head recto: Approved nanopharmaceuticals DOI: http://dx.doi.org/10.2147/IJN.S46900",Non-OADS,/arxiv_data1/oa_pdf/92/42/ijn-9-4357.PMC4172146.pdf
Available from: http://www.nano.gov/nanotech- 101/nanotechnology-facts.,OADS,/arxiv_data1/oa_pdf/92/42/ijn-9-4357.PMC4172146.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/92/42/ijn-9-4357.PMC4172146.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/92/42/ijn-9-4357.PMC4172146.pdf
Available from: http://www.accessdata.fda.,OADS,/arxiv_data1/oa_pdf/92/42/ijn-9-4357.PMC4172146.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e4/94/ijnrd-7-337.PMC4172192.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nephrology and Renovascular Disease 2014:7 337–345International Journal of Nephrology and Renovascular Disease Dove press submit your manuscript | www.dovepress.co m Dove press  337ORIg INal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJNRD.S6639 0The deleterious effects of arteriovenous   fistula-creation on the cardiovascular system:   a longitudinal magnetic resonance imaging study Benjamin K Dundon1–3 Kim T orpey3 adam J Nelson1 Dennis Tl Wong1,2 Rae F Duncan1 Ian T Meredith2 Randall J Faull1,3 stephen g Worthley1,4 Matthew I Worthley1,4 1cardiology Department, Royal  adelaide hospital, central adelaide  local health Network, Discipline  of Medicine, University of adelaide,   adelaide, sa, australia;  2Monash  cardiovascular Research centre,   MonashheaRT, Monash health,   Melbourne, Vic, australia;  3central  Northern Renal and Transplantation  service, Royal adelaide hospital,   central adelaide local health  Network, adelaide, sa, australia;   4south australian health and Medical  Research Institute, adelaide, sa,   australia correspondence: Matthew I Worthley   cardiology Department, central adelaide   local health Network (Royal adelaide   hospital), North Terrace, adelaide,   sa 5000, australia   Tel +61 88 222 4000  Fax +61 88 222 2454  email matthew.worthley@adelaide.edu.a uAim:  Arteriovenous fistula-formation remains critical for the provision of hemodialysis in end- stage renal failure patients.",Non-OADS,/arxiv_data1/oa_pdf/e4/94/ijnrd-7-337.PMC4172192.pdf
"International Journal of Nephrology and Renovascular Disease Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nephrology-and-renovascular-disease-journa lThe International Journal of Nephrology and Renovascular Disease is  an international, peer-reviewed open-access journal focusing on the  pathophysiology of the kidney and vascular supply.",Non-OADS,/arxiv_data1/oa_pdf/e4/94/ijnrd-7-337.PMC4172192.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e4/94/ijnrd-7-337.PMC4172192.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/08/ef/ott-7-1625.PMC4172193.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2014:7 1625–1630OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1625Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6885 4Expression and clinical significance of the long  non-coding rna PVT1 in human gastric cancer Jian Ding1,* Dan li2,* Minzhen gong1 Jinpo Wang1 Xunru huang1 Ting Wu1 chengdang Wang1 1Digestive Department of the First  Affiliated Hospital of Fujian Medical  University, Fuzhou, Fujian, People’s  Republic of China; 2Digestive  Department of Union Hospital of  Fujian Medical University, Fuzhou,   Fujian, People’s Republic of China *These authors contributed equally   to this work correspondence: Jian Ding   Digestive Department of the First   Affiliated Hospital of Fujian Medical   University, Fuzhou, Fujian,   People’s Republic of China   email docdingjian@163.co mBackground:  Highly sensitive markers are urgently needed for the diagnosis and grading of  gastric cancer and for managing drug resistance.",Non-OADS,/arxiv_data1/oa_pdf/08/ef/ott-7-1625.PMC4172193.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/08/ef/ott-7-1625.PMC4172193.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/08/ef/ott-7-1625.PMC4172193.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/69/a8/ppa-8-1255.PMC4172194.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 1255–1263Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1255OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S7001 9Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Spoudeas et al Running head recto: Jet-delivery versus needle-based devices in GH therapy DOI: http://dx.doi.org/10.2147/PPA.S70019 Maintaining persistence and adherence  with subcutaneous growth-hormone therapy  in children: comparing jet-delivery   and needle-based devices Purpose:  Persistence and adherence with subcutaneous growth hormone (GH; somatropin)  therapy in children is widely acknowledged to be suboptimal.,Non-OADS,/arxiv_data1/oa_pdf/69/a8/ppa-8-1255.PMC4172194.pdf
Available from:  http://pqaalliance.org/resources/adherence.asp.,OADS,/arxiv_data1/oa_pdf/69/a8/ppa-8-1255.PMC4172194.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/69/a8/ppa-8-1255.PMC4172194.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/fb/1c/opth-8-1783.PMC4172197.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1783–1785Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1783Case seriesopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S6789 4acute-onset postoperative endophthalmitis  caused by multidrug-resistant Klebsiella  pneumoniae shekhar sanghi1  avinash Pathengay1 animesh Jindal1 Vishal raval2 sameera Nayak2 savitri sharma3 abhishek Bawdekar1 Harry W Flynn Jr4 1Department of Ophthalmology,   L V Prasad eye institute, GM r  Varalakshmi Campus, Visakhapatnam,   andhra Pradesh, india; 2Department  of Ophthalmology, L V Prasad eye  institute, KVC Campus, Vijayawada,   andhra Pradesh, india; 3Department  of Microbiology, Jhaveri Microbiology  Centre, L V Prasad eye institute, K ar  Campus, Hyderabad, andhra Pradesh,   india; 4Department of Ophthalmology,   Bascom Palmer eye institute, Miller  school of Medicine, University  of Miami, Miami, FL, UsaAbstract:  The purpose of this paper is to report outcomes of intravitreal imipenem in the  treatment of multidrug-resistant Klebsiella -related postoperative endophthalmitis.",Non-OADS,/arxiv_data1/oa_pdf/fb/1c/opth-8-1783.PMC4172197.pdf
"Antibiotic Correspondence: avinash Pathengay Department of Ophthalmology, L V  Prasad eye institute, GMr Varalakshmi  Campus, Visakhapatnam, andhra   Pradesh 530040, india  Tel +91 99 8915 6789 email avinash@lvpei.or g Journal name: Clinical Ophthalmology Journal Designation: Case Series Y ear: 2014 Volume: 8 Running head verso: Sanghi et al Running head recto: Acute-onset postoperative endophthalmitis caused by K. pneumoniae DOI: http://dx.doi.org/10.2147/OPTH.S67894",Non-OADS,/arxiv_data1/oa_pdf/fb/1c/opth-8-1783.PMC4172197.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/fb/1c/opth-8-1783.PMC4172197.pdf
"Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.co m Dove press Dove press 1785acute-onset postoperative endophthalmitis caused by K. pneumoniae series was either phthisis or blindness, even after the best  possible treatment.",Non-OADS,/arxiv_data1/oa_pdf/fb/1c/opth-8-1783.PMC4172197.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/74/35/ijgm-7-459.PMC4172199.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of General Medicine 2014:7 459–461International Journal of General Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  459Short reportopen access to scientific and medical research open Access Full text Article http: //dx.doi.org/10.2147/IJGM.S6899 9endoscopic alterations in a cohort   of hemodialysis patients: a cross-sectional study Mr Bacci1 Ft russo1 GD Carvalho1 eZ Chehter2 VC Jordao1 FL Fonseca1 1Department of General practice,   2Department of Gastroenterology,   Faculdade de Medicina do ABC (ABC  Medical School), Santo André, Brazil Correspondence: Marcelo rodrigues  Bacci  Faculdade de Medicina do ABC,   Av príncipe de Gales n  821, Vila príncipe  de Gales, Santo André, Brazil  09060-650   tel +55 11 981 937 005  email mrbacci@yahoo.co mIntroduction:  Although the association between chronic kidney disease and dyspepsia  is widely known, it remains poorly investigated.",Non-OADS,/arxiv_data1/oa_pdf/74/35/ijgm-7-459.PMC4172199.pdf
"International Journal of General Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-general-medicine-journa lThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal  medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat - ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/74/35/ijgm-7-459.PMC4172199.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/74/35/ijgm-7-459.PMC4172199.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ed/24/ppa-8-1265.PMC4172200.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 1265–1275Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1265OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S6500 8intention to use hearing aids: a survey based   on the theory of planned behavior hartmut Meister1 linda grugel1 Markus Meis2 1Jean Uhrmacher institute for clinical  enT research, University of cologne,   cologne, germany; 2hoerzentrum  Oldenburg, Oldenburg, germany correspondence: hartmut Meister   Jean Uhrmacher institute for clinical  enT research, University of cologne,  geibelstr 29-31, D-50931 cologne,  germany   T el +49 221 478 97003   Fax +49 221 478 97010   email hartmut.meister@uni-koeln.de  Objective:  To determine the intention to use hearing aids (HAs) by applying the theory of  planned behavior (TPB).",Non-OADS,/arxiv_data1/oa_pdf/ed/24/ppa-8-1265.PMC4172200.pdf
"Recently,  Knudsen et al10 provided an overview of the research conducted between 1980 and Journal name: Patient Preference and Adherence Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Meister et al Running head recto: Intention to use hearing aids DOI: http://dx.doi.org/10.2147/PPA.S65008",Non-OADS,/arxiv_data1/oa_pdf/ed/24/ppa-8-1265.PMC4172200.pdf
"Furthermore, post  hoc power analyses for the models were performed using  G*Power 3.1 ( http://www.gpower.hhu.de /).",OADS,/arxiv_data1/oa_pdf/ed/24/ppa-8-1265.PMC4172200.pdf
Available from: http://www.euha.org/congress/conference-proceed - ings-on-cd-rom/.,Non-OADS,/arxiv_data1/oa_pdf/ed/24/ppa-8-1265.PMC4172200.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/ed/24/ppa-8-1265.PMC4172200.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d6/96/ppa-8-1223.PMC4172203.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 1223–1228Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1223OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S6975 0effects on caregiver burden of a donepezil  hydrochloride dosage increase to 10 mg/day  in patients with Alzheimer’s disease Kazuhito n akamura1,2 norio Watanabe1 hiroshi Ohkawa3 Michiyasu Ando4 Yukio Ogura5 sumito Funabiki6 Akito Kume7 Kimihiko Urano1 Takashi Osada1 Keiko Yamamura1 1Department of clinical Pharmacy,  school of Pharmacy, Aichi gakuin  University, 2Koyo Pharmacy, 3Ohkawa  clinic, 4Ando clinic, 5Total support  clinic, 6Funabiki clinic, 7Kume clinic,  Aichi, JapanBackground:  In this study, we evaluated changes in functioning and caregiver burden in  Alzheimer’s disease (AD) patients after a dosage increase that was made based on pharmacists’  evaluation of AD patients’ behavior in daily life.",Non-OADS,/arxiv_data1/oa_pdf/d6/96/ppa-8-1223.PMC4172203.pdf
"While the mortality rates for many leading causes of death have declined over  the past decade, deaths from dementia have steadily increased.1 Dementia patients, their  families, and health care providers must understand and be prepared to confront the  end stage of this disease, which is estimated to affect more than 5 million Americans   currently and is expected to affect more than 13 million by 2050.2 Similarly, the number  of dementia patients is expected to grow in countries worldwide, including Japan, as  the elderly population increases.correspondence: Kazuhito nakamura Department of clinical Pharmacy, school  of Pharmacy, Aichi gakuin University,  1-100 Kusumoto-cho, chikusa-ku,  nagoya, Aichi 464-8650, Japan Tel +81 5 2757 6767 Fax +81 5 2757 6799 email ag123a81@dpc.agu.ac.j p Journal name: Patient Preference and Adherence Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Nakamura et al Running head recto: Effects on caregiver burden of donepezil 10 mg/day DOI: http://dx.doi.org/10.2147/PPA.S69750 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/d6/96/ppa-8-1223.PMC4172203.pdf
Or use: http://dvpr.es/1qMBX4 AVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/d6/96/ppa-8-1223.PMC4172203.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/d6/96/ppa-8-1223.PMC4172203.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/38/f4/opth-8-1855.PMC4172211.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1855–1858Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1855Letteropen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/OPTH.S6520 3Efficacy of preservative-free tafluprost in patients  with normal-tension glaucoma previously treated  with latanoprost Matteo Sacchi  edoardo Villani Paolo Nucci University eye Clinic, San Giuseppe  Hospital, University of Milan,    Milan, ItalyDear editor We read with interest the article entitled “Effects of tafluprost treatment for 3 years  in patients with normal-tension glaucoma” by Inoue et al.1 In this study, the authors  reported the efficacy of tafluprost in naïve patients with normal-tension glaucoma  (NTG) over 3 years of follow-up.",Non-OADS,/arxiv_data1/oa_pdf/38/f4/opth-8-1855.PMC4172211.pdf
"Correspondence: Matteo Sacchi University eye Clinic, San Giuseppe  Hospital, Via San Vittore 12, 20123,   Milano, Italy tel +39 02 8599 4975 Fax +39 02 2941 5945 email matteosacchi.hsg@gmail.co mJournal name: Clinical Ophthalmology Journal Designation: Letter Y ear: 2014 Volume: 8 Running head verso: Sacchi et al Running head recto: Preservative-free tafluprost in normal-tension glaucoma DOI: http://dx.doi.org/10.2147/OPTH.S65203",Non-OADS,/arxiv_data1/oa_pdf/38/f4/opth-8-1855.PMC4172211.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/38/f4/opth-8-1855.PMC4172211.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.co m Dove press Dove press 1858Sacchi et al References 1.,Non-OADS,/arxiv_data1/oa_pdf/38/f4/opth-8-1855.PMC4172211.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1038/nature1013 4 Aukrust, P., F. Müller, and S.S. Frøland.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1006/clin.1994.103 2 Barber, D.L., E.J.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1182/blood­2004­04­132 5 Bloom, B.R., and B. Bennett.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
http://dx.doi.org/10.4049/jimmunol.165.8.472 5625NC ­conjugated anti ­CD8 (clone RPA ­T8; eBioscience); and FITC ­ conjugated anti ­CCR7 (clone 150503) and Alexa Fluor 700–conjugated  anti–HLA ­DR (clone LN3; R&D Systems).,OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1007/s10875­010­9371­ z Ishihara, T., S. Takahara, and C.G.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1084/jem.2006166 0 Kuijpers, T.W ., R.J. Bende, P .A.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1146/annurev.immunol.23.021704.11573 2 McMahan, R.H., L. Golden­Mason, M.I.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1172/JCI4312 7 Morita, R., N. Schmitt, S.E.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1016/j.immuni   .2010.12.01 2 Morris, J.A., C. Wray, and W.J.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1099/00222615­13­2­26 5 Nathan, C.F., H.W.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1084/jem.158.3.67 0 Orange, J.S., E.M. Hossny, C.R.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1016/j.jaci.2006.01.01 5 Paquin­Proulx, D., B.A.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1371/ journal.pone.007519 9 Paquin­Proulx, D., B.A.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi   .org/10.1182/blood­2013­04­49944 2 Park, M.A., J.T.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1016/S0140­6736   (08)61199 ­X Parker, D.C. 1993.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1146/annurev.iy.11.040193.00155 5Brandtzaeg, P., K. Valnes, H. Scott, T.O.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
http://dx.doi.org/   10.1038/mi.2007.,Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"200:749– 759. http://dx.doi.org/10.1084/jem.2004087 4 Butcher, B.T., J.E.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
http://dx.doi   .org/10.1111/j.1365­2222.1975.tb01834.,Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi   .org/10.1038/ng160 1 Cellerai, C., M. Perreau, V. Rozot, F. Bellutti Enders, G. Pantaleo, and A.  Harari.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1128/JVI.02565­0 9 Champagne, P ., G.S.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1038/3506511 8 Coruh, G., and D.Y .",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
http://dx.doi.org/10.1111/ j.1365­2133.1980.tb07646.,Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1182/blood ­2010­  01­25441 7 Cunningham ­Rundles, C., and C. Bodian.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1006/clim.1999.472 5 Cunningham­Rundles, C., C. Bodian, H.D.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1006/clim.2001.505 2 David, J.R. 1973.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1056/NEJM19730118288031 1 Day , C.L., D.E.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1038/nature0511 5 De Gast, G.C., S.R.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1016/j.coi.2012   .05.00 4 Giovannetti, A., M. Pierdominici, F. Mazzetta, M. Marziali, C. Renzi,  A.M. Mileo, M. De Felice, B. Mora, A. Esposito, R. Carello, et al.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi   .org/10.4049/jimmunol.178.6.393 2 Grimbacher, B., A. Hutloff, M. Schlesier, E. Glocker, K. Warnatz, R.  Dräger, H. Eibel, B. Fischer, A.A. Schäffer, H.W.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/   10.1038/ni90 2 Haney, D., M.F.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
http://dx.doi.org/   10.1016/j.jim.2011.04.00 3,OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi   .org/10.1128/JVI.00788­1 1 Perreau, M., H.C. Welles, A. Harari, T. Calandra, T. Roger, and G.  Pantaleo.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi   .org/10.1084/jem.2006149 6 Raeiszadeh, M., J. Kopycinski, S.J.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
http://dx.doi.org/10.1111/j.1365­2249.2006.03209.,Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10   .1056/NEJM19810402304140 3 Roederer, M., J.L.",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1002/cyto.a.2101 5 Roger, T., C. Froidevaux, D. Le Roy, M.K.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"12:1198– 1202. http://dx.doi.org/10.1038/nm148 2 Van der Hilst, J.C., B.W .",OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi.org/10.1182/blood­2007­06­09174 4 Yamamoto, T., D.A.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
"http://dx.doi   .org/10.1182/blood­2010­11­31729 7 Ye, P., F.H.",Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
http://dx.doi.org/10.1084/jem.194.4.51 9,Non-OADS,/arxiv_data1/oa_pdf/ae/34/JEM_20140039.PMC4172212.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months after   the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"After six months it is   available under a Creative Commons License (Attribution–Noncommercial–Share  Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/   by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1042/BJ2008006 7 Alam, S.M., P .J.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1038/381616a 0 Baldwin, T.A., and K.A.",Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.4049/   jimmunol.179.2.83 7 Cheng, A.M., I. Negishi, S.J.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
http://dx.doi.org/10.1111/j.1600-065X.2009.00766.,Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1016/S1074-7613   (00)80498- 7 Jameson, S.C., K.A.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10   .1146/annurev.iy.13.040195.00052 1 Kisielow, P., and H. von Boehmer.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/   10.1016/S0065-2776(08)60620- 3 Komander, D., and M. Rape.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1146/annurev-biochem-060310-   17032 8 Liston, A., S. Lesage, D.H. Gray, L.A. O’Reilly, A. Strasser, A.M. Fahrer,  R.L.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1074/jbc.271.39.2406 3 Mantei, A., S. Rutz, M. Janke, D. Kirchhoff, U. Jung, V. Patzel, U. Vogel,  T. Rudel, I. Andreou, M. Weber, and A. Scheffold.",Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1002/eji.20073807 5 Nagai, H., T. Noguchi, K. Homma, K. Katagiri, K. Takeda, A. Matsuzawa,  and H. Ichijo.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
http://dx.doi.org/10.1016/   j.molcel.2009.10.01 6(BD).,OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi   .org/10.1073/pnas.122192511 0 Pivniouk, V., E. Tsitsikov, P. Swinton, G. Rathbun, F.W.",Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1016/S0092-8674(00)81422- 1 Rao, N., M.L.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.4049/jimmunol.164.9.461 6 Rieux-Laucat, F., F. Le Deist, and A. Fischer.",Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1038/sj.cdd.440119 0 Ryan, M.D., A.M. King, and G.P.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi   .org/10.1099/0022-1317-72-11-272 7 Sakaguchi, N., T. Takahashi, H. Hata, T. Nomura, T. Tagami, S. Yamazaki,  T. Sakihama, T. Matsutani, I. Negishi, S. Nakatsuru, and S. Sakaguchi.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1038/nature0864 6 Shlomchik, M.J., J.E.",Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1038/3510057 3 Wood, S.A., W.S.",Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
"http://dx.doi.org/10.1016/S0925-4773(97)00672- 2 W orth, A., A.J.",OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
http://dx.doi.org/10.1111/j.1365-2141.2006.05993.,Non-OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
10:323– 332. http://dx.doi.org/10.1016/S1074-7613(00)80032- 1,OADS,/arxiv_data1/oa_pdf/3d/04/JEM_20140860.PMC4172213.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi   .org/10.2353/ajpath.2010.09091 5 Albrecht, P., A.-K. Müller, M. Südmeyer, S. Ferrea, M. Ringelstein, E.  Cohn, O. Aktas, T. Dietlein, A. Lappas, A. Foerster, et al.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1371/journal.pone.003489 1 Arnold, E.S., S.-C. Ling, S.C. Huelga, C. Lagier-T ourenne, M. Polymenidou,  D. Ditsworth, H.B.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi   .org/10.1038/nature0501 6 Barmada, S.J., G. Skibinski, E. Korb, E.J.",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/ 10.1523/JNEUROSCI   .4988-09.201 0 Bayer, A.U., O.N.",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"133:135– 137. http://dx.doi.org/10.1016/S0002-9394(01)01196- 5 Chen-Plotkin, A.S., F. Geser, J.B. Plotkin, C.M.",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"17:1349– 1362. http://dx.doi.org/10.1093/hmg/ddn02 3 Davidson, Y., T. Kelley, I.R.A.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1007/s00401-006-0189- y De Muynck, L., S. Herdewyn, S. Beel, W. Scheveneels, L. Van Den Bosch,  W. Robberecht, and P. Van Damme.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi   .org/10.1016/j.neurobiolaging.2013.04.02 2 Guo, A., L. Tapia, S.X.",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi   .org/10.1016/j.brainres.2010.09.09 9 Helmer, C., F .",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
Online supplemental material  is available at http://www.jem.org/cgi/content/full/jem.20140214/DC1.,Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10   .1002/ana.2392 6 Hinton, D.R., A.A. Sadun, J.C. Blanks, and C.A.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1056/NEJM19860821315080 4 Igaz, L.M., L.K.",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1172/JCI4486 7 Koronyo-Hamaoui, M., Y .",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1016/   j.neuroimage.2010.06.02 0 Lee, E.B., V.M.-Y.",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10   .1172/JCI6311 3 Melchior, F., T. Guan, B. Paschal, and L. Gerace.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1101/SQB.1995.060.01.07 7 Neumann, M., D.M.",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi   .org/10.1126/science.113410 8Nishimura, A.L., V .",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1093/brain/awq11 1 Paquet, C., M. Boissonnot, F. Roger, P. Dighiero, R. Gil, and J. Hugon.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi   .org/10.1016/j.neulet.2007.02.09 0 Polymenidou, M., C. Lagier-T ourenne, K.R.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10   .1038/nn.277 9 Sephton, C.F ., C. Cenik, A. Kucukural, E.B.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1074/jbc.M110.19088 4 Stewart, M. 2007.",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10 .1038/nrm211 4 Tamura, H., H. Kawakami, T. Kanamoto, T. Kato, T. Y okoyama, K. Sasaki,  Y .",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1016/j.jns.2006.02.00 9 Wegorzewska, I., and R.H. Baloh.",OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
"http://dx.doi.org/10.1159/00032154 7 Yin, F ., M. Dumont, R. Banerjee, Y .",Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
http://dx.doi.org/10.1096/   fj.10-16147 1,Non-OADS,/arxiv_data1/oa_pdf/e2/b8/JEM_20140214.PMC4172214.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/7f/d7/JEM_20130877.PMC4172215.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial–   Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/7f/d7/JEM_20130877.PMC4172215.pdf
"http://dx.doi.org/10.1128/IAI.01335-1 3 Boisson, B., C. Wang, V. Pedergnana, L. Wu, S. Cypowyj, M. Rybojad, A.  Belkadi, C. Picard, L. Abel, C. Fieschi, et al.",Non-OADS,/arxiv_data1/oa_pdf/7f/d7/JEM_20130877.PMC4172215.pdf
"http://dx.doi.org/10   .1016/j.immuni.2013.09.00 2 Brown, G.D., and M.G.",OADS,/arxiv_data1/oa_pdf/7f/d7/JEM_20130877.PMC4172215.pdf
"http://dx.doi.org/10.1038/icb.2010.7 2 Buonocore, S., P.P.",Non-OADS,/arxiv_data1/oa_pdf/7f/d7/JEM_20130877.PMC4172215.pdf
"http://dx.doi.org/10.1038/nature0806 4 Chen, Z., A. Laurence, Y. Kanno, M. Pacher-Zavisin, B.M.",Non-OADS,/arxiv_data1/oa_pdf/7f/d7/JEM_20130877.PMC4172215.pdf
"http://dx.doi.org/10.1073/   pnas.060066610 3 Conti, H.R., F .",Non-OADS,/arxiv_data1/oa_pdf/7f/d7/JEM_20130877.PMC4172215.pdf
"http://dx.doi.org/10.1084/jem.2008146 3 Cua, D.J., and C.M.",OADS,/arxiv_data1/oa_pdf/7f/d7/JEM_20130877.PMC4172215.pdf
